column_name,broad_id,name,dose,screen_id,topFeature,feature_type,drug_category,moa_umap,target,disease.area,indication,phase,bimodality_coef,Cor,hub_url,group,BM,x,y
BRD-A03932035-004-04-3::2.5::HTS,BRD-A03932035-004-04-3,methscopolamine,2.5,HTS,CN_CLPSL2 (389383),CN,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),Launched,0.295096433596605,0.151228638227,methscopolamine,OTHER,0.2948187242922233,4.208507489017701,-2.27903722546979
BRD-A06352418-001-25-9::2.5::HTS,BRD-A06352418-001-25-9,terfenadine,2.5,HTS,Exp_PMEL (ENSG00000185664),GE,noncancer,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",,,Withdrawn,0.372539460786562,0.249776551866,terfenadine,OTHER,0.3717834120171954,4.767394034675579,0.15047812552173667
BRD-A06352508-001-03-7::2.5::HTS,BRD-A06352508-001-03-7,SB-218078,2.5,HTS,Exp_ZBED4 (ENSG00000100426),GE,noncancer,CHK inhibitor,CHEK1,,,Preclinical,0.37856787455488206,0.284481844365,SB-218078,OTHER,0.3793704851734718,3.2210403616844285,-3.210230541083342
BRD-A06627858-236-03-0::2.5::HTS,BRD-A06627858-236-03-0,monensin,2.5,HTS,DEM2_RRM2 (6241),DEMETER2_COM,noncancer,bacterial permeability inducer,,,,Launched,0.400473788935259,0.104196870879,monensin,OTHER,0.3956594975151236,3.891417097435754,-0.4123144878998773
BRD-A07000685-001-04-4::2.5::HTS,BRD-A07000685-001-04-4,hydrocortisone-hemisuccinate,2.5,HTS,Exp_CPNE7 (ENSG00000178773),GE,noncancer,,,,,Phase 2/Phase 3,0.296849521622794,0.170038998261,hydrocortisone-hemisuccinate,OTHER,0.29830070987221435,-4.19754975772237,-2.4954077135202843
BRD-A08187463-001-12-9::2.5::HTS,BRD-A08187463-001-12-9,racecadotril,2.5,HTS,CRISPR_DDX54 (79039),AVANA_PUBLIC_18Q2,noncancer,enkephalinase inhibitor,MME,gastroenterology,diarrhea,Launched,0.24934950853441198,0.188954683875,racecadotril,OTHER,0.2543878572124845,3.577779438082326,-3.4084684146132864
BRD-A08545410-003-07-8::2.38::HTS,BRD-A08545410-003-07-8,doxycycline,2.38,HTS,Exp_TLK1 (ENSG00000198586),GE,noncancer,metalloproteinase inhibitor,MMP8,dental,periodontitis,Launched,0.36924099933970006,0.318156085433,doxycycline,OTHER,0.3420057965483333,0.8740520866360991,-3.3417040499545383
BRD-A08545410-311-03-4::2.5::HTS,BRD-A08545410-311-03-4,doxycycline,2.5,HTS,Exp_DHX33 (ENSG00000005100),GE,noncancer,metalloproteinase inhibitor,MMP8,dental,periodontitis,Launched,0.36924099933970006,0.318156085433,doxycycline,OTHER,0.3703244333477465,3.5120235404513935,-1.810881107936196
BRD-A08840375-001-01-3::2.5::HTS,BRD-A08840375-001-01-3,CID-5458317,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,MAP kinase phosphatase inhibitor,MAPK3,,,Preclinical,0.359445440436363,0.300612010789,CID-5458317,OTHER,0.3619909741147855,4.362019787181293,-1.243830546899216
BRD-A09349126-001-10-7::2.5::HTS,BRD-A09349126-001-10-7,norethindrone-acetate,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progesterone receptor agonist,,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",Launched,0.29272130528231,0.222152263377,norethindrone-acetate,OTHER,0.31465478336721364,3.3585804777898773,-0.5267401073815754
BRD-A10523515-001-07-9::2.5::HTS,BRD-A10523515-001-07-9,GSK429286A,2.5,HTS,METHYL_MAFF,METHYL,noncancer,rho associated kinase inhibitor,ROCK1,,,Preclinical,0.328886007593595,0.131647938081,GSK429286A,OTHER,0.3228598583889897,2.9786857677649867,-3.463061656813526
BRD-A10903566-003-07-7::2.5::HTS,BRD-A10903566-003-07-7,imiloxan,2.5,HTS,DEM2_ITGA2 (3673),DEMETER2_COM,noncancer,adrenergic receptor antagonist,"ADRA2A, ADRA2B",,,Phase 1,0.273496003478559,0.092030156442,imiloxan,OTHER,0.2710347045560559,2.9206716865435527,-0.4589869985434363
BRD-A11551002-001-04-6::2.5::HTS,BRD-A11551002-001-04-6,dehydrocholate-acid,2.5,HTS,MIRNA_hsa-miR-548k,MIRNA,noncancer,,,,,Preclinical,0.2537480734264,0.0788804968583,dehydrocholate-acid,OTHER,0.26597813066278314,5.413891857349695,1.5683104372657897
BRD-A14344385-001-03-2::2.5::HTS,BRD-A14344385-001-03-2,IDRA-21,2.5,HTS,METABOL_choline,METABOL,noncancer,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",,,Preclinical,0.39530659156795706,0.104528729836,IDRA-21,OTHER,0.38559279107084005,2.8775123618909304,0.4442996985250132
BRD-A14577621-001-01-5::2.5::MTS004,BRD-A14577621-001-01-5,peficitinib,2.5,MTS004,PROT_PR,PROT,noncancer,JAK inhibitor,"JAK1, JAK2, JAK3",,,Phase 3,0.300712950604539,0.191426220133,peficitinib,OTHER,0.3048608545654597,1.3195945262989706,-2.9084508730779213
BRD-A16700644-003-04-4::2.5::HTS,BRD-A16700644-003-04-4,isoxsuprine,2.5,HTS,PROT_YB-1_pS102,PROT,noncancer,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",Launched,0.31787019667260696,0.156637041301,isoxsuprine,OTHER,0.31583826689713546,5.256050297205043,-1.9074369908212263
BRD-A21607826-003-05-1::2.5::HTS,BRD-A21607826-003-05-1,medetomidine,2.5,HTS,Exp_MMD (ENSG00000108960),GE,noncancer,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,sedative,Launched,0.29333998305344106,0.215355881982,medetomidine,OTHER,0.2873659903864457,-4.62539830225892,-2.221766813443298
BRD-A22081593-001-11-1::2.5::HTS,BRD-A22081593-001-11-1,sulmazole,2.5,HTS,DEM2_RRAS2 (22800),DEMETER2_COM,noncancer,adenosine receptor antagonist,,,,Phase 1,0.23848731669787898,0.117223055171,sulmazole,OTHER,0.22459751923044616,4.905857982028984,-0.9774052993016559
BRD-A22707317-001-10-8::2.5::HTS,BRD-A22707317-001-10-8,SB-205384,2.5,HTS,Exp_IL11 (ENSG00000095752),GE,noncancer,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",,,Preclinical,0.363898484611004,0.219163325785,SB-205384,OTHER,0.3638094881507075,0.08167318961813458,-3.9113312280022257
BRD-A23067620-300-01-3::2.5::HTS,BRD-A23067620-300-01-3,itraconazole,2.5,HTS,PROT_CD49b,PROT,noncancer,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis",Launched,0.41114490355887207,0.172492514237,itraconazole,OTHER,0.35735383702404233,0.4874523959958715,-3.0777876996431903
BRD-A23124853-001-01-4::2.5::MTS004,BRD-A23124853-001-01-4,PF-06463922,2.5,MTS004,METHYL_CCDC114,METHYL,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, FES, ROS1",,,Phase 2,0.384674107112566,0.0628354942545,PF-06463922,OTHER,0.3838837703658879,-1.222473332029074,0.3643322287044497
BRD-A23127772-001-02-3::2.5::HTS,BRD-A23127772-001-02-3,sclareol,2.5,HTS,DEM2_LRP10 (26020),DEMETER2_COM,noncancer,,,,,Preclinical,0.30738025306982303,0.0309081889072,sclareol,OTHER,0.29144273978849,-4.9388672764263095,-0.9396195222167164
BRD-A25004090-001-08-4::2.5::HTS,BRD-A25004090-001-08-4,erastin,2.5,HTS,Exp_MARCH4 (ENSG00000144583),GE,targeted cancer,ion channel antagonist,VDAC2,,,Preclinical,0.554889438458167,0.335722005971,erastin,OTHER,0.553829500723355,-1.019885127456999,0.4800375810710249
BRD-A25569250-001-03-3::2.5::HTS,BRD-A25569250-001-03-3,KI-16425,2.5,HTS,Exp_HM13-AS1 (ENSG00000230613),GE,targeted cancer,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",,,Preclinical,0.298090505424073,0.0765911220071,KI-16425,OTHER,0.29554580489761,3.611332209280232,-1.5117771532640851
BRD-A25608658-001-01-1::2.5::HTS,BRD-A25608658-001-01-1,narasin,2.5,HTS,Exp_BARD1 (ENSG00000138376),GE,noncancer,antiprotozoal agent,,infectious disease,coccidiosis,Launched,0.3294545051276,0.199310517863,narasin,OTHER,0.3295815713714193,4.655487319449608,-0.6863243834066082
BRD-A27883417-300-01-6::2.5::HTS,BRD-A27883417-300-01-6,alexidine,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,phosphatidylglycerophosphatase inhibitor,PTPMT1,,,Preclinical,0.3751389187655739,0.33594370131,alexidine,OTHER,0.37551841338850106,3.4676148277539616,-2.082755954636646
BRD-A28301258-001-03-0::2.5::HTS,BRD-A28301258-001-03-0,salinomycin,2.5,HTS,Exp_BNIP3P1 (ENSG00000197358),GE,noncancer,,,infectious disease,coccidiosis,Launched,0.35680304171722493,0.300172560108,salinomycin,OTHER,0.33738213852498666,4.714299994132405,-0.9879237967745876
BRD-A28301258-001-04-8::2.5::HTS,BRD-A28301258-001-04-8,salinomycin,2.5,HTS,Exp_KRT7 (ENSG00000135480),GE,noncancer,,,infectious disease,coccidiosis,Launched,0.35680304171722493,0.300172560108,salinomycin,OTHER,0.35485184233060496,4.672176273305377,-1.3264773775671563
BRD-A28970875-300-04-9::2.5::HTS,BRD-A28970875-300-04-9,puromycin,2.5,HTS,CN_NPIPA1 (9284),CN,noncancer,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",,,Preclinical,0.312073865584097,0.0771097501342,puromycin,OTHER,0.3729673329273601,3.9844286959104864,-1.2002721585893852
BRD-A30886737-001-02-9::2.5::HTS,BRD-A30886737-001-02-9,florfenicol,2.5,HTS,DEM2_TBL3 (10607),DEMETER2_COM,noncancer,protein synthesis inhibitor,,pulmonary,bovine respiratory disease (BRD),Launched,0.33042686841219604,0.0429728691066,florfenicol,OTHER,0.3318209446503185,1.7831089538191516,-2.7697292557034703
BRD-A31095847-001-02-3::2.5::HTS,BRD-A31095847-001-02-3,mozavaptan,2.5,HTS,Exp_TMEM255B (ENSG00000184497),GE,noncancer,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,Launched,0.437146057017644,0.272205507131,mozavaptan,OTHER,0.4333184152117917,4.745712724788285,-3.928497318835463
BRD-A36318220-001-08-8::2.5::HTS,BRD-A36318220-001-08-8,necrostatin-1,2.5,HTS,Exp_PPEF1 (ENSG00000086717),GE,noncancer,RIPK inhibitor,RIPK1,,,Preclinical,0.275741899715299,0.18729075821,necrostatin-1,OTHER,0.2931778488530141,-1.5667912971760298,0.9338314970107922
BRD-A36456202-001-01-3::2.5::HTS,BRD-A36456202-001-01-3,colistin-b-sulfate,2.5,HTS,Exp_KIAA1033 (ENSG00000136051),GE,noncancer,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections,Launched,0.232773388680494,0.107425856836,colistin-b-sulfate,OTHER,0.235077072261803,3.759020505572123,2.969991172381225
BRD-A39935389-001-05-9::2.5::HTS,BRD-A39935389-001-05-9,teroxirone,2.5,HTS,Exp_TCF3 (ENSG00000071564),GE,chemo,DNA inhibitor,,,,Phase 1,0.427347237303427,0.34809309168,teroxirone,OTHER,0.4239447960060244,3.2984245384970907,-3.547386607776501
BRD-A40940854-001-01-1::2.5::HTS,BRD-A40940854-001-01-1,ibuproxam,2.5,HTS,CRISPR_RAB6A (5870),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,ALOX5,"endocrinology, rheumatology, neurology/psychiatry","fever, joint inflammation, pain relief",Launched,0.268641969749881,0.153760293388,ibuproxam,OTHER,0.2845167858179711,-4.240728681158864,-1.308169545938452
BRD-A40940854-001-01-1::2.5::HTS,BRD-A40940854-001-01-1,ibuproxam,2.5,HTS,CRISPR_RAB6A (5870),AVANA_PUBLIC_18Q2,noncancer,prostaglandin inhibitor,ALOX5,"endocrinology, rheumatology, neurology/psychiatry","fever, joint inflammation, pain relief",Launched,0.268641969749881,0.153760293388,ibuproxam,OTHER,0.2845167858179711,-4.240728681158864,-1.308169545938452
BRD-A42699921-001-03-6::2.6::HTS,BRD-A42699921-001-03-6,teriflunomide,2.6,HTS,CN_CDH3 (1001),CN,noncancer,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,Launched,0.266132197835524,0.0973166570309,teriflunomide,OTHER,0.19408000079740528,3.94919330919986,-1.8085930604005367
BRD-A42746051-001-02-9::2.5::HTS,BRD-A42746051-001-02-9,melengestrol-acetate,2.5,HTS,DEM2_CLPB (81570),DEMETER2_COM,noncancer,progesterone receptor agonist,,,,Preclinical,0.24393560159670002,0.170729518114,melengestrol-acetate,OTHER,0.2641039383927454,-4.229356985495588,-2.677341821397996
BRD-A44500574-001-01-8::2.5::HTS,BRD-A44500574-001-01-8,FLI-06,2.5,HTS,Exp_CNKSR1 (ENSG00000142675),GE,targeted cancer,notch signaling inhibitor,,,,Preclinical,0.514217598009914,0.397976711727,FLI-06,OTHER,0.515268979202938,4.960814368292168,-1.5735214304016094
BRD-A45889380-300-07-1::2.5::HTS,BRD-A45889380-300-07-1,mepacrine,2.5,HTS,CRISPR_UCP1 (7350),AVANA_PUBLIC_18Q2,noncancer,cytokine production inhibitor,"PLA2G1B, PLA2G4A, PLA2G6, PLCL1",infectious disease,giardiasis,Launched,0.368938447738219,0.325602912477,mepacrine,OTHER,0.3545248048383378,-4.6472550626602445,-1.1846000449411584
BRD-A45889380-300-07-1::2.5::HTS,BRD-A45889380-300-07-1,mepacrine,2.5,HTS,CRISPR_UCP1 (7350),AVANA_PUBLIC_18Q2,noncancer,TP53 activator,"PLA2G1B, PLA2G4A, PLA2G6, PLCL1",infectious disease,giardiasis,Launched,0.368938447738219,0.325602912477,mepacrine,OTHER,0.3545248048383378,-4.6472550626602445,-1.1846000449411584
BRD-A46186775-369-02-0::2.5::HTS,BRD-A46186775-369-02-0,hydrocortisone-phosphate,2.5,HTS,Exp_FGF8 (ENSG00000107831),GE,targeted cancer,,"ANXA1, NOS2, NR3C1","pulmonary, gastroenterology, hematologic malignancy, ophthalmology","asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis",Launched,0.270316922770734,0.135273730552,hydrocortisone-phosphate,OTHER,0.2683180557059145,-3.788223676671652,-2.9367906989805554
BRD-A47953250-001-01-7::2.5::HTS,BRD-A47953250-001-01-7,ecamsule-triethanolamine,2.5,HTS,Exp_MYCN (ENSG00000134323),GE,noncancer,,,dermatology,"skin protectant, sunscreen lotion",Launched,0.304386592866114,0.242722064287,ecamsule-triethanolamine,OTHER,0.31376966058444605,4.847888718572559,-1.5597131367672477
BRD-A48237631-001-04-8::2.5::HTS,BRD-A48237631-001-04-8,mitomycin-c,2.5,HTS,PROT_XBP1_Caution,PROT,chemo,DNA alkylating agent,,oncology,"pancreatic cancer, gastric adenocarcinoma",Launched,0.398034889751289,0.253098043655,mitomycin-c,OTHER,0.3855028116154386,4.450207263728165,-0.9814233876031808
BRD-A48237631-001-04-8::2.5::HTS,BRD-A48237631-001-04-8,mitomycin-c,2.5,HTS,PROT_XBP1_Caution,PROT,chemo,DNA synthesis inhibitor,,oncology,"pancreatic cancer, gastric adenocarcinoma",Launched,0.398034889751289,0.253098043655,mitomycin-c,OTHER,0.3855028116154386,4.450207263728165,-0.9814233876031808
BRD-A49035384-003-28-9::2.39::HTS,BRD-A49035384-003-28-9,methacycline,2.39,HTS,MIRNA_hsa-miR-1266,MIRNA,noncancer,protein synthesis inhibitor,,pulmonary,bronchitis,Launched,0.368897447376822,0.0956589545942,methacycline,OTHER,0.3681165530854047,0.7052493202039496,-3.2335308304114263
BRD-A49358627-001-14-6::2.5::HTS,BRD-A49358627-001-14-6,ciprofibrate,2.5,HTS,DEM2_RECQL4 (9401),DEMETER2_COM,noncancer,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,Launched,0.25343698690426303,0.0448221992919,ciprofibrate,OTHER,0.2605795308086503,-4.351295433660701,-2.84990018984212
BRD-A50311610-300-10-4::2.5::HTS,BRD-A50311610-300-10-4,meclizine,2.5,HTS,Exp_TNFRSF21 (ENSG00000146072),GE,noncancer,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness",Launched,0.251281899297547,0.123344739317,meclizine,OTHER,0.25378577155349913,5.762441574146704,-0.0553740451110154
BRD-A51571244-001-01-9::2.5::HTS,BRD-A51571244-001-01-9,hypoestoxide,2.5,HTS,Exp_TFAP4 (ENSG00000090447),GE,targeted cancer,IKK inhibitor,"IKBKB, IL1B, TNF",,,Phase 1,0.336114385656543,0.220481457194,hypoestoxide,OTHER,0.3336078829627073,0.4299899341117226,-4.018798263667413
BRD-A51964809-003-12-6::2.5::HTS,BRD-A51964809-003-12-6,halofantrine,2.5,HTS,MIRNA_kshv-miR-K12-8,MIRNA,noncancer,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,Launched,0.331688581295445,0.0956183401133,halofantrine,OTHER,0.32072928441981563,4.457228245113086,-2.3243021721629287
BRD-A53151380-001-01-2::2.5::HTS,BRD-A53151380-001-01-2,prednisolone-tebutate,2.5,HTS,Exp_PLAC4 (ENSG00000225745),GE,noncancer,anti-inflammatory agent,,,,Launched,0.259792198942927,0.109089870812,prednisolone-tebutate,OTHER,0.2553093600452119,-4.17886907205028,-2.8823916192921013
BRD-A54927599-001-16-9::2.5::HTS,BRD-A54927599-001-16-9,KF-38789,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,P selectin inhibitor,SELP,,,Preclinical,0.409613876894231,0.341430521739,KF-38789,OTHER,0.410646235898906,5.629864562105608,-3.048246387084584
BRD-A55312468-001-04-7::1.24::HTS,BRD-A55312468-001-04-7,k-strophanthidin,1.24,HTS,METHYL_LTBP4,METHYL,targeted cancer,ATPase inhibitor,ATP1A1,,,Phase 2,0.33991981339639193,0.336750266431,k-strophanthidin,OTHER,0.3508652461380069,5.638307541334004,-1.8691733852377888
BRD-A55416093-001-06-4::2.5::MTS004,BRD-A55416093-001-06-4,colforsin,2.5,MTS004,DEM2_ARL8A (127829),DEMETER2_COM,targeted cancer,adenylyl cyclase activator,"ADCY2, ADCY5",,,Phase 2,0.291713922456788,0.0980944377618,colforsin,OTHER,0.2908400544826458,2.8073679767442887,0.7899574698261496
BRD-A55424491-001-19-9::2.5::HTS,BRD-A55424491-001-19-9,methotrexate,2.5,HTS,PROT_ASNS,PROT,chemo,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis",Launched,0.332646997346747,0.245486515292,methotrexate,OTHER,0.3352486217159817,4.135891606461302,-2.290373193022844
BRD-A55484088-050-02-5::2.5::HTS,BRD-A55484088-050-02-5,BNTX,2.5,HTS,PROT_Caveolin-1,PROT,noncancer,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,Preclinical,0.358296794656537,0.324684528841,BNTX,OTHER,0.35971424474068003,5.802200168905524,-1.6962769285860275
BRD-A58193911-003-18-7::2.5::HTS,BRD-A58193911-003-18-7,oxyphencyclimine,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),Launched,0.305076954654226,0.454095750641,oxyphencyclimine,OTHER,0.3049603988486184,4.327038686397928,-1.7594429380107002
BRD-A65449987-001-10-4::2.5::HTS,BRD-A65449987-001-10-4,flunisolide,2.5,HTS,PROT_TIGAR,PROT,noncancer,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis,Launched,0.291438111720032,0.106927756216,flunisolide,OTHER,0.27591518255054204,-3.612857205544424,-3.0822506101470117
BRD-A67748489-001-10-0::2.5::HTS,BRD-A67748489-001-10-0,K-858,2.5,HTS,DEM2_KIF11 (3832),DEMETER2_COM,targeted cancer,kinesin-like spindle protein inhibitor,KIF11,,,Preclinical,0.401745716160064,0.268859429532,K-858,OTHER,0.4097157628920486,4.925565049588563,-1.2386987951646873
BRD-A68083442-001-01-6::2.5::HTS,BRD-A68083442-001-01-6,pranidipine,2.5,HTS,METHYL_LOC101927243,METHYL,noncancer,calcium channel blocker,CACNA1C,,,Phase 2,0.319091724770939,0.0824007761193,pranidipine,OTHER,0.3271221624129245,0.5988982910775148,-3.3060392020473683
BRD-A68493689-001-01-9::2.5::HTS,BRD-A68493689-001-01-9,simeprevir,2.5,HTS,CRISPR_NLRP1 (22861),AVANA_PUBLIC_18Q2,noncancer,HCV inhibitor,"CYP1A2, CYP3A4",infectious disease,hepatitis C,Launched,0.30056906539588396,0.0440896789824,simeprevir,OTHER,0.2989765243969429,-3.889186605802033,-3.137476762158247
BRD-A68631409-001-05-4::2.5::HTS,BRD-A68631409-001-05-4,evodiamine,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,ATPase inhibitor,TRPV1,,,Preclinical,0.346363834765176,0.282365933521,evodiamine,OTHER,0.34790409579280585,6.110594529393829,-2.087674762312325
BRD-A68631409-001-05-4::2.5::HTS,BRD-A68631409-001-05-4,evodiamine,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,TRPV agonist,TRPV1,,,Preclinical,0.346363834765176,0.282365933521,evodiamine,OTHER,0.34790409579280585,6.110594529393829,-2.087674762312325
BRD-A69815203-001-07-6::2.5::HTS,BRD-A69815203-001-07-6,cyclosporin-a,2.5,HTS,Exp_RBM3 (ENSG00000102317),GE,noncancer,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis",Launched,0.328096024828078,0.139762653074,cyclosporin-a,OTHER,0.3443899978032907,1.1247724449702727,-3.0763924131734983
BRD-A72703248-003-04-9::2.5::HTS,BRD-A72703248-003-04-9,SKF-96365,2.5,HTS,Exp_TMEM255B (ENSG00000184497),GE,noncancer,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",,,Preclinical,0.368573255445981,0.279412183556,SKF-96365,OTHER,0.3672886590707028,4.957797857830569,-3.9615573520595335
BRD-A72711497-236-03-8::2.5::HTS,BRD-A72711497-236-03-8,lasalocid,2.5,HTS,Exp_TNFAIP6 (ENSG00000123610),GE,noncancer,bacterial permeability inducer,,infectious disease,coccidiosis,Launched,0.41789313366849495,0.298464772179,lasalocid,OTHER,0.4187306591097998,4.989558837890383,-1.0261818499298756
BRD-A73871920-236-03-6::2.5::HTS,BRD-A73871920-236-03-6,nanchangmycin,2.5,HTS,METABOL_carnitine,METABOL,noncancer,other antibiotic,,,,Preclinical,0.390094488678488,0.168478454238,nanchangmycin,OTHER,0.37073360966936775,4.432035002060621,-0.5696516752481728
BRD-A74914197-001-02-9::2.5::HTS,BRD-A74914197-001-02-9,pralatrexate,2.5,HTS,Exp_HMGN5 (ENSG00000198157),GE,targeted cancer,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Launched,0.37836061531506604,0.226859621975,pralatrexate,OTHER,0.37803310523795147,3.970053987944538,-2.8796677506861466
BRD-A75975749-001-01-4::2.5::MTS004,BRD-A75975749-001-01-4,bafetinib,2.5,MTS004,CRISPR_BRAF (673),AVANA_PUBLIC_18Q2,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR, LYN",,,Phase 2,0.40215959882747204,0.475446185411,bafetinib,OTHER,0.3942299940242819,0.6674558015465467,4.217434375942652
BRD-A75975749-001-01-4::2.5::MTS004,BRD-A75975749-001-01-4,bafetinib,2.5,MTS004,CRISPR_BRAF (673),AVANA_PUBLIC_18Q2,targeted cancer,LYN tyrosine kinase inhibitor,"ABL1, BCR, LYN",,,Phase 2,0.40215959882747204,0.475446185411,bafetinib,OTHER,0.3942299940242819,0.6674558015465467,4.217434375942652
BRD-A78965079-036-01-8::2.640168331::MTS004,BRD-A78965079-036-01-8,tafenoquine,2.640168331,MTS004,METABOL_5-adenosylhomocysteine,METABOL,noncancer,antimalarial agent,,,,Phase 3,0.35247034426292606,0.10138836915,tafenoquine,OTHER,0.3526339131869369,1.470433896136603,-0.6652607651783929
BRD-A81370665-001-03-6::2.5::HTS,BRD-A81370665-001-03-6,BI-D1870,2.5,HTS,Exp_UGT1A10 (ENSG00000242515),GE,noncancer,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",,,Preclinical,0.426651387072711,0.362541715801,BI-D1870,OTHER,0.4226988117712222,1.2651545501205264,-4.2663816374107215
BRD-A81541225-001-06-8::2.5::HTS,BRD-A81541225-001-06-8,oligomycin-a,2.5,HTS,Exp_C1QBP (ENSG00000108561),GE,noncancer,ATP synthase inhibitor,ATP5A1,,,Preclinical,0.33148976073063,0.290505275539,oligomycin-a,OTHER,0.3401273617088688,2.172754019186544,-2.5959425469420045
BRD-A81541225-001-06-8::2.5::HTS,BRD-A81541225-001-06-8,oligomycin-a,2.5,HTS,Exp_C1QBP (ENSG00000108561),GE,noncancer,ATPase inhibitor,ATP5A1,,,Preclinical,0.33148976073063,0.290505275539,oligomycin-a,OTHER,0.3401273617088688,2.172754019186544,-2.5959425469420045
BRD-A86619021-001-04-8::2.5::HTS,BRD-A86619021-001-04-8,andrographolide,2.5,HTS,PROT_alpha-Catenin,PROT,targeted cancer,tumor necrosis factor production inhibitor,NFKB1,,,Phase 2,0.33782508649216697,0.123245964655,andrographolide,OTHER,0.3378700553829307,0.4485964283873531,-3.893512169208916
BRD-A92439610-001-05-7::2.5::HTS,BRD-A92439610-001-05-7,triamcinolone-acetonide,2.5,HTS,Exp_ZNF738 (ENSG00000172687),GE,noncancer,immunosuppressant,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.26241012502140804,0.116154610103,triamcinolone-acetonide,OTHER,0.2598257683931729,-2.731376049909671,-3.257181662183739
BRD-A93093700-001-02-9::2.5::HTS,BRD-A93093700-001-02-9,temazepam,2.5,HTS,PROT_MDMX_MDM4(BetIHC-00108)_Caution,PROT,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",,,Withdrawn,0.3600011123810671,0.114489693342,temazepam,OTHER,0.3585079249221297,4.224905136481254,-1.2836122566239485
BRD-K00259736-001-16-4::2.5::HTS,BRD-K00259736-001-16-4,colchicine,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,noncancer,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever",Launched,0.42158284991051703,0.343206751193,colchicine,OTHER,0.4219535502522243,5.802952878740113,-2.4442728828490976
BRD-K00337317-001-06-6::2.5::HTS,BRD-K00337317-001-06-6,NU-7441,2.5,HTS,DEM2_GABARAP (11337),DEMETER2_COM,targeted cancer,DNA dependent protein kinase inhibitor,PRKDC,,,Preclinical,0.31788052907100295,0.0486830039204,NU-7441,OTHER,0.33120153278735154,0.8738656443530392,-1.3646249517524778
BRD-K00494077-066-01-9::2.5::HTS,BRD-K00494077-066-01-9,trovafloxacin,2.5,HTS,Exp_CHD4 (ENSG00000111642),GE,noncancer,bacterial DNA gyrase inhibitor,TOP2A,,,Withdrawn,0.168943707483948,0.154534315175,trovafloxacin,OTHER,0.1692810022745765,5.952380982710443,-2.2373062122547593
BRD-K00535541-001-05-5::2.5::HTS,BRD-K00535541-001-05-5,9-aminoacridine,2.5,HTS,Exp_NCAM1 (ENSG00000149294),GE,targeted cancer,,,,,Preclinical,0.234902473978447,0.249157675849,9-aminoacridine,OTHER,0.23469635012399406,4.087214726535483,-2.2385949178372826
BRD-K00535541-001-06-3::2.5::HTS,BRD-K00535541-001-06-3,9-aminoacridine,2.5,HTS,Exp_RAB34 (ENSG00000109113),GE,targeted cancer,,,,,Preclinical,0.234902473978447,0.249157675849,9-aminoacridine,OTHER,0.3224184335295563,4.397975443641274,-1.713675944202615
BRD-K00634421-001-01-0::2.500042819::MTS004,BRD-K00634421-001-01-0,brivaracetam,2.500042819,MTS004,Exp_ABCB1 (ENSG00000085563),GE,noncancer,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,Launched,0.323872047859926,0.465960524775,brivaracetam,OTHER,0.3296973809765913,5.376514918336286,-3.662398854983669
BRD-K01507359-001-22-9::2.5::HTS,BRD-K01507359-001-22-9,rifampin,2.5,HTS,CRISPR_RAB34 (83871),AVANA_PUBLIC_18Q2,noncancer,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis",Launched,0.31450749851379606,0.230508272932,rifampin,OTHER,0.3177120343287302,3.4008914455406534,-2.4518940296822125
BRD-K01624185-001-05-7::2.5::HTS,BRD-K01624185-001-05-7,maltobionic-acid,2.5,HTS,Exp_NPPC (ENSG00000163273),GE,noncancer,matrix metalloprotease inhibitor,,dermatology,cosmetic,Launched,0.31181881412615997,0.17773795057,maltobionic-acid,OTHER,0.3111491397543104,7.168750069180082,-2.0207417585839336
BRD-K01669786-001-02-2::2.5::HTS,BRD-K01669786-001-02-2,triapine,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,chemo,ribonucleotide reductase inhibitor,"RRM1, RRM2",,,Phase 2,0.3681833069553,0.310476896842,triapine,OTHER,0.3672013495591196,4.1800233780681735,-2.520943152076069
BRD-K01773560-001-02-4::2.59::HTS,BRD-K01773560-001-02-4,UNC2250,2.59,HTS,Exp_SMU1 (ENSG00000122692),GE,targeted cancer,MER tyrosine kinase inhibitor,MERTK,,,Preclinical,0.33563903360348807,0.315544851698,UNC2250,OTHER,0.33661057869565425,3.540361056549917,-4.150718362561591
BRD-K02017404-300-06-2::2.5::HTS,BRD-K02017404-300-06-2,NVP-BSK805,2.5,HTS,Exp_LINC00211 (ENSG00000237803),GE,targeted cancer,JAK inhibitor,JAK2,,,Preclinical,0.27307025148796105,0.0351583249629,NVP-BSK805,OTHER,0.2699548766099145,0.4731946242507176,-2.690008456375316
BRD-K02113016-001-15-4::2.5::HTS,BRD-K02113016-001-15-4,olaparib,2.5,HTS,Exp_KDM2B (ENSG00000089094),GE,targeted cancer,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,Launched,0.38269064337114705,0.276169329376,olaparib,OTHER,0.3787662727731039,2.465286319244268,-4.124437188738591
BRD-K02241333-001-02-7::2.5::HTS,BRD-K02241333-001-02-7,CHIR-124,2.5,HTS,Exp_ZFP3 (ENSG00000180787),GE,noncancer,CHK inhibitor,CHEK1,,,Preclinical,0.417469477659745,0.181323306438,CHIR-124,OTHER,0.41617280655093103,5.671232967953338,-0.19473710696980276
BRD-K02528732-001-02-4::2.425128585::MTS004,BRD-K02528732-001-02-4,fluorometholone-acetate,2.425128585,MTS004,PROT_RBM15,PROT,noncancer,,NR3C1,ophthalmology,eye inflammation,Launched,0.28515563158477897,0.0661487329481,fluorometholone-acetate,OTHER,0.2760338338838659,2.3330753449669825,4.726276745234582
BRD-K02764365-001-13-6::2.5::HTS,BRD-K02764365-001-13-6,methiazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,anthelmintic agent,,,,Preclinical,0.426491390323564,0.277707361124,methiazole,OTHER,0.425116372200637,5.2537625466143005,-3.3986095099003863
BRD-K02965346-001-07-5::2.5::HTS,BRD-K02965346-001-07-5,SU-11274,2.5,HTS,METABOL_cotinine,METABOL,targeted cancer,hepatocyte growth factor receptor inhibitor,MET,,,Preclinical,0.227018187785451,0.0917727076059,SU-11274,OTHER,0.2264569448892105,-5.760503135214508,1.4240516444900346
BRD-K02965346-001-07-5::2.5::HTS,BRD-K02965346-001-07-5,SU-11274,2.5,HTS,METABOL_cotinine,METABOL,targeted cancer,tyrosine kinase inhibitor,MET,,,Preclinical,0.227018187785451,0.0917727076059,SU-11274,OTHER,0.2264569448892105,-5.760503135214508,1.4240516444900346
BRD-K03063480-001-05-8::2.5::HTS,BRD-K03063480-001-05-8,PF-477736,2.5,HTS,Exp_ABCG2 (ENSG00000118777),GE,targeted cancer,CHK inhibitor,"CHEK1, CHEK2",,,Phase 1,0.39892247342584997,0.340072271555,PF-477736,OTHER,0.4022879513272519,4.466507721716564,-2.075202987648929
BRD-K03063480-001-06-6::2.42::HTS,BRD-K03063480-001-06-6,PF-477736,2.42,HTS,Exp_EDA2R (ENSG00000131080),GE,targeted cancer,CHK inhibitor,"CHEK1, CHEK2",,,Phase 1,0.39892247342584997,0.340072271555,PF-477736,OTHER,0.38542512748200203,5.1093303795768135,-1.0992658670078743
BRD-K03109492-001-02-2::2.5::HTS,BRD-K03109492-001-02-2,NSC-663284,2.5,HTS,Exp_GSTP1 (ENSG00000084207),GE,targeted cancer,CDC inhibitor,"CDC25A, CDC25B, CDC25C",,,Preclinical,0.4195528109153979,0.408758870024,NSC-663284,OTHER,0.4247105291719364,4.610982088248291,-1.3067170953052014
BRD-K03164761-001-02-1::2.5::HTS,BRD-K03164761-001-02-1,thiazovivin,2.5,HTS,PROT_Rab25,PROT,noncancer,rho associated kinase inhibitor,,,,Preclinical,0.323522236167967,0.175402389452,thiazovivin,OTHER,0.30848027687676244,5.707630636708772,1.1419376756397088
BRD-K03243820-001-23-8::2.37::HTS,BRD-K03243820-001-23-8,trifluridine,2.37,HTS,Exp_SUPT16H (ENSG00000092201),GE,chemo,DNA directed DNA polymerase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV),Launched,0.376715230307386,0.363443930095,trifluridine,OTHER,0.380651665025111,3.94309177253663,-3.2388711987940795
BRD-K03243820-001-23-8::2.37::HTS,BRD-K03243820-001-23-8,trifluridine,2.37,HTS,Exp_SUPT16H (ENSG00000092201),GE,chemo,thymidylate synthase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV),Launched,0.376715230307386,0.363443930095,trifluridine,OTHER,0.380651665025111,3.94309177253663,-3.2388711987940795
BRD-K03243820-001-25-3::2.5::HTS,BRD-K03243820-001-25-3,trifluridine,2.5,HTS,Exp_LTA4H (ENSG00000111144),GE,chemo,DNA directed DNA polymerase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV),Launched,0.376715230307386,0.363443930095,trifluridine,OTHER,0.3722083043224055,3.6622341566390015,-3.5348063957589293
BRD-K03243820-001-25-3::2.5::HTS,BRD-K03243820-001-25-3,trifluridine,2.5,HTS,Exp_LTA4H (ENSG00000111144),GE,chemo,thymidylate synthase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV),Launched,0.376715230307386,0.363443930095,trifluridine,OTHER,0.3722083043224055,3.6622341566390015,-3.5348063957589293
BRD-K03273112-001-01-8::2.5::HTS,BRD-K03273112-001-01-8,1-azakenpaullone,2.5,HTS,DEM2_EIF4G1 (1981),DEMETER2_COM,noncancer,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",,,Preclinical,0.31249779704499103,0.11581208668,1-azakenpaullone,OTHER,0.2883579127463332,-2.2131831267628503,0.9137911309308936
BRD-K03406345-001-27-8::2.5::HTS,BRD-K03406345-001-27-8,azacitidine,2.5,HTS,Exp_RGS16 (ENSG00000143333),GE,chemo,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)",Launched,0.28150666963459803,0.221953077311,azacitidine,OTHER,0.28087446088451673,3.541024658647161,-2.7336075755949456
BRD-K04394237-001-03-7::2.49::HTS,BRD-K04394237-001-03-7,drospirenone,2.49,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,Launched,0.414833385463885,0.211123461697,drospirenone,OTHER,0.4197150458414303,-3.582083994485957,-0.7984976856575852
BRD-K04430056-236-02-1::2.5::HTS,BRD-K04430056-236-02-1,7-nitroindazole,2.5,HTS,Exp_COX10 (ENSG00000006695),GE,noncancer,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,Preclinical,0.319361694262145,0.149524910925,7-nitroindazole,OTHER,0.31887262790806786,3.2916774324393256,-0.5863895366671588
BRD-K04568635-300-01-4::2.5::HTS,BRD-K04568635-300-01-4,octenidine,2.5,HTS,Exp_ABCC3 (ENSG00000108846),GE,noncancer,membrane integrity inhibitor,,,,Launched,0.356782624217653,0.365087717223,octenidine,OTHER,0.3570362947725316,3.638474337248665,-1.6736673911131446
BRD-K04603573-376-01-3::2.542651982::MTS004,BRD-K04603573-376-01-3,"1,12-Besm",2.542651982,MTS004,Exp_ABLIM1 (ENSG00000099204),GE,targeted cancer,polyamine biosynthesis inhibitor,,,,Phase 2,0.3376194570024289,0.252284762543,"1,12-Besm",OTHER,0.3411587639979148,-3.761769334110193,-1.426486240668147
BRD-K04701033-001-04-7::2.499987566::MTS004,BRD-K04701033-001-04-7,VE-822,2.499987566,MTS004,Exp_LBR (ENSG00000143815),GE,targeted cancer,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",,,Phase 2,0.361566975001654,0.33195152746,VE-822,OTHER,0.3613074433910049,5.0790161841347095,-2.6736121558974446
BRD-K04833372-001-06-2::2.5::HTS,BRD-K04833372-001-06-2,GSK1904529A,2.5,HTS,Exp_HSF2 (ENSG00000025156),GE,targeted cancer,IGF-1 inhibitor,"IGF1R, INSR",,,Preclinical,0.326243589281663,0.137021825162,GSK1904529A,OTHER,0.3274430805622233,0.9318535054566256,-3.3809891456397123
BRD-K04833372-001-06-2::2.5::HTS,BRD-K04833372-001-06-2,GSK1904529A,2.5,HTS,Exp_HSF2 (ENSG00000025156),GE,targeted cancer,insulin growth factor receptor inhibitor,"IGF1R, INSR",,,Preclinical,0.326243589281663,0.137021825162,GSK1904529A,OTHER,0.3274430805622233,0.9318535054566256,-3.3809891456397123
BRD-K04833372-001-06-2::2.5::HTS,BRD-K04833372-001-06-2,GSK1904529A,2.5,HTS,Exp_HSF2 (ENSG00000025156),GE,targeted cancer,insulin receptor ligand,"IGF1R, INSR",,,Preclinical,0.326243589281663,0.137021825162,GSK1904529A,OTHER,0.3274430805622233,0.9318535054566256,-3.3809891456397123
BRD-K04923131-001-15-4::2.5::HTS,BRD-K04923131-001-15-4,GSK-3-inhibitor-IX,2.5,HTS,Exp_QSOX2 (ENSG00000165661),GE,targeted cancer,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",,,Preclinical,0.39302375838269504,0.241526968344,GSK-3-inhibitor-IX,OTHER,0.3897712563070901,-2.1910431025325803,0.844123172018082
BRD-K04923131-001-15-4::2.5::HTS,BRD-K04923131-001-15-4,GSK-3-inhibitor-IX,2.5,HTS,Exp_QSOX2 (ENSG00000165661),GE,targeted cancer,lipoxygenase inhibitor,"GSK3A, GSK3B",,,Preclinical,0.39302375838269504,0.241526968344,GSK-3-inhibitor-IX,OTHER,0.3897712563070901,-2.1910431025325803,0.844123172018082
BRD-K04993719-001-01-7::2.5::HTS,BRD-K04993719-001-01-7,LY2334737,2.5,HTS,DEM2_TFEC (22797),DEMETER2_COM,chemo,antitumor agent,,,,Phase 1,0.456722875665507,0.179442760519,LY2334737,OTHER,0.4541989570203829,-3.4122554221205306,-0.8753729409748812
BRD-K04993719-001-01-7::2.5::HTS,BRD-K04993719-001-01-7,LY2334737,2.5,HTS,DEM2_TFEC (22797),DEMETER2_COM,chemo,ribonucleotide reductase inhibitor,,,,Phase 1,0.456722875665507,0.179442760519,LY2334737,OTHER,0.4541989570203829,-3.4122554221205306,-0.8753729409748812
BRD-K05444225-001-01-7::2.5::HTS,BRD-K05444225-001-01-7,E7449,2.5,HTS,CN_FAM181B (220382),CN,targeted cancer,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",,,Phase 1/Phase 2,0.281027587887354,0.109249152786,E7449,OTHER,0.2801350794594549,2.5345378817457087,0.11279200866895026
BRD-K05446112-001-01-8::2.5::HTS,BRD-K05446112-001-01-8,ledipasvir,2.5,HTS,Exp_TMEM155 (ENSG00000164112),GE,noncancer,HCV inhibitor,,infectious disease,hepatitis C,Launched,0.28663729464144605,0.29331498732,ledipasvir,OTHER,0.2857906099907198,-5.455122198422616,-1.0131222945200786
BRD-K05524748-003-04-4::2.5::HTS,BRD-K05524748-003-04-4,dronedarone,2.5,HTS,PROT_alpha-Catenin,PROT,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),Launched,0.209844795982416,0.161198997608,dronedarone,OTHER,0.2278436243559641,2.501787834981454,-3.91695675528948
BRD-K06222852-001-03-2::2.5::HTS,BRD-K06222852-001-03-2,posaconazole,2.5,HTS,CRISPR_WDR24 (84219),AVANA_PUBLIC_18Q2,noncancer,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,Launched,0.323222216071676,0.0803309655141,posaconazole,OTHER,0.30053166239183376,2.509018745317019,-2.8246500111014106
BRD-K06294530-001-01-5::2.5::HTS,BRD-K06294530-001-01-5,UK-383367,2.5,HTS,PROT_C-Raf_pS338,PROT,noncancer,Procollagen C-Endopeptidase Inhibitors,BMP1,,,Phase 1,0.313084682104484,0.176036921602,UK-383367,OTHER,0.32690684432446565,-3.608441745296461,-0.8384278901686959
BRD-K06408664-001-03-5::2.5::HTS,BRD-K06408664-001-03-5,fludrocortisone-acetate,2.5,HTS,PROT_RBM15,PROT,noncancer,,"AR, NR3C1, NR3C2",endocrinology,"Addison's disease, adrenogenital syndrome",Launched,0.30094976711311305,0.0830624949949,fludrocortisone-acetate,OTHER,0.2990600450696257,-2.0585320614330604,-2.9504377010889167
BRD-K06519765-001-01-1::2.5::MTS004,BRD-K06519765-001-01-1,vinblastine,2.5,MTS004,Exp_TBPL1 (ENSG00000028839),GE,chemo,microtubule inhibitor,"JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma",Launched,0.374307588486506,0.402916330164,vinblastine,OTHER,0.3763534084842421,5.672617216773956,-3.807764284022219
BRD-K06543683-066-02-1::2.5::HTS,BRD-K06543683-066-02-1,bisindolylmaleimide-ix,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",,,Preclinical,0.418383426722534,0.484855934981,bisindolylmaleimide-ix,OTHER,0.4161579288460412,4.2898232771182325,-2.5593926212919293
BRD-K06749501-001-02-1::2.5::HTS,BRD-K06749501-001-02-1,GSK1838705A,2.5,HTS,Exp_ST6GAL1 (ENSG00000073849),GE,targeted cancer,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",,,Preclinical,0.33028622574550504,0.166291407194,GSK1838705A,OTHER,0.3749829292287016,2.157246285957804,-3.0445743924509414
BRD-K06858286-001-01-3::2.5::HTS,BRD-K06858286-001-01-3,cabazitaxel,2.5,HTS,PROT_mTOR_pS2448_Caution,PROT,chemo,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,Launched,0.419722438727628,0.226340289168,cabazitaxel,OTHER,0.4136556066589647,5.139944204404794,-2.4725478752576766
BRD-K07106112-003-03-8::2.5::HTS,BRD-K07106112-003-03-8,BMS-599626,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,protein tyrosine kinase inhibitor,"EGFR, ERBB2, ERBB4",,,Phase 1,0.44817107663452505,0.458812662162,BMS-599626,OTHER,0.4247440304764435,1.0136431900793197,-5.059065347105403
BRD-K07265709-003-05-6::2.61::HTS,BRD-K07265709-003-05-6,dexrazoxane,2.61,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,chelating agent,"TOP2A, TOP2B",cardiology,cardiomyopathy,Launched,0.376644810533462,0.388675733791,dexrazoxane,OTHER,0.3758012866050104,5.041303594211862,-3.5743663961363947
BRD-K07487750-001-03-3::2.5::HTS,BRD-K07487750-001-03-3,WHI-P154,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",,,Preclinical,0.346733784424112,0.323532912014,WHI-P154,OTHER,0.3256891773590692,0.8241431519540047,-5.1683183824541015
BRD-K07572174-001-39-4::2.48::HTS,BRD-K07572174-001-39-4,curcumin,2.48,HTS,Exp_UGT1A10 (ENSG00000242515),GE,targeted cancer,cyclooxygenase inhibitor,"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",,,Launched,0.37832256278215104,0.460146229389,curcumin,OTHER,0.3789770977073541,4.075380820463593,-3.5193950398683675
BRD-K07572174-001-39-4::2.48::HTS,BRD-K07572174-001-39-4,curcumin,2.48,HTS,Exp_UGT1A10 (ENSG00000242515),GE,targeted cancer,histone acetyltransferase inhibitor,"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",,,Launched,0.37832256278215104,0.460146229389,curcumin,OTHER,0.3789770977073541,4.075380820463593,-3.5193950398683675
BRD-K07572174-001-39-4::2.48::HTS,BRD-K07572174-001-39-4,curcumin,2.48,HTS,Exp_UGT1A10 (ENSG00000242515),GE,targeted cancer,lipoxygenase inhibitor,"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",,,Launched,0.37832256278215104,0.460146229389,curcumin,OTHER,0.3789770977073541,4.075380820463593,-3.5193950398683675
BRD-K07762753-001-04-4::2.5::HTS,BRD-K07762753-001-04-4,aminopurvalanol-a,2.5,HTS,Exp_DCTN3 (ENSG00000137100),GE,targeted cancer,tyrosine kinase inhibitor,"CDK1, CDK2, CDK5, CDK6",,,Preclinical,0.311502836085631,0.183284558968,aminopurvalanol-a,OTHER,0.3124725757388038,4.634481409922142,-2.1105525080986176
BRD-K07881437-001-03-8::2.5::HTS,BRD-K07881437-001-03-8,danusertib,2.5,HTS,PROT_XBP1_Caution,PROT,targeted cancer,growth factor receptor inhibitor,"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",,,Phase 2,0.3824475784492079,0.335628589551,danusertib,OTHER,0.2837208582858569,4.649412073545898,-2.300150941263573
BRD-K07881437-001-04-6::2.41::HTS,BRD-K07881437-001-04-6,danusertib,2.41,HTS,PROT_HER3,PROT,targeted cancer,growth factor receptor inhibitor,"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",,,Phase 2,0.3824475784492079,0.335628589551,danusertib,OTHER,0.3831285169133298,4.807608421263585,-2.115120817832654
BRD-K08078237-001-19-8::2.5::HTS,BRD-K08078237-001-19-8,tetrandrine,2.5,HTS,Exp_PMEL (ENSG00000185664),GE,targeted cancer,calcium channel blocker,SLC6A3,,,Preclinical,0.39961950152674197,0.305633865108,tetrandrine,OTHER,0.3996904634177592,5.073194231686816,-0.8605365484963716
BRD-K08525451-003-05-2::2.5::HTS,BRD-K08525451-003-05-2,sarafloxacin,2.5,HTS,Exp_MT1H (ENSG00000205358),GE,noncancer,bacterial DNA gyrase inhibitor,,,,Launched,0.275684876441668,0.120655945685,sarafloxacin,OTHER,0.2754721164812623,3.8038578107247942,-1.0891570624673037
BRD-K08542803-001-03-1::0.8::HTS,BRD-K08542803-001-03-1,gambogic-acid,0.8,HTS,METHYL_CCNI2,METHYL,targeted cancer,caspase activator,BCL2,,,Phase 2,0.363980498623811,0.229874026189,gambogic-acid,OTHER,0.3704107553583408,3.9316486335822334,-0.9546035402306554
BRD-K08586861-001-01-1::2.5::HTS,BRD-K08586861-001-01-1,ramatroban,2.5,HTS,PROT_beta-Catenin_pT41_S45,PROT,noncancer,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",Launched,0.222284497229115,0.0853215374027,ramatroban,OTHER,0.15583115451443838,5.3773527995164665,-0.8691576767590679
BRD-K08996725-332-01-7::2.5::HTS,BRD-K08996725-332-01-7,zolantidine,2.5,HTS,PROT_JAK2,PROT,noncancer,histamine receptor antagonist,,,,Preclinical,0.3624253542741379,0.20257393044,zolantidine,OTHER,0.36608438485053535,2.683421157524275,-4.365336215249126
BRD-K09090949-001-01-9::2.5::HTS,BRD-K09090949-001-01-9,"CP-945,598",2.5,HTS,METHYL_NR1H3,METHYL,noncancer,cannabinoid receptor antagonist,CNR1,,,Phase 3,0.25658612445524104,0.10945958112,"CP-945,598",OTHER,0.2005051085794207,3.456077590228372,-0.4283269609694593
BRD-K09372874-001-01-0::2.5::HTS,BRD-K09372874-001-01-0,merimepodib,2.5,HTS,Exp_MYLK (ENSG00000065534),GE,noncancer,inosine monophosphate dehydrogenase inhibitor,IMPDH1,,,Phase 2,0.32617878499386,0.275649940659,merimepodib,OTHER,0.32594435564167384,3.847517653443197,-2.2761791500279647
BRD-K09821361-066-25-8::2.499990088::MTS004,BRD-K09821361-066-25-8,deferoxamine-mesylate,2.499990088,MTS004,CN_SPINT4 (391253),CN,noncancer,chelating agent,,hematology,"acute iron intoxication, iron overload",Launched,0.298398264005396,-0.0034634471225,deferoxamine-mesylate,OTHER,0.29791925480310205,-3.853495114918567,1.1642546665831366
BRD-K09877029-001-01-2::2.5::HTS,BRD-K09877029-001-01-2,VS-4718,2.5,HTS,Exp_CDKN2D (ENSG00000129355),GE,targeted cancer,focal adhesion kinase inhibitor,,,,Phase 1,0.316441479030099,0.273974549238,VS-4718,OTHER,0.31329037113625763,3.7852248126894494,-3.0133686052426256
BRD-K10071630-001-01-0::2.5::HTS,BRD-K10071630-001-01-0,ertugliflozin,2.5,HTS,METHYL_MIR5100,METHYL,noncancer,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,Launched,0.284696636704232,0.11255913075,ertugliflozin,OTHER,0.2857294587432616,3.061609915564065,-2.649102293698066
BRD-K10961822-001-05-1::2.5::HTS,BRD-K10961822-001-05-1,latanoprost,2.5,HTS,Exp_OMP (ENSG00000254550),GE,noncancer,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",Launched,0.308548992801302,0.209526073675,latanoprost,OTHER,0.2962948535223808,4.153185950907941,-0.4203745111658312
BRD-K11267252-001-04-4::2.5::HTS,BRD-K11267252-001-04-4,alectinib,2.5,HTS,PROT_JAK2,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),Launched,0.32881545868913203,0.179164304864,alectinib,OTHER,0.3232365058427085,5.560517825169137,-1.0651359222754304
BRD-K11630072-001-13-2::2.5::HTS,BRD-K11630072-001-13-2,carmofur,2.5,HTS,PROT_HSP70_Caution,PROT,targeted cancer,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer",Launched,0.325861016843475,0.286782765024,carmofur,OTHER,0.3244132441740765,3.9483386588459055,-2.10117994265139
BRD-K11851476-003-01-7::2.499993171::MTS004,BRD-K11851476-003-01-7,pardoprunox,2.499993171,MTS004,Exp_ABCB1 (ENSG00000085563),GE,noncancer,serotonin receptor agonist,"DRD2, DRD3, DRD4, HTR1A, HTR7",,,Phase 3,0.393002187788966,0.431069360903,pardoprunox,OTHER,0.39620888229269213,5.337860056534098,-3.793736336661188
BRD-K11851476-003-01-7::2.499993171::MTS004,BRD-K11851476-003-01-7,pardoprunox,2.499993171,MTS004,Exp_ABCB1 (ENSG00000085563),GE,noncancer,dopamine receptor agonist,"DRD2, DRD3, DRD4, HTR1A, HTR7",,,Phase 3,0.393002187788966,0.431069360903,pardoprunox,OTHER,0.39620888229269213,5.337860056534098,-3.793736336661188
BRD-K11973162-003-01-8::2.5::HTS,BRD-K11973162-003-01-8,tipiracil,2.5,HTS,PROT_Caveolin-1,PROT,targeted cancer,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Launched,0.19880449239056502,0.135036950491,tipiracil,OTHER,0.20515140136704405,5.354970185194693,2.362733336399501
BRD-K12502280-001-08-0::2.5::HTS,BRD-K12502280-001-08-0,TG-101348,2.5,HTS,CRISPR_NCCRP1 (342897),AVANA_PUBLIC_18Q2,targeted cancer,FLT3 inhibitor,"BRD4, JAK1, JAK2, JAK3, TYK2",,,Phase 3,0.28473987190713695,0.174616344486,TG-101348,OTHER,0.2884233313840727,0.7424202011856487,-2.9425849699761932
BRD-K12502280-001-08-0::2.5::HTS,BRD-K12502280-001-08-0,TG-101348,2.5,HTS,CRISPR_NCCRP1 (342897),AVANA_PUBLIC_18Q2,targeted cancer,JAK inhibitor,"BRD4, JAK1, JAK2, JAK3, TYK2",,,Phase 3,0.28473987190713695,0.174616344486,TG-101348,OTHER,0.2884233313840727,0.7424202011856487,-2.9425849699761932
BRD-K12762134-001-06-2::2.5::HTS,BRD-K12762134-001-06-2,XAV-939,2.5,HTS,Exp_LINC00472 (ENSG00000233237),GE,targeted cancer,tankyrase inhibitor,"TNKS, TNKS2",,,Preclinical,0.33750790706581707,0.205146172479,XAV-939,OTHER,0.3342362287111818,-4.557079436065345,0.07283770236442955
BRD-K12787259-001-04-3::2.5::HTS,BRD-K12787259-001-04-3,CX-5461,2.5,HTS,Exp_HEATR1 (ENSG00000119285),GE,targeted cancer,RNA polymerase inhibitor,,,,Phase 1,0.33726960179167403,0.316719531732,CX-5461,OTHER,0.338163199894902,3.4669426188436976,-3.6476238556222333
BRD-K12829205-003-02-8::2.5::HTS,BRD-K12829205-003-02-8,mechlorethamine,2.5,HTS,Exp_DDN (ENSG00000181418),GE,chemo,DNA inhibitor,,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma",Launched,0.385635241747264,0.375757868176,mechlorethamine,OTHER,0.3869383796560793,3.6805037081389465,-2.358975848207721
BRD-K12885236-001-02-7::2.5::HTS,BRD-K12885236-001-02-7,dapivirine,2.5,HTS,Exp_TMEM69 (ENSG00000159596),GE,noncancer,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",,,Phase 3,0.351161970783729,0.226586628858,dapivirine,OTHER,0.3224853202762428,3.468560924651423,-1.5956684860882395
BRD-K13044802-213-20-7::2.5::HTS,BRD-K13044802-213-20-7,ciclopirox,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,noncancer,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,Launched,0.355873088668969,0.264431587481,ciclopirox,OTHER,0.35902740488371226,3.973128313061404,-2.5934557150668542
BRD-K13049116-001-05-7::2.5::HTS,BRD-K13049116-001-05-7,BMS-754807,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,IGF-1 inhibitor,"AKT1, IGF1R",,,Phase 2,0.40598626536087,0.250620086602,BMS-754807,OTHER,0.4030339740763488,3.7879060779073863,-3.1365538227192338
BRD-K13050541-001-01-9::2.8::HTS,BRD-K13050541-001-01-9,acivicin,2.8,HTS,Exp_SLC7A5 (ENSG00000103257),GE,targeted cancer,gamma glutamyltransferase Inhibitors,CTPS1,,,Phase 2,0.36325696129268603,0.311570553809,acivicin,OTHER,0.3639229518677984,3.9902930479341854,-0.7685524658794844
BRD-K13112821-001-17-4::2.5::HTS,BRD-K13112821-001-17-4,artemisinin,2.5,HTS,CN_ZNF670-ZNF695 (100533111),CN,noncancer,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,Launched,0.36541727704959703,0.211390509824,artemisinin,OTHER,0.36387307723033896,1.7048980783978287,-3.214504362036555
BRD-K13183738-317-10-2::2.5::HTS,BRD-K13183738-317-10-2,pentamidine,2.5,HTS,Exp_SLC47A1 (ENSG00000142494),GE,noncancer,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,Launched,0.38662095358613796,0.387862016232,pentamidine,OTHER,0.3865069972529797,2.6081869835000373,-2.026545440738759
BRD-K13249881-001-02-3::2.5::HTS,BRD-K13249881-001-02-3,piperazine,2.5,HTS,Exp_DANCR (ENSG00000226950),GE,noncancer,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,Launched,0.193561873659728,0.137196592661,piperazine,OTHER,0.19323644032625967,4.594821329068331,-2.080687162495044
BRD-K13387373-004-14-5::2.5::HTS,BRD-K13387373-004-14-5,thonzonium,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,ATPase inhibitor,,,,Launched,0.38955381784945897,0.470902073974,thonzonium,OTHER,0.3869897896603857,3.0333995385857557,-2.2502656295647867
BRD-K13409143-001-01-9::2.5::HTS,BRD-K13409143-001-01-9,isopropyl-myristate,2.5,HTS,METHYL_GRIPAP1,METHYL,noncancer,,,dermatology,cosmetic,Launched,0.321742416788566,0.0424603447657,isopropyl-myristate,OTHER,0.3229660012017448,1.5134084133747572,-1.7512955272542623
BRD-K13533483-001-16-2::2.5::MTS004,BRD-K13533483-001-16-2,cyclosporine,2.5,MTS004,CN_TRIM32 (22954),CN,noncancer,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis",Launched,0.383068804770557,0.0503966574231,cyclosporine,OTHER,0.3811751572742466,2.8547977432446814,-0.7061593959277177
BRD-K13566078-001-02-3::2.5::HTS,BRD-K13566078-001-02-3,BMS-345541,2.5,HTS,Exp_GPX3 (ENSG00000211445),GE,targeted cancer,IKK inhibitor,"CHUK, IKBKB",,,Preclinical,0.360255229666415,0.186969702123,BMS-345541,OTHER,0.3573714518428191,5.595968672528417,-2.999342942970878
BRD-K13606314-001-01-3::2.5::HTS,BRD-K13606314-001-01-3,P5091,2.5,HTS,Exp_LRRC49 (ENSG00000137821),GE,targeted cancer,ubiquitin specific protease inhibitor,USP7,,,Preclinical,0.425176890608056,0.250068608242,P5091,OTHER,0.4283035715908117,1.6308433984167934,1.231765252697152
BRD-K13646352-001-03-8::2.5::HTS,BRD-K13646352-001-03-8,midostaurin,2.5,HTS,MIRNA_hsa-miR-375,MIRNA,targeted cancer,FLT3 inhibitor,"FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),Launched,0.358993650561106,0.262333430793,midostaurin,OTHER,0.3640559995471973,4.388920721349135,-1.51697061903397
BRD-K13646352-001-03-8::2.5::HTS,BRD-K13646352-001-03-8,midostaurin,2.5,HTS,MIRNA_hsa-miR-375,MIRNA,targeted cancer,KIT inhibitor,"FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),Launched,0.358993650561106,0.262333430793,midostaurin,OTHER,0.3640559995471973,4.388920721349135,-1.51697061903397
BRD-K13646352-001-03-8::2.5::HTS,BRD-K13646352-001-03-8,midostaurin,2.5,HTS,MIRNA_hsa-miR-375,MIRNA,targeted cancer,PKC inhibitor,"FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),Launched,0.358993650561106,0.262333430793,midostaurin,OTHER,0.3640559995471973,4.388920721349135,-1.51697061903397
BRD-K13756951-001-01-4::2.5::HTS,BRD-K13756951-001-01-4,bitopertin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,glycine transporter inhibitor,"SLC6A5, SLC6A9",,,Phase 3,0.40516880032875396,0.440927204996,bitopertin,OTHER,0.4034463636026648,4.997173004159649,-3.7439200909514887
BRD-K13756951-001-01-4::2.5::HTS,BRD-K13756951-001-01-4,bitopertin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,GlyT-1 inhibitor,"SLC6A5, SLC6A9",,,Phase 3,0.40516880032875396,0.440927204996,bitopertin,OTHER,0.4034463636026648,4.997173004159649,-3.7439200909514887
BRD-K13949769-001-01-7::2.5::HTS,BRD-K13949769-001-01-7,tenovin-6,2.5,HTS,METHYL_AGAP2-AS1,METHYL,targeted cancer,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",,,Preclinical,0.30744367784912396,0.132407574955,tenovin-6,OTHER,0.3178222532877105,2.7768326617965893,-3.6739737557992456
BRD-K14109347-001-03-4::2.5::HTS,BRD-K14109347-001-03-4,LY2603618,2.5,HTS,DEM2_CHEK1 (1111),DEMETER2_COM,targeted cancer,CHK inhibitor,CHEK1,,,Phase 2,0.43790491305785706,0.283388030615,LY2603618,OTHER,0.40612419308907466,5.146764576013639,-0.9271317578562992
BRD-K14529030-001-01-9::2.5::HTS,BRD-K14529030-001-01-9,meisoindigo,2.5,HTS,CRISPR_DYNLRB1 (83658),AVANA_PUBLIC_18Q2,targeted cancer,STAT inhibitor,STAT3,,,Phase 3,0.352935903885762,0.164592975409,meisoindigo,OTHER,0.3487733091041316,-1.8709779806976927,0.7266174419023008
BRD-K14560436-001-01-4::2.5::HTS,BRD-K14560436-001-01-4,TG-02,2.5,HTS,CN_SLC7A6 (9057),CN,targeted cancer,FLT3 inhibitor,"CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",,,Phase 1,0.416665039453543,0.198016287339,TG-02,OTHER,0.41215569180391415,5.044221500614257,-0.7693097555773051
BRD-K14560436-001-01-4::2.5::HTS,BRD-K14560436-001-01-4,TG-02,2.5,HTS,CN_SLC7A6 (9057),CN,targeted cancer,JAK inhibitor,"CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",,,Phase 1,0.416665039453543,0.198016287339,TG-02,OTHER,0.41215569180391415,5.044221500614257,-0.7693097555773051
BRD-K14618467-001-04-6::2.5::HTS,BRD-K14618467-001-04-6,IKK-16,2.5,HTS,MUTpool_THAP3 (90326),MUTpool,noncancer,IKK inhibitor,IKBKB,,,Preclinical,0.30226862251058506,0.223504168775,IKK-16,OTHER,0.3001428569243834,4.231819323058535,-1.5400106977272867
BRD-K14658796-003-01-6::2.368766292::MTS004,BRD-K14658796-003-01-6,drotaverine,2.368766292,MTS004,Exp_TRIM14 (ENSG00000106785),GE,noncancer,phosphodiesterase inhibitor,"CACNA1C, PDE4A",obstetrics/gynecology,labor induction,Launched,0.330355322360047,0.236985529942,drotaverine,OTHER,0.32872435590243737,5.4893068638904365,-0.2699826940888661
BRD-K14796088-003-26-8::2.5::HTS,BRD-K14796088-003-26-8,berberine,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,LDL receptor activator,LDLR,,,Phase 2/Phase 3,0.34249593984868293,0.295339156992,berberine,OTHER,0.3424558995552177,2.724739603099648,-2.200329055215009
BRD-K14991967-001-02-6::2.5::HTS,BRD-K14991967-001-02-6,GSK650394,2.5,HTS,CN_ARHGEF28 (64283),CN,targeted cancer,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",,,Preclinical,0.321801164666881,0.0853988388614,GSK650394,OTHER,0.32058229016981765,1.7035619458704645,-3.9857023396227347
BRD-K15108141-001-06-6::2.5::HTS,BRD-K15108141-001-06-6,gemcitabine,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,chemo,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer",Launched,0.340960428157479,0.249943274074,gemcitabine,OTHER,0.34141906861412313,4.831069482434648,-1.8557826700642612
BRD-K15179513-001-03-4::2.5::HTS,BRD-K15179513-001-03-4,NVP-ADW742,2.5,HTS,PROT_PTEN,PROT,targeted cancer,insulin growth factor receptor inhibitor,IGF1R,,,Preclinical,0.36085617938086706,0.105573574517,NVP-ADW742,OTHER,0.30201954406532106,-6.0336938481826285,2.6641402257861517
BRD-K15409150-001-05-8::2.5::HTS,BRD-K15409150-001-05-8,penfluridol,2.5,HTS,METHYL_CIART,METHYL,noncancer,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,Launched,0.26888325917211703,0.160002975964,penfluridol,OTHER,0.2754230643099099,3.7031220909043583,-0.22031852812098496
BRD-K15424032-001-03-6::2.5::HTS,BRD-K15424032-001-03-6,SB-228357,2.5,HTS,PROT_B-Raf_Caution,PROT,noncancer,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,Preclinical,0.44793226917337897,0.156500642366,SB-228357,OTHER,0.4455826641253263,-0.028113562323769745,-3.1982292528693788
BRD-K15567136-003-27-2::2.5::HTS,BRD-K15567136-003-27-2,papaverine,2.5,HTS,Exp_SYT13 (ENSG00000019505),GE,noncancer,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",Launched,0.288342568012135,0.14726664477,papaverine,OTHER,0.28746773419000793,2.040441812505171,-2.202669252365336
BRD-K15600710-066-04-1::2.5::HTS,BRD-K15600710-066-04-1,obatoclax,2.5,HTS,METHYL_DGKD,METHYL,targeted cancer,BCL inhibitor,BCL2,,,Phase 3,0.37003700679398,0.0343672997725,obatoclax,OTHER,0.3724238803541881,4.804518881781472,-0.8283557647110906
BRD-K15898725-001-01-7::2.5::HTS,BRD-K15898725-001-01-7,maytansinol-isobutyrate,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,,,,,Preclinical,0.38260056000243203,0.339536221147,maytansinol-isobutyrate,OTHER,0.3811845384802369,6.122465840644442,-2.511465164058854
BRD-K16180792-001-01-7::2.5::MTS004,BRD-K16180792-001-01-7,bis(maltolato)oxovanadium(IV),2.5,MTS004,Exp_SLC26A2 (ENSG00000155850),GE,noncancer,tyrosine phosphatase inhibitor,PTPN1,,,Phase 2,0.472699909819384,0.619736235827,bis(maltolato)oxovanadium(IV),OTHER,0.47641199103346,1.7702534768880485,4.096371307036435
BRD-K16189898-003-03-3::2.5::HTS,BRD-K16189898-003-03-3,CHIR-99021,2.5,HTS,CN_ADAMTSL3 (57188),CN,noncancer,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",,,Preclinical,0.285384222317295,0.12448760177,CHIR-99021,OTHER,0.2901421277643567,-2.7071453080551757,0.9666302802847068
BRD-K16551357-001-03-2::2.5::HTS,BRD-K16551357-001-03-2,evacetrapib,2.5,HTS,PROT_Src_pY527,PROT,noncancer,cholesteryl ester transfer protein inhibitor,CETP,,,Phase 3,0.355282526845651,0.123527353966,evacetrapib,OTHER,0.3614810603329596,0.5088452944818743,-3.4460505846432445
BRD-K16664969-001-03-3::2.5::HTS,BRD-K16664969-001-03-3,GTP-14564,2.5,HTS,Exp_CHTOP (ENSG00000160679),GE,targeted cancer,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRB",,,Preclinical,0.306188202151403,0.139715396369,GTP-14564,OTHER,0.30337297595092416,-1.2757643109296586,0.9203131718675964
BRD-K16664969-001-03-3::2.5::HTS,BRD-K16664969-001-03-3,GTP-14564,2.5,HTS,Exp_CHTOP (ENSG00000160679),GE,targeted cancer,tyrosine kinase inhibitor,"CSF1R, FLT3, KIT, PDGFRB",,,Preclinical,0.306188202151403,0.139715396369,GTP-14564,OTHER,0.30337297595092416,-1.2757643109296586,0.9203131718675964
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,Exp_ZNRF2 (ENSG00000180233),GE,targeted cancer,FGFR inhibitor,"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",Launched,0.369487062757553,0.255733352647,regorafenib,OTHER,0.3656727555796573,2.511458387751837,-1.1836226477704903
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,Exp_ZNRF2 (ENSG00000180233),GE,targeted cancer,KIT inhibitor,"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",Launched,0.369487062757553,0.255733352647,regorafenib,OTHER,0.3656727555796573,2.511458387751837,-1.1836226477704903
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,Exp_ZNRF2 (ENSG00000180233),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",Launched,0.369487062757553,0.255733352647,regorafenib,OTHER,0.3656727555796573,2.511458387751837,-1.1836226477704903
BRD-K17026858-001-01-2::2.5::HTS,BRD-K17026858-001-01-2,pibenzimol,2.5,HTS,METABOL_C46:1 TAG,METABOL,targeted cancer,DNA inhibitor,,,,Phase 2,0.36932022813549603,0.147111758393,pibenzimol,OTHER,0.3689306652141264,3.3316336195182275,-3.891342888750433
BRD-K17075857-001-17-6::2.5::HTS,BRD-K17075857-001-17-6,chloroxine,2.5,HTS,Exp_TRPC4 (ENSG00000133107),GE,noncancer,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff",Launched,0.286385349126523,0.178648217826,chloroxine,OTHER,0.3476702405048476,4.877226087164149,-2.7896100935729646
BRD-K17075857-001-18-4::2.5::HTS,BRD-K17075857-001-18-4,chloroxine,2.5,HTS,LIN_Ewings_sarcoma,LIN,noncancer,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff",Launched,0.286385349126523,0.186807257002,chloroxine,OTHER,0.2900225474501338,3.2548311945522816,-2.8612119155259355
BRD-K17203476-001-01-9::2.5::HTS,BRD-K17203476-001-01-9,LY2874455,2.5,HTS,Exp_PDXDC1 (ENSG00000179889),GE,targeted cancer,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",,,Phase 1,0.346517261019826,0.407566497911,LY2874455,OTHER,0.34749043103505245,3.457046067114806,-2.700743730793615
BRD-K17497770-001-03-6::2.5::HTS,BRD-K17497770-001-03-6,butein,2.5,HTS,Exp_BEND5 (ENSG00000162373),GE,noncancer,src inhibitor,ACE,,,Preclinical,0.34813140370888895,0.15719318392,butein,OTHER,0.3463790579989863,-4.07822373954745,-1.1574521940062703
BRD-K17555800-003-01-5::2.5::HTS,BRD-K17555800-003-01-5,talmapimod,2.5,HTS,METHYL_HCG23,METHYL,targeted cancer,p38 MAPK inhibitor,"MAPK11, MAPK14",,,Phase 2,0.35205391830124794,0.165456459532,talmapimod,OTHER,0.35256987476510426,4.713778794984255,-1.1472350766494164
BRD-K17705806-003-04-4::2.5::HTS,BRD-K17705806-003-04-4,JTC-801,2.5,HTS,Exp_CDC42BPA (ENSG00000143776),GE,noncancer,opioid receptor antagonist,OPRL1,,,Phase 2,0.412423317049556,0.287741638325,JTC-801,OTHER,0.4041889699386277,4.434418447186978,-0.9393341705397305
BRD-K17894950-001-14-3::2.5::HTS,BRD-K17894950-001-14-3,indirubin,2.5,HTS,Exp_SLC19A2 (ENSG00000117479),GE,targeted cancer,glycogen synthase kinase inhibitor,"CDK1, CDK5, GSK3A",,,Phase 2/Phase 3,0.301333802448029,0.157385178543,indirubin,OTHER,0.2983403988654041,-1.0704134924591613,0.9983716869621628
BRD-K17979676-001-01-2::2.5::HTS,BRD-K17979676-001-01-2,eprobemide,2.5,HTS,CRISPR_NFKB1 (4790),AVANA_PUBLIC_18Q2,noncancer,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Launched,0.293134302829961,0.0695733909355,eprobemide,OTHER,0.2717337199610915,-1.9939389567874564,-2.671419846923301
BRD-K18157228-001-01-7::2.5::HTS,BRD-K18157228-001-01-7,fdcyd,2.5,HTS,Exp_RNF224 (ENSG00000233198),GE,targeted cancer,DNA methyltransferase inhibitor,,,,Phase 2,0.362864250965426,0.234718363909,fdcyd,OTHER,0.3626240140925862,4.048640760278651,-2.394411232839825
BRD-K18375018-376-02-3::2.5::HTS,BRD-K18375018-376-02-3,spermine,2.5,HTS,CN_SLC38A11 (151258),CN,targeted cancer,,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",,,Preclinical,0.36617085538799604,0.132977479975,spermine,OTHER,0.37046409924831736,3.7450376459558288,-2.22294322447475
BRD-K18424115-003-01-3::2.5::HTS,BRD-K18424115-003-01-3,TG-100572,2.5,HTS,METHYL_MAFF,METHYL,targeted cancer,src inhibitor,"KDR, SRC",,,Preclinical,0.34769718685842405,0.113056931171,TG-100572,OTHER,0.3679078878218813,3.1967957758628835,-1.225139557985246
BRD-K18619710-001-14-4::2.5::HTS,BRD-K18619710-001-14-4,digoxigenin,2.5,HTS,PROT_TAZ,PROT,noncancer,steroid,,,,Preclinical,0.3386136487317,0.0922537714226,digoxigenin,OTHER,0.34395622000180986,4.548661631523352,-0.8931894425852679
BRD-K18834913-001-01-1::2.5::HTS,BRD-K18834913-001-01-1,LB42708,2.5,HTS,PROT_Gab2,PROT,targeted cancer,farnesyltransferase inhibitor,,,,Preclinical,0.34925758077114394,0.243224881919,LB42708,OTHER,0.3483686647713172,4.039475659274402,-2.9128860808306607
BRD-K18961567-001-01-1::2.5::HTS,BRD-K18961567-001-01-1,LY2801653,2.5,HTS,METHYL_RAB34,METHYL,targeted cancer,MET inhibitor,MET,,,Phase 2,0.37134985290753,0.246230596673,LY2801653,OTHER,0.3792347833028255,5.6990205733970125,-1.9371622122607324
BRD-K19034817-001-01-4::2.5::HTS,BRD-K19034817-001-01-4,pacritinib,2.5,HTS,Exp_ZNF702P (ENSG00000242779),GE,targeted cancer,FLT3 inhibitor,"FLT3, JAK1, JAK2, JAK3",,,Phase 3,0.35450106985868796,0.309997170954,pacritinib,OTHER,0.3530889563001092,1.5216939223286627,-3.5390272598331998
BRD-K19034817-001-01-4::2.5::HTS,BRD-K19034817-001-01-4,pacritinib,2.5,HTS,Exp_ZNF702P (ENSG00000242779),GE,targeted cancer,JAK inhibitor,"FLT3, JAK1, JAK2, JAK3",,,Phase 3,0.35450106985868796,0.309997170954,pacritinib,OTHER,0.3530889563001092,1.5216939223286627,-3.5390272598331998
BRD-K19061412-001-02-4::2.5::HTS,BRD-K19061412-001-02-4,mubritinib,2.5,HTS,Exp_FAM129B (ENSG00000136830),GE,targeted cancer,protein tyrosine kinase inhibitor,"EGFR, ERBB2",,,Phase 1,0.32595983396638395,0.254492096342,mubritinib,OTHER,0.3249953894820127,1.817624084248065,-2.8041325645179707
BRD-K19136521-001-08-9::2.5::HTS,BRD-K19136521-001-08-9,indirubin-3-monoxime,2.5,HTS,METHYL_ABCA11P,METHYL,targeted cancer,glycogen synthase kinase inhibitor,"CDK1, CDK2, CDK5, CDK5R1, GSK3B",,,Preclinical,0.327613773413435,0.0323762403882,indirubin-3-monoxime,OTHER,0.3294411690100792,-2.3480012511918407,0.589359530325325
BRD-K19295594-015-14-3::2.29::HTS,BRD-K19295594-015-14-3,gossypol,2.29,HTS,Exp_NR1D2 (ENSG00000174738),GE,targeted cancer,BCL inhibitor,BCL2,,,Phase 2,0.409211177989029,0.227636670808,gossypol,OTHER,0.40993181201097134,5.189436591077652,0.07548300230064564
BRD-K19295594-015-14-3::2.29::HTS,BRD-K19295594-015-14-3,gossypol,2.29,HTS,Exp_NR1D2 (ENSG00000174738),GE,targeted cancer,MCL1 inhibitor,BCL2,,,Phase 2,0.409211177989029,0.227636670808,gossypol,OTHER,0.40993181201097134,5.189436591077652,0.07548300230064564
BRD-K19333160-001-01-3::2.5::HTS,BRD-K19333160-001-01-3,RKI-1447,2.5,HTS,Exp_CDH1 (ENSG00000039068),GE,targeted cancer,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",,,Preclinical,0.37359435683023495,0.320250707166,RKI-1447,OTHER,0.3732297192336484,3.31484074655142,-3.766803173021716
BRD-K19388745-003-01-7::2.5::HTS,BRD-K19388745-003-01-7,colforsin-daproate,2.5,HTS,Exp_GRAMD4P8 (ENSG00000270930),GE,noncancer,adenylyl cyclase activator,,,,Launched,0.29439587027763897,0.0470326027386,colforsin-daproate,OTHER,0.2918816212626624,-3.699428689120477,0.13686775987278074
BRD-K19540840-001-09-4::2.5::HTS,BRD-K19540840-001-09-4,saracatinib,2.5,HTS,Exp_GRB7 (ENSG00000141738),GE,targeted cancer,src inhibitor,"ABL1, LCK, SRC, YES1",,,Phase 2/Phase 3,0.39560446910944497,0.392162692398,saracatinib,OTHER,0.3961234739213966,1.3243000686551682,-4.466581854172591
BRD-K19605405-001-02-7::2.5::HTS,BRD-K19605405-001-02-7,ZM-241385,2.5,HTS,Exp_CYP2C19 (ENSG00000165841),GE,targeted cancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.3055798386186239,0.148336149648,ZM-241385,OTHER,0.3014217157166892,-5.541378240375479,0.3577233292111668
BRD-K19615002-001-02-3::2.5::HTS,BRD-K19615002-001-02-3,creatine,2.5,HTS,CRISPR_IFNA4 (3441),AVANA_PUBLIC_18Q2,targeted cancer,,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",,,Launched,0.297303482106115,0.185367081808,creatine,OTHER,0.32862611284602383,3.823933580805087,-2.708204709618575
BRD-K20285085-001-07-1::2.5::HTS,BRD-K20285085-001-07-1,R406,2.5,HTS,PROT_HER3,PROT,targeted cancer,SYK inhibitor,"RET, SYK",,,Phase 1,0.35756083669499206,0.318725344333,R406,OTHER,0.2710103437881689,1.649548236939805,-2.280522255801804
BRD-K20285085-074-04-5::2.5::HTS,BRD-K20285085-074-04-5,R406,2.5,HTS,PROT_SHP-2_pY542_Caution,PROT,targeted cancer,SYK inhibitor,"RET, SYK",,,Phase 1,0.35756083669499206,0.318725344333,R406,OTHER,0.34234853238133084,1.6410558801775776,-2.754145449135673
BRD-K20463415-300-01-4::2.499966791::MTS004,BRD-K20463415-300-01-4,LY2606368,2.499966791,MTS004,Exp_SH2B3 (ENSG00000111252),GE,targeted cancer,CHK inhibitor,CHEK1,,,Phase 2,0.39720057586176394,0.374800467523,LY2606368,OTHER,0.3962322992253286,1.559869641984971,0.07253993702210915
BRD-K20545304-001-01-6::2.5::HTS,BRD-K20545304-001-01-6,bardoxolone,2.5,HTS,Exp_ITPKC (ENSG00000086544),GE,targeted cancer,nuclear factor erythroid derived,"NOS2, PPARG",,,Phase 1,0.42235265608303296,0.250468256329,bardoxolone,OTHER,0.4179730664902721,5.7350671509569695,-1.454616062603178
BRD-K20545304-001-01-6::2.5::HTS,BRD-K20545304-001-01-6,bardoxolone,2.5,HTS,Exp_ITPKC (ENSG00000086544),GE,targeted cancer,like (NRF2) activator,"NOS2, PPARG",,,Phase 1,0.42235265608303296,0.250468256329,bardoxolone,OTHER,0.4179730664902721,5.7350671509569695,-1.454616062603178
BRD-K20755323-001-05-9::2.5::HTS,BRD-K20755323-001-05-9,SKI-II,2.5,HTS,Exp_HMGB1P3 (ENSG00000250011),GE,targeted cancer,sphingosine kinase inhibitor,SPHK1,,,Preclinical,0.297936207996075,0.301076643425,SKI-II,OTHER,0.2954391345440127,-3.2046910741873216,-0.9587887894257454
BRD-K20958582-001-01-4::2.5::HTS,BRD-K20958582-001-01-4,TH-302,2.5,HTS,Exp_FAM149A (ENSG00000109794),GE,chemo,DNA alkylating agent,,,,Phase 3,0.38731767270773,0.294144559207,TH-302,OTHER,0.3864177941192776,5.7212964902700225,-2.648477246749315
BRD-K21025364-001-04-9::2.5::HTS,BRD-K21025364-001-04-9,NVP-TAE226,2.5,HTS,METHYL_MIR4520-2,METHYL,targeted cancer,protein tyrosine kinase inhibitor,PTK2,,,Preclinical,0.363898736923841,0.361784518401,NVP-TAE226,OTHER,0.2728803893632428,4.7596335423220255,-1.2195479081294187
BRD-K21025364-001-05-6::2.44::HTS,BRD-K21025364-001-05-6,NVP-TAE226,2.44,HTS,METHYL_FAM83A,METHYL,targeted cancer,protein tyrosine kinase inhibitor,PTK2,,,Preclinical,0.363898736923841,0.361784518401,NVP-TAE226,OTHER,0.3671752269334696,4.503969758587428,-0.8793079239682253
BRD-K21164796-001-02-8::2.5::HTS,BRD-K21164796-001-02-8,beta-naphthol,2.5,HTS,CN_CARD8 (22900),CN,noncancer,,,,,Preclinical,0.443177923920699,0.155249869807,beta-naphthol,OTHER,0.4460167270710404,4.368419821072877,0.8435769142780773
BRD-K21283037-001-21-5::2.5::HTS,BRD-K21283037-001-21-5,riluzole,2.5,HTS,CRISPR_MEF2D (4209),AVANA_PUBLIC_18Q2,noncancer,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),Launched,0.29219884515551603,0.0951322726624,riluzole,OTHER,0.2822719543292831,5.43048800999063,-3.0876685576431693
BRD-K21547160-001-01-4::2.5::HTS,BRD-K21547160-001-01-4,sufentanil,2.5,HTS,CRISPR_VENTX (27287),AVANA_PUBLIC_18Q2,noncancer,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,Launched,0.28235848760908505,0.0116888672552,sufentanil,OTHER,0.23292624104207574,1.1653100337541469,-1.6265046080869414
BRD-K21718444-001-06-8::2.5::HTS,BRD-K21718444-001-06-8,KW-2449,2.5,HTS,CRISPR_ANKRD49 (54851),AVANA_PUBLIC_18Q2,targeted cancer,Abl kinase inhibitor,"ABL1, AURKA, AURKB, FLT3",,,Phase 1,0.36775139743891905,0.380965291121,KW-2449,OTHER,0.35710734541267874,3.646363964724309,-3.7587140572181728
BRD-K21718444-001-06-8::2.5::HTS,BRD-K21718444-001-06-8,KW-2449,2.5,HTS,CRISPR_ANKRD49 (54851),AVANA_PUBLIC_18Q2,targeted cancer,FLT3 inhibitor,"ABL1, AURKA, AURKB, FLT3",,,Phase 1,0.36775139743891905,0.380965291121,KW-2449,OTHER,0.35710734541267874,3.646363964724309,-3.7587140572181728
BRD-K21782625-001-03-2::2.45::HTS,BRD-K21782625-001-03-2,AMG458,2.45,HTS,Exp_PCSK6 (ENSG00000140479),GE,targeted cancer,MET inhibitor,MET,,,Preclinical,0.34165567034936706,0.232785749234,AMG458,OTHER,0.3426418946540632,0.4588293877165983,-2.8146828055432245
BRD-K21937671-001-09-2::2.53::HTS,BRD-K21937671-001-09-2,loxistatin-acid,2.53,HTS,PROT_Smad1,PROT,noncancer,cysteine peptidase inhibitor,CTSB,,,Preclinical,0.298166168312993,0.0884366132752,loxistatin-acid,OTHER,0.3000678957730191,4.7899585808988085,-0.3008804996984256
BRD-K22025381-003-01-9::2.5::HTS,BRD-K22025381-003-01-9,U-18666A,2.5,HTS,Exp_RBBP8NL (ENSG00000130701),GE,noncancer,oxidosqualene cyclase inhibitor,,,,Preclinical,0.424582356324985,0.422143669921,U-18666A,OTHER,0.4214789963189672,0.2678321341436856,-3.553213758248935
BRD-K22064724-001-01-8::2.499989634::MTS004,BRD-K22064724-001-01-8,napabucasin,2.499989634,MTS004,METHYL_ZNF655,METHYL,targeted cancer,STAT inhibitor,STAT3,,,Phase 3,0.361867354908956,0.181072833101,napabucasin,OTHER,0.36042378172789896,2.1116386294983767,-0.036831189213115234
BRD-K23190681-001-01-1::2.5::HTS,BRD-K23190681-001-01-1,AV-412,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,protein tyrosine kinase inhibitor,"EGFR, ERBB2",,,Phase 1,0.5083333568901189,0.571900460669,AV-412,OTHER,0.5081345043171889,1.3606726174701778,-4.624374015089041
BRD-K23301018-001-11-7::2.63::HTS,BRD-K23301018-001-11-7,broxyquinoline,2.63,HTS,PROT_PREX1,PROT,noncancer,antiprotozoal agent,,,,Phase 1,0.335827316931125,0.127387554167,broxyquinoline,OTHER,0.3199767330372933,-4.666869181288352,-0.08432336803919728
BRD-K23848629-401-03-7::2.5::MTS004,BRD-K23848629-401-03-7,fosaprepitant-dimeglumine,2.5,MTS004,PROT_NF2_Caution,PROT,noncancer,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting",Launched,0.34505665726561097,0.151931905704,fosaprepitant-dimeglumine,OTHER,0.33237151246240665,5.153118728645828,-3.8257793606284314
BRD-K23925186-001-01-0::2.5::HTS,BRD-K23925186-001-01-0,oridonin,2.5,HTS,Exp_ST13P18 (ENSG00000234322),GE,targeted cancer,BCL inhibitor,BCL2,,,Preclinical,0.37804915182190796,0.258715241468,oridonin,OTHER,0.3706941071400224,1.0619830906808811,-3.798513317734717
BRD-K23925186-001-02-8::2.51::HTS,BRD-K23925186-001-02-8,oridonin,2.51,HTS,Exp_CCDC8 (ENSG00000169515),GE,targeted cancer,BCL inhibitor,BCL2,,,Preclinical,0.37804915182190796,0.258715241468,oridonin,OTHER,0.38219534452591497,5.712263031932813,0.7357492297463968
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,FLT3 inhibitor,"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)",Launched,0.24432473615882502,0.121313424882,sorafenib,OTHER,0.2506560716805934,2.9855040013390832,-1.3240170243076474
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,KIT inhibitor,"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)",Launched,0.24432473615882502,0.121313424882,sorafenib,OTHER,0.2506560716805934,2.9855040013390832,-1.3240170243076474
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)",Launched,0.24432473615882502,0.121313424882,sorafenib,OTHER,0.2506560716805934,2.9855040013390832,-1.3240170243076474
BRD-K24187789-001-01-7::2.5::HTS,BRD-K24187789-001-01-7,VU0238429,2.5,HTS,Exp_YWHAE (ENSG00000108953),GE,noncancer,acetylcholine receptor allosteric modulator,CHRM5,,,Preclinical,0.38655377394478296,0.378965803544,VU0238429,OTHER,0.3879526085056925,5.321087347284803,-1.8688603692635288
BRD-K24452555-001-01-7::2.599377769::MTS004,BRD-K24452555-001-01-7,methylprednisolone-aceponate,2.599377769,MTS004,Exp_TDP1 (ENSG00000042088),GE,noncancer,anti-inflammatory agent,NR3C1,"endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology","congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia",Launched,0.29275996176196506,0.0973387121175,methylprednisolone-aceponate,OTHER,0.2914846333032741,2.5343923036825817,4.622917974238021
BRD-K24556098-001-16-7::2.45::HTS,BRD-K24556098-001-16-7,deoxycorticosterone-acetate,2.45,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progestogen hormone,NR3C2,,,Preclinical,0.377419025074719,0.166777654527,deoxycorticosterone-acetate,OTHER,0.3872461701822008,-4.024737480254147,-2.51521206586428
BRD-K24556407-001-02-3::2.5::HTS,BRD-K24556407-001-02-3,ETP-46464,2.5,HTS,METHYL_MIR196B,METHYL,targeted cancer,ATR kinase inhibitor,,,,Preclinical,0.317804207896385,0.150655393393,ETP-46464,OTHER,0.3216088992754015,2.3350614033691506,-3.6065000540415513
BRD-K24566386-001-01-9::2.5::HTS,BRD-K24566386-001-01-9,SD-208,2.5,HTS,METABOL_cotinine,METABOL,noncancer,TGF beta receptor inhibitor,TGFBR1,,,Preclinical,0.308995368998367,0.176142693311,SD-208,OTHER,0.3062592579124751,5.009352676062903,1.052547884098973
BRD-K24576554-001-04-8::2.5::HTS,BRD-K24576554-001-04-8,AT-9283,2.5,HTS,Exp_CCDC64 (ENSG00000135127),GE,targeted cancer,JAK inhibitor,"AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",,,Phase 2,0.39158450945863393,0.279954599041,AT-9283,OTHER,0.3921450821221964,4.773124769567573,-1.0999671895146412
BRD-K24593301-001-02-3::2.54::HTS,BRD-K24593301-001-02-3,AZD3463,2.54,HTS,Exp_PLEKHD1 (ENSG00000175985),GE,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, IGF1R",,,Preclinical,0.35039418432545605,0.179607051705,AZD3463,OTHER,0.3509052941184259,5.565302350391401,0.9082515657128948
BRD-K24593301-001-02-3::2.54::HTS,BRD-K24593301-001-02-3,AZD3463,2.54,HTS,Exp_PLEKHD1 (ENSG00000175985),GE,targeted cancer,insulin growth factor receptor inhibitor,"ALK, IGF1R",,,Preclinical,0.35039418432545605,0.179607051705,AZD3463,OTHER,0.3509052941184259,5.565302350391401,0.9082515657128948
BRD-K24601397-001-01-1::2.5::HTS,BRD-K24601397-001-01-1,phlorizin,2.5,HTS,Exp_CXCL5 (ENSG00000163735),GE,noncancer,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",,,Preclinical,0.33014727091334495,0.0775957819521,phlorizin,OTHER,0.3307167890792496,-6.3598049242123125,0.43101863481446795
BRD-K24696047-001-02-3::2.5::HTS,BRD-K24696047-001-02-3,NVP-AEW541,2.5,HTS,PROT_TAZ,PROT,targeted cancer,IGF-1 inhibitor,"IGF1R, INSR",,,Preclinical,0.360269405759211,0.206282170681,NVP-AEW541,OTHER,0.3536428941732573,-3.5380001213920806,0.24363490015159384
BRD-K24715592-406-02-1::2.53::HTS,BRD-K24715592-406-02-1,ethacridine-lactate-monohydrate,2.53,HTS,Exp_SLC16A2 (ENSG00000147100),GE,noncancer,DNA intercalating agent,,,,Preclinical,0.43277682874016704,0.426247652757,ethacridine-lactate-monohydrate,OTHER,0.43360598751496665,4.991584904097858,-1.1732004086958585
BRD-K24723746-036-02-5::2.5::HTS,BRD-K24723746-036-02-5,solifenacin-succinate,2.5,HTS,PROT_RSK1-2-3_Caution,PROT,noncancer,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,"urinary incontinence, urinary frequency",Launched,0.251419748874337,0.224953639963,solifenacin-succinate,OTHER,0.243193710439829,-3.74673112044919,-3.3055571943585127
BRD-K24844714-001-24-5::2.5::HTS,BRD-K24844714-001-24-5,5-fluorouracil,2.5,HTS,Exp_AP1S2 (ENSG00000182287),GE,chemo,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma",Launched,0.30726327127093,0.248197681586,5-fluorouracil,OTHER,0.3059102321857283,3.614795852759789,-2.8639220995733434
BRD-K25340465-001-11-1::2.58::HTS,BRD-K25340465-001-11-1,OSI-930,2.58,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,KIT inhibitor,"KDR, KIT",,,Phase 1,0.362401395674544,0.312895010808,OSI-930,OTHER,0.3669385970000413,4.803720341507483,-2.1638536864048463
BRD-K25630527-001-03-8::2.5::HTS,BRD-K25630527-001-03-8,LY2784544,2.5,HTS,Exp_ZNF280C (ENSG00000056277),GE,noncancer,JAK inhibitor,"JAK2, JAK3",,,Phase 2,0.33593893163462696,0.341591148603,LY2784544,OTHER,0.34017091684850764,4.953970186770492,-3.000345598341473
BRD-K25835157-001-01-4::2.5::HTS,BRD-K25835157-001-01-4,PRT062070,2.5,HTS,Exp_TAB3 (ENSG00000157625),GE,targeted cancer,JAK inhibitor,SYK,,,Phase 1,0.332487422556861,0.239260466531,PRT062070,OTHER,0.3283957173620561,2.5094831418339067,-3.5378665260610607
BRD-K25835157-001-01-4::2.5::HTS,BRD-K25835157-001-01-4,PRT062070,2.5,HTS,Exp_TAB3 (ENSG00000157625),GE,targeted cancer,syk inhibitor,SYK,,,Phase 1,0.332487422556861,0.239260466531,PRT062070,OTHER,0.3283957173620561,2.5094831418339067,-3.5378665260610607
BRD-K25970317-001-01-6::2.50000335::MTS004,BRD-K25970317-001-01-6,resibufogenin,2.50000335,MTS004,PROT_MIG-6,PROT,noncancer,Na/K-ATPase inhibitor,,,,Phase 2,0.385936607666272,0.404382683238,resibufogenin,OTHER,0.3885743938994004,5.347308393302672,-1.2403526897543098
BRD-K26253904-001-01-5::2.5::HTS,BRD-K26253904-001-01-5,NMS-873,2.5,HTS,CRISPR_SDHB (6390),AVANA_PUBLIC_18Q2,targeted cancer,ATPase inhibitor,VCP,,,Preclinical,0.37773914423069,0.254342889045,NMS-873,OTHER,0.35374124062490003,2.551147923525896,-1.8409549587228755
BRD-K26530649-001-01-6::2.568078778::MTS004,BRD-K26530649-001-01-6,carboxypyridine-disulfide,2.568078778,MTS004,Exp_NUTF2 (ENSG00000102898),GE,targeted cancer,,,,,Phase 2,0.381068315607565,0.282730556228,carboxypyridine-disulfide,OTHER,0.38312352615568535,2.5752955992103788,-4.260729508020321
BRD-K26756394-001-02-2::2.5::HTS,BRD-K26756394-001-02-2,VE-821,2.5,HTS,DEM2_CHEK1 (1111),DEMETER2_COM,targeted cancer,ATR kinase inhibitor,ATR,,,Preclinical,0.36993173366591603,0.24064598466,VE-821,OTHER,0.33391180459635345,2.8292846346516707,-3.4003694439740766
BRD-K26833429-001-02-8::2.5::HTS,BRD-K26833429-001-02-8,costunolide,2.5,HTS,RMUTmis_ZEB2 (9839),MUTmis,targeted cancer,telomerase inhibitor,,,,Preclinical,0.341114451715648,0.102904878112,costunolide,OTHER,0.3390352998443936,0.3866951967608897,-3.759837832003948
BRD-K26997899-001-02-2::2.5::HTS,BRD-K26997899-001-02-2,D-64131,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,microtubule inhibitor,TUBB,,,Preclinical,0.41463185368126504,0.363413205794,D-64131,OTHER,0.4162983026775585,5.761099015592093,-3.099251771381436
BRD-K27182532-001-02-3::2.5::HTS,BRD-K27182532-001-02-3,metatinib,2.5,HTS,CRISPR_SP6 (80320),AVANA_PUBLIC_18Q2,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,Phase 1,0.22905769749624397,0.127757134218,metatinib,OTHER,0.22869518339296316,5.6506094995852365,0.52798222767017
BRD-K27799744-001-02-8::2.52::HTS,BRD-K27799744-001-02-8,cyclovirobuxin-d,2.52,HTS,MIRNA_ebv-miR-BART1-3p,MIRNA,noncancer,calcium channel modulator,,,,Preclinical,0.29056439355975894,0.108902856675,cyclovirobuxin-d,OTHER,0.29825349542849355,4.400664270281839,-2.0939698165385234
BRD-K28143534-001-02-2::2.5::HTS,BRD-K28143534-001-02-2,cyproheptadine,2.5,HTS,PROT_TIGAR,PROT,noncancer,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism",Launched,0.18331460392298002,0.0667115998723,cyproheptadine,OTHER,0.18527525451520627,3.98022239932912,-0.3199052050155067
BRD-K28360340-001-08-3::2.31::HTS,BRD-K28360340-001-08-3,TW-37,2.31,HTS,Exp_SLFN11 (ENSG00000172716),GE,targeted cancer,BCL inhibitor,"BCL2, BCL2L1, MCL1",,,Preclinical,0.365785940362567,0.261299105821,TW-37,OTHER,0.365762079995828,4.00675065652595,-2.3119939238008502
BRD-K28392481-001-05-1::2.5::HTS,BRD-K28392481-001-05-1,AZD4547,2.5,HTS,PROT_Gab2,PROT,targeted cancer,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",,,Phase 2/Phase 3,0.31272225581845503,0.142596612763,AZD4547,OTHER,0.3244328745494774,3.9734465047808536,-3.3427110148165244
BRD-K28824103-001-02-8::2.5::HTS,BRD-K28824103-001-02-8,genipin,2.5,HTS,PROT_Cyclin_B1,PROT,targeted cancer,choleretic agent,,,,Preclinical,0.4331398058052371,0.285367562364,genipin,OTHER,0.4303610560429579,2.646799421316816,-4.277394563311947
BRD-K28907958-001-04-3::2.5::HTS,BRD-K28907958-001-04-3,CD-437,2.5,HTS,Exp_ZNF701 (ENSG00000167562),GE,targeted cancer,retinoid receptor agonist,RARG,,,Preclinical,0.33606310301041303,0.219447812612,CD-437,OTHER,0.33832541447311537,4.800914950092278,-1.5710142205255346
BRD-K28965160-001-01-1::2.5::HTS,BRD-K28965160-001-01-1,BVD-523,2.5,HTS,Exp_ADORA1 (ENSG00000163485),GE,targeted cancer,MAP kinase inhibitor,,,,Phase 1/Phase 2,0.45469222464901904,0.494593790747,BVD-523,OTHER,0.4502816735615523,0.5172629685174357,4.619371065216948
BRD-K29173907-001-09-2::2.5::HTS,BRD-K29173907-001-09-2,isoflupredone-acetate,2.5,HTS,CRISPR_ANP32A (8125),AVANA_PUBLIC_18Q2,noncancer,,NR3C1,,,Preclinical,0.28879779885535,0.128919867488,isoflupredone-acetate,OTHER,0.28704743755613155,-3.770662409879262,-3.2953498341799614
BRD-K29254801-001-14-7::2.5::HTS,BRD-K29254801-001-14-7,thiram,2.5,HTS,Exp_MT1E (ENSG00000169715),GE,noncancer,,JAK2,ophthalmology,contact dermatitis,Launched,0.4005659825417279,0.339556085055,thiram,OTHER,0.40081095712550413,3.794117274647835,-1.3094434346348018
BRD-K29458283-001-29-9::2.5::HTS,BRD-K29458283-001-29-9,chlorambucil,2.5,HTS,METHYL_TTC30A,METHYL,chemo,DNA inhibitor,,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",Launched,0.393402883194635,0.161218377385,chlorambucil,OTHER,0.3854771305561472,3.882225857855918,-2.517342141890687
BRD-K29462201-001-01-9::2.5::HTS,BRD-K29462201-001-01-9,deserpidine,2.5,HTS,DEM2_FNTA (2339),DEMETER2_COM,noncancer,angiotensin converting enzyme inhibitor,"ACE, SLC18A2",cardiology,hypertension,Launched,0.276259608759344,0.0752695200023,deserpidine,OTHER,0.2833473131162669,-4.853193437151722,-0.1001675149016088
BRD-K29656036-001-02-5::2.5::HTS,BRD-K29656036-001-02-5,MK-8245,2.5,HTS,Exp_IL7R (ENSG00000168685),GE,noncancer,stearoyl-CoA desaturase inhibitor,SCD,,,Phase 2,0.427129417306045,0.272506180001,MK-8245,OTHER,0.4271523510278273,0.11754908459947427,-3.984743531058157
BRD-K29905972-001-06-3::2.5::HTS,BRD-K29905972-001-06-3,axitinib,2.5,HTS,PROT_alpha-Catenin,PROT,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),Launched,0.340687193794764,0.320944722315,axitinib,OTHER,0.34224498067386994,3.5341995082138533,-3.3919041857006613
BRD-K29968218-001-03-2::2.5::HTS,BRD-K29968218-001-03-2,KX2-391,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,targeted cancer,src inhibitor,SRC,,,Phase 2,0.397407500559846,0.334663716673,KX2-391,OTHER,0.39573840199389615,5.91990323244767,-2.416818323557817
BRD-K30431096-004-01-3::2.5::HTS,BRD-K30431096-004-01-3,domiphen,2.5,HTS,METHYL_HGD,METHYL,noncancer,,,,,Preclinical,0.36565700575642296,0.100502262781,domiphen,OTHER,0.3640408958266119,3.137800784900292,-2.2768948312080135
BRD-K30867024-003-03-3::2.5::HTS,BRD-K30867024-003-03-3,SB-216641,2.5,HTS,MIRNA_hsa-miR-760,MIRNA,noncancer,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",,,Preclinical,0.40201028818670204,0.104074752122,SB-216641,OTHER,0.3966323975235743,1.0145996646890487,-2.4339608529227394
BRD-K30933884-001-01-0::2.5::HTS,BRD-K30933884-001-01-0,UNBS-5162,2.5,HTS,Exp_ABCG2 (ENSG00000118777),GE,targeted cancer,CC chemokine receptor antagonist,,,,Phase 1,0.503728812451808,0.462857398265,UNBS-5162,OTHER,0.5055852577161933,3.1258046329141917,-4.251114945360008
BRD-K31086665-005-04-6::2.5::HTS,BRD-K31086665-005-04-6,NH125,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,eukaryotic translation elongation factor 2 inhibitor,,,,Preclinical,0.312206159320351,0.31232444094,NH125,OTHER,0.3120689225871371,3.985445109735719,-1.6220628130240424
BRD-K31309378-001-01-5::2.5::HTS,BRD-K31309378-001-01-5,lucitanib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,FGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",,,Phase 2,0.3929726761430539,0.349685559839,lucitanib,OTHER,0.3927501337186822,2.3923401357074705,-1.4849731669084938
BRD-K31476763-001-01-5::2.5::HTS,BRD-K31476763-001-01-5,AZD9668,2.5,HTS,CRISPR_CSTF1 (1477),AVANA_PUBLIC_18Q2,noncancer,elastase inhibitor,ELANE,,,Phase 2,0.40848270358337896,0.235871369078,AZD9668,OTHER,0.35006780042554403,4.066789464799645,-3.0490843724072985
BRD-K32007074-001-02-9::3.16::HTS,BRD-K32007074-001-02-9,enocitabine,3.16,HTS,MUTpool_ZNF711 (7552),MUTpool,chemo,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",,,Launched,0.276591421832281,0.0956375748906,enocitabine,OTHER,0.2794283781471642,4.2389972107935225,-0.7898665017277167
BRD-K32730239-001-01-0::2.5::HTS,BRD-K32730239-001-01-0,SU3327,2.5,HTS,Exp_ABCC1 (ENSG00000103222),GE,noncancer,JNK inhibitor,MAPK8,,,Preclinical,0.343122713819,0.416842992728,SU3327,OTHER,0.3486617695142661,4.346254591983551,-1.6396705772133318
BRD-K32744045-001-31-2::2.5::HTS,BRD-K32744045-001-31-2,disulfiram,2.5,HTS,Exp_MT1E (ENSG00000169715),GE,noncancer,aldehyde dehydrogenase inhibitor,"ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,Launched,0.41909359351696507,0.385017397154,disulfiram,OTHER,0.41989092976234177,3.733317542020092,-1.597935388096854
BRD-K32744045-001-31-2::2.5::HTS,BRD-K32744045-001-31-2,disulfiram,2.5,HTS,Exp_MT1E (ENSG00000169715),GE,noncancer,DNA methyltransferase inhibitor,"ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,Launched,0.41909359351696507,0.385017397154,disulfiram,OTHER,0.41989092976234177,3.733317542020092,-1.597935388096854
BRD-K32744045-001-31-2::2.5::HTS,BRD-K32744045-001-31-2,disulfiram,2.5,HTS,Exp_MT1E (ENSG00000169715),GE,noncancer,TRPV agonist,"ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,Launched,0.41909359351696507,0.385017397154,disulfiram,OTHER,0.41989092976234177,3.733317542020092,-1.597935388096854
BRD-K32821942-001-21-3::2.5::HTS,BRD-K32821942-001-21-3,azathioprine,2.5,HTS,Exp_CAD (ENSG00000084774),GE,noncancer,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis",Launched,0.33892268094694505,0.234087532194,azathioprine,OTHER,0.3382316419620231,3.6619139241322434,-3.953704927607121
BRD-K32842773-434-01-8::2.5::MTS004,BRD-K32842773-434-01-8,pemetrexed,2.5,MTS004,Exp_TIGIT (ENSG00000181847),GE,targeted cancer,dihydrofolate reductase inhibitor,"ATIC, DHFR, GART, TYMS",oncology,"non-small cell lung cancer (NSCLC), mesothelioma",Launched,0.329596515580604,0.145991309188,pemetrexed,OTHER,0.3290545890871922,3.664497843882424,-3.220893509417129
BRD-K32842773-434-01-8::2.5::MTS004,BRD-K32842773-434-01-8,pemetrexed,2.5,MTS004,Exp_TIGIT (ENSG00000181847),GE,targeted cancer,thymidylate synthase inhibitor,"ATIC, DHFR, GART, TYMS",oncology,"non-small cell lung cancer (NSCLC), mesothelioma",Launched,0.329596515580604,0.145991309188,pemetrexed,OTHER,0.3290545890871922,3.664497843882424,-3.220893509417129
BRD-K33127281-001-05-6::2.5::HTS,BRD-K33127281-001-05-6,adapalene,2.5,HTS,Exp_ZNF674 (ENSG00000251192),GE,noncancer,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),Launched,0.36904519768391,0.233677823201,adapalene,OTHER,0.3635975067078575,3.1709125200711807,-2.861526684331369
BRD-K33131085-001-07-2::2.644499841::MTS004,BRD-K33131085-001-07-2,gentiopicrin,2.644499841,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,noncancer,glutamate receptor downregulator,GRIN2B,,,Phase 3,0.28836926041905603,0.116135731837,gentiopicrin,OTHER,0.28762549686130234,2.4183123786405183,4.797475539094362
BRD-K33379087-001-07-5::2.5::HTS,BRD-K33379087-001-07-5,tivantinib,2.5,HTS,Exp_TCOF1 (ENSG00000070814),GE,targeted cancer,tyrosine kinase inhibitor,MET,,,Phase 3,0.4408612872920539,0.251904243218,tivantinib,OTHER,0.44582229502099385,5.092937202827745,-2.8863365440960163
BRD-K33690734-001-01-5::2.5::HTS,BRD-K33690734-001-01-5,5-BDBD,2.5,HTS,MUTpool_BANP (54971),MUTpool,noncancer,purinergic receptor antagonist,P2RX4,,,Preclinical,0.287873894579047,0.0647562683499,5-BDBD,OTHER,0.2862850156763379,-2.2702264987722622,0.6771680150524353
BRD-K33813875-003-01-8::2.5::HTS,BRD-K33813875-003-01-8,valnemulin,2.5,HTS,Exp_NEURL3 (ENSG00000163121),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",Launched,0.33740718740671194,0.175266623645,valnemulin,OTHER,0.3427979377655529,2.1661536413606486,-2.4317677789027448
BRD-K33882852-003-02-8::2.5::HTS,BRD-K33882852-003-02-8,ZK-93423,2.5,HTS,DEM2_NDUFB5 (4711),DEMETER2_COM,noncancer,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",,,Phase 3,0.324120846320254,0.272559417144,ZK-93423,OTHER,0.3162880336707199,1.8996710969363089,-2.7243158457640293
BRD-K34022604-001-06-6::2.5::HTS,BRD-K34022604-001-06-6,clofarabine,2.5,HTS,CRISPR_FGFR4 (2264),AVANA_PUBLIC_18Q2,chemo,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.435746238918393,0.233034113607,clofarabine,OTHER,0.4029961712688279,4.363674545928056,-1.8106176080015253
BRD-K34073885-001-09-3::2.54::HTS,BRD-K34073885-001-09-3,tanshinone-i,2.54,HTS,CRISPR_EFCAB1 (79645),AVANA_PUBLIC_18Q2,targeted cancer,AP inhibitor,IFNG,,,Phase 2,0.308180633298188,0.151950821135,tanshinone-i,OTHER,0.32108258152276525,2.1809160982724403,-2.3425870964565285
BRD-K35329391-334-01-7::2.5::HTS,BRD-K35329391-334-01-7,GZD824,2.5,HTS,RMUThot_DNAH5 (1767),MUThot,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,Preclinical,0.327792697290445,0.0435603704343,GZD824,OTHER,0.32676026359550475,3.8115760860280443,-1.1138949547461947
BRD-K35520305-001-17-7::2.5::HTS,BRD-K35520305-001-17-7,dacarbazine,2.5,HTS,Exp_SPECC1 (ENSG00000128487),GE,chemo,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma",Launched,0.315123964135552,0.142511068795,dacarbazine,OTHER,0.31367760266759803,3.9015999287364727,-3.3812851531537067
BRD-K35960502-001-20-0::2.5::HTS,BRD-K35960502-001-20-0,niclosamide,2.5,HTS,Exp_PEX14 (ENSG00000142655),GE,noncancer,DNA replication inhibitor,STAT3,infectious disease,tapeworm,Launched,0.388881218795811,0.248797200949,niclosamide,OTHER,0.3851430057768858,4.611231488363099,-1.1211294427613303
BRD-K35960502-001-20-0::2.5::HTS,BRD-K35960502-001-20-0,niclosamide,2.5,HTS,Exp_PEX14 (ENSG00000142655),GE,noncancer,STAT inhibitor,STAT3,infectious disease,tapeworm,Launched,0.388881218795811,0.248797200949,niclosamide,OTHER,0.3851430057768858,4.611231488363099,-1.1211294427613303
BRD-K36055864-001-19-2::2.5::HTS,BRD-K36055864-001-19-2,cycloheximide,2.5,HTS,METHYL_MYCNUT,METHYL,targeted cancer,protein synthesis inhibitor,RPL3,,,Preclinical,0.35741585046234997,0.243069162727,cycloheximide,OTHER,0.36105573818549497,4.177539614314853,-0.44761837305330987
BRD-K36198571-001-02-0::2.5::HTS,BRD-K36198571-001-02-0,WAY-170523,2.5,HTS,PROT_alpha-Catenin,PROT,targeted cancer,metalloproteinase inhibitor,MMP13,,,Preclinical,0.31654567803813105,0.0418241130993,WAY-170523,OTHER,0.31578383221081513,4.300430663923081,-2.3641287187623776
BRD-K36222532-001-01-8::2.5::HTS,BRD-K36222532-001-01-8,broxaldine,2.5,HTS,Exp_RAB22A (ENSG00000124209),GE,noncancer,,,,,Preclinical,0.27757136198403104,0.220150925911,broxaldine,OTHER,0.27775289700808603,3.9671831964705,-2.786391447784436
BRD-K36234266-001-09-8::2.5::HTS,BRD-K36234266-001-09-8,carmustine,2.5,HTS,Exp_MGMT (ENSG00000170430),GE,chemo,DNA alkylating agent,GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",Launched,0.310817201748407,0.320040821953,carmustine,OTHER,0.3085330637283746,1.6701602224547334,-3.4727884478104523
BRD-K36234266-001-09-8::2.5::HTS,BRD-K36234266-001-09-8,carmustine,2.5,HTS,Exp_MGMT (ENSG00000170430),GE,chemo,DNA inhibitor,GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",Launched,0.310817201748407,0.320040821953,carmustine,OTHER,0.3085330637283746,1.6701602224547334,-3.4727884478104523
BRD-K36386086-001-01-1::2.5::HTS,BRD-K36386086-001-01-1,dolutegravir,2.5,HTS,Exp_ROR1 (ENSG00000185483),GE,noncancer,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),Launched,0.32144957837791605,0.132792111995,dolutegravir,OTHER,0.32500421903548565,1.474696417702492,-3.114887761831084
BRD-K36756879-003-08-7::2.5::HTS,BRD-K36756879-003-08-7,ethaverine,2.5,HTS,METHYL_CCDC88C,METHYL,noncancer,calcium channel blocker,,neurology/psychiatry,"muscle relaxant, spasms",Launched,0.30191431312859995,0.128015048805,ethaverine,OTHER,0.2593238474401251,-5.374240846515586,-2.1036242546736403
BRD-K36889451-001-01-1::2.5::HTS,BRD-K36889451-001-01-1,tetramethylthiuram-monosulfide,2.5,HTS,Exp_BMP6 (ENSG00000153162),GE,noncancer,,,,,Preclinical,0.41161257336824797,0.226813253075,tetramethylthiuram-monosulfide,OTHER,0.4097415616643594,4.318483115562087,-0.8982201374832561
BRD-K37237504-001-02-7::2.5::HTS,BRD-K37237504-001-02-7,CEP-33779,2.5,HTS,METHYL_MIR1257,METHYL,targeted cancer,JAK inhibitor,JAK2,,,Preclinical,0.287552618663305,0.177233760236,CEP-33779,OTHER,0.31305885688928103,0.5264639387990041,-2.683423481232796
BRD-K37312348-001-15-0::2.5::HTS,BRD-K37312348-001-15-0,kenpaullone,2.5,HTS,MUTpool_TBC1D32 (221322),MUTpool,targeted cancer,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",,,Preclinical,0.3507938372664411,0.0511107270334,kenpaullone,OTHER,0.3482351808109406,-2.3025104898840363,1.01926451350246
BRD-K37561857-001-15-5::2.5::HTS,BRD-K37561857-001-15-5,zardaverine,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,phosphodiesterase inhibitor,PDE4D,,,Phase 2,0.540057885739793,0.472773541996,zardaverine,OTHER,0.5494402241893005,2.6382713114733027,-1.9524381727048308
BRD-K37590257-001-02-8::2.5::HTS,BRD-K37590257-001-02-8,GSK256066,2.5,HTS,METABOL_C32:1 PC,METABOL,noncancer,phosphodiesterase inhibitor,PDE4A,,,Phase 2,0.309483090813989,0.173302590093,GSK256066,OTHER,0.31463657214072577,4.041266107468603,0.1462540847003737
BRD-K37618799-001-03-0::2.5::HTS,BRD-K37618799-001-03-0,MRS-1220,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,noncancer,adenosine receptor antagonist,"ADORA2B, ADORA3",,,Preclinical,0.477480436580741,0.455139205566,MRS-1220,OTHER,0.4719566006435558,0.5394165549154464,0.7655614474817354
BRD-K37720887-001-07-8::2.5::HTS,BRD-K37720887-001-07-8,SB-525334,2.5,HTS,PROT_Akt,PROT,noncancer,TGF beta receptor inhibitor,TGFBR1,,,Preclinical,0.330748554876072,0.296059674542,SB-525334,OTHER,0.3337548378879567,3.486614887842285,-0.1642463489443058
BRD-K37764012-001-04-1::2.5::HTS,BRD-K37764012-001-04-1,PF-03758309,2.5,HTS,Exp_ARRDC4 (ENSG00000140450),GE,targeted cancer,p21 activated kinase inhibitor,PAK4,,,Phase 1,0.375398153730147,0.280769275417,PF-03758309,OTHER,0.3763635323712125,3.8666167482731466,-1.6008591397374348
BRD-K37865504-001-04-1::2.5::HTS,BRD-K37865504-001-04-1,LY2183240,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,noncancer,FAAH inhibitor,FAAH,,,Preclinical,0.386617183083383,0.185057469821,LY2183240,OTHER,0.386366470305544,5.834963721858883,-2.0484470402217445
BRD-K37865504-001-04-1::2.5::HTS,BRD-K37865504-001-04-1,LY2183240,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,noncancer,FAAH reuptake inhibitor,FAAH,,,Preclinical,0.386617183083383,0.185057469821,LY2183240,OTHER,0.386366470305544,5.834963721858883,-2.0484470402217445
BRD-K38003476-001-09-1::2.5::HTS,BRD-K38003476-001-09-1,clocortolone-pivalate,2.5,HTS,PROT_RBM15,PROT,noncancer,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.24835297813723697,0.159079528316,clocortolone-pivalate,OTHER,0.24747971099906546,-1.7260738987488289,-3.01410864468383
BRD-K38350380-001-01-8::2.5::HTS,BRD-K38350380-001-01-8,FK-3311,2.5,HTS,PROT_NF-kB-p65_pS536_Caution,PROT,noncancer,cyclooxygenase inhibitor,PTGS2,,,Phase 2,0.252887282622695,0.0281319680645,FK-3311,OTHER,0.254466052508047,2.687803192519704,-0.9286770705946128
BRD-K38527262-300-01-0::2.300987371::MTS004,BRD-K38527262-300-01-0,atiprimod,2.300987371,MTS004,Exp_ATP10B (ENSG00000118322),GE,targeted cancer,JAK inhibitor,"JAK2, STAT3",,,Phase 2,0.584374770796491,0.472884666441,atiprimod,OTHER,0.5838914914097504,4.6869190394128815,-0.9708674057868598
BRD-K38527262-300-01-0::2.300987371::MTS004,BRD-K38527262-300-01-0,atiprimod,2.300987371,MTS004,Exp_ATP10B (ENSG00000118322),GE,targeted cancer,STAT inhibitor,"JAK2, STAT3",,,Phase 2,0.584374770796491,0.472884666441,atiprimod,OTHER,0.5838914914097504,4.6869190394128815,-0.9708674057868598
BRD-K38860038-001-01-2::2.5::HTS,BRD-K38860038-001-01-2,JK-184,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,hedgehog pathway inhibitor,,,,Preclinical,0.402265647652025,0.342124878434,JK-184,OTHER,0.4010641551741281,6.031512202954272,-2.7082346375714423
BRD-K39009484-001-01-4::2.5::MTS004,BRD-K39009484-001-01-4,entrectinib,2.5,MTS004,Exp_NHLH2 (ENSG00000177551),GE,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, NTRK1, NTRK2, NTRK3, ROS1",,,Phase 2,0.29935024946216,0.150114815917,entrectinib,OTHER,0.2985686557893001,1.6964920664220378,-2.6898703521283966
BRD-K39009484-001-01-4::2.5::MTS004,BRD-K39009484-001-01-4,entrectinib,2.5,MTS004,Exp_NHLH2 (ENSG00000177551),GE,targeted cancer,proto-oncogene tyrosine protein kinase inhibitor,"ALK, NTRK1, NTRK2, NTRK3, ROS1",,,Phase 2,0.29935024946216,0.150114815917,entrectinib,OTHER,0.2985686557893001,1.6964920664220378,-2.6898703521283966
BRD-K39252998-003-01-5::2.5::HTS,BRD-K39252998-003-01-5,atipamezole,2.5,HTS,Exp_ZNF750 (ENSG00000141579),GE,noncancer,adrenergic receptor antagonist,,neurology/psychiatry,reverse sedative,Launched,0.38738805570880896,0.270606380507,atipamezole,OTHER,0.3934216520255095,5.0719148687697295,-3.8582436853428437
BRD-K39841531-001-02-1::2.5::HTS,BRD-K39841531-001-02-1,TG-101209,2.5,HTS,MIRNA_hsa-miR-454,MIRNA,noncancer,JAK inhibitor,"JAK2, JAK3",,,Preclinical,0.382276592726442,0.312127531301,TG-101209,OTHER,0.3837266241777307,3.4667573764554267,-2.552382293605973
BRD-K39974922-001-04-3::2.5::HTS,BRD-K39974922-001-04-3,lenvatinib,2.5,HTS,Exp_PROSER2 (ENSG00000148426),GE,targeted cancer,FGFR inhibitor,"FLT4, KDR",oncology,thyroid cancer,Launched,0.43004202579957107,0.25944445401,lenvatinib,OTHER,0.4476114527668799,0.004902555430529892,-2.0091548212213137
BRD-K39974922-001-04-3::2.5::HTS,BRD-K39974922-001-04-3,lenvatinib,2.5,HTS,Exp_PROSER2 (ENSG00000148426),GE,targeted cancer,KIT inhibitor,"FLT4, KDR",oncology,thyroid cancer,Launched,0.43004202579957107,0.25944445401,lenvatinib,OTHER,0.4476114527668799,0.004902555430529892,-2.0091548212213137
BRD-K39974922-001-04-3::2.5::HTS,BRD-K39974922-001-04-3,lenvatinib,2.5,HTS,Exp_PROSER2 (ENSG00000148426),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"FLT4, KDR",oncology,thyroid cancer,Launched,0.43004202579957107,0.25944445401,lenvatinib,OTHER,0.4476114527668799,0.004902555430529892,-2.0091548212213137
BRD-K39983086-001-06-1::2.45::HTS,BRD-K39983086-001-06-1,loteprednol,2.45,HTS,CRISPR_DYDC1 (143241),AVANA_PUBLIC_18Q2,noncancer,phospholipase inhibitor,NR3C1,ophthalmology,conjunctivitis,Launched,0.300005099220844,0.101307601724,loteprednol,OTHER,0.31150339013202505,-3.497429019549299,-3.1438115629522634
BRD-K39987650-001-24-1::2.5::HTS,BRD-K39987650-001-24-1,bisacodyl,2.5,HTS,PROT_Fibronectin,PROT,noncancer,laxative,,gastroenterology,constipation,Launched,0.36962550042495207,0.240791579232,bisacodyl,OTHER,0.3704920120491488,-5.144540414727805,-1.6796471986103685
BRD-K40109029-001-02-9::2.5::HTS,BRD-K40109029-001-02-9,SB-505124,2.5,HTS,Exp_AFAP1-AS1 (ENSG00000272620),GE,noncancer,ALK tyrosine kinase receptor inhibitor,TGFBR1,,,Preclinical,0.445188866841818,0.407900443453,SB-505124,OTHER,0.4495658993483232,2.2939280350528337,-2.4358012058227727
BRD-K40255344-001-17-6::2.5::HTS,BRD-K40255344-001-17-6,tyrphostin-A9,2.5,HTS,Exp_SRRM1 (ENSG00000133226),GE,targeted cancer,protein tyrosine kinase inhibitor,,,,Preclinical,0.38807770333105995,0.325089147504,tyrphostin-A9,OTHER,0.3888124391974124,4.672645264652464,-3.1296088307256795
BRD-K40255344-001-17-6::2.5::HTS,BRD-K40255344-001-17-6,tyrphostin-A9,2.5,HTS,Exp_SRRM1 (ENSG00000133226),GE,targeted cancer,tyrosine kinase inhibitor,,,,Preclinical,0.38807770333105995,0.325089147504,tyrphostin-A9,OTHER,0.3888124391974124,4.672645264652464,-3.1296088307256795
BRD-K40308497-001-01-2::2.54::HTS,BRD-K40308497-001-01-2,crizotinib-(S),2.54,HTS,MIRNA_hsa-miR-211,MIRNA,targeted cancer,MTH1 inhibitor,NUDT1,,,Preclinical,0.418444996375318,0.105004277495,crizotinib-(S),OTHER,0.4174059231727606,0.9280788916975974,-2.852522033413398
BRD-K40496271-396-01-1::2.34::HTS,BRD-K40496271-396-01-1,eltrombopag,2.34,HTS,Exp_PARP1 (ENSG00000143799),GE,noncancer,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia",Launched,0.37435172160709,0.278190679586,eltrombopag,OTHER,0.3744102114062543,3.0042608488751545,-3.2780136370615143
BRD-K41104902-001-01-3::2.5::HTS,BRD-K41104902-001-01-3,GSK2656157,2.5,HTS,MUTpool_RBM15B (29890),MUTpool,targeted cancer,PERK inhibitor,,,,Preclinical,0.288537199398664,0.0142365469168,GSK2656157,OTHER,0.2871925723383273,0.6981908421786516,-3.2864294832684724
BRD-K41312087-001-02-7::2.5::HTS,BRD-K41312087-001-02-7,GW-441756,2.5,HTS,PROT_Bcl-xL,PROT,targeted cancer,growth factor receptor inhibitor,NTRK1,,,Preclinical,0.320594335136316,0.229527803287,GW-441756,OTHER,0.2970755904698879,2.6521536330081616,0.2076753075478286
BRD-K41337261-001-03-0::2.5::HTS,BRD-K41337261-001-03-0,ZM-306416,2.5,HTS,Exp_FAM50A (ENSG00000071859),GE,targeted cancer,Abl kinase inhibitor,"EGFR, FLT1, FLT4, KDR",,,Preclinical,0.382202230870648,0.207700681149,ZM-306416,OTHER,0.38084639780289004,3.0806105658677234,-0.5468262841526923
BRD-K41337261-001-03-0::2.5::HTS,BRD-K41337261-001-03-0,ZM-306416,2.5,HTS,Exp_FAM50A (ENSG00000071859),GE,targeted cancer,src inhibitor,"EGFR, FLT1, FLT4, KDR",,,Preclinical,0.382202230870648,0.207700681149,ZM-306416,OTHER,0.38084639780289004,3.0806105658677234,-0.5468262841526923
BRD-K41599323-001-02-3::2.5::HTS,BRD-K41599323-001-02-3,lonafarnib,2.5,HTS,Exp_RCC1 (ENSG00000180198),GE,targeted cancer,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",,,Phase 3,0.371776621185306,0.177979086212,lonafarnib,OTHER,0.3710594244048327,4.309876390916096,-3.0828297324325313
BRD-K41783120-001-02-8::2.5::HTS,BRD-K41783120-001-02-8,STA-5326,2.5,HTS,METHYL_ZFP3,METHYL,noncancer,interleukin synthesis inhibitor,IL12A,,,Phase 2,0.404202856099281,0.35370898696,STA-5326,OTHER,0.39385343008093293,4.113272806412343,-2.601820438307384
BRD-K41876534-001-13-7::2.5::HTS,BRD-K41876534-001-13-7,tioxolone,2.5,HTS,Exp_UGT1A6 (ENSG00000167165),GE,noncancer,carbonic anhydrase inhibitor,CA2,,,Preclinical,0.557303966291342,0.500946714326,tioxolone,OTHER,0.5569602956008161,0.6815688739278282,-4.076616252396843
BRD-K42205652-001-02-7::2.5::HTS,BRD-K42205652-001-02-7,"MNS-(3,4-Methylenedioxy-nitrostyrene)",2.5,HTS,Exp_TTC13 (ENSG00000143643),GE,noncancer,src inhibitor,"SRC, SYK",,,Preclinical,0.354876039729536,0.296397471008,"MNS-(3,4-Methylenedioxy-nitrostyrene)",OTHER,0.35587442931175306,4.761013275456452,-3.25719405309674
BRD-K42205652-001-02-7::2.5::HTS,BRD-K42205652-001-02-7,"MNS-(3,4-Methylenedioxy-nitrostyrene)",2.5,HTS,Exp_TTC13 (ENSG00000143643),GE,noncancer,syk inhibitor,"SRC, SYK",,,Preclinical,0.354876039729536,0.296397471008,"MNS-(3,4-Methylenedioxy-nitrostyrene)",OTHER,0.35587442931175306,4.761013275456452,-3.25719405309674
BRD-K42436189-001-01-2::2.5::HTS,BRD-K42436189-001-01-2,AZ20,2.5,HTS,CN_CASP12 (100506742),CN,targeted cancer,ATR kinase inhibitor,"ATR, MTOR",,,Preclinical,0.37215311851893296,0.202753747465,AZ20,OTHER,0.3875465367647582,4.977518117621576,-1.9625857548298016
BRD-K42495768-001-01-7::2.5::HTS,BRD-K42495768-001-01-7,tasisulam,2.5,HTS,Exp_SYS1 (ENSG00000204070),GE,targeted cancer,apoptosis stimulant,,,,Phase 3,0.4095680885146029,0.340132326546,tasisulam,OTHER,0.4110928600321732,3.815338599228811,-4.196698326747371
BRD-K42497885-001-01-1::2.5::HTS,BRD-K42497885-001-01-1,satraplatin,2.5,HTS,Exp_KDM1A (ENSG00000004487),GE,chemo,DNA alkylating agent,,,,Phase 3,0.415390621335065,0.324865655245,satraplatin,OTHER,0.4132007595956333,4.08665160800064,-2.7814189801563995
BRD-K42828737-044-09-0::2.5::HTS,BRD-K42828737-044-09-0,sunitinib,2.5,HTS,Exp_TSPAN15 (ENSG00000099282),GE,targeted cancer,FLT3 inhibitor,"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)",Launched,0.379885388988003,0.205193823437,sunitinib,OTHER,0.3588897605197444,0.8635142618069186,-2.8037216958190876
BRD-K42828737-044-09-0::2.5::HTS,BRD-K42828737-044-09-0,sunitinib,2.5,HTS,Exp_TSPAN15 (ENSG00000099282),GE,targeted cancer,KIT inhibitor,"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)",Launched,0.379885388988003,0.205193823437,sunitinib,OTHER,0.3588897605197444,0.8635142618069186,-2.8037216958190876
BRD-K42828737-044-09-0::2.5::HTS,BRD-K42828737-044-09-0,sunitinib,2.5,HTS,Exp_TSPAN15 (ENSG00000099282),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)",Launched,0.379885388988003,0.205193823437,sunitinib,OTHER,0.3588897605197444,0.8635142618069186,-2.8037216958190876
BRD-K42973005-001-04-0::2.5::HTS,BRD-K42973005-001-04-0,CHIR-98014,2.5,HTS,Exp_SSR2 (ENSG00000163479),GE,noncancer,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",,,Preclinical,0.341873985011427,0.234565491712,CHIR-98014,OTHER,0.34255107125849543,5.446137433863611,-2.819622413450236
BRD-K42981054-001-01-9::2.5::HTS,BRD-K42981054-001-01-9,mibampator,2.5,HTS,DEM2_NDUFB5 (4711),DEMETER2_COM,noncancer,glutamate receptor modulator,GRIA1,,,Phase 2,0.299395414519623,0.0620503124514,mibampator,OTHER,0.3146434010281097,0.8251414071528409,-3.3193312123548235
BRD-K43002771-034-01-6::2.5::HTS,BRD-K43002771-034-01-6,SR-33805,2.5,HTS,CN_MIR3689A (100500846),CN,noncancer,calcium channel blocker,,,,Phase 1,0.370611571636046,0.0401901888926,SR-33805,OTHER,0.3658157813045379,-2.466811337770072,-0.340565919052608
BRD-K43236057-001-07-1::2.6::HTS,BRD-K43236057-001-07-1,polydatin,2.6,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,ICAM1 expression inhibitor,ICAM1,,,Phase 2,0.38503202591057395,0.548940227879,polydatin,OTHER,0.3880928884767401,4.739073732711199,-3.842809021183049
BRD-K43389698-001-09-9::2.4::HTS,BRD-K43389698-001-09-9,BMS-387032,2.4,HTS,PROT_YAP_pS127_Caution,PROT,noncancer,cell cycle inhibitor,"CDK2, CDK7, CDK9",,,Phase 1,0.34389319060567997,0.0898598329229,BMS-387032,OTHER,0.3468213601011139,5.073693658642744,0.6398439718783115
BRD-K43389698-001-09-9::2.4::HTS,BRD-K43389698-001-09-9,BMS-387032,2.4,HTS,PROT_YAP_pS127_Caution,PROT,noncancer,MCL1 inhibitor,"CDK2, CDK7, CDK9",,,Phase 1,0.34389319060567997,0.0898598329229,BMS-387032,OTHER,0.3468213601011139,5.073693658642744,0.6398439718783115
BRD-K43449605-001-01-0::2.5::HTS,BRD-K43449605-001-01-0,oncrasin-1,2.5,HTS,Exp_SULT1A1 (ENSG00000196502),GE,targeted cancer,apoptosis stimulant,,,,Preclinical,0.617991499365294,0.655962117118,oncrasin-1,OTHER,0.6163011472128322,5.599629506320927,1.5371886838655358
BRD-K43578482-001-01-4::2.5::HTS,BRD-K43578482-001-01-4,defactinib,2.5,HTS,Exp_YIPF5 (ENSG00000145817),GE,targeted cancer,focal adhesion kinase inhibitor,PTK2,,,Phase 2,0.30983436459250296,0.234577715369,defactinib,OTHER,0.30833080481636044,1.8682799998758344,-3.6434370249408965
BRD-K43621685-001-02-5::2.5::HTS,BRD-K43621685-001-02-5,CP-673451,2.5,HTS,Exp_CTDSPL (ENSG00000144677),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",,,Preclinical,0.31475327470845504,0.261033027649,CP-673451,OTHER,0.3134138133618576,3.878172654955764,-2.808416866478697
BRD-K44067360-001-30-3::2.5::HTS,BRD-K44067360-001-30-3,flufenamic-acid,2.5,HTS,PROT_YB-1_pS102,PROT,noncancer,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",,,Preclinical,0.21170825075461,0.143447489462,flufenamic-acid,OTHER,0.21364220171638465,5.27215601046389,-1.6235982949918728
BRD-K44084986-300-08-4::2.5::HTS,BRD-K44084986-300-08-4,Y-27632,2.5,HTS,Exp_RPL31P11 (ENSG00000213075),GE,targeted cancer,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",,,Preclinical,0.340417201538343,0.19776024642,Y-27632,OTHER,0.33626007255537954,5.965668586101893,-2.5058459950572525
BRD-K44227013-001-06-4::2.5::HTS,BRD-K44227013-001-06-4,ponatinib,2.5,HTS,Exp_DUSP8 (ENSG00000184545),GE,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.38209937474291705,0.370848795255,ponatinib,OTHER,0.3823279797566612,2.8700431185048743,-0.905867941465862
BRD-K44227013-001-06-4::2.5::HTS,BRD-K44227013-001-06-4,ponatinib,2.5,HTS,Exp_DUSP8 (ENSG00000184545),GE,targeted cancer,FLT3 inhibitor,"ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.38209937474291705,0.370848795255,ponatinib,OTHER,0.3823279797566612,2.8700431185048743,-0.905867941465862
BRD-K44227013-001-06-4::2.5::HTS,BRD-K44227013-001-06-4,ponatinib,2.5,HTS,Exp_DUSP8 (ENSG00000184545),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.38209937474291705,0.370848795255,ponatinib,OTHER,0.3823279797566612,2.8700431185048743,-0.905867941465862
BRD-K45401373-001-20-9::2.5::HTS,BRD-K45401373-001-20-9,betulinic-acid,2.5,HTS,PROT_Caspase-7_cleavedD198_Caution,PROT,targeted cancer,apoptosis stimulant,GPBAR1,,,Phase 1/Phase 2,0.299733813400325,0.18226666922,betulinic-acid,OTHER,0.2563323520566165,2.2726154308907325,-2.4968564622538274
BRD-K45551181-001-02-1::2.49::HTS,BRD-K45551181-001-02-1,MPI-0479605,2.49,HTS,Exp_RCC1 (ENSG00000180198),GE,targeted cancer,mitotic kinase inhibitor,TTK,,,Preclinical,0.36494982854626395,0.229295376133,MPI-0479605,OTHER,0.3639562015740436,3.6687679065594714,-3.4349490041406394
BRD-K46862739-001-14-3::2.499952208::MTS004,BRD-K46862739-001-14-3,metyrapone,2.499952208,MTS004,MIRNA_hsa-miR-628-5p,MIRNA,noncancer,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,Launched,0.350571217153636,0.0623355111317,metyrapone,OTHER,0.35036737789263633,5.765073474567433,-1.4494773272578383
BRD-K47000838-001-01-6::1.04::HTS,BRD-K47000838-001-01-6,cytochalasin-b,1.04,HTS,Exp_GLIPR1 (ENSG00000139278),GE,noncancer,microtubule inhibitor,ACTB,,,Phase 2,0.21910165211407895,0.222912064821,cytochalasin-b,OTHER,0.22707622856750184,3.9435094436801137,-3.0757986597910483
BRD-K47079459-004-04-6::2.5::HTS,BRD-K47079459-004-04-6,cetrimonium,2.5,HTS,Exp_SLCO4A1 (ENSG00000101187),GE,noncancer,,,dermatology,cosmetic,Launched,0.37358829534618604,0.32876491708,cetrimonium,OTHER,0.3731880858713729,3.668030882421346,-1.8518855579684972
BRD-K47114202-001-14-6::2.58::HTS,BRD-K47114202-001-14-6,chlorogenic-acid,2.58,HTS,CRISPR_FAM129B (64855),AVANA_PUBLIC_18Q2,noncancer,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis",Launched,0.336498998040699,0.0683735695583,chlorogenic-acid,OTHER,0.3225467258771032,4.910110577621849,0.07559636917965218
BRD-K47150025-001-05-3::2.5::HTS,BRD-K47150025-001-05-3,KI-8751,2.5,HTS,Exp_TGFA (ENSG00000163235),GE,targeted cancer,KIT inhibitor,KDR,,,Preclinical,0.37135481267825604,0.26505619223,KI-8751,OTHER,0.37259305966907547,4.724020179158859,-1.2092749597118837
BRD-K47150025-001-05-3::2.5::HTS,BRD-K47150025-001-05-3,KI-8751,2.5,HTS,Exp_TGFA (ENSG00000163235),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,KDR,,,Preclinical,0.37135481267825604,0.26505619223,KI-8751,OTHER,0.37259305966907547,4.724020179158859,-1.2092749597118837
BRD-K47337578-034-02-5::2.5::HTS,BRD-K47337578-034-02-5,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,2.5,HTS,RMUTdmg_LSM1 (27257),MUTdmg,noncancer,serotonin receptor antagonist,HTR2A,,,Preclinical,0.28886403660830495,0.0210178761115,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,OTHER,0.28151080799634115,4.073624089759468,1.9053722393275634
BRD-K47557313-001-02-7::2.5::HTS,BRD-K47557313-001-02-7,LY2109761,2.5,HTS,PROT_AMPK_alpha_Caution,PROT,targeted cancer,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",,,Preclinical,0.282162542755534,0.17918353964,LY2109761,OTHER,0.2847804451635589,4.900358144847859,1.634509356222306
BRD-K47598052-001-15-8::2.5::HTS,BRD-K47598052-001-15-8,PP-1,2.5,HTS,Exp_TAPT1 (ENSG00000169762),GE,targeted cancer,src inhibitor,"HCK, RET",,,Preclinical,0.390602926951334,0.204348409293,PP-1,OTHER,0.3924255052773838,1.930667436728544,-2.5043584732890887
BRD-K47832606-001-30-1::2.5::HTS,BRD-K47832606-001-30-1,floxuridine,2.5,HTS,Exp_EIF4A1 (ENSG00000161960),GE,chemo,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,Launched,0.35417732012013003,0.254781062395,floxuridine,OTHER,0.3546857842691573,4.298860710409956,-2.2064931255115896
BRD-K47869605-001-32-0::2.5::HTS,BRD-K47869605-001-32-0,podophyllotoxin,2.5,HTS,METHYL_ZP2,METHYL,noncancer,microtubule inhibitor,"IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,Launched,0.38159068914812794,0.0972764546144,podophyllotoxin,OTHER,0.3908893499579293,5.375247873157506,-0.578917367296206
BRD-K48141473-001-01-7::2.5::HTS,BRD-K48141473-001-01-7,cebranopadol,2.5,HTS,CN_DEFA3 (1668),CN,noncancer,opioid receptor agonist,"OPRL1, OPRM1",,,Phase 3,0.283878960699532,0.0412148190824,cebranopadol,OTHER,0.29332257595495226,-5.055037088414943,-0.7590792659406262
BRD-K48443249-001-01-0::2.5::HTS,BRD-K48443249-001-01-0,CNX-774,2.5,HTS,Exp_SEMA3G (ENSG00000010319),GE,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,Preclinical,0.31489060123325796,0.239395320665,CNX-774,OTHER,0.31537344992705785,6.581369345372182,-1.6056510922323195
BRD-K48988407-001-01-2::2.5::HTS,BRD-K48988407-001-01-2,cytochlor,2.5,HTS,LIN_melanoma,LIN,targeted cancer,,,,,Phase 1,0.40192549529195204,0.202128962932,cytochlor,OTHER,0.4017715407518127,4.08918940705392,-2.5403048076615318
BRD-K49049886-001-08-7::2.5::HTS,BRD-K49049886-001-08-7,CGS-15943,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.51098898727436,0.506958132877,CGS-15943,OTHER,0.5063152460778902,-0.7359579822230791,0.9072330900572876
BRD-K49075727-001-08-5::2.5::HTS,BRD-K49075727-001-08-5,nintedanib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),Launched,0.39097148638159795,0.298050541055,nintedanib,OTHER,0.3895847014985172,1.7587321479893276,-2.1205049654860684
BRD-K49075727-001-08-5::2.5::HTS,BRD-K49075727-001-08-5,nintedanib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),Launched,0.39097148638159795,0.298050541055,nintedanib,OTHER,0.3895847014985172,1.7587321479893276,-2.1205049654860684
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,Exp_FAM222A (ENSG00000139438),GE,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.399333026614539,0.408796878451,dasatinib,OTHER,0.3965602944379628,4.746727604383424,-0.2325706824651545
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,Exp_FAM222A (ENSG00000139438),GE,targeted cancer,ephrin inhibitor,"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.399333026614539,0.408796878451,dasatinib,OTHER,0.3965602944379628,4.746727604383424,-0.2325706824651545
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,Exp_FAM222A (ENSG00000139438),GE,targeted cancer,KIT inhibitor,"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.399333026614539,0.408796878451,dasatinib,OTHER,0.3965602944379628,4.746727604383424,-0.2325706824651545
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,Exp_FAM222A (ENSG00000139438),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.399333026614539,0.408796878451,dasatinib,OTHER,0.3965602944379628,4.746727604383424,-0.2325706824651545
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,Exp_FAM222A (ENSG00000139438),GE,targeted cancer,src inhibitor,"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.399333026614539,0.408796878451,dasatinib,OTHER,0.3965602944379628,4.746727604383424,-0.2325706824651545
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,Exp_FAM222A (ENSG00000139438),GE,targeted cancer,tyrosine kinase inhibitor,"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)",Launched,0.399333026614539,0.408796878451,dasatinib,OTHER,0.3965602944379628,4.746727604383424,-0.2325706824651545
BRD-K49350383-001-13-7::2.5::HTS,BRD-K49350383-001-13-7,thioguanine,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),Launched,0.41142642716361,0.296921861054,thioguanine,OTHER,0.4116419800127768,3.989619554602284,-3.847017954869628
BRD-K49555808-001-03-9::2.5::HTS,BRD-K49555808-001-03-9,BMS-707035,2.5,HTS,METHYL_USP7,METHYL,noncancer,HIV integrase inhibitor,,,,Phase 2,0.327519162055404,0.244929489117,BMS-707035,OTHER,0.3270366029268765,3.9197764583373065,-2.7021500706844908
BRD-K49669041-001-08-4::2.5::HTS,BRD-K49669041-001-08-4,BX-912,2.5,HTS,Exp_NKX2-5 (ENSG00000183072),GE,targeted cancer,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",,,Preclinical,0.421753437277252,0.267854450466,BX-912,OTHER,0.4225601523009587,3.509298423056168,-4.246950323404442
BRD-K49962337-001-02-9::2.56::HTS,BRD-K49962337-001-02-9,baicalin,2.56,HTS,LIN_kidney,LIN,noncancer,beta glucuronidase inhibitor,PREP,,,Launched,0.376042441835276,0.24381914816,baicalin,OTHER,0.2946623682526589,4.298907490676382,-0.8545082785922165
BRD-K50000283-001-04-4::2.5::HTS,BRD-K50000283-001-04-4,PHA-767491,2.5,HTS,Exp_ABCC4 (ENSG00000125257),GE,targeted cancer,CDC inhibitor,"CDK1, RPS6KB1",,,Preclinical,0.452883751398934,0.206652915145,PHA-767491,OTHER,0.4530697668818965,5.044879683019358,-1.8934164456754123
BRD-K50140147-001-10-1::2.5::HTS,BRD-K50140147-001-10-1,NVP-TAE684,2.5,HTS,PROT_Chk2_pT68_Caution,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",,,Preclinical,0.36336131042184205,0.192690226374,NVP-TAE684,OTHER,0.36949757612169815,4.994435374674978,-1.7441942226531042
BRD-K50388907-001-30-4::2.5::HTS,BRD-K50388907-001-30-4,fenofibrate,2.5,HTS,MIRNA_hsa-miR-200c,MIRNA,noncancer,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia",Launched,0.28633465836709493,0.25554209482,fenofibrate,OTHER,0.261926899992387,1.5519576514439792,-4.621798098099784
BRD-K50406511-001-26-0::2.5::HTS,BRD-K50406511-001-26-0,hycanthone,2.5,HTS,MIRNA_hsa-miR-215,MIRNA,noncancer,RNA synthesis inhibitor,,infectious disease,schistosomiasis,Launched,0.31654320128665697,0.132079633387,hycanthone,OTHER,0.3155144370927789,-4.804959674892009,-0.6071949156566325
BRD-K50677762-001-01-5::2.5::HTS,BRD-K50677762-001-01-5,oxiracetam,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,acetylcholine receptor agonist,,,,Launched,0.380545419537415,0.202038383781,oxiracetam,OTHER,0.38252237856725385,5.795958343035821,-2.4281326827892817
BRD-K50850824-237-04-8::2.5::HTS,BRD-K50850824-237-04-8,acesulfame-potassium,2.5,HTS,DEM2_SPPL2A (84888),DEMETER2_COM,noncancer,,,,,Phase 3,0.327384240844748,0.092374842996,acesulfame-potassium,OTHER,0.3396300463253857,3.364945264029811,-0.02831244536858435
BRD-K50853363-001-02-3::2.5::HTS,BRD-K50853363-001-02-3,dienogest,2.5,HTS,CRISPR_CSTF1 (1477),AVANA_PUBLIC_18Q2,noncancer,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",Launched,0.35721723368512104,0.230373978889,dienogest,OTHER,0.3406141914478054,4.692505540343271,-1.2675490124632631
BRD-K51575138-001-13-2::2.5::HTS,BRD-K51575138-001-13-2,TPCA-1,2.5,HTS,Exp_ARTN (ENSG00000117407),GE,targeted cancer,IKK inhibitor,IKBKB,,,Preclinical,0.405789034039964,0.191379182207,TPCA-1,OTHER,0.4030147301164052,0.5458301673292362,-2.818086684365208
BRD-K52075040-001-09-7::5.6::HTS,BRD-K52075040-001-09-7,cerulenin,5.6,HTS,PROT_Caveolin-1,PROT,noncancer,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection,Launched,0.344534722467324,0.0721924224789,cerulenin,OTHER,0.3269709475368083,-4.0442855685022225,-1.5130190444269729
BRD-K52256627-300-06-6::2.5::HTS,BRD-K52256627-300-06-6,chlorhexidine,2.5,HTS,Exp_EREG (ENSG00000124882),GE,noncancer,membrane integrity inhibitor,,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Launched,0.472692332609723,0.380570370155,chlorhexidine,OTHER,0.4739362413930641,1.54037772056328,-3.8421685355984088
BRD-K52762805-001-01-2::2.5::HTS,BRD-K52762805-001-01-2,epothilone-d,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",,,Phase 2,0.392511332852066,0.232180931769,epothilone-d,OTHER,0.3894586355892942,6.116193740396273,-1.8932784437615575
BRD-K53734668-003-02-0::2.66::HTS,BRD-K53734668-003-02-0,PRT062607,2.66,HTS,METHYL_ITGA2,METHYL,targeted cancer,syk inhibitor,"FGR, MAP3K9, SYK",,,Phase 2,0.18760410798131696,0.0932606568457,PRT062607,OTHER,0.20662616010609725,1.2928690548848047,-3.1983435286881168
BRD-K53972329-001-07-0::2.5::HTS,BRD-K53972329-001-07-0,ruxolitinib,2.5,HTS,CN_CD247 (919),CN,targeted cancer,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",Launched,0.305620972962544,0.132608199736,ruxolitinib,OTHER,0.3185908605641721,4.6977733588717765,-0.7952983862115892
BRD-K54095730-001-03-1::2.5::HTS,BRD-K54095730-001-03-1,CMPD-1,2.5,HTS,CRISPR_TTF2 (8458),AVANA_PUBLIC_18Q2,noncancer,p38 MAPK inhibitor,"GNRHR, MAPK14",,,Preclinical,0.38022512742390796,0.26999750056,CMPD-1,OTHER,0.3803695303592985,5.201670570479791,-2.6500993600649467
BRD-K54187111-001-08-4::2.51::HTS,BRD-K54187111-001-08-4,dichlorisone-acetate,2.51,HTS,PROT_14-3-3_zeta,PROT,noncancer,,,,,Phase 2,0.28639230975521096,0.12835676549,dichlorisone-acetate,OTHER,0.2842511163656329,-3.6007123720821888,-3.2654680392509503
BRD-K54187111-001-09-2::2.5::HTS,BRD-K54187111-001-09-2,dichlorisone-acetate,2.5,HTS,Exp_LOH12CR2 (ENSG00000205791),GE,noncancer,,,,,Phase 2,0.298636035870415,0.0787752918308,dichlorisone-acetate,OTHER,0.2954401662777057,-1.7731104359028045,-2.8267855124659103
BRD-K54262262-001-09-0::2.5::HTS,BRD-K54262262-001-09-0,monobenzone,2.5,HTS,METHYL_MIR4297,METHYL,noncancer,melanin inhibitor,TYR,dermatology,skin depigmentation,Launched,0.38261480307079904,0.235188182685,monobenzone,OTHER,0.3916407375866244,-3.0281059463046374,-0.4559666264213482
BRD-K54330070-001-15-4::2.5::HTS,BRD-K54330070-001-15-4,SB-202190,2.5,HTS,CRISPR_LRRC57 (255252),AVANA_PUBLIC_18Q2,targeted cancer,p38 MAPK inhibitor,"AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.26949883821842996,0.116318573556,SB-202190,OTHER,0.2631687225743732,1.0076169563609292,-5.283829230411394
BRD-K54395039-001-01-7::2.5::HTS,BRD-K54395039-001-01-7,PR-619,2.5,HTS,Exp_GCLC (ENSG00000001084),GE,noncancer,DUB inhibitor,,,,Preclinical,0.491908191869293,0.32479671892,PR-619,OTHER,0.4913986832340397,1.7507822933276689,-3.5895064330915307
BRD-K54634444-001-05-9::2.5::HTS,BRD-K54634444-001-05-9,artesunate,2.5,HTS,Exp_ALDH3B1 (ENSG00000006534),GE,noncancer,DNA synthesis inhibitor,,infectious disease,malaria,Launched,0.36702947709593603,0.302265169101,artesunate,OTHER,0.34354413686861784,1.4873235784925476,-3.436563937524004
BRD-K54955827-001-02-2::2.49997945::MTS004,BRD-K54955827-001-02-2,niraparib,2.49997945,MTS004,Exp_TCF3 (ENSG00000071564),GE,targeted cancer,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),Launched,0.41437852569753403,0.309180857293,niraparib,OTHER,0.4151824653298735,3.4539016679660026,-3.7683739486231267
BRD-K55187425-236-05-2::2.5::HTS,BRD-K55187425-236-05-2,rigosertib,2.5,HTS,METHYL_CNNM4,METHYL,targeted cancer,cell cycle inhibitor,PLK1,,,Phase 3,0.373076461455072,0.129190126737,rigosertib,OTHER,0.3690454991645071,5.512029782903807,-1.070784467256404
BRD-K55187425-236-05-2::2.5::HTS,BRD-K55187425-236-05-2,rigosertib,2.5,HTS,METHYL_CNNM4,METHYL,targeted cancer,PLK inhibitor,PLK1,,,Phase 3,0.373076461455072,0.129190126737,rigosertib,OTHER,0.3690454991645071,5.512029782903807,-1.070784467256404
BRD-K55305701-001-01-2::2.5::HTS,BRD-K55305701-001-01-2,SC-144,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,targeted cancer,P glycoprotein inhibitor,,,,Preclinical,0.39880938884809003,0.319068497165,SC-144,OTHER,0.4050485349193489,4.137803973815686,-2.098746069854724
BRD-K55462201-001-07-3::2.5::HTS,BRD-K55462201-001-07-3,AM-404,2.5,HTS,Exp_CD44 (ENSG00000026508),GE,noncancer,cyclooxygenase inhibitor,"CNR1, CNR2, FAAH, TRPV1",,,Preclinical,0.34359095241021903,0.249844369823,AM-404,OTHER,0.3425342064610264,-5.246861966321298,-1.5545291733815048
BRD-K55462201-001-07-3::2.5::HTS,BRD-K55462201-001-07-3,AM-404,2.5,HTS,Exp_CD44 (ENSG00000026508),GE,noncancer,FAAH inhibitor,"CNR1, CNR2, FAAH, TRPV1",,,Preclinical,0.34359095241021903,0.249844369823,AM-404,OTHER,0.3425342064610264,-5.246861966321298,-1.5545291733815048
BRD-K55462201-001-07-3::2.5::HTS,BRD-K55462201-001-07-3,AM-404,2.5,HTS,Exp_CD44 (ENSG00000026508),GE,noncancer,TRPV antagonist,"CNR1, CNR2, FAAH, TRPV1",,,Preclinical,0.34359095241021903,0.249844369823,AM-404,OTHER,0.3425342064610264,-5.246861966321298,-1.5545291733815048
BRD-K56032964-001-02-1::2.5::HTS,BRD-K56032964-001-02-1,AP26113,2.5,HTS,PROT_CD49b,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",,,Phase 2,0.35334075825424394,0.352713410275,AP26113,OTHER,0.35022051157164513,2.4560142083241883,-2.519333247639709
BRD-K56301217-001-07-4::2.5::HTS,BRD-K56301217-001-07-4,ABT-737,2.5,HTS,Exp_LYPD1 (ENSG00000150551),GE,targeted cancer,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",,,Phase 1/Phase 2,0.43464344713799996,0.160642679536,ABT-737,OTHER,0.43471690273104496,-2.598117266596161,-0.1639332915520173
BRD-K56405753-001-02-4::2.5::HTS,BRD-K56405753-001-02-4,MK-2461,2.5,HTS,PROT_HER3,PROT,targeted cancer,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",,,Phase 1/Phase 2,0.4683058496110529,0.346705398448,MK-2461,OTHER,0.48428806940021396,1.0770514990723847,-2.355992299816582
BRD-K56614220-001-19-0::2.5::HTS,BRD-K56614220-001-19-0,clofazimine,2.5,HTS,CRISPR_GNG5 (2787),AVANA_PUBLIC_18Q2,noncancer,GK0582 inhibitor,,infectious disease,leprosy,Launched,0.33706256713694605,0.126667135166,clofazimine,OTHER,0.33703748007682205,0.8377462691742034,-3.5464142360117705
BRD-K56751279-300-01-4::2.5::HTS,BRD-K56751279-300-01-4,Y-39983,2.5,HTS,PROT_Myosin IIa pS1943,PROT,noncancer,rho associated kinase inhibitor,"ROCK1, ROCK2",,,Phase 2,0.23484367617362198,0.150400998843,Y-39983,OTHER,0.2329938323457509,3.256665161462553,-3.19598375439336
BRD-K56908511-001-01-2::2.5::HTS,BRD-K56908511-001-01-2,fluroxene,2.5,HTS,Exp_M1AP (ENSG00000159374),GE,noncancer,local anesthetic,,,,Preclinical,0.348338111712422,0.0479280686301,fluroxene,OTHER,0.3482828207966577,-3.9686702346642,-2.8335445045288834
BRD-K56981171-001-01-0::2.500008954::MTS004,BRD-K56981171-001-01-0,brigatinib,2.500008954,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),Launched,0.367757423930709,0.274119975957,brigatinib,OTHER,0.3656658992773486,2.4624851837319883,-2.283017707249601
BRD-K58049875-001-04-7::2.5::HTS,BRD-K58049875-001-04-7,thiostrepton,2.5,HTS,Exp_ANXA4 (ENSG00000196975),GE,noncancer,FOXM1 inhibitor,FOXM1,obstetrics/gynecology,mastitis,Launched,0.438400583472128,0.436223920492,thiostrepton,OTHER,0.4371872187105839,4.798335223109503,-1.9371095930235835
BRD-K58049875-001-04-7::2.5::HTS,BRD-K58049875-001-04-7,thiostrepton,2.5,HTS,Exp_ANXA4 (ENSG00000196975),GE,noncancer,protein synthesis inhibitor,FOXM1,obstetrics/gynecology,mastitis,Launched,0.438400583472128,0.436223920492,thiostrepton,OTHER,0.4371872187105839,4.798335223109503,-1.9371095930235835
BRD-K58148589-001-03-6::2.5::HTS,BRD-K58148589-001-03-6,betamethasone-dipropionate,2.5,HTS,Exp_CCNE1 (ENSG00000105173),GE,noncancer,anti-inflammatory agent,,dermatology,corticosteroid-responsive dermatoses,Launched,0.301421366702493,0.207182588018,betamethasone-dipropionate,OTHER,0.29886378564261845,-1.0350335919017977,-2.57517379678008
BRD-K58262659-001-09-7::2.5::HTS,BRD-K58262659-001-09-7,doxifluridine,2.5,HTS,Exp_AIFM3 (ENSG00000183773),GE,targeted cancer,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,Launched,0.329888993883274,0.159017632508,doxifluridine,OTHER,0.3297848967855579,5.582766252938072,0.5299807560112486
BRD-K58299615-001-03-5::2.5::HTS,BRD-K58299615-001-03-5,Ro-90-7501,2.5,HTS,Exp_PRDM13 (ENSG00000112238),GE,noncancer,,APP,,,Preclinical,0.262772148966588,0.107365787967,Ro-90-7501,OTHER,0.2620844478167294,-5.5983514420604585,1.938493962019113
BRD-K58466253-003-14-0::2.5::HTS,BRD-K58466253-003-14-0,palmatine-chloride,2.5,HTS,METABOL_C34:1 DAG,METABOL,noncancer,dopamine synthesis inhibitor,CYP3A4,,,Preclinical,0.30517739646715997,0.110454796293,palmatine-chloride,OTHER,0.3166675458372319,0.5798162826699537,-3.488456545169263
BRD-K58529924-001-01-5::2.648577938::MTS004,BRD-K58529924-001-01-5,ONC201,2.648577938,MTS004,Exp_CLPP (ENSG00000125656),GE,targeted cancer,MAP kinase inhibitor,TNFSF10,,,Phase 2,0.407521886838256,0.299797365554,ONC201,OTHER,0.4074141992397822,5.843474302636162,-3.4015639829355413
BRD-K58550667-001-08-7::2.5::HTS,BRD-K58550667-001-08-7,FK-866,2.5,HTS,Exp_COQ3 (ENSG00000132423),GE,targeted cancer,niacinamide phosphoribosyltransferase inhibitor,NAMPT,,,Phase 2,0.31507375847978397,0.200609440087,FK-866,OTHER,0.32155625285169304,4.020140660177213,-0.8031531359173371
BRD-K59058747-001-18-3::2.5::HTS,BRD-K59058747-001-18-3,acetylcysteine,2.5,HTS,MUTpool_ISLR (3671),MUTpool,noncancer,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury",Launched,0.33246571712127504,0.161176411332,acetylcysteine,OTHER,0.33823524754145473,4.939578743277925,0.4990213848080442
BRD-K59146805-001-03-7::2.5::HTS,BRD-K59146805-001-03-7,AZ3146,2.5,HTS,Exp_SLC2A4 (ENSG00000181856),GE,noncancer,monopolar spindle 1 kinase inhibitor,,,,Preclinical,0.437334619421318,0.296758287176,AZ3146,OTHER,0.4367646458227093,3.0806045298927907,-3.5558640980468565
BRD-K59227464-334-02-4::2.5::HTS,BRD-K59227464-334-02-4,LY2228820,2.5,HTS,Exp_CC2D2A (ENSG00000048342),GE,noncancer,p38 MAPK inhibitor,MAPK14,,,Phase 2,0.293804135663236,0.149375079185,LY2228820,OTHER,0.2937655662513713,1.0966295889031097,-5.274967118920554
BRD-K59369769-001-20-3::2.5::HTS,BRD-K59369769-001-20-3,tozasertib,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Bcr-Abl kinase inhibitor,"AURKA, AURKB, AURKC, LCK",,,Phase 2,0.428469836257435,0.276321736551,tozasertib,OTHER,0.428818440470585,3.6397995088752855,-4.1885734977152715
BRD-K59369769-001-20-3::2.5::HTS,BRD-K59369769-001-20-3,tozasertib,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,FLT3 inhibitor,"AURKA, AURKB, AURKC, LCK",,,Phase 2,0.428469836257435,0.276321736551,tozasertib,OTHER,0.428818440470585,3.6397995088752855,-4.1885734977152715
BRD-K59369769-001-20-3::2.5::HTS,BRD-K59369769-001-20-3,tozasertib,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,JAK inhibitor,"AURKA, AURKB, AURKC, LCK",,,Phase 2,0.428469836257435,0.276321736551,tozasertib,OTHER,0.428818440470585,3.6397995088752855,-4.1885734977152715
BRD-K59436580-001-01-7::2.5::HTS,BRD-K59436580-001-01-7,tedizolid,2.5,HTS,Exp_NABP1 (ENSG00000173559),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,,infectious disease,skin infections,Launched,0.344769645761844,0.25581856529,tedizolid,OTHER,0.34437851065108555,1.983518279256021,-2.7964147752301347
BRD-K59456551-001-22-6::2.51::HTS,BRD-K59456551-001-22-6,methotrexate,2.51,HTS,Exp_RAN (ENSG00000132341),GE,chemo,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis",Launched,0.323518903240038,0.269635867595,methotrexate,OTHER,0.3233668926106857,3.6497395929465175,-3.107763739427796
BRD-K59831625-001-01-6::2.5::HTS,BRD-K59831625-001-01-6,LDN-212854,2.5,HTS,Exp_SGSM1 (ENSG00000167037),GE,noncancer,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",,,Preclinical,0.373557032798389,0.289747272572,LDN-212854,OTHER,0.3735853304059543,4.178600750676427,-0.3935871336243313
BRD-K59866480-001-07-3::2.379655165::MTS004,BRD-K59866480-001-07-3,cyclovalone,2.379655165,MTS004,Exp_UGT1A10 (ENSG00000242515),GE,noncancer,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,Launched,0.46543332969564,0.425051402789,cyclovalone,OTHER,0.4660241302366827,5.567516816428096,-3.2321370771069966
BRD-K60341624-001-02-2::2.5::HTS,BRD-K60341624-001-02-2,GSK1292263,2.5,HTS,DEM2_PSG11 (5680),DEMETER2_COM,noncancer,glucose dependent insulinotropic receptor agonist,GRPR,,,Phase 2,0.27673137280789895,0.0940849029765,GSK1292263,OTHER,0.2998764415698681,1.9058035168509928,-2.6234587603774155
BRD-K60421517-001-01-4::2.499975038::MTS004,BRD-K60421517-001-01-4,olmutinib,2.499975038,MTS004,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, EGFR",,,Launched,0.285950837429763,0.19212203124,olmutinib,OTHER,0.28719374387290925,1.0389407753759945,-4.7472756211085425
BRD-K60443845-001-08-6::2.5::HTS,BRD-K60443845-001-08-6,chlormidazole,2.5,HTS,Exp_TGFBI (ENSG00000120708),GE,noncancer,fungal lanosterol demethylase inhibitor,,infectious disease,fungal infection,Launched,0.3543451188660429,0.359555737398,chlormidazole,OTHER,0.34216905531629616,2.2613846841443723,-2.563899790526074
BRD-K60997853-001-02-3::2.5::HTS,BRD-K60997853-001-02-3,PHA-848125,2.5,HTS,Exp_VIMP (ENSG00000131871),GE,targeted cancer,growth factor receptor inhibitor,"CDK2, CDK4, CDK7, NTRK1",,,Phase 2,0.383647133525259,0.246675312923,PHA-848125,OTHER,0.3816800686915989,4.600710803837272,-0.3425969732370153
BRD-K61228301-001-01-2::2.5::HTS,BRD-K61228301-001-01-2,SGI-1027,2.5,HTS,Exp_ZEB1 (ENSG00000148516),GE,targeted cancer,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",,,Preclinical,0.433014605865255,0.409782147821,SGI-1027,OTHER,0.4304754076375288,5.0783511766521645,-1.7899167122874378
BRD-K61314889-001-05-1::2.5::HTS,BRD-K61314889-001-05-1,endo-IWR-1,2.5,HTS,Exp_ADAMTS9 (ENSG00000163638),GE,targeted cancer,PARP inhibitor,"TNKS, TNKS2",,,Preclinical,0.32119923294479696,0.246458949744,endo-IWR-1,OTHER,0.3272762077265803,-4.654040648177415,-0.30390077927996906
BRD-K61323504-001-04-0::2.5::HTS,BRD-K61323504-001-04-0,SB-225002,2.5,HTS,Exp_ANXA4 (ENSG00000196975),GE,noncancer,CC chemokine receptor antagonist,CXCR2,,,Preclinical,0.397135622457574,0.324414195354,SB-225002,OTHER,0.3969775252454045,5.2713606412634935,-3.4530302796581864
BRD-K61443650-236-13-1::2.5::HTS,BRD-K61443650-236-13-1,thiomersal,2.5,HTS,Exp_TMEM45B (ENSG00000151715),GE,noncancer,other antibiotic,OXCT1,,,Launched,0.38405723066562103,0.386717111546,thiomersal,OTHER,0.387033069393356,4.649908090558196,-1.3032725085614052
BRD-K61734568-003-02-1::2.5::HTS,BRD-K61734568-003-02-1,"2,3-DCPE",2.5,HTS,Exp_C2CD5 (ENSG00000111731),GE,targeted cancer,Bcl-XL downregulator,BCL2L1,,,Preclinical,0.48875772902993503,0.451767037458,"2,3-DCPE",OTHER,0.4914802927320253,4.340651679856122,-3.7444656541224153
BRD-K62196610-001-01-6::2.5::HTS,BRD-K62196610-001-01-6,AVN-944,2.5,HTS,CRISPR_FCGR3B (2215),AVANA_PUBLIC_18Q2,targeted cancer,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",,,Phase 2,0.33545396490744606,0.267587172058,AVN-944,OTHER,0.3459612635142289,2.6737878388123417,-3.4226481951148644
BRD-K62200014-003-10-5::2.5::HTS,BRD-K62200014-003-10-5,anagrelide,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,targeted cancer,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms",Launched,0.41186644278968,0.312634136757,anagrelide,OTHER,0.4233657394898525,2.748733660439179,-2.3553403464243594
BRD-K62213621-001-01-6::2.5::HTS,BRD-K62213621-001-01-6,dihydroartemisinin,2.5,HTS,Exp_CDC25A (ENSG00000164045),GE,noncancer,antimalarial agent,,infectious disease,malaria,Launched,0.393545965161635,0.28756275407,dihydroartemisinin,OTHER,0.3943210923204053,1.1166820431795779,-3.494864206819159
BRD-K62696033-001-01-4::2.5::HTS,BRD-K62696033-001-01-4,G-1,2.5,HTS,DEM2_UGT1A3 (54659),DEMETER2_COM,targeted cancer,G protein-coupled receptor agonist,GPER1,,,Preclinical,0.409392791745646,0.295980867148,G-1,OTHER,0.4094539851467381,5.1620830047298165,-3.2185814952975704
BRD-K62965247-001-04-9::2.5::HTS,BRD-K62965247-001-04-9,tipifarnib,2.5,HTS,Exp_CAD (ENSG00000084774),GE,targeted cancer,farnesyltransferase inhibitor,"FNTA, FNTB",,,Phase 3,0.34741296868028304,0.2509227196,tipifarnib,OTHER,0.3457636080373148,2.676672098137527,-3.628988175787144
BRD-K63750851-001-20-7::2.5::HTS,BRD-K63750851-001-20-7,mycophenolic-acid,2.5,HTS,Exp_CREBRF (ENSG00000164463),GE,noncancer,dehydrogenase inhibitor,"IMPDH1, IMPDH2",transplant,organ rejection,Launched,0.36066723084308705,0.306898397264,mycophenolic-acid,OTHER,0.3598391378625777,2.807586907292055,-3.3326240347035467
BRD-K63750851-001-20-7::2.5::HTS,BRD-K63750851-001-20-7,mycophenolic-acid,2.5,HTS,Exp_CREBRF (ENSG00000164463),GE,noncancer,inositol monophosphatase inhibitor,"IMPDH1, IMPDH2",transplant,organ rejection,Launched,0.36066723084308705,0.306898397264,mycophenolic-acid,OTHER,0.3598391378625777,2.807586907292055,-3.3326240347035467
BRD-K64120610-001-01-4::2.5::MTS004,BRD-K64120610-001-01-4,vinflunine,2.5,MTS004,Exp_BCL2L1 (ENSG00000171552),GE,chemo,microtubule inhibitor,,oncology,bladder cancer,Launched,0.3528620272956429,0.29667900876,vinflunine,OTHER,0.3559878823179365,5.600436462417027,-3.6679086223822304
BRD-K64881305-001-03-7::2.5::HTS,BRD-K64881305-001-03-7,ispinesib,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,targeted cancer,kinesin inhibitor,KIF11,,,Phase 2,0.38238087176218205,0.252655357663,ispinesib,OTHER,0.3830314395636396,5.559164752796629,-2.1816479401400706
BRD-K64888243-001-03-7::2.5::HTS,BRD-K64888243-001-03-7,AZ960,2.5,HTS,Exp_KAT2B (ENSG00000114166),GE,targeted cancer,JAK inhibitor,JAK2,,,Preclinical,0.38573365367690704,0.368571353278,AZ960,OTHER,0.3847858434489003,3.8419466746314495,-3.354439424075609
BRD-K64890080-001-13-8::2.5::HTS,BRD-K64890080-001-13-8,BI-2536,2.5,HTS,Exp_ANAPC1 (ENSG00000153107),GE,targeted cancer,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",,,Phase 2,0.41067411913265994,0.327747244945,BI-2536,OTHER,0.4114876937097006,4.464282520347017,-1.3962876095246837
BRD-K65146499-001-27-9::2.5::HTS,BRD-K65146499-001-27-9,nabumetone,2.5,HTS,RMUTmis_C16orf86 (388284),MUTmis,noncancer,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",Launched,0.287265813889184,0.0931418602346,nabumetone,OTHER,0.28723485717224395,3.9268514699009742,1.2625214628129509
BRD-K65814004-003-02-9::2.5::HTS,BRD-K65814004-003-02-9,diphenyleneiodonium,2.5,HTS,DEM2_DDX27 (55661),DEMETER2_COM,targeted cancer,nitric oxide synthase inhibitor,"NOS2, NOS3",,,Preclinical,0.378745028643943,0.276776327948,diphenyleneiodonium,OTHER,0.40027741991380794,4.191204066321145,-1.9990388665176315
BRD-K65928735-001-04-3::2.5::HTS,BRD-K65928735-001-04-3,AZD1480,2.5,HTS,PROT_Gab2,PROT,targeted cancer,JAK inhibitor,"JAK1, JAK2, JAK3",,,Phase 1,0.337266602679702,0.115222949365,AZD1480,OTHER,0.30981413263113844,5.644047433589159,-2.750766387991246
BRD-K66538826-001-07-2::2.5::HTS,BRD-K66538826-001-07-2,amuvatinib,2.5,HTS,Exp_RTBDN (ENSG00000132026),GE,targeted cancer,FLT3 inhibitor,"KIT, MET",,,Phase 2,0.27399724559714,0.164685101792,amuvatinib,OTHER,0.2780070596740157,0.8926978724172016,-3.3020033144944865
BRD-K66538826-001-07-2::2.5::HTS,BRD-K66538826-001-07-2,amuvatinib,2.5,HTS,Exp_RTBDN (ENSG00000132026),GE,targeted cancer,KIT inhibitor,"KIT, MET",,,Phase 2,0.27399724559714,0.164685101792,amuvatinib,OTHER,0.2780070596740157,0.8926978724172016,-3.3020033144944865
BRD-K66538826-001-07-2::2.5::HTS,BRD-K66538826-001-07-2,amuvatinib,2.5,HTS,Exp_RTBDN (ENSG00000132026),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"KIT, MET",,,Phase 2,0.27399724559714,0.164685101792,amuvatinib,OTHER,0.2780070596740157,0.8926978724172016,-3.3020033144944865
BRD-K66538826-001-07-2::2.5::HTS,BRD-K66538826-001-07-2,amuvatinib,2.5,HTS,Exp_RTBDN (ENSG00000132026),GE,targeted cancer,RAD51 inhibitor,"KIT, MET",,,Phase 2,0.27399724559714,0.164685101792,amuvatinib,OTHER,0.2780070596740157,0.8926978724172016,-3.3020033144944865
BRD-K66808046-065-03-7::2.5::HTS,BRD-K66808046-065-03-7,oxyquinoline,2.5,HTS,Exp_AMPD3 (ENSG00000133805),GE,noncancer,chelating agent,METAP2,dermatology,cosmetic,Launched,0.413222447891725,0.282244023188,oxyquinoline,OTHER,0.4026195366087261,3.4441989301531275,-1.8687283737824412
BRD-K67173685-001-06-9::2.39::HTS,BRD-K67173685-001-06-9,4E1RCat,2.39,HTS,Exp_GLT8D2 (ENSG00000120820),GE,noncancer,protein synthesis inhibitor,"EIF4E, EIF4G1",,,Preclinical,0.35157676195670196,0.149539291446,4E1RCat,OTHER,0.3418339415601519,1.4553555999176329,-3.2234907350974087
BRD-K67298865-001-09-0::2.5::HTS,BRD-K67298865-001-09-0,SB-431542,2.5,HTS,PROT_PAI-1,PROT,targeted cancer,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",,,Preclinical,0.300370013269853,0.0657908332393,SB-431542,OTHER,0.3001957140637233,2.860167267930517,-0.5766815724554433
BRD-K67536197-003-11-4::2.5::HTS,BRD-K67536197-003-11-4,cyclocytidine,2.5,HTS,PROT_Bcl-xL,PROT,chemo,DNA synthesis inhibitor,,,,Preclinical,0.39804866844924,0.186706475954,cyclocytidine,OTHER,0.3873088401768582,4.441358632413109,-1.7215216335107728
BRD-K67536197-003-11-4::2.5::HTS,BRD-K67536197-003-11-4,cyclocytidine,2.5,HTS,PROT_Bcl-xL,PROT,chemo,RNA synthesis inhibitor,,,,Preclinical,0.39804866844924,0.186706475954,cyclocytidine,OTHER,0.3873088401768582,4.441358632413109,-1.7215216335107728
BRD-K67844266-003-01-9::2.5::HTS,BRD-K67844266-003-01-9,pevonedistat,2.5,HTS,Exp_PGM2 (ENSG00000169299),GE,targeted cancer,nedd activating enzyme inhibitor,"NAE1, UBA3",,,Phase 2,0.379891253916675,0.290614553968,pevonedistat,OTHER,0.3801360231187552,4.504968723751986,-1.9045517644570715
BRD-K68164687-001-01-6::2.5::HTS,BRD-K68164687-001-01-6,epothilone-b,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",,,Phase 3,0.417752218533801,0.273207755121,epothilone-b,OTHER,0.4151753887802863,5.175861298526113,-2.5120452124136032
BRD-K68188368-001-09-4::2.5::HTS,BRD-K68188368-001-09-4,nifuroxazide,2.5,HTS,Exp_THBS1 (ENSG00000137801),GE,noncancer,bacterial DNA inhibitor,,gastroenterology,"colitis, diarrhea",Launched,0.30885476387691496,0.210049409357,nifuroxazide,OTHER,0.31354130003239866,-4.673706841905124,-0.705761648366602
BRD-K68408467-065-01-8::2.5::HTS,BRD-K68408467-065-01-8,proflavine-hemisulfate,2.5,HTS,Exp_USP27X-AS1 (ENSG00000234390),GE,noncancer,topical anesthetic,F2,,,Phase 2,0.342344077384886,0.241562703096,proflavine-hemisulfate,OTHER,0.3423436623263326,3.908571468907057,-2.409232056792102
BRD-K68408772-001-05-4::2.420640995::MTS004,BRD-K68408772-001-05-4,carboxyamidotriazole,2.420640995,MTS004,METABOL_C34:1 DAG,METABOL,targeted cancer,calcium channel blocker,CXCL8,,,Phase 3,0.37239988836758897,0.190707062723,carboxyamidotriazole,OTHER,0.3407150472023993,1.5674827152854052,-2.9829192604210113
BRD-K68488863-001-04-9::2.5::HTS,BRD-K68488863-001-04-9,ENMD-2076,2.5,HTS,Exp_VIMP (ENSG00000131871),GE,targeted cancer,FLT3 inhibitor,"AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",,,Phase 2,0.419573999076324,0.330685283464,ENMD-2076,OTHER,0.4160230237769837,3.3497626168475745,-3.5323933776314216
BRD-K68502831-001-01-2::2.5::HTS,BRD-K68502831-001-01-2,dianhydrogalactitol,2.5,HTS,CRISPR_C15orf41 (84529),AVANA_PUBLIC_18Q2,chemo,DNA alkylating agent,,,,Phase 1,0.431389614618363,0.328179574013,dianhydrogalactitol,OTHER,0.4149677082419415,2.5835397035463035,-4.067893498026116
BRD-K68532323-003-02-8::2.5::HTS,BRD-K68532323-003-02-8,SB-743921,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,kinesin-like spindle protein inhibitor,KIF11,,,Phase 1/Phase 2,0.39726442940778295,0.350864161658,SB-743921,OTHER,0.3994934654873061,5.299922154928587,-2.391479683405234
BRD-K68552125-001-05-3::2.03::HTS,BRD-K68552125-001-05-3,12-O-tetradecanoylphorbol-13-acetate,2.03,HTS,Exp_ABI2 (ENSG00000138443),GE,targeted cancer,PKC activator,"KCNT2, TRPV4",,,Phase 2,0.365045579915165,0.0751432568722,12-O-tetradecanoylphorbol-13-acetate,OTHER,0.3580324659557653,-0.2376587155003416,-3.2952089257067376
BRD-K68567222-001-01-2::2.5::HTS,BRD-K68567222-001-01-2,BVT-948,2.5,HTS,PROT_ATM,PROT,noncancer,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",,,Preclinical,0.309269901566963,0.108387439346,BVT-948,OTHER,0.30868491167540185,3.2443460765404604,-2.1948490465326818
BRD-K68633617-003-02-9::2.5::HTS,BRD-K68633617-003-02-9,ACDPP,2.5,HTS,Exp_PTMAP3 (ENSG00000218902),GE,noncancer,glutamate receptor antagonist,GRM5,,,Preclinical,0.305568914246038,0.183516319587,ACDPP,OTHER,0.3127729826452361,-1.7365933492412535,0.8820810644682082
BRD-K68870568-066-01-5::2.5::HTS,BRD-K68870568-066-01-5,flumatinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",,,Phase 3,0.28830478043145097,0.29316189043,flumatinib,OTHER,0.2877824254396794,2.1689786421404595,-1.3756394993715837
BRD-K69688083-004-23-1::2.5::HTS,BRD-K69688083-004-23-1,mestinon,2.5,HTS,PROT_TIGAR,PROT,noncancer,cholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,myasthenia gravis,Launched,0.259445172485159,0.205590096258,mestinon,OTHER,0.27879760389537833,-4.184096611198482,-3.2050387449556528
BRD-K69726595-001-01-2::2.5::HTS,BRD-K69726595-001-01-2,mericitabine,2.5,HTS,CN_LINC00266-1 (140849),CN,noncancer,HCV inhibitor,,,,Phase 2,0.39885937637813107,0.174256186353,mericitabine,OTHER,0.3601680902621154,2.1080827879612314,-2.871410318557917
BRD-K69776681-001-03-8::2.5::HTS,BRD-K69776681-001-03-8,volasertib,2.5,HTS,Exp_SYNCRIP (ENSG00000135316),GE,targeted cancer,PLK inhibitor,PLK1,,,Phase 3,0.412494959073185,0.353806616584,volasertib,OTHER,0.4153937775783579,4.677176340758108,-1.5938765577898426
BRD-K70301465-001-02-6::2.5::HTS,BRD-K70301465-001-02-6,ibrutinib,2.5,HTS,Exp_EPHA1 (ENSG00000146904),GE,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)",Launched,0.460161825324805,0.544113055586,ibrutinib,OTHER,0.4483161795645612,1.1720934931622151,-4.983575100511873
BRD-K70358946-001-15-7::2.5::HTS,BRD-K70358946-001-15-7,aripiprazole,2.5,HTS,DEM2_ADSL (158),DEMETER2_COM,noncancer,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder",Launched,0.308035514598172,0.146393525284,aripiprazole,OTHER,0.3028137096745728,4.326480274021579,-2.5936863675551445
BRD-K70358946-001-15-7::2.5::HTS,BRD-K70358946-001-15-7,aripiprazole,2.5,HTS,DEM2_ADSL (158),DEMETER2_COM,noncancer,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder",Launched,0.308035514598172,0.146393525284,aripiprazole,OTHER,0.3028137096745728,4.326480274021579,-2.5936863675551445
BRD-K71075609-003-01-0::2.5::HTS,BRD-K71075609-003-01-0,dorzolamide,2.5,HTS,PROT_beta-Catenin,PROT,noncancer,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",Launched,0.27220239811045,0.10787074606,dorzolamide,OTHER,0.2807751485853074,4.532269585738664,-1.3583140333048962
BRD-K71106091-001-06-1::2.5::HTS,BRD-K71106091-001-06-1,fludarabine-phosphate,2.5,HTS,PROT_MEK1_pS217_S221,PROT,chemo,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),Launched,0.37666253050504706,0.107465224313,fludarabine-phosphate,OTHER,0.3710802899991829,3.80373087146532,-2.0735362308109897
BRD-K71164191-001-01-0::2.5::HTS,BRD-K71164191-001-01-0,KD-023,2.5,HTS,Exp_DUSP4 (ENSG00000120875),GE,noncancer,ACAT inhibitor,"ACACA, ACACB",,,Phase 2,0.376988146295634,0.217467960773,KD-023,OTHER,0.3800870135902778,0.17057094067218145,-4.14161885003924
BRD-K71823332-001-03-7::2.5::HTS,BRD-K71823332-001-03-7,epothilone-a,2.5,HTS,Exp_TP53INP1 (ENSG00000164938),GE,chemo,microtubule stabilizing agent,,,,Preclinical,0.40867938337677395,0.204401581311,epothilone-a,OTHER,0.4075783057456101,6.166653726361832,-1.752809426720857
BRD-K72167406-001-02-1::2.5::HTS,BRD-K72167406-001-02-1,cefditoren-pivoxil,2.5,HTS,PROT_4E-BP1,PROT,noncancer,bacterial cell wall synthesis inhibitor,,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis",Launched,0.351524390550308,0.209214527402,cefditoren-pivoxil,OTHER,0.35104612359819376,5.920965767190702,-2.077805804477647
BRD-K72280606-001-01-2::2.499993939::MTS004,BRD-K72280606-001-01-2,gilteritinib,2.499993939,MTS004,CN_KLK1 (3816),CN,targeted cancer,FLT3 inhibitor,FLT3,,,Phase 3,0.35626074979837796,0.0935729420253,gilteritinib,OTHER,0.3591658410126348,1.6538711566906423,-2.378962043736041
BRD-K72327355-001-14-7::2.5::HTS,BRD-K72327355-001-14-7,baicalein,2.5,HTS,METHYL_HNRNPA3P1,METHYL,targeted cancer,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",,,Preclinical,0.382081033146156,0.215479518197,baicalein,OTHER,0.3895300992039917,-3.45343489104397,0.22187840784613003
BRD-K72723676-003-17-8::2.5::HTS,BRD-K72723676-003-17-8,benzethonium,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,Launched,0.399975896816741,0.487864972805,benzethonium,OTHER,0.40288718739637824,3.5046876978354913,-1.8513523645158452
BRD-K72815923-034-01-2::2.5::HTS,BRD-K72815923-034-01-2,xanomeline,2.5,HTS,Exp_TCTEX1D4 (ENSG00000188396),GE,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",,,Phase 3,0.352562459806253,0.30540485412,xanomeline,OTHER,0.3531823979496405,5.354969698005793,-2.974644142345512
BRD-K72827473-001-01-0::2.5::HTS,BRD-K72827473-001-01-0,CEP-37440,2.5,HTS,PROT_mTOR_pS2448_Caution,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,ALK,,,Phase 1,0.32774569644235396,0.0904197070595,CEP-37440,OTHER,0.3321357090110255,1.1698176902265185,-2.9423659292655584
BRD-K72912098-001-02-3::2.5::HTS,BRD-K72912098-001-02-3,telaprevir,2.5,HTS,METHYL_SIX4,METHYL,noncancer,HCV inhibitor,"CTSA, PGR",infectious disease,hepatitis C,Launched,0.29556367545176,0.0265483329628,telaprevir,OTHER,0.3004689196482322,0.8452478798380322,-3.4104311364372717
BRD-K72951360-001-01-4::2.5::HTS,BRD-K72951360-001-01-4,valrubicin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,chemo,DNA inhibitor,TOP2A,oncology,bladder cancer,Launched,0.39401892317501,0.223806057429,valrubicin,OTHER,0.3953000624723401,4.289489230790103,-1.6377493918822807
BRD-K73073971-001-01-7::2.5::HTS,BRD-K73073971-001-01-7,ZLN005,2.5,HTS,PROT_Bap1 c-4,PROT,noncancer,,,,,Preclinical,0.29285941361489193,0.0414571611338,ZLN005,OTHER,0.2804439286711608,-4.399982315034057,-2.5678772507701426
BRD-K73132780-001-01-2::2.5::MTS004,BRD-K73132780-001-01-2,pyronaridine,2.5,MTS004,CRISPR_DCLK1 (9201),AVANA_PUBLIC_18Q2,noncancer,antimalarial agent,,,,Phase 3,0.30623718843259395,0.224775488809,pyronaridine,OTHER,0.3114240415709824,4.035050122554559,-2.288617293855534
BRD-K73383190-001-02-3::2.56::HTS,BRD-K73383190-001-02-3,C646,2.56,HTS,METHYL_LRRN4,METHYL,targeted cancer,histone acetyltransferase inhibitor,EP300,,,Preclinical,0.32328175231017,0.171957151883,C646,OTHER,0.3434601805321126,4.729383900676836,-2.2020744456356938
BRD-K73589401-001-23-6::2.5::HTS,BRD-K73589401-001-23-6,corticosterone,2.5,HTS,MIRNA_hsa-miR-153,MIRNA,noncancer,mineralocorticoid receptor agonist,"HSD11B1, NCOA1, NR3C2",,,Preclinical,0.267425789491328,0.109759865771,corticosterone,OTHER,0.2680238073401909,-4.382041803566448,-2.4680194819580734
BRD-K73753850-003-01-6::2.499957259::MTS004,BRD-K73753850-003-01-6,hexaminolevulinate,2.499957259,MTS004,MIRNA_hsa-miR-23b,MIRNA,noncancer,,,radiology,diagnostic agent,Launched,0.441446465470363,0.136649855534,hexaminolevulinate,OTHER,0.4319704613340083,3.460978002226237,-3.065251975385868
BRD-K73982490-001-02-9::2.5::HTS,BRD-K73982490-001-02-9,BI-78D3,2.5,HTS,Exp_FOPNL (ENSG00000133393),GE,noncancer,JNK inhibitor,MAPK8,,,Preclinical,0.373472134569755,0.261153520931,BI-78D3,OTHER,0.3747349193102292,4.268234662849748,-1.4063713358685712
BRD-K74305673-001-06-2::2.5::HTS,BRD-K74305673-001-06-2,IKK-2-inhibitor-V,2.5,HTS,Exp_PDK1 (ENSG00000152256),GE,targeted cancer,IKK inhibitor,IKBKB,,,Phase 1,0.3693223990864679,0.284117600093,IKK-2-inhibitor-V,OTHER,0.3699498297759085,3.9517341243558346,-1.6614229780439596
BRD-K74514084-001-03-9::2.5::HTS,BRD-K74514084-001-03-9,pazopanib,2.5,HTS,Exp_IRS2 (ENSG00000185950),GE,targeted cancer,KIT inhibitor,"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)",Launched,0.368346445231315,0.207058645193,pazopanib,OTHER,0.3750745618453133,0.8877095529391413,-2.216170319595117
BRD-K74514084-001-03-9::2.5::HTS,BRD-K74514084-001-03-9,pazopanib,2.5,HTS,Exp_IRS2 (ENSG00000185950),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)",Launched,0.368346445231315,0.207058645193,pazopanib,OTHER,0.3750745618453133,0.8877095529391413,-2.216170319595117
BRD-K75009076-001-02-1::2.43::HTS,BRD-K75009076-001-02-1,SCH-900776,2.43,HTS,Exp_PRKD3 (ENSG00000115825),GE,targeted cancer,CHK inhibitor,"CDK2, CHEK1",,,Phase 2,0.42185948950345004,0.216424262193,SCH-900776,OTHER,0.4205282807654488,3.0814688080980184,-3.3114744772725624
BRD-K75352575-001-01-3::2.5::HTS,BRD-K75352575-001-01-3,KPT-276,2.5,HTS,Exp_DDX19B (ENSG00000157349),GE,targeted cancer,exportin antagonist,XPO1,,,Preclinical,0.35385999330843604,0.278640317854,KPT-276,OTHER,0.3547195934577096,4.9870774755903,-0.6295462681594706
BRD-K75615183-300-03-9::2.5::HTS,BRD-K75615183-300-03-9,talipexole,2.5,HTS,DEM2_ZNF563 (147837),DEMETER2_COM,noncancer,adrenergic receptor agonist,"ADRA2A, DRD2, HTR3A",infectious disease,genitial herpes,Launched,0.314476800780347,0.00680363461481,talipexole,OTHER,0.2872542075446177,-4.322859524831006,-2.4888734146992673
BRD-K75615183-300-03-9::2.5::HTS,BRD-K75615183-300-03-9,talipexole,2.5,HTS,DEM2_ZNF563 (147837),DEMETER2_COM,noncancer,dopamine receptor agonist,"ADRA2A, DRD2, HTR3A",infectious disease,genitial herpes,Launched,0.314476800780347,0.00680363461481,talipexole,OTHER,0.2872542075446177,-4.322859524831006,-2.4888734146992673
BRD-K75649340-001-13-1::2.5::HTS,BRD-K75649340-001-13-1,tioguanine,2.5,HTS,METHYL_SLC43A3,METHYL,targeted cancer,purine antagonist,,,,Phase 2,0.404745198943381,0.31852120818,tioguanine,OTHER,0.396241943576411,4.018819101350218,-3.8959521894174927
BRD-K75911534-001-01-6::2.5::HTS,BRD-K75911534-001-01-6,SU014813,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,KDR,,,Phase 2,0.28002547514731607,0.270261834357,SU014813,OTHER,0.3111302693401125,-0.11698942133317446,-2.46618881723885
BRD-K76064317-001-07-3::2.5::HTS,BRD-K76064317-001-07-3,tyrphostin-AG-1296,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,targeted cancer,FLT3 inhibitor,FLT3,,,Preclinical,0.3639403159978929,0.224941758706,tyrphostin-AG-1296,OTHER,0.3768735058480663,-4.6085972578599765,-1.258682615934262
BRD-K76180386-001-01-6::2.5::HTS,BRD-K76180386-001-01-6,JIB04,2.5,HTS,Exp_IFI16 (ENSG00000163565),GE,noncancer,histone lysine demethylase inhibitor,KDM4E,,,Preclinical,0.46665026659609704,0.273735707306,JIB04,OTHER,0.4665582677575932,2.0392523675706555,-2.530550600913002
BRD-K76210423-001-01-6::2.5::HTS,BRD-K76210423-001-01-6,resiquimod,2.5,HTS,PROT_Rictor_pT1135,PROT,targeted cancer,toll-like receptor agonist,"TLR7, TLR8",,,Phase 3,0.34768506488870005,0.0859248673139,resiquimod,OTHER,0.3409986988937729,4.637021470535684,-1.1901816247037589
BRD-K76634210-001-12-1::2.5::MTS004,BRD-K76634210-001-12-1,idoxuridine,2.5,MTS004,Exp_IGLV4-69 (ENSG00000211637),GE,noncancer,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV),Launched,0.313007250211217,0.310257589061,idoxuridine,OTHER,0.32122421399836193,4.220286863648485,-3.034938973151519
BRD-K76634210-001-14-7::2.5::HTS,BRD-K76634210-001-14-7,idoxuridine,2.5,HTS,Exp_CYR61 (ENSG00000142871),GE,noncancer,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV),Launched,0.313007250211217,0.310257589061,idoxuridine,OTHER,0.3155599337288328,3.861140058102556,-1.5157787793352604
BRD-K76719364-001-02-5::2.466617435::MTS004,BRD-K76719364-001-02-5,GS-9973,2.466617435,MTS004,CRISPR_ESR2 (2100),AVANA_PUBLIC_18Q2,noncancer,syk inhibitor,SYK,,,Phase 2,0.338430719853152,0.0979067957153,GS-9973,OTHER,0.33946238352422153,2.152663377548216,-1.1783193450742506
BRD-K76840893-003-02-5::2.5::HTS,BRD-K76840893-003-02-5,RS-17053,2.5,HTS,METHYL_SNORA26,METHYL,noncancer,adrenergic receptor antagonist,"ADRA1A, ADRA1D",,,Preclinical,0.29630667619094203,0.016324801868,RS-17053,OTHER,0.2896535490337056,2.104369094656282,-3.9917191582563936
BRD-K76973696-001-12-6::2.01::HTS,BRD-K76973696-001-12-6,tryptanthrin,2.01,HTS,Exp_MGST1 (ENSG00000008394),GE,targeted cancer,cyclooxygenase inhibitor,IDO1,,,Preclinical,0.387762714561363,0.169615243653,tryptanthrin,OTHER,0.38716731371818186,1.9917856758413623,-3.1933912802391
BRD-K77627880-001-04-0::2.5::HTS,BRD-K77627880-001-04-0,A205804,2.5,HTS,PROT_Syk,PROT,noncancer,ICAM1 expression inhibitor,"ICAM1, SELE",,,Preclinical,0.316681386326056,0.0607800503754,A205804,OTHER,0.3155739741056414,1.4074977667406556,-3.7092793272732316
BRD-K77685957-300-09-1::2.5::HTS,BRD-K77685957-300-09-1,dequalinium,2.5,HTS,Exp_DNASE2 (ENSG00000105612),GE,targeted cancer,PKC inhibitor,"KCNN1, KCNN3",,,Launched,0.40836752333442894,0.275318282886,dequalinium,OTHER,0.4080119118181262,2.622641884680261,-1.6573586235155968
BRD-K77943374-001-02-8::2.5::HTS,BRD-K77943374-001-02-8,NVP-BVU972,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,targeted cancer,MET inhibitor,MET,,,Preclinical,0.47644902229912495,0.304670800858,NVP-BVU972,OTHER,0.4717925748525042,-0.2433912717274569,0.9601337316072164
BRD-K78055238-001-01-8::2.5::HTS,BRD-K78055238-001-01-8,LY2090314,2.5,HTS,Exp_SUN3 (ENSG00000164744),GE,targeted cancer,glycogen synthase kinase inhibitor,GSK3B,,,Phase 2,0.446208441457377,0.300638475277,LY2090314,OTHER,0.44790210237622896,3.766985883459067,-3.3482240610009297
BRD-K78096648-001-05-7::2.5::HTS,BRD-K78096648-001-05-7,oxiperomide,2.5,HTS,Exp_KHSRP (ENSG00000088247),GE,noncancer,dopamine receptor antagonist,,,,Phase 2,0.340934565698027,0.270979051035,oxiperomide,OTHER,0.3487018568860133,1.9391441414834607,-2.6457165605017163
BRD-K78126613-001-28-5::2.5::HTS,BRD-K78126613-001-28-5,menadione,2.5,HTS,Exp_TXN (ENSG00000136810),GE,noncancer,mitochondrial DNA polymerase inhibitor,"AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis",Launched,0.365982463689741,0.380122543604,menadione,OTHER,0.3700695881239856,1.7539488721595011,-3.3246065750312384
BRD-K78126613-001-28-5::2.5::HTS,BRD-K78126613-001-28-5,menadione,2.5,HTS,Exp_TXN (ENSG00000136810),GE,noncancer,phosphatase inhibitor,"AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis",Launched,0.365982463689741,0.380122543604,menadione,OTHER,0.3700695881239856,1.7539488721595011,-3.3246065750312384
BRD-K78318619-001-02-7::2.5::HTS,BRD-K78318619-001-02-7,PF-4981517,2.5,HTS,RMUTmis_CYP4B1 (1580),MUTmis,noncancer,cytochrome P450 inhibitor,CYP3A4,,,Preclinical,0.300240208550338,0.119249541959,PF-4981517,OTHER,0.30077158309063595,5.334363606389894,-1.9459976872460416
BRD-K78431006-001-10-2::2.5::HTS,BRD-K78431006-001-10-2,crizotinib,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),Launched,0.38024066812541096,0.249735158069,crizotinib,OTHER,0.3748514187931927,3.115312036685613,-3.844793409437172
BRD-K78496197-001-03-9::2.5::HTS,BRD-K78496197-001-03-9,SCS,2.5,HTS,Exp_BEND4 (ENSG00000188848),GE,noncancer,,,,,Preclinical,0.38169480380929,0.160849659318,SCS,OTHER,0.38038215777829343,3.281279818801855,-2.8540579483545723
BRD-K78789465-001-02-4::2.5::HTS,BRD-K78789465-001-02-4,pentagastrin,2.5,HTS,RMUTmis_PCSK1N (27344),MUT,noncancer,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic",Launched,0.27809989856906897,0.0541821033662,pentagastrin,OTHER,0.27860354607787,-1.6614959619110412,-2.629157314057798
BRD-K78960041-001-03-2::2.5::HTS,BRD-K78960041-001-03-2,oxaliplatin,2.5,HTS,Exp_FDXR (ENSG00000161513),GE,chemo,DNA inhibitor,,oncology,colorectal cancer,Launched,0.4044682120540529,0.387962702632,oxaliplatin,OTHER,0.4047515072848979,3.1344480275365543,-1.5933306320948653
BRD-K78960041-001-05-7::2.54::HTS,BRD-K78960041-001-05-7,oxaliplatin,2.54,HTS,Exp_DHX33 (ENSG00000005100),GE,chemo,DNA inhibitor,,oncology,colorectal cancer,Launched,0.4044682120540529,0.387962702632,oxaliplatin,OTHER,0.3596616732132571,3.406969133209727,-3.335131826965561
BRD-K79095980-001-09-6::2.5::HTS,BRD-K79095980-001-09-6,broxuridine,2.5,HTS,Exp_RXRG (ENSG00000143171),GE,targeted cancer,antimetabolite,,,,Phase 2,0.34543696045795597,0.328477621188,broxuridine,OTHER,0.34813895780463977,3.844027494838621,-3.300230507742933
BRD-K79239947-001-06-8::2.5::HTS,BRD-K79239947-001-06-8,PF-573228,2.5,HTS,Exp_DLX6 (ENSG00000006377),GE,targeted cancer,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",,,Preclinical,0.32695185723203807,0.278311044114,PF-573228,OTHER,0.3247653954996983,1.3854161418481232,-3.527444112663108
BRD-K79254416-001-22-6::2.5::HTS,BRD-K79254416-001-22-6,decitabine,2.5,HTS,PROT_Caveolin-1,PROT,targeted cancer,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)",Launched,0.336811773305953,0.266408416379,decitabine,OTHER,0.3463481423982133,4.4383794885183985,-1.89879964184089
BRD-K79259477-001-04-9::2.5::HTS,BRD-K79259477-001-04-9,NVP-BHG712,2.5,HTS,Exp_ARMCX1 (ENSG00000126947),GE,targeted cancer,ephrin inhibitor,EPHB4,,,Preclinical,0.35973486766030605,0.390925476486,NVP-BHG712,OTHER,0.3615210064538831,1.5179018271092413,-2.3778750301123885
BRD-K79612754-001-19-1::2.62::HTS,BRD-K79612754-001-19-1,inosine,2.62,HTS,CN_MIR874 (100126343),CN,noncancer,neurotrophic agent,"PARP1, PNP",,,Launched,0.40672121439395204,0.267490748226,inosine,OTHER,0.40590431439553787,2.870361200647163,-4.111501920094681
BRD-K79711234-001-18-3::2.5::HTS,BRD-K79711234-001-18-3,thiamphenicol,2.5,HTS,Exp_SKOR1 (ENSG00000188779),GE,noncancer,bacterial 50S ribosomal subunit inhibitor,,infectious disease,pelvic inflammatory disease,Launched,0.279377266087428,0.0937339128968,thiamphenicol,OTHER,0.28185266821000843,0.4898464952087144,-3.4097120090143083
BRD-K80480517-001-02-4::2.5::HTS,BRD-K80480517-001-02-4,repsox,2.5,HTS,Exp_ARF4P2 (ENSG00000236527),GE,noncancer,TGF beta receptor inhibitor,TGFBR1,,,Preclinical,0.34950684101813106,0.152285303946,repsox,OTHER,0.33376854087477503,4.363456978051813,-0.9219238271746466
BRD-K81197548-003-01-4::2.5::HTS,BRD-K81197548-003-01-4,NSC-632839,2.5,HTS,Exp_CHST7 (ENSG00000147119),GE,targeted cancer,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",,,Preclinical,0.402727462266002,0.0795232152145,NSC-632839,OTHER,0.36683176739760615,4.750055996966776,0.2207688097198268
BRD-K81225797-001-02-3::2.5::HTS,BRD-K81225797-001-02-3,SCH-58261,2.5,HTS,Exp_FOXA1 (ENSG00000129514),GE,noncancer,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,Preclinical,0.359200931608214,0.231970347432,SCH-58261,OTHER,0.35566165813325845,-1.2725544404406128,0.8689867709463788
BRD-K81405859-300-01-4::2.5::MTS004,BRD-K81405859-300-01-4,JTE-607,2.5,MTS004,Exp_HES7 (ENSG00000179111),GE,noncancer,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",,,Phase 2,0.400334315512565,0.230225595269,JTE-607,OTHER,0.4059820641055381,4.941886706029576,-3.206662039205689
BRD-K81458380-001-04-9::2.5::HTS,BRD-K81458380-001-04-9,CX-4945,2.5,HTS,Exp_C10orf35 (ENSG00000171224),GE,targeted cancer,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",,,Phase 1/Phase 2,0.289062186893456,0.12029831628,CX-4945,OTHER,0.2907713577276801,3.3269333427067296,-2.4507810405259893
BRD-K81528515-001-13-8::2.5::HTS,BRD-K81528515-001-13-8,nilotinib,2.5,HTS,Exp_ELFN1 (ENSG00000225968),GE,targeted cancer,Abl kinase inhibitor,"ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Launched,0.238626865283068,0.122763394996,nilotinib,OTHER,0.2388433404560248,3.0255011572375072,-0.4119071484158163
BRD-K81528515-001-13-8::2.5::HTS,BRD-K81528515-001-13-8,nilotinib,2.5,HTS,Exp_ELFN1 (ENSG00000225968),GE,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Launched,0.238626865283068,0.122763394996,nilotinib,OTHER,0.2388433404560248,3.0255011572375072,-0.4119071484158163
BRD-K81613478-001-01-8::2.5::HTS,BRD-K81613478-001-01-8,gastrodin,2.5,HTS,CN_DNAH11 (8701),CN,noncancer,,,,,Phase 2,0.30170246124506106,0.0735005291992,gastrodin,OTHER,0.2883684179315796,4.471863360954513,-0.7539845218718888
BRD-K81801188-001-02-8::2.5::HTS,BRD-K81801188-001-02-8,PP-121,2.5,HTS,Exp_IL6 (ENSG00000136244),GE,noncancer,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",,,Preclinical,0.37385281808028104,0.22174037605,PP-121,OTHER,0.38033188975138205,2.4265603972509604,-0.6959009454990102
BRD-K82091397-001-03-0::2.5::HTS,BRD-K82091397-001-03-0,SB-239063,2.5,HTS,MIRNA_hsa-miR-100,MIRNA,noncancer,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",,,Preclinical,0.276903573686189,0.263477635264,SB-239063,OTHER,0.2747344067979472,4.086575687972753,-0.247044836031562
BRD-K82135108-001-04-3::2.5::HTS,BRD-K82135108-001-04-3,elesclomol,2.5,HTS,Exp_CCT5 (ENSG00000150753),GE,targeted cancer,oxidative stress inducer,HSPA1A,,,Phase 3,0.35460271790087106,0.24419373054,elesclomol,OTHER,0.353275713205187,3.9028976926442263,-1.0939050656294933
BRD-K82746043-001-15-1::2.5::HTS,BRD-K82746043-001-15-1,navitoclax,2.5,HTS,DEM2_BCL2L1 (598),DEMETER2_COM,targeted cancer,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",,,Phase 2,0.380985702948247,0.430368100161,navitoclax,OTHER,0.4386407978459547,5.881185812047794,-0.3621917871480361
BRD-K82818427-001-02-2::2.39::HTS,BRD-K82818427-001-02-2,batimastat,2.39,HTS,Exp_KBTBD11 (ENSG00000176595),GE,targeted cancer,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",,,Phase 3,0.35895189590023907,0.243640391837,batimastat,OTHER,0.35696236264247105,4.0289344703994665,-2.10034423700451
BRD-K82818427-001-04-8::2.5::HTS,BRD-K82818427-001-04-8,batimastat,2.5,HTS,Exp_TBC1D10A (ENSG00000099992),GE,targeted cancer,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",,,Phase 3,0.35895189590023907,0.243640391837,batimastat,OTHER,0.3595998566286925,3.806071447645016,-1.754767057652737
BRD-K82823804-001-04-1::2.5::HTS,BRD-K82823804-001-04-1,PD-407824,2.5,HTS,DEM2_CHEK1 (1111),DEMETER2_COM,targeted cancer,PKC inhibitor,WEE1,,,Preclinical,0.42400055090235206,0.300496230364,PD-407824,OTHER,0.4223325308807216,3.1653627727019544,-3.0048152445819314
BRD-K83003151-057-02-4::2.35::HTS,BRD-K83003151-057-02-4,alogliptin,2.35,HTS,CRISPR_GANAB (23193),AVANA_PUBLIC_18Q2,noncancer,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Launched,0.33641598365960396,0.0994418636108,alogliptin,OTHER,0.3175522383853337,3.1300467595479415,-3.877217182377156
BRD-K83029223-001-01-3::2.500025378::MTS004,BRD-K83029223-001-01-3,litronesib,2.500025378,MTS004,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,kinesin-like spindle protein inhibitor,KIF11,,,Phase 2,0.38426421445314796,0.305522530592,litronesib,OTHER,0.3875993133860684,5.477335081056327,-3.3935873028302064
BRD-K83257731-003-23-5::2.5::HTS,BRD-K83257731-003-23-5,chloropyramine,2.5,HTS,Exp_RAB34 (ENSG00000109113),GE,noncancer,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",Launched,0.313162470353634,0.247487543947,chloropyramine,OTHER,0.31502797262844623,3.98536643742415,-1.7104362422101662
BRD-K83508485-001-02-7::2.5::HTS,BRD-K83508485-001-02-7,FK-888,2.5,HTS,CN_SPINT4 (391253),CN,noncancer,tachykinin antagonist,"TACR1, TACR2",,,Phase 2,0.284216398606338,0.143324440932,FK-888,OTHER,0.28227317683814745,4.17376711301122,-3.2228501384169848
BRD-K83834509-001-01-1::2.5::HTS,BRD-K83834509-001-01-1,PTC-209,2.5,HTS,Exp_SRA1 (ENSG00000213523),GE,targeted cancer,BMI-1 inhibitor,,,,Preclinical,0.34289320243982596,0.354844625407,PTC-209,OTHER,0.3442804101593254,2.429606111247127,-3.4971130999843982
BRD-K84564571-001-02-4::2.5::HTS,BRD-K84564571-001-02-4,telatinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,KIT inhibitor,KDR,,,Phase 2,0.32797773378045103,0.224507479283,telatinib,OTHER,0.3241875064136507,-3.6786908742942703,0.052515351755042065
BRD-K84564571-001-02-4::2.5::HTS,BRD-K84564571-001-02-4,telatinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,KDR,,,Phase 2,0.32797773378045103,0.224507479283,telatinib,OTHER,0.3241875064136507,-3.6786908742942703,0.052515351755042065
BRD-K84683831-001-01-0::2.5::HTS,BRD-K84683831-001-01-0,radezolid,2.5,HTS,MIRNA_hsa-miR-181a,MIRNA,noncancer,bacterial 30S ribosomal subunit inhibitor,,,,Phase 2,0.340990793441792,0.148978728913,radezolid,OTHER,0.3538387646155585,2.0910125442185152,-2.597648334044032
BRD-K84683831-001-01-0::2.5::HTS,BRD-K84683831-001-01-0,radezolid,2.5,HTS,MIRNA_hsa-miR-181a,MIRNA,noncancer,bacterial 50S ribosomal subunit inhibitor,,,,Phase 2,0.340990793441792,0.148978728913,radezolid,OTHER,0.3538387646155585,2.0910125442185152,-2.597648334044032
BRD-K84810405-003-01-1::2.5::HTS,BRD-K84810405-003-01-1,almorexant,2.5,HTS,CRISPR_MCUR1 (63933),AVANA_PUBLIC_18Q2,noncancer,orexin receptor antagonist,"HCRTR1, HCRTR2",,,Phase 3,0.242256298048061,0.114534956119,almorexant,OTHER,0.25814064180873936,5.759187456935918,2.9094857795421936
BRD-K84868168-001-01-0::2.500006364::MTS004,BRD-K84868168-001-01-0,erdafitinib,2.500006364,MTS004,Exp_IRS2 (ENSG00000185950),GE,targeted cancer,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",,,Phase 2,0.35618456281008704,0.280717900924,erdafitinib,OTHER,0.3748345278686712,1.061811425825637,-2.4102213412973725
BRD-K84996356-001-01-1::2.5::HTS,BRD-K84996356-001-01-1,AZD3514,2.5,HTS,Exp_CPT2 (ENSG00000157184),GE,targeted cancer,androgen receptor modulator,AR,,,Phase 1,0.333998568535456,0.283912920711,AZD3514,OTHER,0.3313313418264485,-3.848967027707739,-0.626452104990264
BRD-K85014146-001-02-5::2.5::HTS,BRD-K85014146-001-02-5,AZD2461,2.5,HTS,METHYL_AGAP2-AS1,METHYL,targeted cancer,PARP inhibitor,,,,Phase 1,0.41023448464251505,0.153222854469,AZD2461,OTHER,0.4058927587358672,2.248180405957924,-4.219396343538353
BRD-K85090592-008-22-7::2.5::HTS,BRD-K85090592-008-22-7,pilocarpine,2.5,HTS,RMUTmis_CC2D1A (54862),MUT,noncancer,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension",Launched,0.263737642171477,0.0136399795613,pilocarpine,OTHER,0.2640411697503265,-0.5699049468445659,-2.2052238347816573
BRD-K85178109-001-02-3::2.5::HTS,BRD-K85178109-001-02-3,fostamatinib,2.5,HTS,PROT_HER3,PROT,noncancer,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP),Launched,0.38155948676445,0.31458132088,fostamatinib,OTHER,0.37707791398114576,1.6700633072138251,-2.4331470630547427
BRD-K85402309-001-06-6::2.5::HTS,BRD-K85402309-001-06-6,dovitinib,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,targeted cancer,FGFR inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,OTHER,0.3209116212941136,4.798277110517273,-1.861827140155172
BRD-K85402309-001-06-6::2.5::HTS,BRD-K85402309-001-06-6,dovitinib,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,targeted cancer,FLT3 inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,OTHER,0.3209116212941136,4.798277110517273,-1.861827140155172
BRD-K85402309-001-06-6::2.5::HTS,BRD-K85402309-001-06-6,dovitinib,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,OTHER,0.3209116212941136,4.798277110517273,-1.861827140155172
BRD-K85402309-389-03-2::2.5::HTS,BRD-K85402309-389-03-2,dovitinib,2.5,HTS,Exp_NASP (ENSG00000132780),GE,targeted cancer,FGFR inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,OTHER,0.39269199754946216,3.339171570179825,-3.737822379584856
BRD-K85402309-389-03-2::2.5::HTS,BRD-K85402309-389-03-2,dovitinib,2.5,HTS,Exp_NASP (ENSG00000132780),GE,targeted cancer,FLT3 inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,OTHER,0.39269199754946216,3.339171570179825,-3.737822379584856
BRD-K85402309-389-03-2::2.5::HTS,BRD-K85402309-389-03-2,dovitinib,2.5,HTS,Exp_NASP (ENSG00000132780),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,OTHER,0.39269199754946216,3.339171570179825,-3.737822379584856
BRD-K85479953-001-11-3::2.5::HTS,BRD-K85479953-001-11-3,STF-62247,2.5,HTS,CRISPR_RNF111 (54778),AVANA_PUBLIC_18Q2,targeted cancer,autophagy inducer,,,,Preclinical,0.305934813134565,0.149062672362,STF-62247,OTHER,0.2972332998965821,5.623682050259154,-0.19539105364522769
BRD-K85554912-001-06-3::2.5::HTS,BRD-K85554912-001-06-3,ivermectin,2.5,HTS,Exp_ISG20 (ENSG00000172183),GE,noncancer,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies",Launched,0.370169298262183,0.116024036019,ivermectin,OTHER,0.3648514988817351,0.6813950567477994,-3.3425514806418146
BRD-K85554912-001-08-9::2.5::HTS,BRD-K85554912-001-08-9,ivermectin,2.5,HTS,DEM2_PNPT1 (87178),DEMETER2_COM,noncancer,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies",Launched,0.33124383641481603,0.189703156785,ivermectin,OTHER,0.31150066928995085,0.3475973877112224,-3.4034219515804214
BRD-K85849709-001-01-5::2.5::HTS,BRD-K85849709-001-01-5,AZD2858,2.5,HTS,Exp_PTGES3P1 (ENSG00000234518),GE,noncancer,glycogen synthase kinase inhibitor,GSK3B,,,Preclinical,0.41480975302834994,0.306682300541,AZD2858,OTHER,0.4124094374711516,5.642496409256357,-0.5365443297230663
BRD-K86118762-001-01-8::2.5::HTS,BRD-K86118762-001-01-8,linsitinib,2.5,HTS,DEM2_AP5M1 (55745),DEMETER2_COM,targeted cancer,IGF-1 inhibitor,"IGF1R, INSR, INSRR",,,Phase 3,0.318858197384646,0.0975038239925,linsitinib,OTHER,0.31744150782898745,-3.8241818156442258,-0.5143709395407905
BRD-K86525559-001-04-5::2.5::HTS,BRD-K86525559-001-04-5,AZD7762,2.5,HTS,METABOL_DHAP/glyceraldehyde 3P,METABOL,targeted cancer,CHK inhibitor,"CHEK1, CHEK2",,,Phase 1,0.35136719954104806,0.248498546072,AZD7762,OTHER,0.35412861966729103,6.0106948753098814,0.5535268766932826
BRD-K86930074-001-05-0::2.5::HTS,BRD-K86930074-001-05-0,cediranib,2.5,HTS,Exp_MICU3 (ENSG00000155970),GE,targeted cancer,KIT inhibitor,"CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.418711644201704,0.356042510685,cediranib,OTHER,0.4197369795690476,1.358577123496744,-2.2751079959301537
BRD-K87158025-001-01-6::2.5::HTS,BRD-K87158025-001-01-6,benzamil,2.5,HTS,METHYL_CAV2,METHYL,noncancer,sodium channel blocker,"ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1",,,Phase 2,0.303344005946349,0.0977927359604,benzamil,OTHER,0.3044558003549349,-2.248272612852336,0.7266974673168329
BRD-K87700323-003-05-1::2.5::HTS,BRD-K87700323-003-05-1,cetylpyridinium,2.5,HTS,Exp_SLCO4A1 (ENSG00000101187),GE,noncancer,,,dental,"gingivitis, mouth inflammation",Launched,0.30970984213034997,0.278212419512,cetylpyridinium,OTHER,0.3076788761089378,3.6270031809942798,-2.003252625859776
BRD-K87737963-001-06-0::2.5::HTS,BRD-K87737963-001-06-0,cyt387,2.5,HTS,MIRNA_hsa-miR-548a-3p,MIRNA,targeted cancer,,"JAK1, JAK2, JAK3",,,Phase 3,0.338859434417612,0.25160427523,cyt387,OTHER,0.34048629400513897,1.6996075579543537,-3.5102428461429684
BRD-K87782578-001-01-4::2.5::HTS,BRD-K87782578-001-01-4,AVL-292,2.5,HTS,PROT_FOXO3a_pS318_S321_Caution,PROT,targeted cancer,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",,,Phase 2,0.40420987317887896,0.180136921482,AVL-292,OTHER,0.4023052957646589,1.6969124184007174,-3.1243143593329616
BRD-K87827419-001-16-8::2.5::HTS,BRD-K87827419-001-16-8,melphalan,2.5,HTS,Exp_NCEH1 (ENSG00000144959),GE,chemo,DNA alkylating agent,,hematologic malignancy,multiple myeloma,Launched,0.4540207928752629,0.350466535022,melphalan,OTHER,0.4533685687301758,3.4365541210206163,-3.0485786035282567
BRD-K87827419-001-16-8::2.5::HTS,BRD-K87827419-001-16-8,melphalan,2.5,HTS,Exp_NCEH1 (ENSG00000144959),GE,chemo,DNA inhibitor,,hematologic malignancy,multiple myeloma,Launched,0.4540207928752629,0.350466535022,melphalan,OTHER,0.4533685687301758,3.4365541210206163,-3.0485786035282567
BRD-K88429204-001-35-1::2.5::HTS,BRD-K88429204-001-35-1,pyrimethamine,2.5,HTS,Exp_C11orf68 (ENSG00000175573),GE,noncancer,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,Launched,0.38918721171350396,0.369375643654,pyrimethamine,OTHER,0.3898910857162395,2.222802564529449,-3.5910356740876
BRD-K88506063-001-01-8::2.5::HTS,BRD-K88506063-001-01-8,KD025,2.5,HTS,Exp_PSG11 (ENSG00000243130),GE,targeted cancer,rho associated kinase inhibitor,ROCK2,,,Phase 2,0.279789749392662,0.141075613065,KD025,OTHER,0.2705523238592695,0.6089107304001253,-3.2586765019707977
BRD-K88625236-001-04-2::2.5::HTS,BRD-K88625236-001-04-2,nonoxynol-9,2.5,HTS,METHYL_LOC101927100,METHYL,noncancer,membrane integrity inhibitor,,endocrinology,contraceptive,Launched,0.37210924529232203,0.225807816729,nonoxynol-9,OTHER,0.3682872130451125,2.2140697950524126,-2.351063785058277
BRD-K88677950-001-03-9::2.5::HTS,BRD-K88677950-001-03-9,PD-198306,2.5,HTS,Exp_FMN1 (ENSG00000248905),GE,targeted cancer,MAP kinase inhibitor,"MAP2K1, MAP2K2",,,Preclinical,0.45965829503979794,0.425544990723,PD-198306,OTHER,0.4547396266675545,0.450190287910457,4.858630073130459
BRD-K89015388-001-01-7::2.5::HTS,BRD-K89015388-001-01-7,GSK923295,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,centromere associated protein inhibitor,CENPE,,,Phase 1,0.384311805724046,0.422525804999,GSK923295,OTHER,0.3883427030359593,4.961148890022101,-3.637148465115285
BRD-K89053832-001-01-0::2.5::HTS,BRD-K89053832-001-01-0,VLX600,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,targeted cancer,ubiquitin C-terminal hydrolase inhibitor,USP14,,,Phase 1,0.41527454538904895,0.262248311228,VLX600,OTHER,0.3945977324013584,4.10929345518541,-1.7196108418914662
BRD-K89085489-001-23-2::2.499967871::MTS004,BRD-K89085489-001-23-2,fenretinide,2.499967871,MTS004,Exp_CASKIN1 (ENSG00000167971),GE,targeted cancer,apoptosis stimulant,RARA,,,Phase 3,0.380905916585394,0.301715458699,fenretinide,OTHER,0.3522846467187311,3.1277377841074867,-4.092922830077573
BRD-K89085489-001-23-2::2.499967871::MTS004,BRD-K89085489-001-23-2,fenretinide,2.499967871,MTS004,Exp_CASKIN1 (ENSG00000167971),GE,targeted cancer,retinoid receptor agonist,RARA,,,Phase 3,0.380905916585394,0.301715458699,fenretinide,OTHER,0.3522846467187311,3.1277377841074867,-4.092922830077573
BRD-K89121095-001-01-7::2.499999138::MTS004,BRD-K89121095-001-01-7,tedizolid-phosphate,2.499999138,MTS004,Exp_TP63 (ENSG00000073282),GE,noncancer,protein synthesis inhibitor,,infectious disease,skin infections,Launched,0.42411527280933,0.312003056807,tedizolid-phosphate,OTHER,0.4215759731766988,5.302212658886606,-4.046252481301118
BRD-K89299012-001-06-0::2.5::HTS,BRD-K89299012-001-06-0,DCEBIO,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,potassium channel activator,"KCNN2, KCNN3, KCNN4",,,Preclinical,0.48478252176321707,0.426929556856,DCEBIO,OTHER,0.4929783525293603,2.7649510800279584,-1.8314626281042328
BRD-K89490285-001-08-1::2.521612095::MTS004,BRD-K89490285-001-08-1,bentazepam,2.521612095,MTS004,METABOL_C22:1 SM,METABOL,noncancer,benzodiazepine receptor agonist,,neurology/psychiatry,"anxiety, sedative, muscle relaxant",Launched,0.356188573653408,0.104605367456,bentazepam,OTHER,0.35216353017090896,4.9915779260111215,-3.886656044257372
BRD-K89714990-001-01-5::2.5::HTS,BRD-K89714990-001-01-5,tepoxalin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,cyclooxygenase inhibitor,ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia",Launched,0.400335224639358,0.340309304664,tepoxalin,OTHER,0.3977027237336369,5.968924853301365,-0.5735700779753583
BRD-K89714990-001-01-5::2.5::HTS,BRD-K89714990-001-01-5,tepoxalin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,lipoxygenase inhibitor,ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia",Launched,0.400335224639358,0.340309304664,tepoxalin,OTHER,0.3977027237336369,5.968924853301365,-0.5735700779753583
BRD-K89839824-001-05-3::2.5::HTS,BRD-K89839824-001-05-3,raltitrexed,2.5,HTS,DEM2_CDK14 (5218),DEMETER2_COM,targeted cancer,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,Launched,0.378478011536352,0.113819164428,raltitrexed,OTHER,0.3618011656839857,3.9157755539003514,-3.2094139059946567
BRD-K90027355-001-13-3::2.44::HTS,BRD-K90027355-001-13-3,spironolactone,2.44,HTS,Exp_FBLN7 (ENSG00000144152),GE,noncancer,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia",Launched,0.42290579182496296,0.30624307613,spironolactone,OTHER,0.4224969194755288,1.4507043021999606,-4.585880288996154
BRD-K90374350-001-09-2::2.5::HTS,BRD-K90374350-001-09-2,chlorquinaldol,2.5,HTS,Exp_C11orf1 (ENSG00000137720),GE,noncancer,other antibiotic,,infectious disease,fungal infection,Launched,0.33984031873217097,0.179888328292,chlorquinaldol,OTHER,0.33705452381483825,3.106946688799004,-2.931626385845867
BRD-K90382497-001-10-7::2.5::HTS,BRD-K90382497-001-10-7,GW-843682X,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,PLK inhibitor,"PLK1, PLK3",,,Preclinical,0.3720912013758089,0.296025042573,GW-843682X,OTHER,0.3706841745710716,5.944760061744058,-2.78690416530387
BRD-K90497590-001-04-2::2.5::HTS,BRD-K90497590-001-04-2,AR-12,2.5,HTS,CN_CLEC18B (497190),CN,targeted cancer,phosphoinositide dependent kinase inhibitor,PDPK1,,,Phase 1,0.374224572595668,0.125810028193,AR-12,OTHER,0.3716895784122992,3.198977530798645,-3.058812817472975
BRD-K90647725-001-07-3::2.5::HTS,BRD-K90647725-001-07-3,oleanolic-acid,2.5,HTS,Exp_LPCAT2 (ENSG00000087253),GE,noncancer,G protein-coupled receptor agonist,GPBAR1,,,Preclinical,0.303647354895017,0.179306788834,oleanolic-acid,OTHER,0.3043663102778372,4.58238493374753,-0.4978991546759164
BRD-K91370081-001-25-1::2.5::HTS,BRD-K91370081-001-25-1,anisomycin,2.5,HTS,CRISPR_MYC (4609),AVANA_PUBLIC_18Q2,noncancer,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",,,Preclinical,0.40008690701782795,0.0992420297861,anisomycin,OTHER,0.3743549632526414,5.079599198909311,-0.8446409716274159
BRD-K91601245-001-12-0::2.5::HTS,BRD-K91601245-001-12-0,mercaptopurine,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,immunosuppressant,"HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.357806372894776,0.278849917866,mercaptopurine,OTHER,0.3593176407853801,3.7889997435007836,-3.758793341785228
BRD-K91601245-001-12-0::2.5::HTS,BRD-K91601245-001-12-0,mercaptopurine,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,protein synthesis inhibitor,"HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.357806372894776,0.278849917866,mercaptopurine,OTHER,0.3593176407853801,3.7889997435007836,-3.758793341785228
BRD-K91601245-001-12-0::2.5::HTS,BRD-K91601245-001-12-0,mercaptopurine,2.5,HTS,Exp_ANP32A (ENSG00000140350),GE,targeted cancer,purine antagonist,"HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.357806372894776,0.278849917866,mercaptopurine,OTHER,0.3593176407853801,3.7889997435007836,-3.758793341785228
BRD-K91825936-001-01-2::2.5::HTS,BRD-K91825936-001-01-2,ZK811752,2.5,HTS,PROT_p70S6K,PROT,targeted cancer,CC chemokine receptor antagonist,CCR1,,,Phase 2,0.312100236232693,0.140189099047,ZK811752,OTHER,0.3133845509706849,1.0986046691387492,-3.2144842425908458
BRD-K91900765-001-07-6::2.500030257::MTS004,BRD-K91900765-001-07-6,VX-745,2.500030257,MTS004,PROT_Fibronectin,PROT,targeted cancer,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",,,Phase 2,0.32837219792565303,0.17505433468,VX-745,OTHER,0.3256803111566912,-0.285238458944026,-1.8877749430792379
BRD-K92049597-001-20-8::2.5::HTS,BRD-K92049597-001-20-8,triamterene,2.5,HTS,MIRNA_hsa-miR-346,MIRNA,noncancer,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema",Launched,0.324019694479683,0.164063756344,triamterene,OTHER,0.32143048760212456,-2.9273262198673358,0.4584560167330021
BRD-K92241597-001-06-0::2.5::HTS,BRD-K92241597-001-06-0,tosedostat,2.5,HTS,Exp_FMN1 (ENSG00000248905),GE,targeted cancer,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",,,Phase 2,0.37445984426334905,0.268478464041,tosedostat,OTHER,0.3716976424853837,4.644227552219071,-2.282116146083233
BRD-K92428153-001-04-4::2.5::HTS,BRD-K92428153-001-04-4,mycophenolate-mofetil,2.5,HTS,Exp_TCTA (ENSG00000145022),GE,noncancer,dehydrogenase inhibitor,"IMPDH1, IMPDH2",transplant,organ rejection,Launched,0.37285325141756104,0.253347268789,mycophenolate-mofetil,OTHER,0.3695616035480502,3.4492559036449983,-2.5088368919424884
BRD-K92428153-001-04-4::2.5::HTS,BRD-K92428153-001-04-4,mycophenolate-mofetil,2.5,HTS,Exp_TCTA (ENSG00000145022),GE,noncancer,inositol monophosphatase inhibitor,"IMPDH1, IMPDH2",transplant,organ rejection,Launched,0.37285325141756104,0.253347268789,mycophenolate-mofetil,OTHER,0.3695616035480502,3.4492559036449983,-2.5088368919424884
BRD-K92428232-001-10-6::2.5::HTS,BRD-K92428232-001-10-6,GSK461364,2.5,HTS,Exp_COQ3 (ENSG00000132423),GE,targeted cancer,PLK inhibitor,PLK1,,,Phase 1,0.377140029471395,0.308423858274,GSK461364,OTHER,0.375804521821895,4.55435145847577,-1.320208522167534
BRD-K92991072-001-04-9::2.5::HTS,BRD-K92991072-001-04-9,PAC-1,2.5,HTS,Exp_C22orf24 (ENSG00000128254),GE,targeted cancer,caspase activator,CASP3,,,Phase 1,0.255335870925484,0.139964432376,PAC-1,OTHER,0.2541909577932584,2.9622694588956135,-3.032555355759753
BRD-K93034159-001-25-8::2.5::HTS,BRD-K93034159-001-25-8,cladribine,2.5,HTS,METHYL_LOC100134391,METHYL,chemo,adenosine deaminase inhibitor,"ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Launched,0.36560620848838704,0.0859270534083,cladribine,OTHER,0.3705754486953171,4.209458045307586,-1.92954211115173
BRD-K93034159-001-25-8::2.5::HTS,BRD-K93034159-001-25-8,cladribine,2.5,HTS,METHYL_LOC100134391,METHYL,chemo,ribonucleotide reductase inhibitor,"ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Launched,0.36560620848838704,0.0859270534083,cladribine,OTHER,0.3705754486953171,4.209458045307586,-1.92954211115173
BRD-K93918653-001-08-9::2.5::HTS,BRD-K93918653-001-08-9,quizartinib,2.5,HTS,METHYL_CXorf21,METHYL,targeted cancer,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",,,Phase 3,0.382219210356292,0.0960249204476,quizartinib,OTHER,0.38325683574115854,0.599357911606306,-3.1043466318201247
BRD-K94176593-001-09-4::2.5::HTS,BRD-K94176593-001-09-4,TWS-119,2.5,HTS,Exp_TFPT (ENSG00000105619),GE,noncancer,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",,,Preclinical,0.33197013126115804,0.157041529062,TWS-119,OTHER,0.32997087258182256,1.4788597427421464,-4.564286532258556
BRD-K94455792-001-01-8::2.5::HTS,BRD-K94455792-001-01-8,ICG-001,2.5,HTS,Exp_CD83 (ENSG00000112149),GE,targeted cancer,beta-catenin inhibitor,CTNNB1,,,Preclinical,0.35152659585230894,0.352329780801,ICG-001,OTHER,0.3539202530003946,2.606761968480133,-2.7936463337596216
BRD-K94485812-001-02-9::2.55::HTS,BRD-K94485812-001-02-9,LDN-57444,2.55,HTS,MIRNA_hsa-miR-934,MIRNA,noncancer,ubiquitin C-terminal hydrolase inhibitor,,,,Preclinical,0.276405855026229,0.150003853081,LDN-57444,OTHER,0.2898042178313945,-0.8065263115379607,-2.672493392117623
BRD-K94723713-001-10-6::2.5::HTS,BRD-K94723713-001-10-6,rutaecarpine,2.5,HTS,CRISPR_TICAM1 (148022),AVANA_PUBLIC_18Q2,noncancer,cyclooxygenase inhibitor,PTGS2,,,Preclinical,0.40900521701498405,0.174108964098,rutaecarpine,OTHER,0.3701827759933256,-1.9313333222712368,0.7308296552675566
BRD-K95142244-001-01-5::2.5::HTS,BRD-K95142244-001-01-5,talazoparib,2.5,HTS,Exp_HNRNPC (ENSG00000092199),GE,targeted cancer,PARP inhibitor,PARP2,,,Phase 3,0.39706645269454205,0.347232919642,talazoparib,OTHER,0.3954384831904734,3.906241368568661,-3.3788598544732285
BRD-K95435023-001-10-1::2.5::HTS,BRD-K95435023-001-10-1,PHA-665752,2.5,HTS,PROT_VHL_Caution,PROT,targeted cancer,c-Met inhibitor,MET,,,Preclinical,0.38635460030431107,0.163467999571,PHA-665752,OTHER,0.3862645463920513,-6.775438290220227,1.6731693465479194
BRD-K95523387-001-09-6::2.5::HTS,BRD-K95523387-001-09-6,OLDA,2.5,HTS,Exp_CARD10 (ENSG00000100065),GE,noncancer,TRPV agonist,GPR119,,,Preclinical,0.4393146101698,0.340694623954,OLDA,OTHER,0.4411634355301423,3.3659279671588465,-3.916438838981284
BRD-K95573441-001-01-2::2.5::HTS,BRD-K95573441-001-01-2,PFK-015,2.5,HTS,PROT_HSP70_Caution,PROT,targeted cancer,phosphofructokinase inhibitor,PFKFB3,,,Phase 1,0.353394251913723,0.297257150931,PFK-015,OTHER,0.3596345759448296,5.0988187099203035,-1.4441940370653592
BRD-K95785537-001-23-1::2.5::HTS,BRD-K95785537-001-23-1,PP-2,2.5,HTS,Exp_GYG2 (ENSG00000056998),GE,targeted cancer,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",,,Preclinical,0.324435726032246,0.164629178995,PP-2,OTHER,0.32192073855545233,1.6465578294906529,-2.8403816051113857
BRD-K95926480-003-03-6::2.5::HTS,BRD-K95926480-003-03-6,SRT1720,2.5,HTS,DEM2_BAAT (570),DEMETER2_COM,noncancer,SIRT activator,SIRT1,,,Preclinical,0.426226326037235,0.20029072347,SRT1720,OTHER,0.3999713186665028,0.3492427716909763,-2.7264524531644403
BRD-K96123349-236-02-8::2.5::HTS,BRD-K96123349-236-02-8,brequinar,2.5,HTS,Exp_SUPT16H (ENSG00000092201),GE,targeted cancer,dihydroorotate dehydrogenase inhibitor,DHODH,,,Phase 2,0.29512470705029803,0.220552021476,brequinar,OTHER,0.29410005685906243,3.086595486692464,-3.2806981288319124
BRD-K96159438-001-06-3::2.5::HTS,BRD-K96159438-001-06-3,adefovir-dipivoxil,2.5,HTS,METHYL_HSD17B1,METHYL,noncancer,DNA polymerase inhibitor,,infectious disease,hepatitis B,Launched,0.386354170994915,0.235122328164,adefovir-dipivoxil,OTHER,0.3950918226364605,3.73939093990152,-3.341743923241885
BRD-K96188950-001-16-9::2.5::HTS,BRD-K96188950-001-16-9,caffeic-acid-phenethyl-ester,2.5,HTS,METHYL_LOC647323,METHYL,targeted cancer,HIV integrase inhibitor,RELA,,,Preclinical,0.283727811687926,0.187667910255,caffeic-acid-phenethyl-ester,OTHER,0.2806804024090337,-3.614994751386871,-0.9389902263178111
BRD-K96233303-001-01-9::2.5::HTS,BRD-K96233303-001-01-9,TMS,2.5,HTS,Exp_COQ3 (ENSG00000132423),GE,targeted cancer,,,,,Preclinical,0.41683894328688703,0.294438440136,TMS,OTHER,0.4177950692877515,5.029461040266439,-2.3186732123077785
BRD-K96259238-001-01-4::2.5::HTS,BRD-K96259238-001-01-4,Y-320,2.5,HTS,Exp_LINC00337 (ENSG00000225077),GE,noncancer,interleukin inhibitor,IL17A,,,Preclinical,0.42001917429193103,0.323039703723,Y-320,OTHER,0.420901600786454,5.003582802492342,-0.7220534041491202
BRD-K96344439-002-02-7::2.500011072::MTS004,BRD-K96344439-002-02-7,tofogliflozin,2.500011072,MTS004,CRISPR_VWA9 (81556),AVANA_PUBLIC_18Q2,noncancer,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus",Launched,0.44790221650083795,0.152135149649,tofogliflozin,OTHER,0.4591623499330409,4.527136121478663,-1.9740149474771629
BRD-K96631475-001-02-4::2.43::HTS,BRD-K96631475-001-02-4,10-deacetylbaccatin,2.43,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,antitumor agent,,,,Preclinical,0.403664124544914,0.560032043653,10-deacetylbaccatin,OTHER,0.40551943566990944,4.738151385341589,-3.7156911555064687
BRD-K96631475-001-04-0::2.5::HTS,BRD-K96631475-001-04-0,10-deacetylbaccatin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,antitumor agent,,,,Preclinical,0.403664124544914,0.560032043653,10-deacetylbaccatin,OTHER,0.36181193489145613,3.799105524062029,-1.6572124282240788
BRD-K96809896-300-02-3::2.5::HTS,BRD-K96809896-300-02-3,SKF-86002,2.5,HTS,Exp_CASP16 (ENSG00000228146),GE,noncancer,p38 MAPK inhibitor,"ALOX5, MAPK14",,,Preclinical,0.30011562356718996,0.212946127965,SKF-86002,OTHER,0.2967516639613572,-4.1659044367660085,-2.938779710117675
BRD-K97010173-001-04-1::2.5::HTS,BRD-K97010173-001-04-1,deferasirox,2.5,HTS,Exp_HMGA1P4 (ENSG00000234705),GE,noncancer,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",Launched,0.348215352206856,0.284282932373,deferasirox,OTHER,0.3489760681427184,2.827165965792285,-3.4166899105517214
BRD-K97472745-001-01-8::2.5::HTS,BRD-K97472745-001-01-8,gestrinone,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,Launched,0.40080535874868495,0.172266878124,gestrinone,OTHER,0.4081288009520477,2.655695925595088,-1.740301322154453
BRD-K97714174-001-01-3::2.5::HTS,BRD-K97714174-001-01-3,P22077,2.5,HTS,Exp_GSTA2 (ENSG00000244067),GE,noncancer,ubiquitin specific protease inhibitor,USP7,,,Preclinical,0.44851284022508203,0.330328404482,P22077,OTHER,0.4468387747414604,-0.5988986151819229,0.6481435755295273
BRD-K97764662-001-17-3::2.5::HTS,BRD-K97764662-001-17-3,PD-173074,2.5,HTS,CRISPR_RELB (5971),AVANA_PUBLIC_18Q2,targeted cancer,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",,,Preclinical,0.362749258239907,0.151819476088,PD-173074,OTHER,0.365906831220606,0.3087459488449005,-2.4099803204810284
BRD-K98203492-003-04-1::2.5::HTS,BRD-K98203492-003-04-1,GSK-J4,2.5,HTS,Exp_IFI44 (ENSG00000137965),GE,targeted cancer,histone lysine demethylase inhibitor,"KDM6A, KDM6B",,,Preclinical,0.384826978710271,0.224262557079,GSK-J4,OTHER,0.38388712805977104,3.0601400636803744,-3.130178923213866
BRD-K99170882-001-04-3::2.5::HTS,BRD-K99170882-001-04-3,NSC-319726,2.5,HTS,Exp_SLFN11 (ENSG00000172716),GE,targeted cancer,p53 activator,,,,Preclinical,0.370392529997099,0.252444071494,NSC-319726,OTHER,0.371435479030334,3.8472092213221187,-1.3355887468661067
BRD-K99545815-001-06-3::2.5::HTS,BRD-K99545815-001-06-3,PF-562271,2.5,HTS,Exp_SVIP (ENSG00000198168),GE,targeted cancer,focal adhesion kinase inhibitor,"PTK2, PTK2B",,,Phase 1,0.35800229300203296,0.276406547131,PF-562271,OTHER,0.3572589556814118,3.8394010564055225,-3.1206612042176567
BRD-K99604664-001-01-1::2.5::HTS,BRD-K99604664-001-01-1,tanaproget,2.5,HTS,Exp_PDE3A (ENSG00000172572),GE,noncancer,progesterone receptor agonist,PGR,,,Phase 2,0.345225236889209,0.328988588763,tanaproget,OTHER,0.3491140239785451,2.1245131605716274,-2.526762931039228
BRD-K99749624-001-07-0::2.5::HTS,BRD-K99749624-001-07-0,linifanib,2.5,HTS,Exp_FAM117A (ENSG00000121104),GE,targeted cancer,PDGFR tyrosine kinase receptor inhibitor,"CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",,,Phase 3,0.43568075834821,0.217416119842,linifanib,OTHER,0.4343455162765053,2.4379490139389124,-1.969361521698416
BRD-K99792991-001-34-9::2.5::HTS,BRD-K99792991-001-34-9,hexachlorophene,2.5,HTS,Exp_BTC (ENSG00000174808),GE,noncancer,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Launched,0.35579242058984206,0.164521036538,hexachlorophene,OTHER,0.35537373043017745,2.37514854209455,-3.552040677461906
BRD-K99879819-001-02-1::2.5187366::MTS004,BRD-K99879819-001-02-1,lorlatinib,2.5187366,MTS004,PROT_p90RSK_Caution,PROT,targeted cancer,ALK tyrosine kinase receptor inhibitor,ALK,,,Phase 2,0.299647958497746,0.123124949908,lorlatinib,OTHER,0.29833464972543994,-0.9340626163438176,0.2604620366745505
BRD-K99919177-001-01-3::2.5::MTS004,BRD-K99919177-001-01-3,deslanoside,2.5,MTS004,DEM2_MED12 (9968),DEMETER2_COM,noncancer,Na/K-ATPase inhibitor,"ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2",cardiology,"congestive heart failure, cardiac arrythmia",Launched,0.38338006180663103,0.0437424682729,deslanoside,OTHER,0.3812523558853747,1.6485064625527008,-0.10903139445120713
BRD-K99964838-001-11-9::2.5::HTS,BRD-K99964838-001-11-9,bosutinib,2.5,HTS,Exp_SYNE3 (ENSG00000176438),GE,targeted cancer,Abl kinase inhibitor,"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),Launched,0.333008403266226,0.348764351563,bosutinib,OTHER,0.3279798592470373,1.1746528884047374,-4.727997289249939
BRD-K99964838-001-11-9::2.5::HTS,BRD-K99964838-001-11-9,bosutinib,2.5,HTS,Exp_SYNE3 (ENSG00000176438),GE,targeted cancer,Bcr-Abl kinase inhibitor,"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),Launched,0.333008403266226,0.348764351563,bosutinib,OTHER,0.3279798592470373,1.1746528884047374,-4.727997289249939
BRD-K99964838-001-11-9::2.5::HTS,BRD-K99964838-001-11-9,bosutinib,2.5,HTS,Exp_SYNE3 (ENSG00000176438),GE,targeted cancer,src inhibitor,"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),Launched,0.333008403266226,0.348764351563,bosutinib,OTHER,0.3279798592470373,1.1746528884047374,-4.727997289249939
BRD-K22149900-001-03-9::2.371298578::MTS004,BRD-K22149900-001-03-9,ceritinib,2.371298578,,,,,ALK tyrosine kinase receptor inhibitor,"ALK, FLT3, IGF1R, INSR, TSSK1B",oncology,,,0,0,ceritinib,OTHER,0.4128600281418436,2.196081080004077,0.07174035351875352
BRD-K56211775-001-03-8::2.5::MTS004,BRD-K56211775-001-03-8,RTA-408,2.5,,,,,nitric oxide production inhibitor,NFE2L2,,,,0,0,RTA-408,OTHER,0.4001389528906102,2.480912998186607,-0.029211753957622214
BRD-A11815689-001-01-1::2.5::HTS,BRD-A11815689-001-01-1,proscillaridin-a,2.5,,,,,,,cardiology,,,0,0,proscillaridin-a,OTHER,0.4214300228120894,3.244367837441504,0.08360464820301639
BRD-A25687296-300-04-3::2.5::HTS,BRD-A25687296-300-04-3,emetine,2.5,,,,,protein synthesis inhibitor,RPS2,,,,0,0,emetine,OTHER,0.395299361201609,3.4654448480086133,0.5979257904509725
BRD-A27376179-001-01-3::2.5::HTS,BRD-A27376179-001-01-3,lestaurtinib,2.5,,,,,FLT3 inhibitor,"FLT3, NTRK1",,,,0,0,lestaurtinib,OTHER,0.38937919909846097,4.330680649391558,-0.1908043558782362
BRD-A27376179-001-01-3::2.5::HTS,BRD-A27376179-001-01-3,lestaurtinib,2.5,,,,,growth factor receptor inhibitor,"FLT3, NTRK1",,,,0,0,lestaurtinib,OTHER,0.38937919909846097,4.330680649391558,-0.1908043558782362
BRD-A27376179-001-01-3::2.5::HTS,BRD-A27376179-001-01-3,lestaurtinib,2.5,,,,,JAK inhibitor,"FLT3, NTRK1",,,,0,0,lestaurtinib,OTHER,0.38937919909846097,4.330680649391558,-0.1908043558782362
BRD-A64064900-001-02-3::2.5::HTS,BRD-A64064900-001-02-3,sangivamycin,2.5,,,,,DNA inhibitor,,,,,0,0,sangivamycin,OTHER,0.3388307446906945,3.690814581401816,0.652655830631554
BRD-A64242993-001-05-6::2.5::HTS,BRD-A64242993-001-05-6,lanatoside-c,2.5,,,,,cardiac glycoside,,,,,0,0,lanatoside-c,OTHER,0.36693422717870094,3.8486958009759817,0.3193772785985054
BRD-A72716251-001-01-5::0.91::HTS,BRD-A72716251-001-01-5,peruvoside,0.91,,,,,cardiac glycoside,,,,,0,0,peruvoside,OTHER,0.3664535291111059,4.3002594939875305,-0.4727500310133981
BRD-A93236127-001-04-5::2.5::HTS,BRD-A93236127-001-04-5,digitoxin,2.5,,,,,ATPase inhibitor,ATP1A1,,,,0,0,digitoxin,OTHER,0.33635045686119674,3.871014862571692,0.51893329718332
BRD-K00152668-001-01-5::2.5::HTS,BRD-K00152668-001-01-5,adarotene,2.5,,,,,retinoid receptor agonist,"RARB, RARG",,,,0,0,adarotene,OTHER,0.3949830133299368,4.0970720040786865,0.688426548986254
BRD-K03601870-001-01-2::2.5::HTS,BRD-K03601870-001-01-2,ixabepilone,2.5,,,,,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,,,0,0,ixabepilone,OTHER,0.373797926342158,4.857292801943375,-0.3818299780551668
BRD-K05445342-001-05-3::2.57::HTS,BRD-K05445342-001-05-3,WP1066,2.57,,,,,STAT inhibitor,STAT3,,,,0,0,WP1066,OTHER,0.4173832587374393,4.613432773235327,0.016823597768107934
BRD-K06814349-304-01-9::2.5::HTS,BRD-K06814349-304-01-9,fosbretabulin,2.5,,,,,VE-cadherin antagonist,CDH5,,,,0,0,fosbretabulin,OTHER,0.3864183522343652,3.642578115510759,-1.010424722972247
BRD-K07612980-001-05-3::2.59::HTS,BRD-K07612980-001-05-3,sparfloxacin,2.59,,,,,bacterial DNA gyrase inhibitor,TOP2A,,,,0,0,sparfloxacin,OTHER,0.4023880262540404,4.675318747501821,0.4129949548724095
BRD-K11927976-050-02-9::2.5::HTS,BRD-K11927976-050-02-9,ER-27319,2.5,,,,,mediator release inhibitor,SYK,,,,0,0,ER-27319,OTHER,0.3765028120405239,4.195640287716688,0.4809453503486405
BRD-K11927976-050-02-9::2.5::HTS,BRD-K11927976-050-02-9,ER-27319,2.5,,,,,SYK inhibitor,SYK,,,,0,0,ER-27319,OTHER,0.3765028120405239,4.195640287716688,0.4809453503486405
BRD-K17061841-001-03-5::2.5::HTS,BRD-K17061841-001-03-5,stattic,2.5,,,,,,,,,,0,0,stattic,OTHER,0.37492284588504576,4.19467104038537,-0.861245734817667
BRD-K18518344-001-15-9::2.5::HTS,BRD-K18518344-001-15-9,digitoxigenin,2.5,,,,,ATPase inhibitor,ATP1A1,,,,0,0,digitoxigenin,OTHER,0.3826885898206486,4.432067061657566,-0.4801149969107698
BRD-K20605374-001-05-4::2.5::HTS,BRD-K20605374-001-05-4,NSC-697923,2.5,,,,,ubiquitin-conjugating enzyme inhibitor,UBE2N,,,,0,0,NSC-697923,OTHER,0.3610229945501113,4.329803662289832,-0.09966327165507316
BRD-K21361524-001-01-1::2.5::HTS,BRD-K21361524-001-01-1,selinexor,2.5,,,,,exportin antagonist,XPO1,,,,0,0,selinexor,OTHER,0.3988085751756169,3.7957347811340534,-0.3900252220997822
BRD-K22127577-001-03-7::2.58::HTS,BRD-K22127577-001-03-7,crenolanib,2.58,,,,,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",,,,0,0,crenolanib,OTHER,0.3975808410096602,4.914672882728,0.4521102213408299
BRD-K33277808-331-01-3::2.5::HTS,BRD-K33277808-331-01-3,ouabain,2.5,,,,,ATPase inhibitor,ATP1A1,cardiology,,,0,0,ouabain,OTHER,0.3470016268935308,4.20275523197402,0.6341567238184653
BRD-K37379014-001-01-2::2.5::HTS,BRD-K37379014-001-01-2,filanesib,2.5,,,,,kinesin inhibitor,KIF11,,,,0,0,filanesib,OTHER,0.425491884951693,4.811762842730189,-1.2393296456876084
BRD-K37379014-001-01-2::2.5::HTS,BRD-K37379014-001-01-2,filanesib,2.5,,,,,kinesin-like spindle protein inhibitor,KIF11,,,,0,0,filanesib,OTHER,0.425491884951693,4.811762842730189,-1.2393296456876084
BRD-K39171998-001-01-1::2.5::HTS,BRD-K39171998-001-01-1,STF-118804,2.5,,,,,NAMPT inhibitor,NAMPT,,,,0,0,STF-118804,OTHER,0.33571646054311755,4.185498354888945,-1.063424657629128
BRD-K39484304-001-16-5::2.5::HTS,BRD-K39484304-001-16-5,triptolide,2.5,,,,,RNA polymerase inhibitor,RELA,,,,0,0,triptolide,OTHER,0.37643214676103176,4.2547244123512105,-0.13270446527384827
BRD-K43389675-003-16-7::2.35::HTS,BRD-K43389675-003-16-7,daunorubicin,2.35,,,,,RNA synthesis inhibitor,"TOP2A, TOP2B",hematologic malignancy,,,0,0,daunorubicin,OTHER,0.4192604989756199,5.056183458415956,1.1701337977209394
BRD-K43389675-003-20-9::2.5::HTS,BRD-K43389675-003-20-9,daunorubicin,2.5,,,,,RNA synthesis inhibitor,"TOP2A, TOP2B",hematologic malignancy,,,0,0,daunorubicin,OTHER,0.4156963575262875,4.6006767655628344,-0.6466485046124437
BRD-K43644456-001-04-0::2.38::HTS,BRD-K43644456-001-04-0,WP1130,2.38,,,,,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",,,,0,0,WP1130,OTHER,0.4018677220777524,4.973788948233091,0.8048155198184279
BRD-K45724504-001-01-6::1.36::HTS,BRD-K45724504-001-01-6,anguidine,1.36,,,,,protein synthesis inhibitor,SLC5A1,,,,0,0,anguidine,OTHER,0.3604232568786223,4.172547757941712,0.6311403392302108
BRD-K49371609-003-03-8::2.5::HTS,BRD-K49371609-003-03-8,PIK-75,2.5,,,,,DNA protein kinase inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",,,,0,0,PIK-75,OTHER,0.3720754562542195,5.131841846389084,0.6040279384697529
BRD-K53417444-003-03-1::2.5::HTS,BRD-K53417444-003-03-1,OTS167,2.5,,,,,maternal embryonic leucine zipper kinase inhibitor,MELK,,,,0,0,OTS167,OTHER,0.2699836327895184,5.379763050317337,1.0414982573979958
BRD-K54247840-004-01-3::2.5::HTS,BRD-K54247840-004-01-3,halofuginone,2.5,,,,,collagenase inhibitor,"COL1A1, MMP2",rheumatology,,,0,0,halofuginone,OTHER,0.3934399326766445,4.664486905703577,-0.05341202144422619
BRD-K54256913-001-08-7::2.5::HTS,BRD-K54256913-001-08-7,MK-1775,2.5,,,,,WEE1 kinase inhibitor,WEE1,,,,0,0,MK-1775,OTHER,0.4025822017404274,4.7966034694580415,-0.8139495208109917
BRD-K58435339-001-03-0::2.5::HTS,BRD-K58435339-001-03-0,AT13387,2.5,,,,,HSP antagonist,HSP90AA1,,,,0,0,AT13387,OTHER,0.3860596931951939,4.667937395336242,-0.39654692557984506
BRD-K60025295-003-06-6::2.5::HTS,BRD-K60025295-003-06-6,crystal-violet,2.5,,,,,other antibiotic,,,,,0,0,crystal-violet,OTHER,0.3798046826111384,4.144633419521705,-1.4361210319066848
BRD-K60348325-065-09-9::2.5::HTS,BRD-K60348325-065-09-9,brilliant-green,2.5,,,,,,,,,,0,0,brilliant-green,OTHER,0.3819197504993114,4.336776049904523,-0.2515334782181609
BRD-K68904758-001-03-5::2.5::HTS,BRD-K68904758-001-03-5,cephalomannine,2.5,,,,,DNA polymerase inhibitor,,,,,0,0,cephalomannine,OTHER,0.3826006161352633,4.686729963576899,-1.46950249276754
BRD-K69694239-001-02-2::2.5::HTS,BRD-K69694239-001-02-2,bardoxolone-methyl,2.5,,,,,nuclear factor erythroid derived,"PPARG, STAT3",,,,0,0,bardoxolone-methyl,OTHER,0.38034346043740425,3.6660767572686392,-0.3423337552488639
BRD-K69694239-001-02-2::2.5::HTS,BRD-K69694239-001-02-2,bardoxolone-methyl,2.5,,,,,like (NRF2) activator,"PPARG, STAT3",,,,0,0,bardoxolone-methyl,OTHER,0.38034346043740425,3.6660767572686392,-0.3423337552488639
BRD-K70511574-001-06-9::2.5::HTS,BRD-K70511574-001-06-9,HMN-214,2.5,,,,,PLK inhibitor,PLK1,,,,0,0,HMN-214,OTHER,0.3861745727900338,4.984107370406199,-1.4087042629838766
BRD-K71467466-001-02-3::2.5::HTS,BRD-K71467466-001-02-3,KPT-185,2.5,,,,,exportin antagonist,XPO1,,,,0,0,KPT-185,OTHER,0.3833514066630258,5.002455132968832,-1.2304036924925694
BRD-K74193284-001-04-8::2.5::HTS,BRD-K74193284-001-04-8,phenylmercuric-acetate,2.5,,,,,other antifungal,,,,,0,0,phenylmercuric-acetate,OTHER,0.3864653587073159,5.146389151822591,0.029858708361302003
BRD-K76674262-001-03-3::2.5::HTS,BRD-K76674262-001-03-3,homoharringtonine,2.5,,,,,protein synthesis inhibitor,RPL3,hematologic malignancy,,,0,0,homoharringtonine,OTHER,0.4070100772338767,3.906624577067678,0.04546401270081457
BRD-K76703230-004-03-3::2.5::HTS,BRD-K76703230-004-03-3,YM-155,2.5,,,,,survivin inhibitor,BIRC5,,,,0,0,YM-155,OTHER,0.3393245664418395,4.955982908592947,-0.7551847566528571
BRD-K76703230-004-04-1::2.5::HTS,BRD-K76703230-004-04-1,YM-155,2.5,,,,,survivin inhibitor,BIRC5,,,,0,0,YM-155,OTHER,0.34127123837114137,4.096087391691687,-0.5888054538730243
BRD-K77841042-001-14-1::2.5::HTS,BRD-K77841042-001-14-1,brefeldin-a,2.5,,,,,protein synthesis inhibitor,"ARF1, CYTH2",,,,0,0,brefeldin-a,OTHER,0.3610571033795405,4.234129640331633,0.09796406362623644
BRD-K83699324-001-01-1::2.5::HTS,BRD-K83699324-001-01-1,NMS-1286937,2.5,,,,,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",,,,0,0,NMS-1286937,OTHER,0.367395217565139,4.2860984544893235,-1.0869288620145068
BRD-K86525559-001-07-8::2.52::HTS,BRD-K86525559-001-07-8,AZD7762,2.52,,,,,CHK inhibitor,"CHEK1, CHEK2",,,,0,0,AZD7762,OTHER,0.391178211382175,4.998372886857782,0.09099580228251147
BRD-K96104201-001-01-5::2.5::HTS,BRD-K96104201-001-01-5,azalomycin-b,2.5,,,,,bacterial 50S ribosomal subunit inhibitor,,,,,0,0,azalomycin-b,OTHER,0.4005285385964213,3.6699648017421875,0.12297450025578538
BRD-K96358241-001-01-9::0.94::HTS,BRD-K96358241-001-01-9,harringtonine,0.94,,,,,protein synthesis inhibitor,,,,,0,0,harringtonine,OTHER,0.36748334726710696,3.5396077354418862,-0.8838283950826931
BRD-K08248804-001-01-8::2.5::HTS,BRD-K08248804-001-01-8,LCL-161,2.5,HTS,Exp_RIPK1 (ENSG00000137275),GE,targeted cancer,XIAP inhibitor,"BIRC2, XIAP",,,Phase 2,0.443605934389414,0.367897107999,LCL-161,XIAP INHIBITOR,0.4449477833329341,4.875151993458472,-2.260915031304023
BRD-K68938568-001-01-7::2.5::HTS,BRD-K68938568-001-01-7,GDC-0152,2.5,HTS,Exp_RIPK1 (ENSG00000137275),GE,targeted cancer,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",,,Phase 1,0.37425576116136894,0.361515465101,GDC-0152,XIAP INHIBITOR,0.3731202193725408,4.848086845438114,-2.3577378059152383
BRD-K71221037-001-01-6::2.5::HTS,BRD-K71221037-001-01-6,birinapant,2.5,HTS,Exp_RIPK1 (ENSG00000137275),GE,targeted cancer,XIAP inhibitor,"BIRC2, XIAP",,,Phase 2,0.513663229248262,0.460161756399,birinapant,XIAP INHIBITOR,0.5133703505319652,4.76486395628375,-2.083826417737124
BRD-K74671368-001-01-8::2.5::MTS004,BRD-K74671368-001-01-8,idronoxil,2.5,MTS004,Exp_NAALAD2 (ENSG00000077616),GE,targeted cancer,XIAP inhibitor,"ENOX2, SPHK1",,,Phase 3,0.40205972717322996,0.214343479422,idronoxil,XIAP INHIBITOR,0.3986319019790872,3.2279785564069567,-4.109913970465246
BRD-K08251020-001-01-0::2.5::HTS,BRD-K08251020-001-01-0,falecalcitriol,2.5,HTS,METHYL_S100A14,METHYL,noncancer,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,Launched,0.325355124773793,0.25658416568,falecalcitriol,VITAMIN D RECEPTOR AGONIST,0.3240369976895801,0.3068969909447711,-1.4454633341750212
BRD-K27316855-001-13-3::2.44::HTS,BRD-K27316855-001-13-3,calcitriol,2.44,HTS,Exp_ZBP1 (ENSG00000124256),GE,noncancer,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis",Launched,0.353830391762423,0.257683808528,calcitriol,VITAMIN D RECEPTOR AGONIST,0.3349823708355824,0.3162279439853538,-1.601898815797414
BRD-K27316855-001-19-0::2.5::HTS,BRD-K27316855-001-19-0,calcitriol,2.5,HTS,Exp_TAS2R38 (ENSG00000257138),GE,noncancer,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis",Launched,0.353830391762423,0.257683808528,calcitriol,VITAMIN D RECEPTOR AGONIST,0.3286617749493958,0.4584585407418578,-1.3139100857088972
BRD-K28456624-001-01-1::2.5::HTS,BRD-K28456624-001-01-1,seocalcitol,2.5,HTS,Exp_NLGN2 (ENSG00000169992),GE,targeted cancer,vitamin D receptor agonist,VDR,,,Phase 3,0.269120133538698,0.131451413166,seocalcitol,VITAMIN D RECEPTOR AGONIST,0.2674568067876395,0.2841216371195492,-1.3921323621058614
BRD-K49522529-001-02-9::2.53::HTS,BRD-K49522529-001-02-9,alfacalcidol,2.53,HTS,CRISPR_PTK2 (5747),AVANA_PUBLIC_18Q2,noncancer,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,Launched,0.355442402286188,0.194923523568,alfacalcidol,VITAMIN D RECEPTOR AGONIST,0.3529607649023792,0.37979155019968425,-1.5610122650554032
BRD-K49522529-001-03-7::2.5::HTS,BRD-K49522529-001-03-7,alfacalcidol,2.5,HTS,CRISPR_ESRP1 (54845),AVANA_PUBLIC_18Q2,noncancer,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,Launched,0.355442402286188,0.194923523568,alfacalcidol,VITAMIN D RECEPTOR AGONIST,0.3349120140337989,0.3339534594421137,-1.635520850303715
BRD-K56429665-001-09-6::2.500032186::MTS004,BRD-K56429665-001-09-6,calcipotriol,2.500032186,MTS004,CN_CTSZ (1522),CN,noncancer,vitamin D receptor agonist,VDR,dermatology,psoriasis,Launched,0.34250802459466495,0.134156141009,calcipotriol,VITAMIN D RECEPTOR AGONIST,0.355756149897004,0.9864217453921176,-0.5590870422587653
BRD-K60585088-001-01-5::2.5::HTS,BRD-K60585088-001-01-5,paricalcitol,2.5,HTS,Exp_CBX6 (ENSG00000183741),GE,noncancer,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",Launched,0.3225654270215,0.27106132852,paricalcitol,VITAMIN D RECEPTOR AGONIST,0.3209006281759064,1.0394318044118345,-0.5054086526142156
BRD-K73237276-001-01-0::2.5::HTS,BRD-K73237276-001-01-0,tacalcitol,2.5,HTS,Exp_CBX6 (ENSG00000183741),GE,noncancer,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",Launched,0.317052301760802,0.164100685805,tacalcitol,VITAMIN D RECEPTOR AGONIST,0.3167727195810381,0.7235614370359925,-0.7678308298395082
BRD-K77175907-001-08-0::2.555048691::MTS004,BRD-K77175907-001-08-0,calcifediol,2.555048691,MTS004,METABOL_C18:1 LPC,METABOL,noncancer,vitamin D receptor agonist,VDR,,,Launched,0.41385251509397797,0.0814624717617,calcifediol,VITAMIN D RECEPTOR AGONIST,0.41085611373649855,1.0604068022038642,-0.6423104336989507
BRD-K81332461-001-01-4::2.5::HTS,BRD-K81332461-001-01-4,maxacalcitol,2.5,HTS,Exp_SMIM22 (ENSG00000267795),GE,noncancer,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,Launched,0.25501131714971803,0.234661129239,maxacalcitol,VITAMIN D RECEPTOR AGONIST,0.2621822665111273,0.5222134547568827,-1.1981262510131452
BRD-K82928892-001-02-5::2.46::HTS,BRD-K82928892-001-02-5,doxercalciferol,2.46,HTS,Exp_ITGB3 (ENSG00000259207),GE,noncancer,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism",Launched,0.32634299949601503,0.240459617821,doxercalciferol,VITAMIN D RECEPTOR AGONIST,0.32495281605296217,1.4149192255072331,-0.14154940530994375
BRD-K84163249-001-01-9::2.5::HTS,BRD-K84163249-001-01-9,ercalcitriol,2.5,HTS,PROT_Syk,PROT,noncancer,vitamin D receptor agonist,VDR,,,Phase 1,0.267181010459849,0.180180498307,ercalcitriol,VITAMIN D RECEPTOR AGONIST,0.2516914154913968,1.3619274890733233,0.07315620564036962
BRD-K03449891-001-08-6::2.5::HTS,BRD-K03449891-001-08-6,foretinib,2.5,HTS,PROT_XBP1_Caution,PROT,targeted cancer,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",,,Phase 2,0.371140239492623,0.262552969348,foretinib,VEGFR INHIBITOR,0.3773544967210353,4.7496658738714155,-1.5614888317262945
BRD-K03765900-001-01-9::2.499986292::MTS004,BRD-K03765900-001-01-9,XL-647,2.499986292,MTS004,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,VEGFR inhibitor,"EGFR, EPHB4, ERBB2, FLT4, KDR",,,Phase 3,0.4449515305581721,0.53038806092,XL-647,VEGFR INHIBITOR,0.4423696251612983,1.2941219405176367,-4.7272797385165966
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,Exp_ZNRF2 (ENSG00000180233),GE,targeted cancer,VEGFR inhibitor,"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",Launched,0.369487062757553,0.255733352647,regorafenib,VEGFR INHIBITOR,0.3656727555796573,2.511458387751837,-1.1836226477704903
BRD-K18424115-003-01-3::2.5::HTS,BRD-K18424115-003-01-3,TG-100572,2.5,HTS,METHYL_MAFF,METHYL,targeted cancer,VEGFR inhibitor,"KDR, SRC",,,Preclinical,0.34769718685842405,0.113056931171,TG-100572,VEGFR INHIBITOR,0.3679078878218813,3.1967957758628835,-1.225139557985246
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,VEGFR inhibitor,"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)",Launched,0.24432473615882502,0.121313424882,sorafenib,VEGFR INHIBITOR,0.2506560716805934,2.9855040013390832,-1.3240170243076474
BRD-K25340465-001-11-1::2.58::HTS,BRD-K25340465-001-11-1,OSI-930,2.58,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,VEGFR inhibitor,"KDR, KIT",,,Phase 1,0.362401395674544,0.312895010808,OSI-930,VEGFR INHIBITOR,0.3669385970000413,4.803720341507483,-2.1638536864048463
BRD-K29905972-001-06-3::2.5::HTS,BRD-K29905972-001-06-3,axitinib,2.5,HTS,PROT_alpha-Catenin,PROT,targeted cancer,VEGFR inhibitor,"CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),Launched,0.340687193794764,0.320944722315,axitinib,VEGFR INHIBITOR,0.34224498067386994,3.5341995082138533,-3.3919041857006613
BRD-K31309378-001-01-5::2.5::HTS,BRD-K31309378-001-01-5,lucitanib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",,,Phase 2,0.3929726761430539,0.349685559839,lucitanib,VEGFR INHIBITOR,0.3927501337186822,2.3923401357074705,-1.4849731669084938
BRD-K39974922-001-04-3::2.5::HTS,BRD-K39974922-001-04-3,lenvatinib,2.5,HTS,Exp_PROSER2 (ENSG00000148426),GE,targeted cancer,VEGFR inhibitor,"FLT4, KDR",oncology,thyroid cancer,Launched,0.43004202579957107,0.25944445401,lenvatinib,VEGFR INHIBITOR,0.4476114527668799,0.004902555430529892,-2.0091548212213137
BRD-K40718343-001-02-6::2.5::HTS,BRD-K40718343-001-02-6,AEE788,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,VEGFR inhibitor,"EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",,,Phase 1/Phase 2,0.436712051885135,0.500281956291,AEE788,VEGFR INHIBITOR,0.4304378492381693,1.1361527127541766,-4.895200267640384
BRD-K41337261-001-03-0::2.5::HTS,BRD-K41337261-001-03-0,ZM-306416,2.5,HTS,Exp_FAM50A (ENSG00000071859),GE,targeted cancer,VEGFR inhibitor,"EGFR, FLT1, FLT4, KDR",,,Preclinical,0.382202230870648,0.207700681149,ZM-306416,VEGFR INHIBITOR,0.38084639780289004,3.0806105658677234,-0.5468262841526923
BRD-K42828737-044-09-0::2.5::HTS,BRD-K42828737-044-09-0,sunitinib,2.5,HTS,Exp_TSPAN15 (ENSG00000099282),GE,targeted cancer,VEGFR inhibitor,"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)",Launched,0.379885388988003,0.205193823437,sunitinib,VEGFR INHIBITOR,0.3588897605197444,0.8635142618069186,-2.8037216958190876
BRD-K47150025-001-05-3::2.5::HTS,BRD-K47150025-001-05-3,KI-8751,2.5,HTS,Exp_TGFA (ENSG00000163235),GE,targeted cancer,VEGFR inhibitor,KDR,,,Preclinical,0.37135481267825604,0.26505619223,KI-8751,VEGFR INHIBITOR,0.37259305966907547,4.724020179158859,-1.2092749597118837
BRD-K49075727-001-08-5::2.5::HTS,BRD-K49075727-001-08-5,nintedanib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),Launched,0.39097148638159795,0.298050541055,nintedanib,VEGFR INHIBITOR,0.3895847014985172,1.7587321479893276,-2.1205049654860684
BRD-K51544265-001-04-2::2.5::HTS,BRD-K51544265-001-04-2,cabozantinib,2.5,HTS,PROT_SHP-2_pY542_Caution,PROT,targeted cancer,VEGFR inhibitor,"KDR, MET",oncology,medullary thyroid cancer (MTC),Launched,0.372061453816323,0.234655735689,cabozantinib,VEGFR INHIBITOR,0.382836261777951,0.7054930113445562,-2.2952267007309715
BRD-K53414658-001-08-2::2.5::HTS,BRD-K53414658-001-08-2,tivozanib,2.5,HTS,MIRNA_hsa-miR-216a,MIRNA,targeted cancer,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.291306935341937,0.126809937532,tivozanib,VEGFR INHIBITOR,0.2720105359014036,4.597206134584806,-1.8160616187633492
BRD-K56277358-001-07-5::2.5::HTS,BRD-K56277358-001-07-5,MGCD-265,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,"AXL, MET",,,Preclinical,0.333056385596755,0.297762576594,MGCD-265,VEGFR INHIBITOR,0.3358867673577928,-3.0605927207947428,-0.18164926195621775
BRD-K56405753-001-02-4::2.5::HTS,BRD-K56405753-001-02-4,MK-2461,2.5,HTS,PROT_HER3,PROT,targeted cancer,VEGFR inhibitor,"FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",,,Phase 1/Phase 2,0.4683058496110529,0.346705398448,MK-2461,VEGFR INHIBITOR,0.48428806940021396,1.0770514990723847,-2.355992299816582
BRD-K68488863-001-04-9::2.5::HTS,BRD-K68488863-001-04-9,ENMD-2076,2.5,HTS,Exp_VIMP (ENSG00000131871),GE,targeted cancer,VEGFR inhibitor,"AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",,,Phase 2,0.419573999076324,0.330685283464,ENMD-2076,VEGFR INHIBITOR,0.4160230237769837,3.3497626168475745,-3.5323933776314216
BRD-K69001009-001-02-8::2.5::HTS,BRD-K69001009-001-02-8,golvatinib,2.5,HTS,PROT_c-Met_pY1235,PROT,targeted cancer,VEGFR inhibitor,"KDR, MET",,,Phase 2,0.3796007029549389,0.168488621749,golvatinib,VEGFR INHIBITOR,0.3867258062867393,0.6095660460543921,-2.5448261992784724
BRD-K74514084-001-03-9::2.5::HTS,BRD-K74514084-001-03-9,pazopanib,2.5,HTS,Exp_IRS2 (ENSG00000185950),GE,targeted cancer,VEGFR inhibitor,"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)",Launched,0.368346445231315,0.207058645193,pazopanib,VEGFR INHIBITOR,0.3750745618453133,0.8877095529391413,-2.216170319595117
BRD-K75911534-001-01-6::2.5::HTS,BRD-K75911534-001-01-6,SU014813,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,KDR,,,Phase 2,0.28002547514731607,0.270261834357,SU014813,VEGFR INHIBITOR,0.3111302693401125,-0.11698942133317446,-2.46618881723885
BRD-K76239644-001-01-8::2.5::HTS,BRD-K76239644-001-01-8,BMS-690514,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,targeted cancer,VEGFR inhibitor,"EGFR, ERBB2, FLT3, KDR",,,Phase 2,0.441821971624813,0.522720299356,BMS-690514,VEGFR INHIBITOR,0.44202865570474464,1.4657815232256688,-4.6620873601305215
BRD-K77625799-001-07-7::2.5::HTS,BRD-K77625799-001-07-7,vandetanib,2.5,HTS,Exp_FGFR2 (ENSG00000066468),GE,targeted cancer,VEGFR inhibitor,"EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),Launched,0.37330229889289707,0.402053233963,vandetanib,VEGFR INHIBITOR,0.3673003579456741,1.4716504090361735,-4.637272982724372
BRD-K84564571-001-02-4::2.5::HTS,BRD-K84564571-001-02-4,telatinib,2.5,HTS,Exp_PDGFRA (ENSG00000134853),GE,targeted cancer,VEGFR inhibitor,KDR,,,Phase 2,0.32797773378045103,0.224507479283,telatinib,VEGFR INHIBITOR,0.3241875064136507,-3.6786908742942703,0.052515351755042065
BRD-K85402309-001-06-6::2.5::HTS,BRD-K85402309-001-06-6,dovitinib,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,targeted cancer,VEGFR inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,VEGFR INHIBITOR,0.3209116212941136,4.798277110517273,-1.861827140155172
BRD-K85402309-389-03-2::2.5::HTS,BRD-K85402309-389-03-2,dovitinib,2.5,HTS,Exp_NASP (ENSG00000132780),GE,targeted cancer,VEGFR inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,VEGFR INHIBITOR,0.39269199754946216,3.339171570179825,-3.737822379584856
BRD-K86930074-001-05-0::2.5::HTS,BRD-K86930074-001-05-0,cediranib,2.5,HTS,Exp_MICU3 (ENSG00000155970),GE,targeted cancer,VEGFR inhibitor,"CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.418711644201704,0.356042510685,cediranib,VEGFR INHIBITOR,0.4197369795690476,1.358577123496744,-2.2751079959301537
BRD-K93123848-001-04-1::2.5::HTS,BRD-K93123848-001-04-1,RAF265,2.5,HTS,Exp_PLEKHA6 (ENSG00000143850),GE,targeted cancer,VEGFR inhibitor,BRAF,,,Phase 2,0.410228004642371,0.318815125393,RAF265,VEGFR INHIBITOR,0.40331883615929054,3.6888583227367615,-2.482930255468452
BRD-K97764662-001-17-3::2.5::HTS,BRD-K97764662-001-17-3,PD-173074,2.5,HTS,CRISPR_RELB (5971),AVANA_PUBLIC_18Q2,targeted cancer,VEGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",,,Preclinical,0.362749258239907,0.151819476088,PD-173074,VEGFR INHIBITOR,0.365906831220606,0.3087459488449005,-2.4099803204810284
BRD-K99749624-001-07-0::2.5::HTS,BRD-K99749624-001-07-0,linifanib,2.5,HTS,Exp_FAM117A (ENSG00000121104),GE,targeted cancer,VEGFR inhibitor,"CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",,,Phase 3,0.43568075834821,0.217416119842,linifanib,VEGFR INHIBITOR,0.4343455162765053,2.4379490139389124,-1.969361521698416
BRD-K02407574-001-09-7::2.5::HTS,BRD-K02407574-001-09-7,parbendazole,2.5,HTS,Exp_SNRNP40 (ENSG00000060688),GE,noncancer,tubulin polymerization inhibitor,TUBB,,,Preclinical,0.39207434140786895,0.352066470481,parbendazole,TUBULIN POLYMERIZATION INHIBITOR,0.3952633423353972,5.925110594848253,-2.7629474544309818
BRD-K06519765-001-01-1::2.5::MTS004,BRD-K06519765-001-01-1,vinblastine,2.5,MTS004,Exp_TBPL1 (ENSG00000028839),GE,chemo,tubulin polymerization inhibitor,"JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma",Launched,0.374307588486506,0.402916330164,vinblastine,TUBULIN POLYMERIZATION INHIBITOR,0.3763534084842421,5.672617216773956,-3.807764284022219
BRD-K12251893-065-04-7::2.5::HTS,BRD-K12251893-065-04-7,vincristine,2.5,HTS,Exp_YWHAE (ENSG00000108953),GE,chemo,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.35551054409447796,0.222659440993,vincristine,TUBULIN POLYMERIZATION INHIBITOR,0.35890922744210524,5.750968346463982,-2.022256313645824
BRD-K12539581-001-23-7::2.5::HTS,BRD-K12539581-001-23-7,nocodazole,2.5,HTS,Exp_PLGLB2 (ENSG00000125551),GE,targeted cancer,tubulin polymerization inhibitor,HPGDS,,,Preclinical,0.37131078964137604,0.0518694839367,nocodazole,TUBULIN POLYMERIZATION INHIBITOR,0.3650091859756092,4.9252568420971,-2.0098799199427297
BRD-K20468903-001-01-6::2.49996519::MTS004,BRD-K20468903-001-01-6,BNC105,2.49996519,MTS004,Exp_TNFAIP8L1 (ENSG00000185361),GE,chemo,tubulin polymerization inhibitor,,,,Phase 2,0.389394983825307,0.345259496133,BNC105,TUBULIN POLYMERIZATION INHIBITOR,0.3912611631439378,5.9600468858070945,-3.5595601346598427
BRD-K29968218-001-03-2::2.5::HTS,BRD-K29968218-001-03-2,KX2-391,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,targeted cancer,tubulin polymerization inhibitor,SRC,,,Phase 2,0.397407500559846,0.334663716673,KX2-391,TUBULIN POLYMERIZATION INHIBITOR,0.39573840199389615,5.91990323244767,-2.416818323557817
BRD-K30577245-001-04-3::2.5::HTS,BRD-K30577245-001-04-3,docetaxel,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)",Launched,0.373500390599039,0.25555168675,docetaxel,TUBULIN POLYMERIZATION INHIBITOR,0.3200138251347359,6.165900811579388,-1.8610676981893064
BRD-K30577245-341-01-9::2.5::HTS,BRD-K30577245-341-01-9,docetaxel,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)",Launched,0.373500390599039,0.25555168675,docetaxel,TUBULIN POLYMERIZATION INHIBITOR,0.3753999016741466,5.027236624014705,-1.4301151028779646
BRD-K42673188-001-01-1::2.363355746::MTS004,BRD-K42673188-001-01-1,verubulin,2.363355746,MTS004,Exp_TBPL1 (ENSG00000028839),GE,chemo,tubulin polymerization inhibitor,TUBB,,,Phase 2,0.40882496026486004,0.345114447301,verubulin,TUBULIN POLYMERIZATION INHIBITOR,0.413005421978568,5.856832536460214,-3.8061942351239297
BRD-K47869605-001-32-0::2.5::HTS,BRD-K47869605-001-32-0,podophyllotoxin,2.5,HTS,METHYL_ZP2,METHYL,noncancer,tubulin polymerization inhibitor,"IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,Launched,0.38159068914812794,0.0972764546144,podophyllotoxin,TUBULIN POLYMERIZATION INHIBITOR,0.3908893499579293,5.375247873157506,-0.578917367296206
BRD-K51318897-001-15-3::2.5::HTS,BRD-K51318897-001-15-3,fenbendazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms",Launched,0.282070159701193,0.251112160526,fenbendazole,TUBULIN POLYMERIZATION INHIBITOR,0.2819550333364852,6.165813244475388,-2.1757213243172746
BRD-K52075715-001-06-7::2.5::HTS,BRD-K52075715-001-06-7,oxibendazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,Launched,0.40407579064530796,0.27807389918,oxibendazole,TUBULIN POLYMERIZATION INHIBITOR,0.4030711029375416,5.504008717394713,-2.8618212868220048
BRD-K52762805-001-01-2::2.5::HTS,BRD-K52762805-001-01-2,epothilone-d,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",,,Phase 2,0.392511332852066,0.232180931769,epothilone-d,TUBULIN POLYMERIZATION INHIBITOR,0.3894586355892942,6.116193740396273,-1.8932784437615575
BRD-K59753975-001-02-6::2.5::MTS004,BRD-K59753975-001-02-6,vindesine,2.5,MTS004,Exp_TTC39A (ENSG00000085831),GE,chemo,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",Launched,0.3893839264965229,0.400229746201,vindesine,TUBULIN POLYMERIZATION INHIBITOR,0.3916119505494929,5.7602081771732765,-3.7960716601618474
BRD-K61195623-001-01-4::2.5::HTS,BRD-K61195623-001-01-4,combretastatin-A-4,2.5,HTS,Exp_SCO1 (ENSG00000133028),GE,chemo,tubulin polymerization inhibitor,,,,Phase 2,0.42890765175224604,0.225694345621,combretastatin-A-4,TUBULIN POLYMERIZATION INHIBITOR,0.4309839758514848,4.08692192940776,-1.3186032820850184
BRD-K62008436-001-22-1::2.5::HTS,BRD-K62008436-001-22-1,paclitaxel,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,chemo,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)",Launched,0.40504734544188703,0.23955984227,paclitaxel,TUBULIN POLYMERIZATION INHIBITOR,0.4035264766491036,5.831260866817032,-1.6777908822268337
BRD-K68164687-001-01-6::2.5::HTS,BRD-K68164687-001-01-6,epothilone-b,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",,,Phase 3,0.417752218533801,0.273207755121,epothilone-b,TUBULIN POLYMERIZATION INHIBITOR,0.4151753887802863,5.175861298526113,-2.5120452124136032
BRD-K69280563-001-01-8::2.5::HTS,BRD-K69280563-001-01-8,vinorelbine,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),Launched,0.4378090314031579,0.296580062206,vinorelbine,TUBULIN POLYMERIZATION INHIBITOR,0.4361107121887789,6.065643779588902,-2.1402350324814394
BRD-K74057757-001-01-9::2.5::HTS,BRD-K74057757-001-01-9,indibulin,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,chemo,tubulin polymerization inhibitor,,,,Phase 1/Phase 2,0.380745566726054,0.30481776312,indibulin,TUBULIN POLYMERIZATION INHIBITOR,0.379766055927822,5.4940067014415925,-3.001937312625638
BRD-K77987382-001-13-2::2.5::HTS,BRD-K77987382-001-13-2,mebendazole,2.5,HTS,DEM2_BATF (10538),DEMETER2_COM,noncancer,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",Launched,0.41950175475708096,0.285210484251,mebendazole,TUBULIN POLYMERIZATION INHIBITOR,0.4226685136013294,5.109001014540107,-3.134684598427373
BRD-K78567475-001-01-4::2.5::HTS,BRD-K78567475-001-01-4,dolastatin-10,2.5,HTS,Exp_PDK1 (ENSG00000152256),GE,targeted cancer,tubulin polymerization inhibitor,TUBB,,,Phase 2,0.403003978016177,0.248807375166,dolastatin-10,TUBULIN POLYMERIZATION INHIBITOR,0.4003324389846388,5.80765754140126,-2.0513319585842016
BRD-K79131256-001-17-9::2.5::HTS,BRD-K79131256-001-17-9,albendazole,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,noncancer,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis",Launched,0.41505908516553497,0.255394712189,albendazole,TUBULIN POLYMERIZATION INHIBITOR,0.4186299775609527,5.566051144924168,-2.733373283702817
BRD-K86003836-001-10-5::2.5::HTS,BRD-K86003836-001-10-5,flubendazole,2.5,HTS,Exp_SIAH2 (ENSG00000181788),GE,noncancer,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,Launched,0.38047518259999497,0.238069832741,flubendazole,TUBULIN POLYMERIZATION INHIBITOR,0.3853317091552823,5.589393228798657,-2.9386120972252616
BRD-K87512222-019-01-7::2.5::HTS,BRD-K87512222-019-01-7,taltobulin,2.5,HTS,Exp_PTPRA (ENSG00000132670),GE,chemo,tubulin polymerization inhibitor,,,,Phase 1,0.392475911860582,0.177041992513,taltobulin,TUBULIN POLYMERIZATION INHIBITOR,0.3862923441870058,4.471114542704604,-0.8395511348992915
BRD-K91623615-001-05-0::2.46::HTS,BRD-K91623615-001-05-0,ABT-751,2.46,HTS,Exp_COQ3 (ENSG00000132423),GE,chemo,tubulin polymerization inhibitor,TUBB,,,Phase 2,0.413037323107545,0.346103026501,ABT-751,TUBULIN POLYMERIZATION INHIBITOR,0.4141087594605762,6.245009994681617,-2.735499490389284
BRD-K99498722-001-02-6::2.5::HTS,BRD-K99498722-001-02-6,plinabulin,2.5,HTS,Exp_HSP90AB1 (ENSG00000096384),GE,chemo,tubulin polymerization inhibitor,,,,Phase 3,0.346589718350491,0.293943872068,plinabulin,TUBULIN POLYMERIZATION INHIBITOR,0.3504862510840291,6.1272204095265925,-2.2062382117926798
BRD-K06814349-304-01-9::2.5::HTS,BRD-K06814349-304-01-9,fosbretabulin,2.5,,,,,tubulin polymerization inhibitor,CDH5,,,,0,0,fosbretabulin,TUBULIN POLYMERIZATION INHIBITOR,0.3864183522343652,3.642578115510759,-1.010424722972247
BRD-K23363278-001-02-1::2.5::HTS,BRD-K23363278-001-02-1,CYT-997,2.5,,,,,tubulin polymerization inhibitor,TUBB,,,,0,0,CYT-997,TUBULIN POLYMERIZATION INHIBITOR,0.3536653382451552,3.500055006240905,-0.820192275769553
BRD-A35588707-001-05-5::2.5::HTS,BRD-A35588707-001-05-5,teniposide,2.5,HTS,DEM2_CDX4 (1046),DEMETER2_COM,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.37919941860096795,0.116999470995,teniposide,TOPOISOMERASE INHIBITOR,0.3770620959138941,5.136812739337668,-1.212969451617493
BRD-K07265709-003-05-6::2.61::HTS,BRD-K07265709-003-05-6,dexrazoxane,2.61,HTS,Exp_ABCB1 (ENSG00000085563),GE,noncancer,topoisomerase inhibitor,"TOP2A, TOP2B",cardiology,cardiomyopathy,Launched,0.376644810533462,0.388675733791,dexrazoxane,TOPOISOMERASE INHIBITOR,0.3758012866050104,5.041303594211862,-3.5743663961363947
BRD-K08547377-394-03-5::2.5::HTS,BRD-K08547377-394-03-5,irinotecan,2.5,HTS,Exp_EDA2R (ENSG00000131080),GE,chemo,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,Launched,0.291528500539335,0.267568033885,irinotecan,TOPOISOMERASE INHIBITOR,0.29113542741333576,4.626762903016814,-2.589856350248934
BRD-K09426783-300-01-0::2.5::HTS,BRD-K09426783-300-01-0,TAS-103,2.5,HTS,DEM2_USP1 (7398),DEMETER2_COM,chemo,topoisomerase inhibitor,TOP1,,,Phase 1,0.351838791701481,0.211791183243,TAS-103,TOPOISOMERASE INHIBITOR,0.3713923539283257,4.8271165627614385,-0.8988571339046123
BRD-K10362825-001-03-4::2.5::HTS,BRD-K10362825-001-03-4,teniposide,2.5,HTS,DEM2_DHRS1 (115817),DEMETER2_COM,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),Launched,0.38298754958898606,0.163340900636,teniposide,TOPOISOMERASE INHIBITOR,0.3725798225354496,5.346628429557206,-0.5224288039204716
BRD-K23677682-003-01-2::2.5::HTS,BRD-K23677682-003-01-2,voreloxin,2.5,HTS,Exp_TBPL1 (ENSG00000028839),GE,chemo,topoisomerase inhibitor,TOP2A,,,Phase 3,0.368153569614973,0.333396416831,voreloxin,TOPOISOMERASE INHIBITOR,0.36981988523709936,3.952981369100298,-3.1991567334208373
BRD-K28061410-001-06-6::2.5::MTS004,BRD-K28061410-001-06-6,beta-lapachone,2.5,MTS004,Exp_KIF6 (ENSG00000164627),GE,chemo,topoisomerase inhibitor,TOP1,,,Phase 2,0.468077268349341,0.351562153896,beta-lapachone,TOPOISOMERASE INHIBITOR,0.4577214683426839,3.1813289787445767,-1.04892753886084
BRD-K37798499-001-27-2::2.5::HTS,BRD-K37798499-001-27-2,etoposide,2.5,HTS,Exp_CCT8 (ENSG00000156261),GE,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),Launched,0.41684997040337196,0.332354068204,etoposide,TOPOISOMERASE INHIBITOR,0.41902399710353866,4.30870396880527,-3.0818266554345297
BRD-K55696337-003-24-4::2.50001813::MTS004,BRD-K55696337-003-24-4,topotecan,2.50001813,MTS004,Exp_TOP1 (ENSG00000198900),GE,chemo,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer",Launched,0.39256436408624107,0.360834559306,topotecan,TOPOISOMERASE INHIBITOR,0.3913563604184497,2.0641157340344463,-0.3743863435140065
BRD-K56334280-001-05-1::2.5::HTS,BRD-K56334280-001-05-1,amonafide,2.5,HTS,Exp_HNRNPC (ENSG00000092199),GE,chemo,topoisomerase inhibitor,"TOP2A, TOP2B",,,Phase 3,0.36810773029055605,0.394345338724,amonafide,TOPOISOMERASE INHIBITOR,0.3673980213445154,3.579854499475587,-3.549695922024724
BRD-K68346641-001-01-4::2.5::HTS,BRD-K68346641-001-01-4,amsacrine,2.5,HTS,Exp_GEMIN4 (ENSG00000179409),GE,chemo,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",Launched,0.382644312489669,0.251936618255,amsacrine,TOPOISOMERASE INHIBITOR,0.3710298158744496,4.80260665128697,-1.9248547044015
BRD-K68346641-001-02-2::2.5::HTS,BRD-K68346641-001-02-2,amsacrine,2.5,HTS,Exp_PTCHD4 (ENSG00000244694),GE,chemo,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",Launched,0.382644312489669,0.251936618255,amsacrine,TOPOISOMERASE INHIBITOR,0.38307453109075057,4.240215934211228,-2.3297709181198902
BRD-K72533376-001-01-2::2.5::MTS004,BRD-K72533376-001-01-2,etoposide-phosphate,2.5,MTS004,CRISPR_SUB1 (10923),AVANA_PUBLIC_18Q2,chemo,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",Launched,0.32830811110799296,0.243229613095,etoposide-phosphate,TOPOISOMERASE INHIBITOR,0.339534517699433,3.8159071045744337,-3.4806934604995035
BRD-K72951360-001-01-4::2.5::HTS,BRD-K72951360-001-01-4,valrubicin,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,chemo,topoisomerase inhibitor,TOP2A,oncology,bladder cancer,Launched,0.39401892317501,0.223806057429,valrubicin,TOPOISOMERASE INHIBITOR,0.3953000624723401,4.289489230790103,-1.6377493918822807
BRD-K79821389-001-03-5::2.562009205::MTS004,BRD-K79821389-001-03-5,rubitecan,2.562009205,MTS004,Exp_ERO1L (ENSG00000197930),GE,chemo,topoisomerase inhibitor,TOP1,,,Phase 3,0.42919069047454794,0.285634087647,rubitecan,TOPOISOMERASE INHIBITOR,0.4266283242659185,2.382929836349001,-0.5002000758756053
BRD-K04548931-003-16-5::2.5::HTS,BRD-K04548931-003-16-5,epirubicin,2.5,,,,,topoisomerase inhibitor,"CHD1, TOP2A",oncology,,,0,0,epirubicin,TOPOISOMERASE INHIBITOR,0.3908599004985632,4.393254682488903,-0.9831726496144296
BRD-K21680192-300-14-4::2.5::HTS,BRD-K21680192-300-14-4,mitoxantrone,2.5,,,,,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy",,,0,0,mitoxantrone,TOPOISOMERASE INHIBITOR,0.3716710866413601,5.097599224714531,-0.2127888455280238
BRD-K37890730-001-15-1::2.5::HTS,BRD-K37890730-001-15-1,SN-38,2.5,,,,,topoisomerase inhibitor,TOP1,oncology,,,0,0,SN-38,TOPOISOMERASE INHIBITOR,0.3686651342308559,4.074462868743817,0.24023379774497175
BRD-K43389675-003-16-7::2.35::HTS,BRD-K43389675-003-16-7,daunorubicin,2.35,,,,,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,,,0,0,daunorubicin,TOPOISOMERASE INHIBITOR,0.4192604989756199,5.056183458415956,1.1701337977209394
BRD-K43389675-003-20-9::2.5::HTS,BRD-K43389675-003-20-9,daunorubicin,2.5,,,,,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,,,0,0,daunorubicin,TOPOISOMERASE INHIBITOR,0.4156963575262875,4.6006767655628344,-0.6466485046124437
BRD-K51911221-001-01-2::2.5::HTS,BRD-K51911221-001-01-2,nemorubicin,2.5,,,,,topoisomerase inhibitor,"TOP1, TOP2A",,,,0,0,nemorubicin,TOPOISOMERASE INHIBITOR,0.4354708188516133,4.1805434106928825,-0.5345209970573772
BRD-K63784565-001-06-2::2.51::HTS,BRD-K63784565-001-06-2,10-hydroxycamptothecin,2.51,,,,,topoisomerase inhibitor,TOP1,,,,0,0,10-hydroxycamptothecin,TOPOISOMERASE INHIBITOR,0.3546111768822107,5.2991118942663515,0.2178628331708068
BRD-K69650333-003-14-0::2.5::HTS,BRD-K69650333-003-14-0,idarubicin,2.5,,,,,topoisomerase inhibitor,TOP2A,hematologic malignancy,,,0,0,idarubicin,TOPOISOMERASE INHIBITOR,0.4078197358311676,4.257520193618109,-0.5925590046724638
BRD-K89561498-001-01-7::2.5::HTS,BRD-K89561498-001-01-7,SN-38,2.5,,,,,topoisomerase inhibitor,TOP1,oncology,,,0,0,SN-38,TOPOISOMERASE INHIBITOR,0.4124049180061644,3.695038177168382,-0.43299971716078994
BRD-K92093830-003-30-8::2.5::HTS,BRD-K92093830-003-30-8,doxorubicin,2.5,,,,,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology",,,0,0,doxorubicin,TOPOISOMERASE INHIBITOR,0.3981629257438549,5.327436830483856,1.2738064318936773
BRD-K99475619-001-01-2::2.5::HTS,BRD-K99475619-001-01-2,genz-644282,2.5,,,,,topoisomerase inhibitor,TOP1,,,,0,0,genz-644282,TOPOISOMERASE INHIBITOR,0.4130432736718839,3.9721872932570745,0.0610759235539855
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,Exp_ZNRF2 (ENSG00000180233),GE,targeted cancer,RET tyrosine kinase inhibitor,"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",Launched,0.369487062757553,0.255733352647,regorafenib,RET TYROSINE KINASE INHIBITOR,0.3656727555796573,2.511458387751837,-1.1836226477704903
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,RET tyrosine kinase inhibitor,"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)",Launched,0.24432473615882502,0.121313424882,sorafenib,RET TYROSINE KINASE INHIBITOR,0.2506560716805934,2.9855040013390832,-1.3240170243076474
BRD-K25244359-066-03-4::2.68::HTS,BRD-K25244359-066-03-4,apatinib,2.68,HTS,MIRNA_hsa-miR-199a-5p,MIRNA,targeted cancer,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",,,Phase 3,0.37017729148818,0.157696655304,apatinib,RET TYROSINE KINASE INHIBITOR,0.367434370286835,0.6799202208958381,-3.124016944266457
BRD-K42828737-044-09-0::2.5::HTS,BRD-K42828737-044-09-0,sunitinib,2.5,HTS,Exp_TSPAN15 (ENSG00000099282),GE,targeted cancer,RET tyrosine kinase inhibitor,"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)",Launched,0.379885388988003,0.205193823437,sunitinib,RET TYROSINE KINASE INHIBITOR,0.3588897605197444,0.8635142618069186,-2.8037216958190876
BRD-K51544265-001-04-2::2.5::HTS,BRD-K51544265-001-04-2,cabozantinib,2.5,HTS,PROT_SHP-2_pY542_Caution,PROT,targeted cancer,RET tyrosine kinase inhibitor,"KDR, MET",oncology,medullary thyroid cancer (MTC),Launched,0.372061453816323,0.234655735689,cabozantinib,RET TYROSINE KINASE INHIBITOR,0.382836261777951,0.7054930113445562,-2.2952267007309715
BRD-K66538826-001-07-2::2.5::HTS,BRD-K66538826-001-07-2,amuvatinib,2.5,HTS,Exp_RTBDN (ENSG00000132026),GE,targeted cancer,RET tyrosine kinase inhibitor,"KIT, MET",,,Phase 2,0.27399724559714,0.164685101792,amuvatinib,RET TYROSINE KINASE INHIBITOR,0.2780070596740157,0.8926978724172016,-3.3020033144944865
BRD-K77625799-001-07-7::2.5::HTS,BRD-K77625799-001-07-7,vandetanib,2.5,HTS,Exp_FGFR2 (ENSG00000066468),GE,targeted cancer,RET tyrosine kinase inhibitor,"EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),Launched,0.37330229889289707,0.402053233963,vandetanib,RET TYROSINE KINASE INHIBITOR,0.3673003579456741,1.4716504090361735,-4.637272982724372
BRD-A56085258-001-01-8::2.5::HTS,BRD-A56085258-001-01-8,LGX818,2.5,HTS,Exp_RAB38 (ENSG00000123892),GE,targeted cancer,RAF inhibitor,BRAF,,,Phase 3,0.44810961682059897,0.567752462194,LGX818,RAF INHIBITOR,0.4300122222666944,1.08224664660821,-3.0961365755080847
BRD-K05804044-001-06-0::2.5::HTS,BRD-K05804044-001-06-0,AZ-628,2.5,HTS,Exp_SPRY4 (ENSG00000187678),GE,targeted cancer,RAF inhibitor,"BRAF, RAF1",,,Preclinical,0.471543045631854,0.557943202955,AZ-628,RAF INHIBITOR,0.4677598573297166,0.5680648233775349,4.506307507371487
BRD-K09951645-001-06-8::2.5::HTS,BRD-K09951645-001-06-8,dabrafenib,2.5,HTS,DEM2_BRAF (673),DEMETER2_COM,targeted cancer,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,Launched,0.389754464300569,0.498900689281,dabrafenib,RAF INHIBITOR,0.3872259850587587,1.4995789029045268,3.6157406011155633
BRD-K16478699-001-09-2::2.5::HTS,BRD-K16478699-001-09-2,PLX-4720,2.5,HTS,DEM2_BRAF (673),DEMETER2_COM,targeted cancer,RAF inhibitor,"BRAF, KDR",,,Preclinical,0.35461275912986895,0.414495480983,PLX-4720,RAF INHIBITOR,0.3515845228819439,1.5685635426314568,3.147103146345177
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,Exp_ZNRF2 (ENSG00000180233),GE,targeted cancer,RAF inhibitor,"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",Launched,0.369487062757553,0.255733352647,regorafenib,RAF INHIBITOR,0.3656727555796573,2.511458387751837,-1.1836226477704903
BRD-K20722021-001-02-1::2.5::HTS,BRD-K20722021-001-02-1,CEP-32496,2.5,HTS,Exp_CHST15 (ENSG00000182022),GE,targeted cancer,RAF inhibitor,"BRAF, RAF1",,,Phase 1/Phase 2,0.308278821202966,0.283343374638,CEP-32496,RAF INHIBITOR,0.30600524914152183,2.9260694379533896,-1.200258826223887
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,MIRNA_hsa-miR-199b-5p,MIRNA,targeted cancer,RAF inhibitor,"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)",Launched,0.24432473615882502,0.121313424882,sorafenib,RAF INHIBITOR,0.2506560716805934,2.9855040013390832,-1.3240170243076474
BRD-K31866293-001-01-6::2.5::HTS,BRD-K31866293-001-01-6,TAK-632,2.5,HTS,Exp_CHST15 (ENSG00000182022),GE,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.39234576780911495,0.467082193446,TAK-632,RAF INHIBITOR,0.38893095634520697,0.682512945067741,4.273751896626126
BRD-K56343971-001-10-6::2.5::HTS,BRD-K56343971-001-10-6,vemurafenib,2.5,HTS,RMUThot_BRAF (673),MUThot,targeted cancer,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,Launched,0.43011531895809,0.472175129846,vemurafenib,RAF INHIBITOR,0.4263214951724831,1.286412776964137,3.250078831360125
BRD-K67578145-001-09-7::2.38::HTS,BRD-K67578145-001-09-7,GDC-0879,2.38,HTS,Exp_RXRG (ENSG00000143171),GE,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.41980457527485704,0.453712527295,GDC-0879,RAF INHIBITOR,0.3959570253412782,1.0990038562797009,3.923203904155877
BRD-K67578145-001-12-1::2.5::HTS,BRD-K67578145-001-12-1,GDC-0879,2.5,HTS,Exp_UCN2 (ENSG00000145040),GE,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.41980457527485704,0.453712527295,GDC-0879,RAF INHIBITOR,0.3337577711309578,1.285491762840318,3.686672506852124
BRD-K78809024-001-05-7::2.5::HTS,BRD-K78809024-001-05-7,SB-590885,2.5,HTS,RMUThot_BRAF (673),MUT,targeted cancer,RAF inhibitor,BRAF,,,Preclinical,0.39463602531535796,0.397684532349,SB-590885,RAF INHIBITOR,0.3934480280758277,1.1400561491374668,3.6944562174215587
BRD-K93123848-001-04-1::2.5::HTS,BRD-K93123848-001-04-1,RAF265,2.5,HTS,Exp_PLEKHA6 (ENSG00000143850),GE,targeted cancer,RAF inhibitor,BRAF,,,Phase 2,0.410228004642371,0.318815125393,RAF265,RAF INHIBITOR,0.40331883615929054,3.6888583227367615,-2.482930255468452
BRD-A36331462-001-02-1::2.5::HTS,BRD-A36331462-001-02-1,oprozomib,2.5,,,,,proteasome inhibitor,,,,,0,0,oprozomib,PROTEASOME INHIBITOR,0.39614689162085936,3.8228709133214434,-0.07327077728186149
BRD-A66419424-001-02-4::2.5::HTS,BRD-A66419424-001-02-4,ixazomib-citrate,2.5,,,,,proteasome inhibitor,,hematologic malignancy,,,0,0,ixazomib-citrate,PROTEASOME INHIBITOR,0.3687491100910335,4.559524662021247,-0.3019993956836955
BRD-K59325863-001-03-6::2.46::HTS,BRD-K59325863-001-03-6,delanzomib,2.46,,,,,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",,,,0,0,delanzomib,PROTEASOME INHIBITOR,0.3972521168988082,4.487135170490793,0.6539695153449829
BRD-K60230970-001-17-5::2.4::HTS,BRD-K60230970-001-17-5,MG-132,2.4,,,,,proteasome inhibitor,PSMB1,,,,0,0,MG-132,PROTEASOME INHIBITOR,0.3709175058655697,4.687639245283145,0.0728064945922422
BRD-K60446698-001-01-2::2.5::HTS,BRD-K60446698-001-01-2,ONX-0914,2.5,,,,,proteasome inhibitor,,,,,0,0,ONX-0914,PROTEASOME INHIBITOR,0.3205068414744207,4.261814739480638,0.5508481679079431
BRD-K78659596-001-03-9::2.5::HTS,BRD-K78659596-001-03-9,ixazomib,2.5,,,,,proteasome inhibitor,,hematologic malignancy,,,0,0,ixazomib,PROTEASOME INHIBITOR,0.3719177296438981,4.4417013517402735,0.4601796643266074
BRD-K88510285-001-11-1::2.5::HTS,BRD-K88510285-001-11-1,bortezomib,2.5,,,,,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,,,0,0,bortezomib,PROTEASOME INHIBITOR,0.370212908917695,4.613194074333759,1.2574111672693185
BRD-K43187018-001-03-3::2.52::HTS,BRD-K43187018-001-03-3,GDC-0349,2.52,HTS,Exp_FBXL19-AS1 (ENSG00000260852),GE,targeted cancer,Pim kinase inhibitor,PIK3CA,,,Phase 1,0.308414972567047,0.28839047639,GDC-0349,PIM KINASE INHIBITOR,0.30808689544269985,2.480885384720411,-1.1720900683676407
BRD-K80700417-001-04-2::2.5::HTS,BRD-K80700417-001-04-2,SGI-1776,2.5,HTS,Exp_ATP10A (ENSG00000206190),GE,targeted cancer,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",,,Phase 1,0.32682258200826697,0.112022125203,SGI-1776,PIM KINASE INHIBITOR,0.33582774431341955,2.3933309735103903,-1.2718981117068435
BRD-K07955840-001-02-3::2.5::HTS,BRD-K07955840-001-02-3,PF-05212384,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,PI3K inhibitor,"MTOR, PIK3CA",,,Phase 2,0.382687800620755,0.564858659535,PF-05212384,PI3K INHIBITOR,0.3852296565502841,3.989082123526386,-1.4161922013574806
BRD-K12184916-001-15-4::2.5::HTS,BRD-K12184916-001-15-4,NVP-BEZ235,2.5,HTS,Exp_PPP2CB (ENSG00000104695),GE,targeted cancer,PI3K inhibitor,"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",,,Phase 2,0.34121656967012004,0.265464996979,NVP-BEZ235,PI3K INHIBITOR,0.3445319543727742,2.336388135743562,-1.100654595623761
BRD-K23228615-001-02-8::2.5::HTS,BRD-K23228615-001-02-8,GDC-0980,2.5,HTS,Exp_ELP3 (ENSG00000134014),GE,targeted cancer,PI3K inhibitor,"FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",,,Phase 2,0.30084307307744296,0.247061919705,GDC-0980,PI3K INHIBITOR,0.3032016771793324,2.9478329653309148,-1.33768074963867
BRD-K24666289-001-04-9::2.499988887::MTS004,BRD-K24666289-001-04-9,copanlisib,2.499988887,MTS004,Exp_ATP6V0E2-AS1 (ENSG00000204934),GE,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,follicular lymphoma,Launched,0.418081005437764,0.30219684814,copanlisib,PI3K INHIBITOR,0.4162811217191591,1.9539783954306211,-0.39326921151237615
BRD-K28352084-001-02-3::2.5::HTS,BRD-K28352084-001-02-3,CH5132799,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1,0.38835376407003297,0.446512158108,CH5132799,PI3K INHIBITOR,0.37618184022541024,1.0241747672843324,-1.4979519393694385
BRD-K29395450-001-06-8::2.5::HTS,BRD-K29395450-001-06-8,PIK-93,2.5,HTS,CRISPR_ZNF689 (115509),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PI4KB, PIK3C3, PIK3CG",,,Preclinical,0.36168119494936496,0.208511414279,PIK-93,PI3K INHIBITOR,0.3633863383670989,0.7101886765763821,-1.3442657074484619
BRD-K42191735-001-05-3::2.5::HTS,BRD-K42191735-001-05-3,buparlisib,2.5,HTS,METHYL_ANO4,METHYL,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CG",,,Phase 3,0.360500594519615,0.175616687096,buparlisib,PI3K INHIBITOR,0.3617882377248671,4.077432187749252,-1.0861615375764249
BRD-K44844162-001-01-6::2.5::HTS,BRD-K44844162-001-01-6,taselisib,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,PIK3CA,,,Phase 3,0.430041046918619,0.502719679653,taselisib,PI3K INHIBITOR,0.4343244753187693,0.6344122627609565,-1.7697257077162272
BRD-K46392623-001-02-5::2.5::HTS,BRD-K46392623-001-02-5,TG-100713,2.5,HTS,Exp_SLC43A3 (ENSG00000134802),GE,targeted cancer,PI3K inhibitor,,,,Preclinical,0.31680025109431603,0.208016647323,TG-100713,PI3K INHIBITOR,0.3153062298172066,3.6528921730733885,-0.6416698133922849
BRD-K48488978-001-05-3::2.5::HTS,BRD-K48488978-001-05-3,YM-201636,2.5,HTS,Exp_KCNMB3 (ENSG00000171121),GE,targeted cancer,PI3K inhibitor,,,,Preclinical,0.376206305681492,0.275694669744,YM-201636,PI3K INHIBITOR,0.3757278835781863,1.6128716520222133,-1.97069076959428
BRD-K49055432-001-04-2::2.5::HTS,BRD-K49055432-001-04-2,A66,2.5,HTS,DEM2_PIK3CA (5290),DEMETER2_COM,targeted cancer,PI3K inhibitor,PIK3CA,,,Preclinical,0.34120786303993894,0.339314677791,A66,PI3K INHIBITOR,0.31975641345437844,0.5931369765905694,-1.5686908948556044
BRD-K52911425-001-09-8::2.5::HTS,BRD-K52911425-001-09-8,GDC-0941,2.5,HTS,CRISPR_PNN (5411),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 2,0.344252502838951,0.367778243192,GDC-0941,PI3K INHIBITOR,0.3420933284019244,0.680298498810724,-1.4459033534674923
BRD-K54997624-001-06-0::2.5::HTS,BRD-K54997624-001-06-0,alpelisib,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 3,0.42583744790027606,0.452714774665,alpelisib,PI3K INHIBITOR,0.4260672503281087,0.6496688237187089,-1.7253785706650475
BRD-K56291712-001-01-0::2.5::HTS,BRD-K56291712-001-01-0,voxtalisib,2.5,HTS,Exp_MCOLN3 (ENSG00000055732),GE,targeted cancer,PI3K inhibitor,"MTOR, PIK3CA",,,Phase 2,0.33936887593476506,0.0937165653991,voxtalisib,PI3K INHIBITOR,0.327449755965424,0.8075320851236577,-1.382729904285524
BRD-K58772419-001-07-0::2.5::HTS,BRD-K58772419-001-07-0,AZD6482,2.5,HTS,CRISPR_SHB (6461),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1,0.34097612690002194,0.079912332754,AZD6482,PI3K INHIBITOR,0.3367992100683447,2.1952598781028305,-1.0231041302454535
BRD-K62374002-001-01-5::2.499972663::MTS004,BRD-K62374002-001-01-5,PI3K-IN-2,2.499972663,MTS004,DEM2_PIK3CA (5290),DEMETER2_COM,targeted cancer,PI3K inhibitor,,,,Phase 2,0.38551696743457603,0.260826767472,PI3K-IN-2,PI3K INHIBITOR,0.3851570891702296,1.6867546151267885,-1.0605978150250783
BRD-K63068307-001-08-9::2.5::HTS,BRD-K63068307-001-08-9,ZSTK-474,2.5,HTS,CRISPR_PIK3CA (5290),AVANA_PUBLIC_18Q2,targeted cancer,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",,,Phase 1/Phase 2,0.371911181512344,0.353805473262,ZSTK-474,PI3K INHIBITOR,0.35382442310918283,1.9538269207929144,-1.3109245350936891
BRD-K67868012-001-07-6::2.5::HTS,BRD-K67868012-001-07-6,PI-103,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",,,Preclinical,0.29464258959735307,0.279593750407,PI-103,PI3K INHIBITOR,0.2940556044411721,2.0191468011182483,-1.4470930158010782
BRD-K82967180-001-01-6::2.500024493::MTS004,BRD-K82967180-001-01-6,LY3023414,2.500024493,MTS004,Exp_PFKFB3 (ENSG00000170525),GE,targeted cancer,PI3K inhibitor,MTOR,,,Phase 2,0.37864104722169606,0.273963456701,LY3023414,PI3K INHIBITOR,0.3823782223416795,1.8457137705834223,-0.2465944601256313
BRD-K93468883-001-02-0::2.5::HTS,BRD-K93468883-001-02-0,IPI-145,2.5,HTS,DEM2_HSPA4 (3308),DEMETER2_COM,targeted cancer,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 3,0.329902585566009,0.134928752357,IPI-145,PI3K INHIBITOR,0.3363087143545117,1.6859055506235796,-2.224646057915584
BRD-K97365803-001-02-1::2.5::HTS,BRD-K97365803-001-02-1,PI-828,2.5,HTS,Exp_UGT1A10 (ENSG00000242515),GE,noncancer,PI3K inhibitor,,,,Preclinical,0.327760477676259,0.3583420816,PI-828,PI3K INHIBITOR,0.3270719363267902,1.0201200071596577,-1.0853515270108582
BRD-K98795921-001-01-7::2.5::HTS,BRD-K98795921-001-01-7,SB-2343,2.5,HTS,Exp_EML6 (ENSG00000214595),GE,targeted cancer,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1,0.350603657327445,0.18149064893,SB-2343,PI3K INHIBITOR,0.35165475946111874,2.7146587380723357,-1.220520328702252
BRD-A28467416-002-01-0::2.5::HTS,BRD-A28467416-002-01-0,PKI-179,2.5,,,,,PI3K inhibitor,MTOR,,,,0,0,PKI-179,PI3K INHIBITOR,0.3641327117615762,2.780098177817959,-0.5920692820399664
BRD-K07310275-001-02-5::2.5::HTS,BRD-K07310275-001-02-5,PF-04691502,2.5,,,,,PI3K inhibitor,"MTOR, PIK3CA",,,,0,0,PF-04691502,PI3K INHIBITOR,0.4127838406336721,3.783044756796776,0.3480280973097174
BRD-K29415052-050-04-8::2.5::HTS,BRD-K29415052-050-04-8,BGT226,2.5,,,,,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",,,,0,0,BGT226,PI3K INHIBITOR,0.3693575705110199,4.273204039513924,0.8964338721553529
BRD-K49371609-003-03-8::2.5::HTS,BRD-K49371609-003-03-8,PIK-75,2.5,,,,,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",,,,0,0,PIK-75,PI3K INHIBITOR,0.3720754562542195,5.131841846389084,0.6040279384697529
BRD-K77638923-001-02-0::2.5::HTS,BRD-K77638923-001-02-0,CUDC-907,2.5,,,,,PI3K inhibitor,"HDAC2, PIK3R1",,,,0,0,CUDC-907,PI3K INHIBITOR,0.3586919947042553,4.7232189297076665,1.7641755286518368
BRD-A45889380-300-07-1::2.5::HTS,BRD-A45889380-300-07-1,mepacrine,2.5,HTS,CRISPR_UCP1 (7350),AVANA_PUBLIC_18Q2,noncancer,NFkB pathway inhibitor,"PLA2G1B, PLA2G4A, PLA2G6, PLCL1",infectious disease,giardiasis,Launched,0.368938447738219,0.325602912477,mepacrine,NFKB PATHWAY INHIBITOR,0.3545248048383378,-4.6472550626602445,-1.1846000449411584
BRD-A53134341-001-03-2::2.5::HTS,BRD-A53134341-001-03-2,Ro-106-9920,2.5,HTS,Exp_ITGA7 (ENSG00000135424),GE,noncancer,NFkB pathway inhibitor,,,,Preclinical,0.357985482786965,0.185123874296,Ro-106-9920,NFKB PATHWAY INHIBITOR,0.3623236306765081,3.4610383821207287,-2.473321398398526
BRD-K07572174-001-39-4::2.48::HTS,BRD-K07572174-001-39-4,curcumin,2.48,HTS,Exp_UGT1A10 (ENSG00000242515),GE,targeted cancer,NFkB pathway inhibitor,"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",,,Launched,0.37832256278215104,0.460146229389,curcumin,NFKB PATHWAY INHIBITOR,0.3789770977073541,4.075380820463593,-3.5193950398683675
BRD-K15025317-001-15-1::2.5::HTS,BRD-K15025317-001-15-1,BAY-11-7082,2.5,HTS,Exp_LAMTOR3 (ENSG00000109270),GE,noncancer,NFkB pathway inhibitor,RELA,,,Preclinical,0.317965843895433,0.205980159426,BAY-11-7082,NFKB PATHWAY INHIBITOR,0.3213906452490388,5.101642264119144,-1.3832818906798303
BRD-K28120222-001-08-4::2.5::HTS,BRD-K28120222-001-08-4,parthenolide-(alternate-stereo),2.5,HTS,DEM2_KATNA1 (11104),DEMETER2_COM,targeted cancer,NFkB pathway inhibitor,"IKBKB, RELA",,,Preclinical,0.31636248376425,0.134985767888,parthenolide-(alternate-stereo),NFKB PATHWAY INHIBITOR,0.30819213065780643,0.2946666536722525,-3.9436744333324736
BRD-K34851558-001-02-3::2.5::HTS,BRD-K34851558-001-02-3,parthenolide-(-),2.5,HTS,CRISPR_RREB1 (6239),AVANA_PUBLIC_18Q2,targeted cancer,NFkB pathway inhibitor,HDAC1,,,Preclinical,0.398603600014711,0.0949879812362,parthenolide-(-),NFKB PATHWAY INHIBITOR,0.3609504765925669,0.4937497437960312,-3.875002472607105
BRD-K45401373-001-20-9::2.5::HTS,BRD-K45401373-001-20-9,betulinic-acid,2.5,HTS,PROT_Caspase-7_cleavedD198_Caution,PROT,targeted cancer,NFkB pathway inhibitor,GPBAR1,,,Phase 1/Phase 2,0.299733813400325,0.18226666922,betulinic-acid,NFKB PATHWAY INHIBITOR,0.2563323520566165,2.2726154308907325,-2.4968564622538274
BRD-K48684885-001-04-2::2.5::HTS,BRD-K48684885-001-04-2,BAY-11-7085,2.5,HTS,MIRNA_hsa-miR-626,MIRNA,targeted cancer,NFkB pathway inhibitor,NFKBIA,,,Preclinical,0.372425255820258,0.152597135562,BAY-11-7085,NFKB PATHWAY INHIBITOR,0.37857568610633385,4.930139054587566,-0.8924838327510272
BRD-K68395654-001-03-1::2.5::HTS,BRD-K68395654-001-03-1,EVP4593,2.5,HTS,Exp_KRT80 (ENSG00000167767),GE,noncancer,NFkB pathway inhibitor,,,,Preclinical,0.359822948085759,0.353335947881,EVP4593,NFKB PATHWAY INHIBITOR,0.3311559429995433,1.896315694764936,-2.7097955077935363
BRD-K74305673-001-06-2::2.5::HTS,BRD-K74305673-001-06-2,IKK-2-inhibitor-V,2.5,HTS,Exp_PDK1 (ENSG00000152256),GE,targeted cancer,NFkB pathway inhibitor,IKBKB,,,Phase 1,0.3693223990864679,0.284117600093,IKK-2-inhibitor-V,NFKB PATHWAY INHIBITOR,0.3699498297759085,3.9517341243558346,-1.6614229780439596
BRD-K98548675-001-05-9::2.5::HTS,BRD-K98548675-001-05-9,parthenolide,2.5,HTS,DEM2_GZF1 (64412),DEMETER2_COM,targeted cancer,NFkB pathway inhibitor,,,,Phase 1,0.33926857977245695,0.127202053291,parthenolide,NFKB PATHWAY INHIBITOR,0.34111410608747256,0.4436799617656748,-3.9832957359039303
BRD-K88510285-001-11-1::2.5::HTS,BRD-K88510285-001-11-1,bortezomib,2.5,,,,,NFkB pathway inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,,,0,0,bortezomib,NFKB PATHWAY INHIBITOR,0.370212908917695,4.613194074333759,1.2574111672693185
BRD-A45498368-001-07-1::2.5::HTS,BRD-A45498368-001-07-1,WYE-125132,2.5,HTS,METHYL_MIR6825,METHYL,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.33176117688545304,0.032434197946,WYE-125132,MTOR INHIBITOR,0.32275503765631397,2.715883771004011,-0.5580620836692529
BRD-A79768653-001-12-0::2.5::HTS,BRD-A79768653-001-12-0,sirolimus,2.5,HTS,Exp_NBR1 (ENSG00000188554),GE,noncancer,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis",Launched,0.33544717133822805,0.290675351696,sirolimus,MTOR INHIBITOR,0.3389631866009944,0.6867315868482158,-1.6916955190674343
BRD-K03549949-001-01-0::2.5::HTS,BRD-K03549949-001-01-0,XL388,2.5,HTS,DEM2_STK19 (8859),DEMETER2_COM,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.35385696725801097,0.205035831207,XL388,MTOR INHIBITOR,0.35122344440715403,0.9294631199936776,-1.4546738964700272
BRD-K07955840-001-02-3::2.5::HTS,BRD-K07955840-001-02-3,PF-05212384,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,mTOR inhibitor,"MTOR, PIK3CA",,,Phase 2,0.382687800620755,0.564858659535,PF-05212384,MTOR INHIBITOR,0.3852296565502841,3.989082123526386,-1.4161922013574806
BRD-K12184916-001-15-4::2.5::HTS,BRD-K12184916-001-15-4,NVP-BEZ235,2.5,HTS,Exp_PPP2CB (ENSG00000104695),GE,targeted cancer,mTOR inhibitor,"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",,,Phase 2,0.34121656967012004,0.265464996979,NVP-BEZ235,MTOR INHIBITOR,0.3445319543727742,2.336388135743562,-1.100654595623761
BRD-K13514097-001-05-3::2.5::HTS,BRD-K13514097-001-05-3,everolimus,2.5,HTS,Exp_FBLN1 (ENSG00000077942),GE,targeted cancer,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma",Launched,0.325673483684225,0.285059480134,everolimus,MTOR INHIBITOR,0.3239258224630583,0.9765448800234804,-1.79803941156674
BRD-K23228615-001-02-8::2.5::HTS,BRD-K23228615-001-02-8,GDC-0980,2.5,HTS,Exp_ELP3 (ENSG00000134014),GE,targeted cancer,mTOR inhibitor,"FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",,,Phase 2,0.30084307307744296,0.247061919705,GDC-0980,MTOR INHIBITOR,0.3032016771793324,2.9478329653309148,-1.33768074963867
BRD-K42898655-001-01-8::2.5::HTS,BRD-K42898655-001-01-8,temsirolimus,2.5,HTS,Exp_ZEB2 (ENSG00000169554),GE,targeted cancer,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),Launched,0.33475538202637395,0.216965072449,temsirolimus,MTOR INHIBITOR,0.32919032698143924,0.8123165347196505,-1.806225967941708
BRD-K46843573-001-01-9::2.5::MTS004,BRD-K46843573-001-01-9,zotarolimus,2.5,MTS004,DEM2_RPTOR (57521),DEMETER2_COM,noncancer,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis,Launched,0.318574528839445,0.185836996417,zotarolimus,MTOR INHIBITOR,0.3204689692779133,0.6097939973990579,-1.6464796296738529
BRD-K56291712-001-01-0::2.5::HTS,BRD-K56291712-001-01-0,voxtalisib,2.5,HTS,Exp_MCOLN3 (ENSG00000055732),GE,targeted cancer,mTOR inhibitor,"MTOR, PIK3CA",,,Phase 2,0.33936887593476506,0.0937165653991,voxtalisib,MTOR INHIBITOR,0.327449755965424,0.8075320851236577,-1.382729904285524
BRD-K59317601-001-05-5::2.5::HTS,BRD-K59317601-001-05-5,MLN0128,2.5,HTS,PROT_4E-BP1_pT70,PROT,targeted cancer,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",,,Phase 2,0.359877322290091,0.205500103831,MLN0128,MTOR INHIBITOR,0.3620365101906841,2.286182434776358,-0.8569604707898506
BRD-K62304154-001-04-2::2.5::HTS,BRD-K62304154-001-04-2,deforolimus,2.5,HTS,Exp_TDG (ENSG00000139372),GE,targeted cancer,mTOR inhibitor,MTOR,,,Phase 3,0.305180115742803,0.30108841319,deforolimus,MTOR INHIBITOR,0.2971084038457764,0.9355458663148464,-1.7613058547361282
BRD-K67566344-001-07-5::2.5::HTS,BRD-K67566344-001-07-5,ku-0063794,2.5,HTS,Exp_THAP9-AS1 (ENSG00000251022),GE,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.342070676179628,0.267559737063,ku-0063794,MTOR INHIBITOR,0.3427989549492713,1.1176418054321382,-1.6408025177670058
BRD-K67868012-001-07-6::2.5::HTS,BRD-K67868012-001-07-6,PI-103,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,mTOR inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",,,Preclinical,0.29464258959735307,0.279593750407,PI-103,MTOR INHIBITOR,0.2940556044411721,2.0191468011182483,-1.4470930158010782
BRD-K77008974-001-03-2::2.5::HTS,BRD-K77008974-001-03-2,WYE-354,2.5,HTS,METHYL_SLC39A13,METHYL,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.32835703645003994,0.147994312358,WYE-354,MTOR INHIBITOR,0.3317610436516548,1.0376881663961623,-1.3438041707197628
BRD-K82967180-001-01-6::2.500024493::MTS004,BRD-K82967180-001-01-6,LY3023414,2.500024493,MTS004,Exp_PFKFB3 (ENSG00000170525),GE,targeted cancer,mTOR inhibitor,MTOR,,,Phase 2,0.37864104722169606,0.273963456701,LY3023414,MTOR INHIBITOR,0.3823782223416795,1.8457137705834223,-0.2465944601256313
BRD-K84937637-001-09-9::2.5::HTS,BRD-K84937637-001-09-9,sirolimus,2.5,HTS,Exp_HAGHL (ENSG00000103253),GE,noncancer,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis",Launched,0.32433840192078994,0.259921459956,sirolimus,MTOR INHIBITOR,0.3259635482160741,3.8170893080536934,-1.9333352048270225
BRD-K85920262-001-02-1::2.5::HTS,BRD-K85920262-001-02-1,WAY-600,2.5,HTS,Exp_UGT1A6 (ENSG00000167165),GE,targeted cancer,mTOR inhibitor,MTOR,,,Preclinical,0.388277336833294,0.298947439163,WAY-600,MTOR INHIBITOR,0.38910620332058704,1.824910256981565,-1.583965508957851
BRD-K87112191-001-04-5::2.5::HTS,BRD-K87112191-001-04-5,PP242,2.5,HTS,Exp_ZNF506 (ENSG00000081665),GE,targeted cancer,mTOR inhibitor,"MTOR, PASK",,,Preclinical,0.36448344541703903,0.293809275034,PP242,MTOR INHIBITOR,0.36559684371254986,2.1035952858539235,-1.099700686970083
BRD-K87124298-001-03-4::2.5::HTS,BRD-K87124298-001-03-4,OSI-027,2.5,HTS,Exp_AOC1 (ENSG00000002726),GE,targeted cancer,mTOR inhibitor,MTOR,,,Phase 1,0.40666010427002797,0.238929267564,OSI-027,MTOR INHIBITOR,0.4090784082976193,1.527573685311825,-1.3511501139048696
BRD-K98795921-001-01-7::2.5::HTS,BRD-K98795921-001-01-7,SB-2343,2.5,HTS,Exp_EML6 (ENSG00000214595),GE,targeted cancer,mTOR inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,Phase 1,0.350603657327445,0.18149064893,SB-2343,MTOR INHIBITOR,0.35165475946111874,2.7146587380723357,-1.220520328702252
BRD-K99113996-001-02-0::2.5::HTS,BRD-K99113996-001-02-0,AZD2014,2.5,HTS,DEM2_MTOR (2475),DEMETER2_COM,targeted cancer,mTOR inhibitor,MTOR,,,Phase 2,0.32905706719421,0.178492765532,AZD2014,MTOR INHIBITOR,0.3277067716469897,2.7108829098412697,-1.0474096841838592
BRD-A28467416-002-01-0::2.5::HTS,BRD-A28467416-002-01-0,PKI-179,2.5,,,,,mTOR inhibitor,MTOR,,,,0,0,PKI-179,MTOR INHIBITOR,0.3641327117615762,2.780098177817959,-0.5920692820399664
BRD-K07310275-001-02-5::2.5::HTS,BRD-K07310275-001-02-5,PF-04691502,2.5,,,,,mTOR inhibitor,"MTOR, PIK3CA",,,,0,0,PF-04691502,MTOR INHIBITOR,0.4127838406336721,3.783044756796776,0.3480280973097174
BRD-K69932463-001-10-6::2.5::HTS,BRD-K69932463-001-10-6,AZD8055,2.5,,,,,mTOR inhibitor,MTOR,,,,0,0,AZD8055,MTOR INHIBITOR,0.4180541680870295,4.694726387492018,-1.0778605808007329
BRD-A57798112-001-03-7::2.5::HTS,BRD-A57798112-001-03-7,PD-318088,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Preclinical,0.47407218195218,0.550297958437,PD-318088,MEK INHIBITOR,0.4702692636768581,0.4422520244508662,4.773551654541441
BRD-K03390685-001-01-7::2.5::HTS,BRD-K03390685-001-01-7,cobimetinib,2.5,HTS,Exp_C1QL1 (ENSG00000131094),GE,targeted cancer,MEK inhibitor,,oncology,melanoma,Launched,0.41442344925464003,0.543088474306,cobimetinib,MEK INHIBITOR,0.4142149861256813,0.33070752536389003,4.870681702366238
BRD-K05104363-001-10-0::2.5::HTS,BRD-K05104363-001-10-0,PD-184352,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",,,Phase 2,0.4249449059285039,0.442763304083,PD-184352,MEK INHIBITOR,0.4246853743277095,0.6235357895053986,4.476836369656759
BRD-K12244279-001-05-8::2.5::HTS,BRD-K12244279-001-05-8,MEK1-2-inhibitor,2.5,HTS,RMUThot_BRAF (673),MUThot,noncancer,MEK inhibitor,MAP2K2,,,Preclinical,0.286036229903955,0.0842624219982,MEK1-2-inhibitor,MEK INHIBITOR,0.28583105209411963,-6.100342423924926,1.7658187412290598
BRD-K12343256-001-08-9::2.5::HTS,BRD-K12343256-001-08-9,trametinib,2.5,HTS,Exp_CEACAM1 (ENSG00000079385),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,Launched,0.406465000584262,0.548928642324,trametinib,MEK INHIBITOR,0.4048279408743857,0.33501276923196355,4.974271598475147
BRD-K18787491-001-08-6::2.5::HTS,BRD-K18787491-001-08-6,U-0126,2.5,HTS,Exp_TTBK2 (ENSG00000128881),GE,targeted cancer,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.318333461407703,0.284682620627,U-0126,MEK INHIBITOR,0.3023027234116865,2.7949124311200864,-0.1306064330600245
BRD-K26667523-001-02-5::2.5::HTS,BRD-K26667523-001-02-5,TAK-733,2.5,HTS,Exp_ETV4 (ENSG00000175832),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 1,0.414270339522114,0.464319045888,TAK-733,MEK INHIBITOR,0.41492268257847503,0.3347795300880411,5.01264951209501
BRD-K37687095-001-06-9::2.5::HTS,BRD-K37687095-001-06-9,AZD8330,2.5,HTS,Exp_CEACAM1 (ENSG00000079385),GE,targeted cancer,MEK inhibitor,,,,Phase 1,0.4462774557759389,0.563077852398,AZD8330,MEK INHIBITOR,0.4473763830239305,0.3275659812370819,5.046145101693247
BRD-K49865102-001-08-4::2.5::HTS,BRD-K49865102-001-08-4,PD-0325901,2.5,HTS,Exp_CEACAM1 (ENSG00000079385),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 2,0.470274705728401,0.557783767375,PD-0325901,MEK INHIBITOR,0.4691728190396805,0.2977417707587833,4.9766014558326575
BRD-K53523901-001-04-4::2.5::HTS,BRD-K53523901-001-04-4,arctigenin,2.5,HTS,CRISPR_CHCHD7 (79145),AVANA_PUBLIC_18Q2,targeted cancer,MEK inhibitor,"CHUK, MAP2K1",,,Preclinical,0.286041868449262,0.14964140894,arctigenin,MEK INHIBITOR,0.27485585672482793,0.6232641218423822,-3.4552997198370563
BRD-K57080016-001-15-9::2.5::HTS,BRD-K57080016-001-15-9,selumetinib,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 3,0.497730143542748,0.516927703605,selumetinib,MEK INHIBITOR,0.4948112080917145,0.4759093286349534,4.683015584079701
BRD-K62810658-001-12-2::2.5::HTS,BRD-K62810658-001-12-2,PD-98059,2.5,HTS,Exp_RPS6 (ENSG00000137154),GE,targeted cancer,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.308873577661648,0.0554908596212,PD-98059,MEK INHIBITOR,0.3021297579331715,4.272375336123259,-2.6961656592962604
BRD-K64538373-001-01-4::2.5::HTS,BRD-K64538373-001-01-4,Ro-4987655,2.5,HTS,Exp_PHLDA1 (ENSG00000139289),GE,targeted cancer,MEK inhibitor,MAP2K1,,,Phase 1,0.45657456396773294,0.519670104753,Ro-4987655,MEK INHIBITOR,0.4555045112843197,0.3194791367773261,4.950820675009756
BRD-K82244583-001-01-3::2.5::HTS,BRD-K82244583-001-01-3,MEK162,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",,,Phase 3,0.42288478493428205,0.521343691633,MEK162,MEK INHIBITOR,0.42179372453150094,0.40596626860011975,4.813111352303714
BRD-K85751432-001-03-3::2.5::HTS,BRD-K85751432-001-03-3,refametinib,2.5,HTS,RMUThot_BRAF (673),MUThot,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",,,Phase 2,0.5320757822836889,0.471774715852,refametinib,MEK INHIBITOR,0.5136224061734835,0.5490112316325853,4.766147019695176
BRD-K88677950-001-03-9::2.5::HTS,BRD-K88677950-001-03-9,PD-198306,2.5,HTS,Exp_FMN1 (ENSG00000248905),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",,,Preclinical,0.45965829503979794,0.425544990723,PD-198306,MEK INHIBITOR,0.4547396266675545,0.450190287910457,4.858630073130459
BRD-K89014967-001-04-3::2.5::HTS,BRD-K89014967-001-04-3,AS-703026,2.5,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"MAP2K1, MAP2K2",,,Phase 2,0.44644425998157894,0.524775525953,AS-703026,MEK INHIBITOR,0.4460171735748528,0.453188102608736,4.776749515680903
BRD-K91701654-001-03-1::2.38::HTS,BRD-K91701654-001-03-1,U-0126,2.38,HTS,Exp_SH3TC2 (ENSG00000169247),GE,targeted cancer,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,Preclinical,0.395071124529589,0.365509090001,U-0126,MEK INHIBITOR,0.3900976174070792,0.5409891418466737,4.6813457537330985
BRD-A12230535-001-06-7::2.5::HTS,BRD-A12230535-001-06-7,nutlin-3,2.5,HTS,CRISPR_MDM2 (4193),AVANA_PUBLIC_18Q2,targeted cancer,MDM inhibitor,"MDM2, TP53",,,Preclinical,0.383159005772464,0.508204663257,nutlin-3,MDM INHIBITOR,0.3890998760191139,3.1553676467612863,-1.9277548013360024
BRD-K00317371-001-06-1::2.4::HTS,BRD-K00317371-001-06-1,RITA,2.4,HTS,Exp_SULT1A1 (ENSG00000196502),GE,targeted cancer,MDM inhibitor,MDM2,,,Preclinical,0.482510433982741,0.53822052441,RITA,MDM INHIBITOR,0.481484150573667,4.346613295519049,-0.5283717008040485
BRD-K62627508-001-01-5::2.5::HTS,BRD-K62627508-001-01-5,idasanutlin,2.5,HTS,CRISPR_MDM2 (4193),AVANA_PUBLIC_18Q2,targeted cancer,MDM inhibitor,"MDM2, TP53",,,Phase 3,0.6983561657843621,0.814597591505,idasanutlin,MDM INHIBITOR,0.6858689077520054,2.9745854318703713,-1.907911881189107
BRD-K64925568-001-01-8::2.5::HTS,BRD-K64925568-001-01-8,AMG-232,2.5,HTS,CRISPR_MDM2 (4193),AVANA_PUBLIC_18Q2,targeted cancer,MDM inhibitor,MDM2,,,Phase 1/Phase 2,0.6383310197241769,0.774941076314,AMG-232,MDM INHIBITOR,0.6496494663589717,3.219380286530073,-1.6275777368750637
BRD-K65924316-001-03-1::2.5::HTS,BRD-K65924316-001-03-1,serdemetan,2.5,HTS,PROT_JAK2,PROT,targeted cancer,MDM inhibitor,MDM2,,,Phase 1,0.34691055409244204,0.250737423555,serdemetan,MDM INHIBITOR,0.3528615824998228,4.030608072902047,-2.4682558965530412
BRD-K79584249-001-01-3::2.5::HTS,BRD-K79584249-001-01-3,CGM097,2.5,HTS,DEM2_MDM2 (4193),DEMETER2_COM,targeted cancer,MDM inhibitor,MDM2,,,Phase 1,0.674455226700119,0.804112007016,CGM097,MDM INHIBITOR,0.6610313540698002,3.262711245983482,-1.8614594785057068
BRD-K38548312-001-01-0::2.5::HTS,BRD-K38548312-001-01-0,VER-49009,2.5,HTS,Exp_HMGN4 (ENSG00000182952),GE,targeted cancer,HSP inhibitor,HSP90AA1,,,Preclinical,0.380311995277962,0.326069459629,VER-49009,HSP INHIBITOR,0.38075177146326294,5.037056900312075,-1.6957083940461717
BRD-K38852836-001-02-1::2.5::HTS,BRD-K38852836-001-02-1,ganetespib,2.5,HTS,METHYL_IL17RB,METHYL,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 3,0.394284983830923,0.135872898623,ganetespib,HSP INHIBITOR,0.3840379639483542,3.1963890495745284,-0.561879150695944
BRD-K41213548-001-02-0::2.5::HTS,BRD-K41213548-001-02-0,KW-2478,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,HSP inhibitor,,,,Phase 1/Phase 2,0.42432017373448105,0.548712832275,KW-2478,HSP INHIBITOR,0.4239152243792927,3.79371651887271,-1.6562543978231554
BRD-K41859756-001-06-8::2.5::HTS,BRD-K41859756-001-06-8,NVP-AUY922,2.5,HTS,METABOL_pipecolic acid,METABOL,targeted cancer,HSP inhibitor,"HSP90AA1, HSP90AB1",,,Phase 2,0.363282126214155,0.261268472918,NVP-AUY922,HSP INHIBITOR,0.3554022140112777,5.1950957176643495,-0.4886742931062758
BRD-K58770988-001-01-8::2.5::HTS,BRD-K58770988-001-01-8,NMS-E973,2.5,HTS,METHYL_RAB34,METHYL,targeted cancer,HSP inhibitor,,,,Preclinical,0.364367493325447,0.403327291802,NMS-E973,HSP INHIBITOR,0.3609718944850287,5.204390823926793,-0.515050671549528
BRD-K81473043-001-14-6::2.5::HTS,BRD-K81473043-001-14-6,tanespimycin,2.5,HTS,PROT_Gab2,PROT,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 3,0.35965515243038604,0.216321367862,tanespimycin,HSP INHIBITOR,0.34990239940121576,4.855349286646348,-0.7221369840770042
BRD-K83988098-001-02-0::2.5::HTS,BRD-K83988098-001-02-0,alvespimycin,2.5,HTS,Exp_GJC1 (ENSG00000182963),GE,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 2,0.40768180341461896,0.136458012236,alvespimycin,HSP INHIBITOR,0.3998062952827556,4.9375587977411435,-0.5467238525385505
BRD-K83988098-003-03-4::2.5::HTS,BRD-K83988098-003-03-4,alvespimycin,2.5,HTS,Exp_SMAD7 (ENSG00000101665),GE,targeted cancer,HSP inhibitor,HSP90AA1,,,Phase 2,0.40768180341461896,0.136458012236,alvespimycin,HSP INHIBITOR,0.370358845576073,5.326623664637968,0.1392914829033769
BRD-A03506276-001-01-5::2.5::HTS,BRD-A03506276-001-01-5,XL888,2.5,,,,,HSP inhibitor,,,,,0,0,XL888,HSP INHIBITOR,0.4038078002454418,4.678939227294699,-0.31026071420641577
BRD-K36529613-001-02-6::2.5::HTS,BRD-K36529613-001-02-6,PU-H71,2.5,,,,,HSP inhibitor,HSP90AA1,,,,0,0,PU-H71,HSP INHIBITOR,0.40858698113850217,4.354369069762496,-0.5703547640948958
BRD-K51967704-001-03-6::2.5::HTS,BRD-K51967704-001-03-6,BIIB021,2.5,,,,,HSP inhibitor,HSP90AA1,,,,0,0,BIIB021,HSP INHIBITOR,0.4099120465156516,4.344920639790166,-0.04442802303691762
BRD-K73197500-001-02-2::2.5::HTS,BRD-K73197500-001-02-2,SNX-5422,2.5,,,,,HSP inhibitor,HSP90AA1,,,,0,0,SNX-5422,HSP INHIBITOR,0.3667048039597549,4.434135838199783,0.07054421044764059
BRD-K09416995-001-39-9::2.5::HTS,BRD-K09416995-001-39-9,lovastatin,2.5,HTS,Exp_TSKU (ENSG00000182704),GE,noncancer,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia",Launched,0.509039639666836,0.330185139721,lovastatin,HMGCR INHIBITOR,0.5153199239063254,1.7476398817897498,5.340249958634682
BRD-K22134346-001-22-3::2.5::HTS,BRD-K22134346-001-22-3,simvastatin,2.5,HTS,Exp_TMEM45B (ENSG00000151715),GE,noncancer,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia",Launched,0.45577765016445004,0.428373350071,simvastatin,HMGCR INHIBITOR,0.4788054966982619,1.7748186592083377,5.302407706928071
BRD-K22134346-001-24-9::2.42::HTS,BRD-K22134346-001-24-9,simvastatin,2.42,HTS,Exp_ADAMTSL1 (ENSG00000178031),GE,noncancer,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia",Launched,0.45577765016445004,0.428373350071,simvastatin,HMGCR INHIBITOR,0.456255620169743,1.7539002621997932,4.845737253555429
BRD-K66296774-236-11-3::2.63::HTS,BRD-K66296774-236-11-3,fluvastatin,2.63,HTS,Exp_GPX8 (ENSG00000164294),GE,noncancer,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects",Launched,0.43742974010697605,0.370941456644,fluvastatin,HMGCR INHIBITOR,0.4351019801369141,5.0325914531551845,-0.2668109211576333
BRD-K69726342-238-02-4::2.5::HTS,BRD-K69726342-238-02-4,atorvastatin,2.5,HTS,Exp_PAFAH1B1 (ENSG00000007168),GE,noncancer,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack",Launched,0.47794424792584905,0.382217144493,atorvastatin,HMGCR INHIBITOR,0.4911522235568417,1.75300590070493,5.3044665328758365
BRD-K75958547-238-01-0::2.5::HTS,BRD-K75958547-238-01-0,pitavastatin,2.5,HTS,Exp_GPX2 (ENSG00000176153),GE,noncancer,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,Launched,0.4809389037573929,0.43929497599,pitavastatin,HMGCR INHIBITOR,0.4812966784487095,1.8486395467600676,4.833342295739994
BRD-K94441233-001-13-0::2.6::HTS,BRD-K94441233-001-13-0,mevastatin,2.6,HTS,PROT_Paxillin_Caution,PROT,noncancer,HMGCR inhibitor,HMGCR,,,Preclinical,0.48809771899430604,0.38945069269,mevastatin,HMGCR INHIBITOR,0.4739397865621333,1.7595255719579952,5.0075305606717775
BRD-K94441233-001-17-1::2.5::HTS,BRD-K94441233-001-17-1,mevastatin,2.5,HTS,PROT_E-Cadherin,PROT,noncancer,HMGCR inhibitor,HMGCR,,,Preclinical,0.48809771899430604,0.38945069269,mevastatin,HMGCR INHIBITOR,0.4836388775413653,1.763828137985529,5.238064174438363
BRD-K02988401-001-01-2::2.5::MTS004,BRD-K02988401-001-01-2,UNC0737,2.5,MTS004,Exp_RN7SKP296 (ENSG00000223117),GE,noncancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.37202967655506897,0.204264667054,UNC0737,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.37084548629275305,1.9053473956031617,-0.7341238846406903
BRD-K06426971-001-02-7::2.5::HTS,BRD-K06426971-001-02-7,ryuvidine,2.5,HTS,Exp_PGD (ENSG00000142657),GE,noncancer,histone lysine methyltransferase inhibitor,"CDK2, CDK4",,,Preclinical,0.40780339200481497,0.37476396424,ryuvidine,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.4080770292425621,3.94856715315891,-0.6531890747817841
BRD-K11215326-001-03-7::2.31::HTS,BRD-K11215326-001-03-7,tazemetostat,2.31,HTS,CRISPR_KIAA1524 (57650),AVANA_PUBLIC_18Q2,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Phase 2,0.347130168122753,0.230977416761,tazemetostat,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3464881677782277,4.4241468812698255,-2.0046919044104925
BRD-K13060017-001-02-1::2.499994836::MTS004,BRD-K13060017-001-02-1,UNC0631,2.499994836,MTS004,METHYL_PLEKHO2,METHYL,targeted cancer,histone lysine methyltransferase inhibitor,EHMT2,,,Preclinical,0.38779862340593396,0.29295346794,UNC0631,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3939790645955226,4.344667709032758,-1.9956111507753145
BRD-K26531771-001-02-2::2.35::HTS,BRD-K26531771-001-02-2,EPZ-5676,2.35,HTS,Exp_FANCE (ENSG00000112039),GE,targeted cancer,histone lysine methyltransferase inhibitor,DOT1L,,,Phase 1,0.411219173948939,0.264567420168,EPZ-5676,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3873840940067252,1.6433725958133143,-3.8571715325420186
BRD-K26818574-305-04-3::2.5::HTS,BRD-K26818574-305-04-3,BIX-01294,2.5,HTS,Exp_PMEL (ENSG00000185664),GE,targeted cancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.40725969092650205,0.368465692473,BIX-01294,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3675148473551251,4.562808201766867,-1.474052246887129
BRD-K60130390-001-02-1::2.5::MTS004,BRD-K60130390-001-02-1,UNC0642,2.5,MTS004,DEM2_BCL2L1 (598),DEMETER2_COM,targeted cancer,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,Preclinical,0.36594866898893796,0.134120449624,UNC0642,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.33992176814781805,5.520213841464126,-1.1916647105201503
BRD-K72264770-001-03-2::2.5::MTS004,BRD-K72264770-001-03-2,BRD4770,2.5,MTS004,Exp_IL31RA (ENSG00000164509),GE,targeted cancer,histone lysine methyltransferase inhibitor,EHMT2,,,Preclinical,0.347942356677956,0.239362342001,BRD4770,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3489644759273051,3.037409906523727,-3.588044457600738
BRD-K74236984-001-04-8::2.5::MTS004,BRD-K74236984-001-04-8,UNC0321,2.5,MTS004,DEM2_BCL2L1 (598),DEMETER2_COM,targeted cancer,histone lysine methyltransferase inhibitor,EHMT2,,,Preclinical,0.44295631285260706,0.271298971017,UNC0321,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.4083356588590553,5.8632179975804135,-1.3225108817662052
BRD-K77791657-001-01-1::2.5::HTS,BRD-K77791657-001-01-1,3-deazaneplanocin-A,2.5,HTS,Exp_LAMP2 (ENSG00000005893),GE,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Preclinical,0.3880833573317129,0.330864216137,3-deazaneplanocin-A,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.4041992374418002,2.145703800839535,-3.953870045271581
BRD-K77791657-003-01-7::2.67::HTS,BRD-K77791657-003-01-7,3-deazaneplanocin-A,2.67,HTS,Exp_C8orf46 (ENSG00000169085),GE,targeted cancer,histone lysine methyltransferase inhibitor,EZH2,,,Preclinical,0.3880833573317129,0.330864216137,3-deazaneplanocin-A,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3857539323632793,2.484244980598477,-3.8318497698838954
BRD-K26818574-305-07-6::2.5::MTS004,BRD-K26818574-305-07-6,BIX-01294,2.5,,,,,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,,0,0,BIX-01294,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,0.3799858185929479,1.8818099957951369,-0.10994809118705008
BRD-K01291782-001-01-1::2.50002964::MTS004,BRD-K01291782-001-01-1,molidustat,2.50002964,MTS004,Exp_MT1G (ENSG00000125144),GE,noncancer,hypoxia inducible factor inhibitor,EGLN2,,,Phase 2,0.30336150260866196,0.211722297452,molidustat,HIF PROLYL HYDROXYLASE,0.302959284557636,-7.3970286529636144,0.762834257421692
BRD-K06455935-001-01-3::2.499992329::MTS004,BRD-K06455935-001-01-3,daprodustat,2.499992329,MTS004,Exp_NDRG1 (ENSG00000104419),GE,noncancer,hypoxia inducible factor inhibitor,EGLN1,,,Phase 3,0.346738581608312,0.355638845275,daprodustat,HIF PROLYL HYDROXYLASE,0.3479482812084938,-7.402190002526455,0.6919605281634054
BRD-K14385366-001-04-4::2.59::HTS,BRD-K14385366-001-04-4,FG-4592,2.59,HTS,CRISPR_RELT (84957),AVANA_PUBLIC_18Q2,noncancer,hypoxia inducible factor inhibitor,EGLN2,,,Phase 3,0.354486151392349,0.157794792201,FG-4592,HIF PROLYL HYDROXYLASE,0.3075982876339975,-7.238441251734287,0.7566810241125346
BRD-K44408410-001-17-6::2.5::HTS,BRD-K44408410-001-17-6,2-methoxyestradiol,2.5,HTS,Exp_NCEH1 (ENSG00000144959),GE,targeted cancer,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",,,Phase 2,0.37733724710227295,0.267673454098,2-methoxyestradiol,HIF PROLYL HYDROXYLASE,0.3816974447382275,4.812109146818554,-3.758595116500839
BRD-K70463136-001-01-5::2.5::HTS,BRD-K70463136-001-01-5,BAY-87-2243,2.5,HTS,Exp_SLC2A1 (ENSG00000117394),GE,targeted cancer,hypoxia inducible factor inhibitor,HIF1A,,,Phase 1,0.364096532552087,0.360377250409,BAY-87-2243,HIF PROLYL HYDROXYLASE,0.3613064996461231,1.8081622063123013,-2.8656641532985647
BRD-K02389548-001-02-5::2.5::HTS,BRD-K02389548-001-02-5,RG2833,2.5,HTS,METHYL_LEKR1,METHYL,noncancer,HDAC inhibitor,"HDAC1, HDAC3",,,Phase 1,0.28851080817984803,0.192221674876,RG2833,HDAC INHIBITOR,0.2993314863206562,-1.0101233201151083,-2.436020908684833
BRD-K11663430-001-02-3::2.5::HTS,BRD-K11663430-001-02-3,pyroxamide,2.5,HTS,PROT_CD49b,PROT,targeted cancer,HDAC inhibitor,HDAC1,,,Phase 1,0.32908914400531797,0.0674064010255,pyroxamide,HDAC INHIBITOR,0.3285536723799529,7.1740379932256255,-2.1646096547919003
BRD-K12867552-001-04-7::2.5::HTS,BRD-K12867552-001-04-7,PCI-24781,2.5,HTS,METHYL_MIR4265,METHYL,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",,,Phase 1/Phase 2,0.386813395291418,0.15717804776,PCI-24781,HDAC INHIBITOR,0.3618524634124952,6.238271742037539,-0.492029941617552
BRD-K13167095-001-02-9::2.5::HTS,BRD-K13167095-001-02-9,AR-42,2.5,HTS,PROT_VEGFR2,PROT,targeted cancer,HDAC inhibitor,HDAC1,,,Phase 1,0.442126157839965,0.0465548154316,AR-42,HDAC INHIBITOR,0.43223523994206375,6.026329152669554,-0.6505133907252163
BRD-K13169950-001-14-4::2.5::HTS,BRD-K13169950-001-14-4,NSC-3852,2.5,HTS,Exp_TBPL1 (ENSG00000028839),GE,targeted cancer,HDAC inhibitor,HDAC1,,,Preclinical,0.331516212075269,0.394564979747,NSC-3852,HDAC INHIBITOR,0.3341238133758708,4.958530857451478,-2.0624552595384342
BRD-K13810148-311-03-2::2.5::HTS,BRD-K13810148-311-03-2,givinostat,2.5,HTS,CRISPR_BRD2 (6046),AVANA_PUBLIC_18Q2,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,Phase 2,0.450275692050925,0.131335631051,givinostat,HDAC INHIBITOR,0.4078393621714961,5.872543405785465,-0.6881788222050051
BRD-K17743125-001-08-4::2.5::HTS,BRD-K17743125-001-08-4,belinostat,2.5,HTS,Exp_EN1 (ENSG00000163064),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Launched,0.42282490157331504,0.171561244731,belinostat,HDAC INHIBITOR,0.42531548719814294,6.257025435667624,-0.7786242497268265
BRD-K22503835-001-11-0::2.5::HTS,BRD-K22503835-001-11-0,scriptaid,2.5,HTS,Exp_KCNQ2 (ENSG00000075043),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,Preclinical,0.382011219305684,0.354841598089,scriptaid,HDAC INHIBITOR,0.3793499339376492,6.594070369332041,-1.5547706859577848
BRD-K28537285-001-01-8::2.499968715::MTS004,BRD-K28537285-001-01-8,chidamide,2.499968715,MTS004,METHYL_REXO1L2P,METHYL,targeted cancer,HDAC inhibitor,"HDAC10, HDAC3",,,Launched,0.34813180086304096,0.230016392726,chidamide,HDAC INHIBITOR,0.36001414422290295,6.839338277855022,-2.1168458679386766
BRD-K28822270-001-01-1::2.5::HTS,BRD-K28822270-001-01-1,resminostat,2.5,HTS,Exp_SLC2A4 (ENSG00000181856),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",,,Phase 2,0.34802245594319003,0.271560047358,resminostat,HDAC INHIBITOR,0.3435685487570231,5.918415732720924,-1.251134799869365
BRD-K45528773-001-06-4::2.5::HTS,BRD-K45528773-001-06-4,M-344,2.5,HTS,METABOL_stearoylcarnitine,METABOL,targeted cancer,HDAC inhibitor,,,,Preclinical,0.34936729790061494,0.164620821903,M-344,HDAC INHIBITOR,0.3478350085317576,6.178521390755843,-0.9320619168502629
BRD-K52313696-001-12-3::2.5::HTS,BRD-K52313696-001-12-3,tacedinaline,2.5,HTS,CRISPR_PPIL1 (51645),AVANA_PUBLIC_18Q2,targeted cancer,HDAC inhibitor,HDAC1,,,Phase 3,0.335289356780877,0.222571851133,tacedinaline,HDAC INHIBITOR,0.31732385523826184,6.967467912447919,-1.9239692423266923
BRD-K61688984-001-02-9::2.5::HTS,BRD-K61688984-001-02-9,RGFP966,2.5,HTS,Exp_HACE1 (ENSG00000085382),GE,targeted cancer,HDAC inhibitor,HDAC3,,,Preclinical,0.35530978564853005,0.322431730745,RGFP966,HDAC INHIBITOR,0.3570267335603505,2.833962153048484,-4.331447986787284
BRD-K70402238-001-02-8::2.5::HTS,BRD-K70402238-001-02-8,nexturastat-a,2.5,HTS,Exp_ZMYND8 (ENSG00000101040),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC6",,,Preclinical,0.32508977063728006,0.182159926624,nexturastat-a,HDAC INHIBITOR,0.31026071494637825,6.995235218795272,-2.034355746759502
BRD-K77908580-001-09-6::2.5::HTS,BRD-K77908580-001-09-6,entinostat,2.5,HTS,Exp_ANKS1A (ENSG00000064999),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",,,Phase 3,0.368808518902544,0.377082610272,entinostat,HDAC INHIBITOR,0.3698708581653991,6.232230927554808,-1.2499069518022572
BRD-K81418486-001-47-5::2.5::HTS,BRD-K81418486-001-47-5,vorinostat,2.5,HTS,Exp_PARS2 (ENSG00000162396),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Launched,0.39084154394416704,0.218249965138,vorinostat,HDAC INHIBITOR,0.3904897959308937,6.40861490716446,-1.1284321521037834
BRD-K82928847-001-04-7::2.5::HTS,BRD-K82928847-001-04-7,ACY-1215,2.5,HTS,Exp_IFI35 (ENSG00000068079),GE,targeted cancer,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",,,Phase 1/Phase 2,0.348217183658667,0.291092137822,ACY-1215,HDAC INHIBITOR,0.34322078750986906,7.1059038567342965,-1.988685644511067
BRD-K86797399-001-04-4::2.5::HTS,BRD-K86797399-001-04-4,SB-939,2.5,HTS,METHYL_ELAVL4,METHYL,targeted cancer,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",,,Phase 2,0.360136784621431,0.103537727731,SB-939,HDAC INHIBITOR,0.3585646982502147,6.31374705692155,-0.4975747040522149
BRD-K16485616-001-08-9::2.5::HTS,BRD-K16485616-001-08-9,mocetinostat,2.5,,,,,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",,,,0,0,mocetinostat,HDAC INHIBITOR,0.3657597571795368,5.711302217201747,-0.5374159757998429
BRD-K45528773-001-07-2::2.59::HTS,BRD-K45528773-001-07-2,M-344,2.59,,,,,HDAC inhibitor,,,,,0,0,M-344,HDAC INHIBITOR,0.3887618145330085,5.724128053025585,-0.05172608186713523
BRD-K61397605-001-03-4::2.5::HTS,BRD-K61397605-001-03-4,romidepsin,2.5,,,,,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,,,0,0,romidepsin,HDAC INHIBITOR,0.4388131773291968,3.9167440741669943,-0.7725397692981724
BRD-K86687746-001-01-3::2.5::HTS,BRD-K86687746-001-01-3,R306465,2.5,,,,,HDAC inhibitor,,,,,0,0,R306465,HDAC INHIBITOR,0.3788172130015909,4.801869091581192,0.17739076148847488
BRD-K86797399-001-05-1::2.55::HTS,BRD-K86797399-001-05-1,SB-939,2.55,,,,,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",,,,0,0,SB-939,HDAC INHIBITOR,0.3825974131598049,5.354700331504065,0.6117979009158365
BRD-A01643550-001-04-9::2.5::HTS,BRD-A01643550-001-04-9,prednisolone-acetate,2.5,HTS,Exp_BHLHE41 (ENSG00000123095),GE,noncancer,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis",Launched,0.271068644222136,0.244093999812,prednisolone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.2781512119393608,4.0846858785388624,-2.481163187136203
BRD-A02180903-001-04-5::2.5::HTS,BRD-A02180903-001-04-5,betamethasone,2.5,HTS,PROT_53BP1,PROT,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.23296290580891502,0.134934559687,betamethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.2514294844168785,-3.9944578680181633,-2.8736801297440664
BRD-A10188456-001-04-9::2.5::MTS004,BRD-A10188456-001-04-9,dexamethasone,2.5,MTS004,Exp_ZNF211 (ENSG00000121417),GE,noncancer,glucocorticoid receptor agonist,"ANXA1, NOS2, NR0B1, NR3C1, NR3C2","endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis",Launched,0.27827415345917,0.084433800779,dexamethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.28577897236204713,2.448911165308005,4.67544394056798
BRD-A13133631-001-04-0::2.5::HTS,BRD-A13133631-001-04-0,fluorometholone,2.5,HTS,METABOL_AMP,METABOL,noncancer,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,Launched,0.31992846357641996,0.0893830347405,fluorometholone,GLUCOCORTICOID RECEPTOR AGONIST,0.3197261178940481,-1.3734734686143342,-2.8639436817060027
BRD-A15297126-001-04-3::2.5::HTS,BRD-A15297126-001-04-3,fluocinolone-acetonide,2.5,HTS,RMUTmis_TTN (7273),MUTmis,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,Launched,0.267551082485177,0.0485881319275,fluocinolone-acetonide,GLUCOCORTICOID RECEPTOR AGONIST,0.26712513995403325,-1.6013649146834004,-3.0045613238666373
BRD-A17407635-001-04-0::2.5::HTS,BRD-A17407635-001-04-0,alclometasone-dipropionate,2.5,HTS,CRISPR_RPS27L (51065),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"CYP3A4, NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,Launched,0.27156941087696695,0.224079896149,alclometasone-dipropionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2499515226624148,-3.829309794183389,-2.971086957641285
BRD-A25143711-001-02-2::2.5::HTS,BRD-A25143711-001-02-2,hydrocortisone-valerate,2.5,HTS,PROT_XRCC1_Caution,PROT,noncancer,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,Launched,0.250831679847372,0.106584108993,hydrocortisone-valerate,GLUCOCORTICOID RECEPTOR AGONIST,0.2503317293969236,-4.1593119742875135,-2.885341482148596
BRD-A27887842-001-04-0::2.5::HTS,BRD-A27887842-001-04-0,prednisolone,2.5,HTS,RMUTmis_POLRMT (5442),MUT,noncancer,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis",Launched,0.24512680526184696,0.0263133044824,prednisolone,GLUCOCORTICOID RECEPTOR AGONIST,0.2443795585207873,-1.2808761348108684,-2.6770004020617035
BRD-A36010170-001-04-0::2.5::HTS,BRD-A36010170-001-04-0,amcinonide,2.5,HTS,CRISPR_RPS27L (51065),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"ANXA1, NR3C1",dermatology,corticosteroid-responsive dermatoses,Launched,0.23188904445577105,0.0663565883012,amcinonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2349389758109275,-3.7547086082488312,-3.1594781087701005
BRD-A45044890-236-02-3::2.5::HTS,BRD-A45044890-236-02-3,methylprednisolone-sodium-succinate,2.5,HTS,Exp_PLAC4 (ENSG00000225745),GE,noncancer,glucocorticoid receptor agonist,,"endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry","hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis",Launched,0.271640844934811,0.109015270929,methylprednisolone-sodium-succinate,GLUCOCORTICOID RECEPTOR AGONIST,0.28481891260487674,-4.534260512954382,-2.617096617543868
BRD-A49447682-001-02-4::2.5::HTS,BRD-A49447682-001-02-4,desoximetasone,2.5,HTS,Exp_TDP1 (ENSG00000042088),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.258881574170255,0.170268838183,desoximetasone,GLUCOCORTICOID RECEPTOR AGONIST,0.25781441816172723,-3.905086271088084,-3.0259383463894127
BRD-A49765801-001-04-1::2.5::HTS,BRD-A49765801-001-04-1,fludroxycortide,2.5,HTS,CRISPR_ALMS1 (7840),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",Launched,0.270833195198176,0.0319603999344,fludroxycortide,GLUCOCORTICOID RECEPTOR AGONIST,0.2663099218639568,-1.8618724999724447,-3.1110282370776368
BRD-A50064262-001-04-7::2.5::HTS,BRD-A50064262-001-04-7,flumethasone-pivalate,2.5,HTS,Exp_CCDC22 (ENSG00000101997),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",,,Launched,0.23069904610372802,0.0804697195723,flumethasone-pivalate,GLUCOCORTICOID RECEPTOR AGONIST,0.2347117512131857,-1.680618461277095,-2.8892472019315965
BRD-A65767837-001-04-4::2.5::HTS,BRD-A65767837-001-04-4,hydrocortisone-acetate,2.5,HTS,CRISPR_EGLN3 (112399),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, NR3C2",dermatology,corticosteroid-responsive dermatoses,Launched,0.21027418108644103,0.00840877311364,hydrocortisone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.21938335972098466,-3.911246520805953,-3.0282515161604504
BRD-A66869276-001-02-9::2.5::HTS,BRD-A66869276-001-02-9,diflorasone-diacetate,2.5,HTS,CN_RHD (6007),CN,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.27148731572457,0.123130090042,diflorasone-diacetate,GLUCOCORTICOID RECEPTOR AGONIST,0.2683907881114175,-3.9989907665861137,-3.0849842251199675
BRD-A73385064-001-01-5::2.603473418::MTS004,BRD-A73385064-001-01-5,beclomethasone,2.603473418,MTS004,METABOL_C18:2 LPC,METABOL,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,Launched,0.287375935013944,0.0806721966091,beclomethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.2888130742587232,2.5661592919120544,4.600033987536116
BRD-A78391468-001-02-8::2.5::HTS,BRD-A78391468-001-02-8,prednisolone-hemisuccinate,2.5,HTS,CRISPR_KIAA0586 (9786),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,,,Preclinical,0.269377669070041,0.138426429933,prednisolone-hemisuccinate,GLUCOCORTICOID RECEPTOR AGONIST,0.2657955746429717,-3.955027635797848,-3.136768384948647
BRD-A83802939-304-04-2::2.5::HTS,BRD-A83802939-304-04-2,dexamethasone-sodium-phosphate,2.5,HTS,METABOL_trimethylamine-N-oxide,METABOL,noncancer,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis",Launched,0.282248717483595,0.0903172851705,dexamethasone-sodium-phosphate,GLUCOCORTICOID RECEPTOR AGONIST,0.2865963643212687,-4.075175736723643,-2.97255462882354
BRD-A88138582-001-04-8::2.5::HTS,BRD-A88138582-001-04-8,halcinonide,2.5,HTS,CRISPR_RPS27L (51065),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.260581558217579,0.137338441879,halcinonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2726816088208294,-1.7406042441211036,-2.90907220173186
BRD-A92177080-001-02-1::2.5::MTS004,BRD-A92177080-001-02-1,betamethasone-acetate,2.5,MTS004,CRISPR_LGR4 (55366),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.30055078212035996,0.035615938558,betamethasone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.3092618822892069,2.2144882201421794,4.612779046450769
BRD-A92439610-001-05-7::2.5::HTS,BRD-A92439610-001-05-7,triamcinolone-acetonide,2.5,HTS,Exp_ZNF738 (ENSG00000172687),GE,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.26241012502140804,0.116154610103,triamcinolone-acetonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2598257683931729,-2.731376049909671,-3.257181662183739
BRD-A94523291-304-02-7::2.5::HTS,BRD-A94523291-304-02-7,prednisolone-sodium-phosphate,2.5,HTS,CRISPR_KCNK13 (56659),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,"allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology","allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, asthma, meningitis, psoriatic arthritis, rheumatoid arthritis",Launched,0.267308155787252,0.0987601665087,prednisolone-sodium-phosphate,GLUCOCORTICOID RECEPTOR AGONIST,0.26501982067357444,-4.038814817705432,-2.9017224721044013
BRD-K10799896-001-26-2::2.5::HTS,BRD-K10799896-001-26-2,clobetasol-propionate,2.5,HTS,METHYL_ZNF71,METHYL,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.293026290538289,0.0873548591807,clobetasol-propionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2912176899445477,-1.9818466665009573,-3.1470636434458923
BRD-K21528677-001-02-8::2.44::HTS,BRD-K21528677-001-02-8,desonide,2.44,HTS,PROT_N-Cadherin,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,Launched,0.32094866222491397,0.155887145015,desonide,GLUCOCORTICOID RECEPTOR AGONIST,0.3175639725971348,-0.5946219975964909,-2.3652107690694257
BRD-K21528677-001-03-6::2.5::HTS,BRD-K21528677-001-03-6,desonide,2.5,HTS,PROT_RBM15,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,Launched,0.32094866222491397,0.155887145015,desonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2298288739810081,-2.2311041736343418,-3.267368875628283
BRD-K24452555-001-01-7::2.599377769::MTS004,BRD-K24452555-001-01-7,methylprednisolone-aceponate,2.599377769,MTS004,Exp_TDP1 (ENSG00000042088),GE,noncancer,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology","congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia",Launched,0.29275996176196506,0.0973387121175,methylprednisolone-aceponate,GLUCOCORTICOID RECEPTOR AGONIST,0.2914846333032741,2.5343923036825817,4.622917974238021
BRD-K31627533-001-09-5::2.5::HTS,BRD-K31627533-001-09-5,rimexolone,2.5,HTS,CRISPR_SLC19A1 (6573),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,Launched,0.309402841604276,0.1076601938,rimexolone,GLUCOCORTICOID RECEPTOR AGONIST,0.3104141890206382,-1.9828873110800969,-3.098194298867352
BRD-K33720171-001-01-0::2.5::HTS,BRD-K33720171-001-01-0,difluprednate,2.5,HTS,Exp_POU5F1P5 (ENSG00000236375),GE,noncancer,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,Launched,0.264145847636023,0.0962332996117,difluprednate,GLUCOCORTICOID RECEPTOR AGONIST,0.2619951428366373,-2.9613686493439424,-3.2646505597912867
BRD-K34032314-001-04-1::2.5::HTS,BRD-K34032314-001-04-1,betamethasone-valerate,2.5,HTS,PROT_TIGAR,PROT,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.24335719816211,0.113466046437,betamethasone-valerate,GLUCOCORTICOID RECEPTOR AGONIST,0.2543800083714637,-3.6472679479487407,-3.160297565555987
BRD-K35240538-001-26-2::2.5::HTS,BRD-K35240538-001-26-2,methylprednisolone,2.5,HTS,METABOL_thymidine,METABOL,noncancer,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis",Launched,0.24585924337658,0.185867098747,methylprednisolone,GLUCOCORTICOID RECEPTOR AGONIST,0.2467615266848221,-0.8129970493601559,-2.461268890260607
BRD-K35245662-001-01-2::2.5::HTS,BRD-K35245662-001-01-2,ciclesonide,2.5,HTS,DEM2_SLC4A7 (9497),DEMETER2_COM,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,Launched,0.257108222986245,0.110047069121,ciclesonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2619630841320635,-3.1221481547570287,-3.0827776017215864
BRD-K39983086-001-06-1::2.45::HTS,BRD-K39983086-001-06-1,loteprednol,2.45,HTS,CRISPR_DYDC1 (143241),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,ophthalmology,conjunctivitis,Launched,0.300005099220844,0.101307601724,loteprednol,GLUCOCORTICOID RECEPTOR AGONIST,0.31150339013202505,-3.497429019549299,-3.1438115629522634
BRD-K45664306-001-19-6::2.52::HTS,BRD-K45664306-001-19-6,prednisolone-acetate,2.52,HTS,Exp_PNPLA3 (ENSG00000100344),GE,noncancer,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis",Launched,0.26760852455716,0.118210516942,prednisolone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.26651892720603954,-1.207329549323052,-2.737161678431961
BRD-K47635719-001-21-1::2.5::HTS,BRD-K47635719-001-21-1,dexamethasone-acetate,2.5,HTS,Exp_FOXRED2 (ENSG00000100350),GE,noncancer,glucocorticoid receptor agonist,,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis",Launched,0.235661002604668,0.0526134071812,dexamethasone-acetate,GLUCOCORTICOID RECEPTOR AGONIST,0.2386834138889365,-1.517745983887402,-2.794380792371617
BRD-K56515112-001-21-6::2.5::HTS,BRD-K56515112-001-21-6,medrysone,2.5,HTS,MIRNA_hsa-miR-211,MIRNA,noncancer,glucocorticoid receptor agonist,NR3C1,ophthalmology,"conjunctivitis, episcleritis",Launched,0.249758943607807,0.0549190599748,medrysone,GLUCOCORTICOID RECEPTOR AGONIST,0.2408098691009926,-4.360166580399431,-2.6683071794773143
BRD-K57886322-001-16-6::2.5::MTS004,BRD-K57886322-001-16-6,fluocinonide,2.5,MTS004,Exp_TDP1 (ENSG00000042088),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6, SMO",dermatology,"seborrheic dermatitis, eczema",Launched,0.35664863586487106,0.106693210088,fluocinonide,GLUCOCORTICOID RECEPTOR AGONIST,0.3375919592674048,2.44385331858705,4.603922258585384
BRD-K58810291-001-16-2::2.564588683::MTS004,BRD-K58810291-001-16-2,clobetasone-butyrate,2.564588683,MTS004,CRISPR_FZD5 (7855),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,"eczema, psoriasis, dermatitis",Launched,0.30649038779530796,0.155925582134,clobetasone-butyrate,GLUCOCORTICOID RECEPTOR AGONIST,0.3056420143933197,2.452025814682421,4.304377260351949
BRD-K60640630-001-11-0::2.5::HTS,BRD-K60640630-001-11-0,mometasone-furoate,2.5,HTS,CRISPR_ANP32A (8125),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,Launched,0.25072477840007,0.0309639323224,mometasone-furoate,GLUCOCORTICOID RECEPTOR AGONIST,0.2430744620255936,-2.6988315476757827,-3.1816036526482034
BRD-K61496577-001-19-4::2.5::MTS004,BRD-K61496577-001-19-4,flumethasone,2.5,MTS004,PROT_MYH11,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.33283653325485496,0.190862676397,flumethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.33813293558064034,2.501259705015786,4.8313800517428565
BRD-K61496577-001-20-2::2.5::HTS,BRD-K61496577-001-20-2,flumethasone,2.5,HTS,PROT_STAT3_Caution,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.33283653325485496,0.190862676397,flumethasone,GLUCOCORTICOID RECEPTOR AGONIST,0.28048612641106685,-2.7628696586381927,-3.2195220978873462
BRD-K62310379-001-10-5::2.5::HTS,BRD-K62310379-001-10-5,fluticasone-propionate,2.5,HTS,Exp_SUN2 (ENSG00000100242),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,Launched,0.329241347790672,0.128315499002,fluticasone-propionate,GLUCOCORTICOID RECEPTOR AGONIST,0.32612320679824675,-2.2699305581259392,-3.315863320006116
BRD-K65877271-001-01-8::2.5::HTS,BRD-K65877271-001-01-8,halobetasol-propionate,2.5,HTS,Exp_CREG2 (ENSG00000175874),GE,noncancer,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,Launched,0.31445196402483805,0.164634760277,halobetasol-propionate,GLUCOCORTICOID RECEPTOR AGONIST,0.31410792023188144,-1.7550351357870475,-3.0017774749502144
BRD-K77554836-001-11-6::2.57::HTS,BRD-K77554836-001-11-6,triamcinolone,2.57,HTS,PROT_14-3-3_zeta,PROT,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,Launched,0.271628967442343,0.151095762145,triamcinolone,GLUCOCORTICOID RECEPTOR AGONIST,0.2860553232756325,-1.2963504347586166,-2.6822110029516093
BRD-K77554836-001-14-0::2.5::HTS,BRD-K77554836-001-14-0,triamcinolone,2.5,HTS,METABOL_C36:4 PC-A,METABOL,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,Launched,0.271628967442343,0.132168844179,triamcinolone,GLUCOCORTICOID RECEPTOR AGONIST,0.28887639166579704,-2.2110217452817453,-3.261524715618741
BRD-K93568044-001-32-0::2.5::HTS,BRD-K93568044-001-32-0,hydrocortisone,2.5,HTS,CRISPR_PIGM (93183),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching",Launched,0.321027711367711,0.208101693583,hydrocortisone,GLUCOCORTICOID RECEPTOR AGONIST,0.3002482023954378,-4.076856524948506,-3.1062959562766483
BRD-K94353609-001-21-6::2.5::HTS,BRD-K94353609-001-21-6,fluocinolone-acetonide,2.5,HTS,CRISPR_KIAA0586 (9786),AVANA_PUBLIC_18Q2,noncancer,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,Launched,0.268175867719735,0.0931202401299,fluocinolone-acetonide,GLUCOCORTICOID RECEPTOR AGONIST,0.2630742906734965,-2.1093571738678274,-3.0835597038073743
BRD-K96006502-001-02-6::2.5::HTS,BRD-K96006502-001-02-6,deflazacort,2.5,HTS,CN_PITRM1-AS1 (100507034),CN,noncancer,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,Launched,0.30413678278781703,0.0670076072107,deflazacort,GLUCOCORTICOID RECEPTOR AGONIST,0.3019696146349685,-1.4830526595601583,-2.768537059667172
BRD-K97810537-001-12-8::2.54::HTS,BRD-K97810537-001-12-8,beclomethasone-dipropionate,2.54,HTS,DEM2_C1orf74 (148304),DEMETER2_COM,noncancer,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,Launched,0.292280849085579,0.107821240269,beclomethasone-dipropionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2912757818618376,-2.0696969209726563,-3.1957492101685228
BRD-K97810537-001-13-6::2.5::HTS,BRD-K97810537-001-13-6,beclomethasone-dipropionate,2.5,HTS,DEM2_WNT4 (54361),DEMETER2_COM,noncancer,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,Launched,0.292280849085579,0.107821240269,beclomethasone-dipropionate,GLUCOCORTICOID RECEPTOR AGONIST,0.2879234180035132,-2.4244479811229915,-3.1756520569631914
BRD-K99199077-001-16-1::2.603211317::MTS004,BRD-K99199077-001-16-1,hydrocortisone-butyrate,2.603211317,MTS004,METABOL_C18:2 LPC,METABOL,noncancer,glucocorticoid receptor agonist,NR3C1,dermatology,"corticosteroid-responsive dermatoses, eczema",Launched,0.28155313546094296,-0.010710211324,hydrocortisone-butyrate,GLUCOCORTICOID RECEPTOR AGONIST,0.2815208141924003,2.3430326807663486,4.592571581907533
BRD-K03765900-001-01-9::2.499986292::MTS004,BRD-K03765900-001-01-9,XL-647,2.499986292,MTS004,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,"EGFR, EPHB4, ERBB2, FLT4, KDR",,,Phase 3,0.4449515305581721,0.53038806092,XL-647,EGFR INHIBITOR,0.4423696251612983,1.2941219405176367,-4.7272797385165966
BRD-K07106112-003-03-8::2.5::HTS,BRD-K07106112-003-03-8,BMS-599626,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4",,,Phase 1,0.44817107663452505,0.458812662162,BMS-599626,EGFR INHIBITOR,0.4247440304764435,1.0136431900793197,-5.059065347105403
BRD-K08799216-001-05-3::2.5::HTS,BRD-K08799216-001-05-3,pelitinib,2.5,HTS,Exp_GRB7 (ENSG00000141738),GE,targeted cancer,EGFR inhibitor,EGFR,,,Phase 2,0.327475309570815,0.29880108215,pelitinib,EGFR INHIBITOR,0.3229821376454882,4.026639438102257,-1.7492747571805165
BRD-K17497770-001-03-6::2.5::HTS,BRD-K17497770-001-03-6,butein,2.5,HTS,Exp_BEND5 (ENSG00000162373),GE,noncancer,EGFR inhibitor,ACE,,,Preclinical,0.34813140370888895,0.15719318392,butein,EGFR INHIBITOR,0.3463790579989863,-4.07822373954745,-1.1574521940062703
BRD-K17702546-001-03-2::2.5::HTS,BRD-K17702546-001-03-2,PD-168393,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, SRC",,,Preclinical,0.44722495178451793,0.537780071912,PD-168393,EGFR INHIBITOR,0.4503270312788369,0.9703824987247894,-5.1801434083536515
BRD-K19687926-379-07-4::2.5::HTS,BRD-K19687926-379-07-4,lapatinib,2.5,HTS,Exp_CDH1 (ENSG00000039068),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,Launched,0.427739400427997,0.497752716732,lapatinib,EGFR INHIBITOR,0.4253178996391905,0.8516761282538033,-5.0643122326247765
BRD-K22514639-001-05-7::2.500015058::MTS004,BRD-K22514639-001-05-7,EGF816,2.500015058,MTS004,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,EGFR,,,Phase 2,0.35722679656081296,0.333039939389,EGF816,EGFR INHIBITOR,0.35856790556925383,1.1927069784492328,-5.040163972963789
BRD-K24869513-001-02-1::2.5::HTS,BRD-K24869513-001-02-1,CNX-2006,2.5,HTS,PROT_GSK3_pS9,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.33333894023249394,0.197554243353,CNX-2006,EGFR INHIBITOR,0.3171973699178206,0.9421808869711608,-5.066159200428287
BRD-K26026438-001-01-0::2.499979456::MTS004,BRD-K26026438-001-01-0,tucatinib,2.499979456,MTS004,Exp_PGAP3 (ENSG00000161395),GE,targeted cancer,EGFR inhibitor,ERBB2,,,Phase 2,0.30537396083315504,0.358437592792,tucatinib,EGFR INHIBITOR,0.30374454143214663,1.0708324777907905,-5.122392906569769
BRD-K26603252-003-04-9::2.5::HTS,BRD-K26603252-003-04-9,PD-153035,2.5,HTS,Exp_CDH1 (ENSG00000039068),GE,targeted cancer,EGFR inhibitor,"EGFR, KDR",,,Phase 1,0.432760301802387,0.510488932054,PD-153035,EGFR INHIBITOR,0.4272990396560319,1.06671992973089,-5.263855457378938
BRD-K26838195-075-04-9::2.5::HTS,BRD-K26838195-075-04-9,AST-1306,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Phase 1,0.44592577938152395,0.466423065302,AST-1306,EGFR INHIBITOR,0.4380699003610072,0.9285657245855238,-5.163226386009617
BRD-K31698212-001-02-9::2.5::HTS,BRD-K31698212-001-02-9,icotinib,2.5,HTS,Exp_EGFR (ENSG00000146648),GE,targeted cancer,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),Launched,0.35067050013004397,0.298859125169,icotinib,EGFR INHIBITOR,0.3445224455852446,1.2632169200016734,-4.8960343770435575
BRD-K33610132-001-02-9::2.5::HTS,BRD-K33610132-001-02-9,rociletinib,2.5,HTS,Exp_TET3 (ENSG00000187605),GE,targeted cancer,EGFR inhibitor,EGFR,,,Phase 3,0.337357749914565,0.337756462072,rociletinib,EGFR INHIBITOR,0.3374139766790705,2.526545384767147,-3.4928259241722017
BRD-K40718343-001-02-6::2.5::HTS,BRD-K40718343-001-02-6,AEE788,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",,,Phase 1/Phase 2,0.436712051885135,0.500281956291,AEE788,EGFR INHIBITOR,0.4304378492381693,1.1361527127541766,-4.895200267640384
BRD-K41278234-001-03-0::2.5::HTS,BRD-K41278234-001-03-0,CUDC-101,2.5,HTS,Exp_ABCG2 (ENSG00000118777),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Phase 1,0.390484116367459,0.253517717723,CUDC-101,EGFR INHIBITOR,0.3890288962131621,5.8738757810806765,-1.3856586174829966
BRD-K42805893-001-04-9::2.5::HTS,BRD-K42805893-001-04-9,osimertinib,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),Launched,0.439029743347816,0.53608640338,osimertinib,EGFR INHIBITOR,0.4335821099087843,0.8100716144978829,-4.907425781031169
BRD-K46386702-001-02-1::2.5::HTS,BRD-K46386702-001-02-1,ARRY-334543,2.5,HTS,CRISPR_ITGAV (3685),AVANA_PUBLIC_18Q2,targeted cancer,EGFR inhibitor,ERBB2,,,Phase 2,0.4346574043083,0.484762393669,ARRY-334543,EGFR INHIBITOR,0.4305030672246092,0.3522077241606513,-2.108934988585454
BRD-K49294207-300-03-8::2.5::HTS,BRD-K49294207-300-03-8,BIBU-1361,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.42899030566157603,0.446887572034,BIBU-1361,EGFR INHIBITOR,0.3894995449868105,1.1326069078799952,-5.396724646843059
BRD-K50010139-001-02-3::2.5::MTS004,BRD-K50010139-001-02-3,poziotinib,2.5,MTS004,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4",,,Phase 2,0.46440552719184897,0.524461296828,poziotinib,EGFR INHIBITOR,0.4621716473168822,1.235026426907074,-4.903157800496
BRD-K50168500-001-07-9::2.5::HTS,BRD-K50168500-001-07-9,canertinib,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",,,Phase 3,0.44782039099235205,0.412117532412,canertinib,EGFR INHIBITOR,0.42055014321500855,0.9758855022491768,-5.06070546381342
BRD-K56981171-001-01-0::2.500008954::MTS004,BRD-K56981171-001-01-0,brigatinib,2.500008954,MTS004,PROT_Caspase-7_cleavedD198_Caution,PROT,targeted cancer,EGFR inhibitor,"ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),Launched,0.367757423930709,0.274119975957,brigatinib,EGFR INHIBITOR,0.3656658992773486,2.4624851837319883,-2.283017707249601
BRD-K57169635-001-04-5::2.5::HTS,BRD-K57169635-001-04-5,dacomitinib,2.5,HTS,PROT_Shc_pY317,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4",,,Phase 3,0.43415864020504996,0.442606811944,dacomitinib,EGFR INHIBITOR,0.4182885382373995,0.8866766979862327,-4.951795808184809
BRD-K60421517-001-01-4::2.499975038::MTS004,BRD-K60421517-001-01-4,olmutinib,2.499975038,MTS004,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,"BTK, EGFR",,,Launched,0.285950837429763,0.19212203124,olmutinib,EGFR INHIBITOR,0.28719374387290925,1.0389407753759945,-4.7472756211085425
BRD-K64052750-001-17-5::2.5::HTS,BRD-K64052750-001-17-5,gefitinib,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),Launched,0.44363296686048903,0.476164958373,gefitinib,EGFR INHIBITOR,0.4348208672152679,0.9950024248165648,-5.169844837759602
BRD-K66175015-001-09-0::2.5::HTS,BRD-K66175015-001-09-0,afatinib,2.5,HTS,Exp_GRB7 (ENSG00000141738),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),Launched,0.41291335219417796,0.432148978648,afatinib,EGFR INHIBITOR,0.4084109933478121,0.8777716957362737,-4.9255965114273295
BRD-K68336408-001-10-9::2.5::HTS,BRD-K68336408-001-10-9,tyrphostin-AG-1478,2.5,HTS,Exp_EPHA1 (ENSG00000146904),GE,targeted cancer,EGFR inhibitor,"EGFR, MAPK14",,,Preclinical,0.39688808181573,0.497379472739,tyrphostin-AG-1478,EGFR INHIBITOR,0.41458063905171183,0.9167179771637928,-5.199247396765233
BRD-K70401845-003-09-6::2.5::HTS,BRD-K70401845-003-09-6,erlotinib,2.5,HTS,Exp_IRF6 (ENSG00000117595),GE,targeted cancer,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer",Launched,0.40630030561703295,0.38610926851,erlotinib,EGFR INHIBITOR,0.4089099286754243,1.0057298203224287,-4.351595381829201
BRD-K70914287-300-02-8::2.5::HTS,BRD-K70914287-300-02-8,BIBX-1382,2.5,HTS,DEM2_EGFR (1956),DEMETER2_COM,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Phase 1,0.403801716843192,0.463004979652,BIBX-1382,EGFR INHIBITOR,0.4040055637319845,1.0690363733856905,-5.400798738935901
BRD-K72420232-001-12-3::2.5::HTS,BRD-K72420232-001-12-3,WZ-4002,2.5,HTS,CRISPR_WDR4 (10785),AVANA_PUBLIC_18Q2,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Preclinical,0.35196991166989294,0.28536734718,WZ-4002,EGFR INHIBITOR,0.33629188381800884,1.0668439441837938,-5.024952406324467
BRD-K73293050-001-03-1::2.5::HTS,BRD-K73293050-001-03-1,WZ-3146,2.5,HTS,PROT_Annexin 1,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.357436791682455,0.301513105205,WZ-3146,EGFR INHIBITOR,0.36674171904919295,4.609658662141582,-1.2387756047800345
BRD-K73309154-003-02-8::2.5::HTS,BRD-K73309154-003-02-8,OSI-420,2.5,HTS,PROT_Shc_pY317,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.498378189722727,0.501159691586,OSI-420,EGFR INHIBITOR,0.4934040148112999,1.1035948997745575,-4.969230814816026
BRD-K76239644-001-01-8::2.5::HTS,BRD-K76239644-001-01-8,BMS-690514,2.5,HTS,PROT_EGFR_pY1068_Caution,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, FLT3, KDR",,,Phase 2,0.441821971624813,0.522720299356,BMS-690514,EGFR INHIBITOR,0.44202865570474464,1.4657815232256688,-4.6620873601305215
BRD-K77625799-001-07-7::2.5::HTS,BRD-K77625799-001-07-7,vandetanib,2.5,HTS,Exp_FGFR2 (ENSG00000066468),GE,targeted cancer,EGFR inhibitor,"EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),Launched,0.37330229889289707,0.402053233963,vandetanib,EGFR INHIBITOR,0.3673003579456741,1.4716504090361735,-4.637272982724372
BRD-K79930101-300-03-7::2.5::HTS,BRD-K79930101-300-03-7,GW-583340,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,"EGFR, ERBB2",,,Preclinical,0.46952131060494295,0.511894893675,GW-583340,EGFR INHIBITOR,0.4678735966826801,0.7361439981172478,-5.0426647898441885
BRD-K80343549-001-02-6::2.5::HTS,BRD-K80343549-001-02-6,TAK-285,2.5,HTS,METHYL_LOC102723927,METHYL,targeted cancer,EGFR inhibitor,ERBB2,,,Phase 1,0.24543202699260602,0.343913882571,TAK-285,EGFR INHIBITOR,0.25534460737687953,4.918257047972253,1.3254911800490672
BRD-K81728688-001-04-4::2.5::HTS,BRD-K81728688-001-04-4,WZ8040,2.5,HTS,PROT_E-Cadherin,PROT,targeted cancer,EGFR inhibitor,EGFR,,,Preclinical,0.288637857177547,0.363431175608,WZ8040,EGFR INHIBITOR,0.30655161321349705,1.0135591652707934,-4.867557064025284
BRD-K85402309-001-06-6::2.5::HTS,BRD-K85402309-001-06-6,dovitinib,2.5,HTS,Exp_LRP4-AS1 (ENSG00000247675),GE,targeted cancer,EGFR inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,EGFR INHIBITOR,0.3209116212941136,4.798277110517273,-1.861827140155172
BRD-K85402309-389-03-2::2.5::HTS,BRD-K85402309-389-03-2,dovitinib,2.5,HTS,Exp_NASP (ENSG00000132780),GE,targeted cancer,EGFR inhibitor,"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,Phase 3,0.394554792169286,0.354142247602,dovitinib,EGFR INHIBITOR,0.39269199754946216,3.339171570179825,-3.737822379584856
BRD-K85606544-001-09-1::2.5::HTS,BRD-K85606544-001-09-1,neratinib,2.5,HTS,Exp_FAM83B (ENSG00000168143),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, KDR",,,Phase 3,0.363259191356945,0.454553104957,neratinib,EGFR INHIBITOR,0.36519727466838897,0.937268709121678,-4.973267676447599
BRD-K98572433-001-02-9::2.5::HTS,BRD-K98572433-001-02-9,AZD8931,2.5,HTS,Exp_MARVELD3 (ENSG00000140832),GE,targeted cancer,EGFR inhibitor,"EGFR, ERBB2, ERBB3",,,Phase 2,0.49567019791760103,0.538199163953,AZD8931,EGFR INHIBITOR,0.4653878098519101,1.076845857063517,-5.136897609427157
BRD-K03294269-001-08-0::2.5::HTS,BRD-K03294269-001-08-0,NU6027,2.5,HTS,Exp_GSR (ENSG00000104687),GE,targeted cancer,CDK inhibitor,"CCNA2, CDK2",,,Preclinical,0.3778694362565321,0.358654954709,NU6027,CDK INHIBITOR,0.3755856809360565,1.1411434825106117,1.0918575444708023
BRD-K07762753-001-04-4::2.5::HTS,BRD-K07762753-001-04-4,aminopurvalanol-a,2.5,HTS,Exp_DCTN3 (ENSG00000137100),GE,targeted cancer,CDK inhibitor,"CDK1, CDK2, CDK5, CDK6",,,Preclinical,0.311502836085631,0.183284558968,aminopurvalanol-a,CDK INHIBITOR,0.3124725757388038,4.634481409922142,-2.1105525080986176
BRD-K11636097-001-03-1::2.5::HTS,BRD-K11636097-001-03-1,JNJ-7706621,2.5,HTS,Exp_C1QBP (ENSG00000108561),GE,targeted cancer,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",,,Preclinical,0.3428053162825301,0.278923923122,JNJ-7706621,CDK INHIBITOR,0.3427143878190421,4.6700754433425455,-3.0302143160272617
BRD-K14560436-001-01-4::2.5::HTS,BRD-K14560436-001-01-4,TG-02,2.5,HTS,CN_SLC7A6 (9057),CN,targeted cancer,CDK inhibitor,"CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",,,Phase 1,0.416665039453543,0.198016287339,TG-02,CDK INHIBITOR,0.41215569180391415,5.044221500614257,-0.7693097555773051
BRD-K17610631-001-03-3::2.421190843::MTS004,BRD-K17610631-001-03-3,indisulam,2.421190843,MTS004,Exp_DCAF15 (ENSG00000132017),GE,targeted cancer,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",,,Phase 2,0.46505516054461504,0.393099327153,indisulam,CDK INHIBITOR,0.4724312219594145,5.324284690705121,-3.894970665490989
BRD-K17894950-001-14-3::2.5::HTS,BRD-K17894950-001-14-3,indirubin,2.5,HTS,Exp_SLC19A2 (ENSG00000117479),GE,targeted cancer,CDK inhibitor,"CDK1, CDK5, GSK3A",,,Phase 2/Phase 3,0.301333802448029,0.157385178543,indirubin,CDK INHIBITOR,0.2983403988654041,-1.0704134924591613,0.9983716869621628
BRD-K19136521-001-08-9::2.5::HTS,BRD-K19136521-001-08-9,indirubin-3-monoxime,2.5,HTS,METHYL_ABCA11P,METHYL,targeted cancer,CDK inhibitor,"CDK1, CDK2, CDK5, CDK5R1, GSK3B",,,Preclinical,0.327613773413435,0.0323762403882,indirubin-3-monoxime,CDK INHIBITOR,0.3294411690100792,-2.3480012511918407,0.589359530325325
BRD-K33622447-066-01-9::2.5::HTS,BRD-K33622447-066-01-9,abemaciclib,2.5,HTS,Exp_EIF2D (ENSG00000143486),GE,targeted cancer,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,Launched,0.36781875448140794,0.32415152461,abemaciclib,CDK INHIBITOR,0.3676215181046015,1.6305539838422345,-3.3626926891725697
BRD-K37312348-001-15-0::2.5::HTS,BRD-K37312348-001-15-0,kenpaullone,2.5,HTS,MUTpool_TBC1D32 (221322),MUTpool,targeted cancer,CDK inhibitor,"CCNB1, CDK1, CDK5, GSK3B",,,Preclinical,0.3507938372664411,0.0511107270334,kenpaullone,CDK INHIBITOR,0.3482351808109406,-2.3025104898840363,1.01926451350246
BRD-K43389698-001-09-9::2.4::HTS,BRD-K43389698-001-09-9,BMS-387032,2.4,HTS,PROT_YAP_pS127_Caution,PROT,noncancer,CDK inhibitor,"CDK2, CDK7, CDK9",,,Phase 1,0.34389319060567997,0.0898598329229,BMS-387032,CDK INHIBITOR,0.3468213601011139,5.073693658642744,0.6398439718783115
BRD-K51313569-003-03-3::2.5::HTS,BRD-K51313569-003-03-3,palbociclib,2.5,HTS,CRISPR_ZC3H14 (79882),AVANA_PUBLIC_18Q2,targeted cancer,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,Launched,0.326245891243462,0.222903527872,palbociclib,CDK INHIBITOR,0.32505404172120184,-4.206599789524887,-1.5953204300445805
BRD-K60997853-001-02-3::2.5::HTS,BRD-K60997853-001-02-3,PHA-848125,2.5,HTS,Exp_VIMP (ENSG00000131871),GE,targeted cancer,CDK inhibitor,"CDK2, CDK4, CDK7, NTRK1",,,Phase 2,0.383647133525259,0.246675312923,PHA-848125,CDK INHIBITOR,0.3816800686915989,4.600710803837272,-0.3425969732370153
BRD-K62814476-001-03-3::2.5::HTS,BRD-K62814476-001-03-3,BMS-265246,2.5,HTS,Exp_C1QBP (ENSG00000108561),GE,targeted cancer,CDK inhibitor,"CDK1, CDK2",,,Preclinical,0.342226881496436,0.294443153103,BMS-265246,CDK INHIBITOR,0.34375900191339154,4.856631389444134,-2.290075881634753
BRD-K64800655-001-07-4::2.5::HTS,BRD-K64800655-001-07-4,PHA-793887,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",,,Phase 1,0.394962718433861,0.316592431343,PHA-793887,CDK INHIBITOR,0.39579194086055103,4.080084083237193,-1.7996860455600254
BRD-K72726508-001-02-1::2.5::HTS,BRD-K72726508-001-02-1,arcyriaflavin-a,2.5,HTS,Exp_AGR2 (ENSG00000106541),GE,targeted cancer,CDK inhibitor,"CCND1, CDK4",,,Preclinical,0.41405131687230395,0.312339348209,arcyriaflavin-a,CDK INHIBITOR,0.4114360399208638,-0.2490111444072336,0.9337664608567248
BRD-K13390322-001-06-3::2.5::HTS,BRD-K13390322-001-06-3,AT-7519,2.5,,,,,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",,,,0,0,AT-7519,CDK INHIBITOR,0.3445528554678905,3.8665378129236014,-0.9281926089092184
BRD-K13662825-001-07-5::2.5::HTS,BRD-K13662825-001-07-5,dinaciclib,2.5,,,,,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",,,,0,0,dinaciclib,CDK INHIBITOR,0.43751114346526304,3.3187094852081107,0.3353738259749481
BRD-K40331046-305-01-5::2.5::HTS,BRD-K40331046-305-01-5,CR8-(R),2.5,,,,,CDK inhibitor,CCNA2,,,,0,0,CR8-(R),CDK INHIBITOR,0.4052039202777539,5.234065251748258,0.6566454974819316
BRD-K51791723-003-01-7::2.5::HTS,BRD-K51791723-003-01-7,P276-00,2.5,,,,,CDK inhibitor,"CDK1, CDK4, CDK9",,,,0,0,P276-00,CDK INHIBITOR,0.36399739385665547,5.041180731099502,0.5947093552137699
BRD-K52233191-001-02-4::2.5::HTS,BRD-K52233191-001-02-4,R547,2.5,,,,,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",,,,0,0,R547,CDK INHIBITOR,0.3669846486942179,4.7796514826071705,0.7803084594435628
BRD-K87909389-003-03-4::2.5::HTS,BRD-K87909389-003-03-4,alvocidib,2.5,,,,,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",,,,0,0,alvocidib,CDK INHIBITOR,0.3861734173836712,5.240408651660209,1.2466229790039287
BRD-K08109215-001-06-4::2.5::HTS,BRD-K08109215-001-06-4,I-BET-762,2.5,HTS,PROT_p38_MAPK,PROT,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Phase 2,0.30116579822616996,0.188425739311,I-BET-762,BROMODOMAIN INHIBITOR,0.2992486390162427,-0.3304865239185704,3.085886346552537
BRD-K13094524-001-07-5::2.63::HTS,BRD-K13094524-001-07-5,PFI-1,2.63,HTS,CRISPR_APLP1 (333),AVANA_PUBLIC_18Q2,targeted cancer,bromodomain inhibitor,BRD4,,,Preclinical,0.38157120214294893,0.266638199536,PFI-1,BROMODOMAIN INHIBITOR,0.3996785263630317,-0.3543883184452394,3.200987968040427
BRD-K36363294-001-04-2::2.5::HTS,BRD-K36363294-001-04-2,I-BET151,2.5,HTS,Exp_U2SURP (ENSG00000163714),GE,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Preclinical,0.301693195600542,0.262173484561,I-BET151,BROMODOMAIN INHIBITOR,0.2714089487903982,-0.263708866687339,3.1181232677562933
BRD-K43471985-001-03-0::2.69::HTS,BRD-K43471985-001-03-0,OTX015,2.69,HTS,Exp_XPO5 (ENSG00000124571),GE,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Phase 1/Phase 2,0.392750751026659,0.257251406466,OTX015,BROMODOMAIN INHIBITOR,0.3878112270886288,-0.41948158015798137,3.298809429462448
BRD-K43471985-001-05-5::2.5::HTS,BRD-K43471985-001-05-5,OTX015,2.5,HTS,Exp_MTG1 (ENSG00000148824),GE,targeted cancer,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,Phase 1/Phase 2,0.392750751026659,0.257251406466,OTX015,BROMODOMAIN INHIBITOR,0.3358759386996415,-0.439662641400295,3.2842568019784992
BRD-K44665581-001-01-8::2.5::HTS,BRD-K44665581-001-01-8,bromosporine,2.5,HTS,PROT_Fibronectin,PROT,noncancer,bromodomain inhibitor,,,,Preclinical,0.3808726639219579,0.325363615459,bromosporine,BROMODOMAIN INHIBITOR,0.3688194486501979,-0.3992974067582145,3.2848667946619776
BRD-K54606188-001-13-1::2.5::HTS,BRD-K54606188-001-13-1,JQ1-(+),2.5,HTS,Exp_U2SURP (ENSG00000163714),GE,targeted cancer,bromodomain inhibitor,"BRD4, BRDT",,,Preclinical,0.355873287611933,0.31432776468,JQ1-(+),BROMODOMAIN INHIBITOR,0.3556495729149801,-0.5205566131923942,3.2001038404350184
BRD-K01683783-001-02-6::2.5::HTS,BRD-K01683783-001-02-6,TAK-901,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,Aurora kinase inhibitor,AURKB,,,Phase 1,0.340299958233312,0.428379884634,TAK-901,AURORA KINASE INHIBITOR,0.3417370161140996,4.156913556272688,-1.6860975397639884
BRD-K03289018-001-02-7::2.5::HTS,BRD-K03289018-001-02-7,CCT137690,2.5,HTS,Exp_KCNMB3 (ENSG00000171121),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Preclinical,0.35895843164284297,0.32739649773,CCT137690,AURORA KINASE INHIBITOR,0.3551666459992621,3.9347986028060764,-0.95746212578706
BRD-K07881437-001-03-8::2.5::HTS,BRD-K07881437-001-03-8,danusertib,2.5,HTS,PROT_XBP1_Caution,PROT,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",,,Phase 2,0.3824475784492079,0.335628589551,danusertib,AURORA KINASE INHIBITOR,0.2837208582858569,4.649412073545898,-2.300150941263573
BRD-K07881437-001-04-6::2.41::HTS,BRD-K07881437-001-04-6,danusertib,2.41,HTS,PROT_HER3,PROT,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",,,Phase 2,0.3824475784492079,0.335628589551,danusertib,AURORA KINASE INHIBITOR,0.3831285169133298,4.807608421263585,-2.115120817832654
BRD-K09443272-001-03-3::2.5::HTS,BRD-K09443272-001-03-3,PHA-680632,2.5,HTS,Exp_ABCB1 (ENSG00000085563),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Preclinical,0.394879622964546,0.425459329737,PHA-680632,AURORA KINASE INHIBITOR,0.3971930737469404,4.328504927549684,-3.9034382471952753
BRD-K21718444-001-06-8::2.5::HTS,BRD-K21718444-001-06-8,KW-2449,2.5,HTS,CRISPR_ANKRD49 (54851),AVANA_PUBLIC_18Q2,targeted cancer,Aurora kinase inhibitor,"ABL1, AURKA, AURKB, FLT3",,,Phase 1,0.36775139743891905,0.380965291121,KW-2449,AURORA KINASE INHIBITOR,0.35710734541267874,3.646363964724309,-3.7587140572181728
BRD-K21728777-001-02-3::2.5::HTS,BRD-K21728777-001-02-3,AMG900,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Phase 1,0.36604230247668296,0.30971031726,AMG900,AURORA KINASE INHIBITOR,0.3668769243039424,4.0569067357653985,-3.112343970878338
BRD-K24576554-001-04-8::2.5::HTS,BRD-K24576554-001-04-8,AT-9283,2.5,HTS,Exp_CCDC64 (ENSG00000135127),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",,,Phase 2,0.39158450945863393,0.279954599041,AT-9283,AURORA KINASE INHIBITOR,0.3921450821221964,4.773124769567573,-1.0999671895146412
BRD-K25279140-001-01-5::2.5::HTS,BRD-K25279140-001-01-5,MK-8745,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Preclinical,0.39392893612703495,0.241616916397,MK-8745,AURORA KINASE INHIBITOR,0.3953522750975241,4.461661659269818,-3.4983205556095918
BRD-K31928526-001-02-1::2.5::HTS,BRD-K31928526-001-02-1,barasertib,2.5,HTS,Exp_RCOR2 (ENSG00000167771),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB",,,Phase 2/Phase 3,0.343978207981335,0.26548781931,barasertib,AURORA KINASE INHIBITOR,0.344694962171153,4.115935773880047,-3.445905733788486
BRD-K36740062-001-06-6::2.5::HTS,BRD-K36740062-001-06-6,GSK1070916,2.5,HTS,PROT_HER3,PROT,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",,,Phase 1,0.385414175110141,0.305479473428,GSK1070916,AURORA KINASE INHIBITOR,0.3844879802352341,3.4656409075861663,-3.963869078946286
BRD-K53561341-001-07-5::2.5::HTS,BRD-K53561341-001-07-5,aurora-a-inhibitor-i,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Preclinical,0.397554766874425,0.259366297332,aurora-a-inhibitor-i,AURORA KINASE INHIBITOR,0.385171362168646,5.45253093793096,-2.768414133420274
BRD-K53665955-001-03-0::2.5::HTS,BRD-K53665955-001-03-0,MK-5108,2.5,HTS,Exp_NUP88 (ENSG00000108559),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Phase 1,0.3789933941977629,0.223262609599,MK-5108,AURORA KINASE INHIBITOR,0.381235641951481,5.035420815587724,-3.0614947916630646
BRD-K57136142-001-02-4::2.5::HTS,BRD-K57136142-001-02-4,CCT129202,2.5,HTS,PROT_HER3,PROT,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Preclinical,0.34981165355433,0.294175846607,CCT129202,AURORA KINASE INHIBITOR,0.3495272271778743,3.8541204196620544,-2.9992936389079303
BRD-K59369769-001-20-3::2.5::HTS,BRD-K59369769-001-20-3,tozasertib,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, LCK",,,Phase 2,0.428469836257435,0.276321736551,tozasertib,AURORA KINASE INHIBITOR,0.428818440470585,3.6397995088752855,-4.1885734977152715
BRD-K63923597-001-10-0::2.5::HTS,BRD-K63923597-001-10-0,barasertib-HQPA,2.5,HTS,Exp_RFPL3S (ENSG00000205853),GE,targeted cancer,Aurora kinase inhibitor,AURKB,,,Phase 2/Phase 3,0.374960394906877,0.234206641957,barasertib-HQPA,AURORA KINASE INHIBITOR,0.3736579260356863,4.16244257655484,-3.2882191407460173
BRD-K64866502-001-03-9::2.5::HTS,BRD-K64866502-001-03-9,CYC116,2.5,HTS,Exp_SERBP1 (ENSG00000142864),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, KDR",,,Phase 1,0.330310638012,0.287297045131,CYC116,AURORA KINASE INHIBITOR,0.331545946472744,3.930136617386044,-3.1208262921896215
BRD-K68488863-001-04-9::2.5::HTS,BRD-K68488863-001-04-9,ENMD-2076,2.5,HTS,Exp_VIMP (ENSG00000131871),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",,,Phase 2,0.419573999076324,0.330685283464,ENMD-2076,AURORA KINASE INHIBITOR,0.4160230237769837,3.3497626168475745,-3.5323933776314216
BRD-K68747584-001-02-0::2.5::HTS,BRD-K68747584-001-02-0,PF-03814735,2.5,HTS,Exp_KHDRBS1 (ENSG00000121774),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB",,,Phase 1,0.37727972312694297,0.335455581443,PF-03814735,AURORA KINASE INHIBITOR,0.3760133868679617,3.672954661375975,-3.5664150234124223
BRD-K71512533-066-02-8::2.5::HTS,BRD-K71512533-066-02-8,SNS-314,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,Phase 1,0.332236870985276,0.301854492234,SNS-314,AURORA KINASE INHIBITOR,0.33351078375907417,4.2165874946212885,-3.089086406716161
BRD-K72703948-001-10-1::2.5::HTS,BRD-K72703948-001-10-1,ZM-447439,2.5,HTS,Exp_MAP3K4 (ENSG00000085511),GE,targeted cancer,Aurora kinase inhibitor,"AURKA, AURKB",,,Preclinical,0.37759411906597296,0.199537391082,ZM-447439,AURORA KINASE INHIBITOR,0.3795252580322136,4.382685544288516,-3.0397495078272687
BRD-K75295174-001-05-0::2.5::HTS,BRD-K75295174-001-05-0,alisertib,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Phase 3,0.38575343325704603,0.269986299385,alisertib,AURORA KINASE INHIBITOR,0.38946205930071937,3.385814165394237,-4.1007378305518065
BRD-K83963101-001-06-9::2.5::HTS,BRD-K83963101-001-06-9,MLN-8054,2.5,HTS,Exp_BCL2L1 (ENSG00000171552),GE,targeted cancer,Aurora kinase inhibitor,AURKA,,,Phase 1,0.34639080210870504,0.285901518553,MLN-8054,AURORA KINASE INHIBITOR,0.34541003435266515,4.093711268233679,-3.2688817014325755
BRD-K58122457-001-02-2::2.5::HTS,BRD-K58122457-001-02-2,hesperadin,2.5,,,,,Aurora kinase inhibitor,AURKB,,,,0,0,hesperadin,AURORA KINASE INHIBITOR,0.3120823867453512,4.6386149658133045,-0.30276686353618665
BRD-A89082344-001-08-7::2.500026693::MTS004,BRD-A89082344-001-08-7,perifosine,2.500026693,MTS004,RMUThot_KRAS (3845),MUThot,targeted cancer,AKT inhibitor,AKT1,,,Phase 3,0.190429363189965,0.1633092204,perifosine,AKT INHIBITOR,0.21900427069592135,4.8178230361778684,1.7689863545946776
BRD-K12040459-001-06-0::2.5::HTS,BRD-K12040459-001-06-0,AT7867,2.5,HTS,Exp_IL6R (ENSG00000160712),GE,targeted cancer,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",,,Preclinical,0.36208107519315,0.379387021143,AT7867,AKT INHIBITOR,0.3682857341712445,3.2961172557476868,-3.687938112136143
BRD-K25412176-001-01-9::2.5::HTS,BRD-K25412176-001-01-9,GSK2110183,2.5,HTS,Exp_AKT3 (ENSG00000117020),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.385126932206104,0.424869249604,GSK2110183,AKT INHIBITOR,0.3921378863473861,0.5371378515870229,-2.050139373623729
BRD-K38332599-001-01-3::2.5::HTS,BRD-K38332599-001-01-3,uprosertib,2.5,HTS,METHYL_GLIS3,METHYL,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.395423804811757,0.225551631457,uprosertib,AKT INHIBITOR,0.3958209757764556,5.424787852696356,-2.014003175203122
BRD-K58529924-001-01-5::2.648577938::MTS004,BRD-K58529924-001-01-5,ONC201,2.648577938,MTS004,Exp_CLPP (ENSG00000125656),GE,targeted cancer,AKT inhibitor,TNFSF10,,,Phase 2,0.407521886838256,0.299797365554,ONC201,AKT INHIBITOR,0.4074141992397822,5.843474302636162,-3.4015639829355413
BRD-K68065987-300-09-1::2.5::HTS,BRD-K68065987-300-09-1,MK-2206,2.5,HTS,Exp_AKT3 (ENSG00000117020),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.36915618032698,0.322756972577,MK-2206,AKT INHIBITOR,0.366484040922232,0.6015008429743662,-1.9447001702962456
BRD-K71480163-001-01-4::2.5::HTS,BRD-K71480163-001-01-4,GDC-0068,2.5,HTS,PROT_Akt_pS473,PROT,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",,,Phase 2,0.414832600260785,0.456791290483,GDC-0068,AKT INHIBITOR,0.4114147508756591,0.41947834447798,-2.188279906572796
BRD-K76406695-001-02-9::2.5::HTS,BRD-K76406695-001-02-9,CCT128930,2.5,HTS,RMUTdmg_ARID1A (8289),MUTdmg,targeted cancer,AKT inhibitor,"PKIA, PRKACA",,,Preclinical,0.35859515594513797,0.197446953645,CCT128930,AKT INHIBITOR,0.3233740980224972,0.33778552053998834,-2.0943094275959
BRD-K80431395-001-07-3::2.49::HTS,BRD-K80431395-001-07-3,triciribine,2.49,HTS,Exp_ADK (ENSG00000156110),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 1/Phase 2,0.357973694137944,0.302242289976,triciribine,AKT INHIBITOR,0.3774242245902242,2.2627121402774284,-3.943794978919106
BRD-K80431395-001-09-9::2.5::HTS,BRD-K80431395-001-09-9,triciribine,2.5,HTS,Exp_DHRSX (ENSG00000169084),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 1/Phase 2,0.357973694137944,0.302242289976,triciribine,AKT INHIBITOR,0.35615359343862635,2.0729645182631664,-3.857397009482625
BRD-K99023089-001-03-7::2.5::HTS,BRD-K99023089-001-03-7,AZD5363,2.5,HTS,Exp_MSANTD4 (ENSG00000170903),GE,targeted cancer,AKT inhibitor,"AKT1, AKT2, AKT3",,,Phase 2,0.458985352177641,0.409270156243,AZD5363,AKT INHIBITOR,0.4413405794192759,0.5501228502405617,-2.1156922189823604
BRD-K78177893-001-02-4::2.5::HTS,BRD-K78177893-001-02-4,A-674563,2.5,,,,,AKT inhibitor,"AKT1, PKIA, PRKACA",,,,0,0,A-674563,AKT INHIBITOR,0.408294223132687,4.984078124783591,0.012144473160237812